Phylogenomic and structure-function relationship studies of proteins involved in EBV associated oncogenesis by Hussain, Mushtaq
  
 
 
 
 
 
Hussain , Mushtaq (2013) Phylogenomic and structure-function 
relationship studies of proteins involved in EBV associated 
oncogenesis. PhD thesis. 
 
 
 
 
http://theses.gla.ac.uk/5357/  
 
 
 
 
Copyright and moral rights for this work are retained by the author 
A copy can be downloaded for personal non-commercial research or study, without prior 
permission or charge 
This work cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
Enlighten:Theses 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The research presented in this thesis was sponsored by Dow University of Health 
Sciences, Karachi, Pakistan and Higher Education Commission, Pakistan and is 
author’s original work unless otherwise stated. 
 
Mushtaq Hussain 
 
 
 
 
Phylogenomic and Structure-Function 
Relationship Studies of Proteins Involved in 
EBV Associated Oncogenesis 
 
by 
Mushtaq Hussain 
Mushtaq Hussain, 2013  2 
 
 
 
 
 
 
 
 
 
 
In the memory of my Paternal Grand Father and Maternal Grand Mother 
 
 
 
                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wali Bhai Dadu Bhai 
Junagadh Wala (Late) 
Hawan Ji Bai Chand 
Ibrahim (Late) 
Mushtaq Hussain, 2013  3 
Abstract 
This study covers the investigation of evolutionary and structure-function relationship 
aspects of several cancer related proteins. One part of the study deals with the investigation 
of a critical protein of Epstein-Barr Virus (EBV) the Nuclear Antigen 1 (EBNA1), and its 
interactions with different host proteins. One of these host proteins is a member of a large 
gene family, encoding ubiquitin specific proteases (USP), known as USP7. The second 
section of the thesis deals with the molecular evolution of the USP gene family. Another 
set of cellular proteins deregulated during EBV associated oncogenesis are members of the 
glycoside hydrolase (GH18) family. Their phylogenetic relationships and protein structures 
were investigated in the third section of this thesis.   
EBNA1 is the only EBV protein that consistently expressed in all latent forms of the EBV 
infections. The protein is involved in the genome maintenance and a substantial body of 
evidence suggests that it has a role in EBV associated oncogenesis. In this study, full 
length molecular models of the EBNA1 protein were generated using the programmes, I-
TASSER, MOE and Modeller. The best models were selected on the basis of plausibility in 
structural and thermodynamical parameters and from this models of EBNA1 homologues 
of primates lymphocryptoviruses (LCVs) were generated. The C-terminal DNA binding 
and homodimerisation domain was predicted to be structurally similar between different 
LCV EBNA1 homologues, indicative of functional conservation. The central glycine 
alanine repeat (GAr) domain was predicted to be primarily composed of α helices, while 
almost all of the protein interaction region was found to be unstructured, irrespective of the 
prediction approach used and sequence origin. Predicted USP7 and Casein kinase 2 (CK2) 
binding sites and GAr were observed in the EBNA1 homologues of Old World primate 
LCVs, but not in the marmoset homologue suggesting the co-evolution of both these sites. 
Dimer conformations of the EBNA1 monomer models were constructed using SymmDock, 
where the C-terminal tail was predicted to wrap around the proline rich loop of another 
monomer, possibly contributing to dimer stability. This feature could be exploited in 
therapeutic design, hence an inhibitor peptide was designed and a preliminary evaluation 
was conducted to explore its ability to inhibit EBNA1 function in cell survival. The peptide 
array libraries of EBNA1 were used to investigate the binding regions and critical contact 
points between EBNA1 and partner proteins. Human EBP2 and USP7 proteins were 
expressed in bacteria and probed on the EBNA1 array. The data confirm the previously 
known binding region for EBNA1-EBP2 and EBNA1-USP7 interactions. In addition 
further information was gained regarding the critical contact residues and the potential role 
of phosphorylation of serine residues of EBNA1 in its binding with EBP2 and USP7.  
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The human genome encodes nearly 100 USPs which contribute to regulate the turnover of 
cellular proteins. These homologues are divided into 16 paralogous groups, all sharing a 
characteristic peptidase C19 domain. Evolutionary relationships between these 
homologues were explored by datamining and the phylogenetic reconstruction of peptidase 
C19 domain sequences. The data reveal an ancient relationship between the genes, with 
expansion occurring throughout the course of evolution, but particularly at the base of the 
vertebrates, at the time of the two whole genome duplications. A comparison between the 
phylogenetic architecture and protein interaction networks suggests the parallel emergence 
of many molecular pathways and the associated USPs.  
The GH18 gene family includes chitinases and related non catalytic proteins. Most 
mammals encode at least three chitinases (CHIT1, CHIA/AMCase and CTBS), as well as 
several homologues encoding catalytically inactive chitinase-like proteins or chilectins. 
Phylogenomic analysis shows that the family has undergone extensive expansion, initiating 
with a duplication event at the root of the vertebrate tree, resulting in the origin of the 
ancestors of CHIT1 and CHIA. Two further duplications of ancestral CHIA predate the 
divergence of bony fishes, one leading to a newly identified paralogous group (we have 
termed CHIO). In tetrapods, additional CHIA duplications predate and postdate the 
amphibian/mammalian split and relics of some exist as pseudogenes in the human genome. 
Homology modelling of structurally unresolved GH18 homologues in mouse and human 
was conducted using Modeller and I-TASSER. All resolved and predicted structures share 
a TIM barrel (β/α)8 and α+β domain. A central ligand binding cavity was also found in all 
GH18 homologues. The variation in size and shape of different paralogous proteins, 
indicate the difference in their ligands specificity and in turn potential functions.  
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CD56+NK Cluster of differentiation 56+ natural killer cells 
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TEMED N,N,N’,N’-tetramethylethylenediamine 
USP Ubiquitin Specific Peptidase/Protease 
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1. Introduction 
The work in this thesis covers the investigation of evolutionary and structure-function 
aspects of several cancer related proteins. One part of the study deals with a critical protein 
of Epstein-Barr Virus (EBV), the EBV Nuclear Antigen 1 (EBNA1). An important cellular 
protein that interacts with EBNA1 is the ubiquitin specific protease 7 (USP7), the second 
section of the thesis explores the phylogenomics of the USP gene family. Another set of 
cellular proteins deregulated during EBV associated oncogenesis are members of the 
glycoside hydrolase-18 (GH18) family and the third section of this thesis investigated 
GH18 gene family phylogenomics and protein structure. 
1.1. Epstein-Barr Virus 
Epstein-Barr Virus (EBV), also called human herpesvirus 4 (HHV-4), is a linear double 
stranded DNA containing virus. Taxonomically, it belongs to genus lymphocryptovirus 
(LCV) or gamma-1 herpesvirus of family herpesviradae and subfamily 
gammaherpesvirinae. The virus normally infects B cells and can undergo a lytic cycle, 
leading to the release of viral particles, and a latent cycle in which viral genome is stably 
maintained within the infected cells. The genome is around 172Kbp in size and contains 
approximately 100 distinct genes (Baer et al., 1984; Kieff and Rickinson, 2007). Out of 
these, 11 genes are expressed early in viral infection and variably in different latent states. 
These include: six Epstein-Barr virus Nuclear Antigens: EBNA1, 2, 3A, 3B, 3C and –LP, 
three Latent Membrane Proteins: LMP1, LMP2A and LMP2B, two Epstein-Barr virus 
Encoded RNAs: EBER1 and EBER2 as well as multiple microRNAs. The viral genome is 
surrounded by a protein capsid and between the capsid and inner envelope lies a protein 
tegument which anchors several glycoprotein that define cell tropism, host range and 
receptor recognition of the virus (Kieff and Rickinson, 2007). To date, two viral subtypes, 
type 1 and type 2 have been identified which differ at EBNA loci. The two types also differ 
in their transforming ability (Takimoto et al., 1989) and epidemiology (Kieff and 
Rickinson, 2007) as EBV type 1 is prevalent in many parts of the world whereas type 2 is 
more prevalent in Africa. Since the global infection rate of EBV is more than 90%, it is 
included among the most successful viruses in evolutionary terms (Cohen, 2000). EBV 
was the first virus proposed to be associated with the human cancers (Epstein et al., 1964) 
but absolute recognition of the oncogenic potential of EBV and its association with other 
human disorders is still a growing area.  
1.2. Brief time line of EBV research 
EBV was first discovered by Epstein and co-workers using electron microscopy of a cell 
line derived from a Burkitt’s lymphoma patient (Epstein et al., 1964). Since its discovery,  
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a wealth of information has been gathered that enable us to understand many key aspects 
of EBV biology. One reflection of this is the presence of over 30,000 research articles 
(papers and reviews) in the National Center for Biotechnology Information (NCBI) 
database having the key word Epstein-Barr Virus (Figure 1.1).  
1.3. EBV infections in humans 
Normally, EBV infections are asymptomatic and the virus is spread via saliva. The primary 
site of infection is the oropharynx where the virus comes into contact with B lymphocytes 
in the lymphoid tissue of Waldeyer’s ring. However, it is now increasingly evident that 
EBV can also infect epithelial cells, T cells, natural killer (NK) cells, smooth cells and 
monocytes (reviewed in Hutt Fletcher, 2007). 
Initial attachment of EBV is predominantly mediated by the interaction between its 
envelope protein (gp350/220) and the cellular complement component receptor 2 
(CR2/CD21) a protein found on the B cell surface (Fingeroth et al., 1984; Johannsen et al., 
2004).  However, a gp350 deletion mutant of EBV retains the ability to transform B cells, 
although with much reduced efficiency, suggesting other portal(s) may also present to 
facilitate EBV infection. Nevertheless, gp350 is a major requirement as antibodies to 
gp350 neutralize the infection of B cells by impairing virus attachment (Tanner et al., 
1988). Additionally, the structure of CR2 has been resolved by crystallography and critical 
regions for gp350 binding have been identified (Prota et al., 2002). Intriguingly, epithelial 
cells lack CR2 or express it at a very low level and the underlying mechanism of virus 
attachment with the epithelial cells is still unclear. However, possible mechanisms include 
viral attachment via gp350 antibodies binding to the IgA receptor on epithelial cells 
(Sixbey et al., 1992), and attachment of viral glycoproteins gH and gL to an unknown 
receptor on epithelial cells (Molesworth et al., 2000) and binding between the viral 
membrane protein BMRF2 with integrins on epithelial cells (Tugizov et al., 2003).  
Virus fusion with either B cells or epithelial cells requires three glycoproteins gH, gL and 
gB. Briefly, the attachment of gp350/220 with the CR2 receptor potentially triggers 
signalling events that initiate the process of endocytosis. CR2 switches its binding from 
gp350 to gp220 which in turn allows gp42 to interact with HLA class II (HLAII). This 
interaction facilitates the core fusion machinery (gH, gL and gB) to interact with the 
endosomal membrane allowing cellular internalization of the virus (Hutt-Fletcher, 2007).  
Viral fusion in epithelial cells is proposed to be independent of the gp42-HLAII interaction 
but mediated predominantly by the gH, gL and gB complex (Wang et al., 1998).  
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Figure 1.1. Brief timeline of EBV research. The graph demonstrates the continuous 
increase in the number of scientific publications related to EBV over the years. Note, only 
the NCBI database was consulted in developing the graph and only some of the key 
observations are indicated here. Key: Burkitt’s lymphoma (BL), Hodgkin’s lymphoma 
(HL), multiple sclerosis (MS), systematic lupus erythematous (SL), oral hairy leukoplakia 
(OHL), gastric carcinoma (GC), infectious mononucleosis (IM), nasopharyngeal 
carcinoma (NPC), Epstein Barr Virus Nuclear Antigen (EBNA), Latent Membrane Protein 
(LMP), Epstein Barr Virus encoded RNA (EBER), Ubiquitin Specific Protease (USP), 
Transgenic (Tg). Note: the association of EBV with breast cancer and any functional role 
in this disease is still controversial.  
tje dfkldsjlfjd 
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Once inside the cell, EBV can undergo two routes in its life cycle: 1) Lytic infection which 
is marked by the active propagation of virus in the host. 2) Latent infection which ensures 
the persistence of the virus in the host without viral particle propagation. The virus can be 
reactivated into lytic infection from latency. 
1.3.1. Lytic infection 
After cellular internalization the nucleocapsid is dissolved and the genome enters into the 
cell nucleus. The lytic cycle is differentiated into three stages: Immediate-early (IE), early 
(E) and late (L). The IE stage is marked by the expression of BZLF1 and BRLF1 genes, the 
encoded proteins subsequently act as transactivators for other lytic genes and lead to the 
expression of early stage genes (BMRF1, BALF2, BAL55, BBL2/3, BBLF4 and BSF1 etc) 
and subsequently late stage genes for viral structural proteins (gp350/220, VCA, gp85, 
gp25 and gp42). In this productive life cycle, the EBV genome is amplified by 100 to 1000 
fold (Hammerschmidt and Sugden, 1988) and multiple rounds of DNA replication 
originating at two sites make lytic infection distinct from latent infection (reviewed in 
Tsurumi et al., 2005). 
1.3.2. Latent infection  
Latent infection of EBV does not support the active propagation of virus but it ensures the 
stable persistence of the viral genome in the host cell. Unlike lytic infection, replication of 
the viral genome in latent infection occurs via host DNA polymerase (Amon et al., 2005) 
and from a separate origin, OriP. During latent infection the viral genome exists as a 
closed circular extrachromosomal plasmid or episome, packaged around host histone 
molecules (Dyson and Farell, 1985) and it stably replicates once during the cell cycle along 
with the host genome (Kirchmaier and Sugden, 1995). It is interesting to note that all 
primary or lytic infections of EBV begin with the expression of all latent genes which 
drives the infected B cell into proliferation. However, soon the expression of these genes is 
suppressed to evade immune recognition and if entering the lytic cycle, superseded by lytic 
genes. However, if the virus enters latency, all viral protein shuts off, ultimately entering 
latency 0. To date four main latency programmes have been categorized on the basis of 
latent gene expression profile of EBV infected cell lines and in the healthy host: latency 0, 
I, II and III. Table 1.1. shows latent gene expression pattern in different latency 
programmes of EBV. Moreover, these are broad categorization and different patterns can 
be found. 
1.4. Spectrum of EBV associated human diseases 
In most cases, primary infection of pre-adolescents of EBV lacks any clinical 
manifestation and is countered by the host immune response. However, the immune system  
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Latent genes Latency 0 Latency I Latency II Latency III 
EBNA1 - + + + 
EBNA2 - - - + 
EBNA3A - - - + 
EBNA3B - - - + 
EBNA3C - - - + 
EBNA-LP - - + + 
LMP1 - - + + 
LMP2A - - + + 
LMP2B - - + + 
EBER1 - + + + 
EBER2 - + + + 
Diseases Healthy 
individuals 
Burkitt’s 
lymphoma 
Nasopharyngeal 
carcinoma 
Hodgkin’s 
lymphoma 
Infectious 
mononucleosis, 
PTLD, LCLs 
 
Table 1.1. EBV latencies types and latent gene expressions. The table shows the 
expression of the genes (indicated by +) in different types of latencies associated with 
EBV. Note, all lytic infections of EBV generally start with the expression of all latent 
genes (latency III programme) as exemplified by infectious mononucleosis, Post transplant 
lympho proliferative disorder (PTLD) and lymphoblast cell lines (LCLs).  
fails to completely purge the virus from the host as EBV hides in resting memory B cells 
which then act as a persistent reservoir for the virus upon reactivation from the latent state. 
To date the diseases associated or proposed to be associated with EBV could be broadly 
classified into two categories: non malignant diseases and malignant diseases. 
1.4.1. EBV associated non malignant diseases  
Most common non malignant diseases known or proposed to be associated with EBV are: 
infectious mononucleosis, chronic active infection, oral hairy leukoplakia and multiple 
sclerosis.  
EBV infection in the post adolescent can result in infectious mononucleosis 
(approximately one third of the infections), a self limiting lymphoproliferative disease 
marked by the latency III programme and lytic infection. Clinically, the patients recover 
from the disease without any recurrence or developing any severe pathology, however, 
complications like splenic infarction, airway obstruction and neurological problems have 
been observed (reviewed in Odumade et al., 2011). Chronic active infection of EBV is 
characterized by chronic or recurrence of infectious mononucleosis like symptoms. The 
clinical hallmarks of the disease are abnormally high titre of the EBV antibodies, 
splenomegaly and/or persistent hepatitis, interstitial pneumonia and lymphadenitis (Kimura 
et al., 2001). Oral hairy leukoplakia is another form of persistent primary infection of EBV 
that almost exclusively affects HIV infected individuals (Reichart et al., 1989). The disease 
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is characterized by the extensive replication of EBV particles in oral epithelial cells (Green 
span et al., 1985) with hyperkeratotic and squamous epithelial cell lesions present on the 
lateral side of tongue. The association of EBV with multiple sclerosis, an autoimmune  
disease characterized by the depletion of the myelin sheath of neurons, is not currently 
understood. However, some lines of the evidence point to EBV being a causal and/or 
contributing factor in the pathogenesis of multiple sclerosis. These include increased 
incidence of multiple sclerosis among individuals with prior EBV infection, and elevated 
levels of EBNA1 antibodies before the onset of multiple sclerosis (DeLorenze et al., 2006; 
Levin et al., 2010). While EBV does not infect neurons or Schwann cells it is thought that 
EBV has an effect upon the immune system that promotes this disease. As such, it may 
also exacerbate multiple other autoimmune disorders.  
1.4.2. EBV associated malignant diseases 
EBV was the first virus to be associated with human cancer, specifically Burkitt’s 
lymphoma (Epstein et al., 1964). Since then several human malignancies have been linked 
with EBV. The most highly EBV-associated malignancies are: endemic Burkitt’s 
lymphoma (BL), Hodgkin’s lymphoma (HL), post transplant lymphoproliferative disease 
(PTLD), nasopharyngeal carcinoma (NPC) and gastric carcinoma (GC).  
BL is a very aggressive B cell lymphoma with three clinical variants: endemic BL, 
sporadic BL and immunodeficiency associated BL. Each variant differs in their association 
with EBV, endemic BL has 100% positivity with EBV, while sporadic BL and 
immunodeficiency associated BL range between 5%-80% and 25%-40% association with 
EBV respectively (Blum et al., 2004). All forms of BL involve translocation of the 
oncogene, c-myc, to the regulatory region of immunoglobulin gene elements, thereby 
deregulating c-myc expression (Gutierrez et al., 1992).  
HL is another commonly associated B cell lymphoma with EBV. Clinically, HL is 
differentiated into two main variants: non nodular lymphocyte predominant HL (NHL) and 
classical HL (CHL). NHL accounts for only 5% of the total cases of HL and is usually not 
associated with EBV. CHL is variably associated with the EBV (10%-90%) depending on 
the geographical location and co existence of other diseases (Gandhi et al., 2004; Jarrett et 
al., 2005).  
Post Transplant Lymphoproliferative Disease (PTLD) affects cumulatively 3% of the 
patients that have undergone transplantation (1% hematopoietic and 2% solid organ 
transplantation).  With around 80% of PTLD being EBV associated, the disease may take 5 
months (hematopoietic transplantation) to 5 years (solid organ transplantation) to develop 
(reviewed in Maeda et al., 2009). 
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NPC is an epithelial carcinoma and on the basis of keratinisation and differentiation of the 
affected region it is further categorized into three types: differentiated non keratinizing 
NPC, undifferentiated non keratinizing NPC and keratinizing squamous cell carcinoma. 
Both types of non keratinizing NPC are totally associated with EBV (100%). As 
abnormally high titre of IgG and IgA antibodies to the viral capsid antigen (VCA) and 
early antigen (EA) can be used to predict the onset of NPC (Henle and Henle, 1976), it has 
been proposed that EBV reactivation and subsequent replication may contribute to the 
development of NPC. Additionally, since EBV DNA in the NPC tumours appears to be 
clonal (based on the terminal repeats), it suggests the contribution of proliferating latently 
infected cells in the development of NPC (Raab-Traub and Flynn, 1986). A caveat to this 
conclusion is that Moody et al. (2003) demonstrated that cells with EBV episomes 
containing fewer terminal repeats proliferate much faster than cells with longer terminal 
repeats, suggesting that the previously observed clonality of cells may be the result of 
selection, rather than evidence of EBV presence at the origin of the tumour. 
EBV associated GC is the highest in terms of worldwide incidence amongst all the EBV 
associated cancers, however, EBV association is lower in this cancer (between 5.2% to 
16.0% (van Beek et al., 2004)). Clinically, EBV associated gastric carcinoma is now 
considered as a distinct molecular and pathological entity (Fukayama et al., 2001; Ojima et 
al., 1996).  
1.5. EBV latent genes 
The six EBNA proteins can be expressed from differentially spliced mRNAs, initiated at 
one of the two promoters (Cp or Wp) that span more than half of the viral genome. 
Additionally, EBNA1 can be expressed from message initiated at Fp or Qp promoters 
(Figure 1.2). LMP2 is expressed in the same direction as the EBNAs, but the mRNA spans 
the terminal repeats and can therefore only be expressed from the episomal genome. LMP1 
is expressed in the opposite orientation, using the same promoter as LMP2B. EBERs are 
the non coding double stranded structural RNAs present just upstream to OriP, whereas 
other microRNAs are the present upstream to LMP1 and LMP2A (Figure 1.2).  
1.5.1. EBNA1 
EBNA1 is the only protein coding latent gene of EBV which is expressed in three major 
programmes of latency (latency I-III). Its main role is to ensure propagation and 
segregation of the viral genome in latently infected dividing cells. EBNA1 structure and 
functions will be described in detail in section 1.6. 
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Figure 1.2. Structure of EBV genome. A schematic linear representation of 172 kb 
circular EBV genome is shown. The latent genes, promoter regions and OriP site are 
shown. Terminal repeats are represented by dots. Promoters are represented by flags with 
the arrow indicating the transcription direction. For simplicity only three BARTs (micro 
RNAs clusters; light blue arrows) are shown.  
 
1.5.2. EBNA2 
EBNA2 is a transcriptional activator of two viral genes (LMP1 and LMP2s) and cellular 
genes (CD21, CD23 and others) (Gross et al., 2012; Kieff and Rickinson, 2007; Wang et 
al., 1990a; 1990b). EBNA2 interacts indirectly with DNA at the EBNA2 responsive 
elements (ER2Es) located within the promoter of the LMPs and several cellular genes via 
DNA binding proteins including Jk-recombination binding protein (RBP-Jk) (Grossman et 
al., 1994). Only recently it has been demonstrated that nuclear chaperone nucleophosmin 
(NPM1) also plays a critical role in escorting EBNA2 to the promoter region of LMPs (Liu 
et al., 2012). EBNA2 regulates the expression of several viral and host genes including 
LMP1 and c-myc genes pointing to the role of EBNA2 in B cell survival, which in turn 
facilitate prevalence of the virus in the infected host (Kaiser et al., 1999).  
1.5.3. EBNA3 gene family 
The EBNA3 gene family comprise three related protein: EBNA3A, EBNA3B and 
EBNA3C orfs located tandemly in the EBV genome (Sample et al., 1990). The encoded 
proteins contain seven repeats of leucine, isoleucine or valine that may enable those 
proteins to dimerise. Their expression results when viral transcription switches to the C 
promoter (Cp) from the W promoter (Wp) (Gahn and Sugden, 1995). EBNA3A and 
EBNA3C have been shown to be essential for the B cell transformation (Tomkinson et al., 
1992; 1993) and growth maintenance of LCLs (Maruo et al., 2003; 2005). All EBNA3 
proteins competitively inhibit the binding of EBNA2 with RBP-Jks and consequently DNA 
association (Waltzer et al., 1996; Zhao et al., 1996) thereby negatively regulating the 
expression of several viral and host genes which are positively regulated by EBNA2. 
Conversely, EBNA3C can act as transactivator as its expression in Raji cells (which have 
the coding exon of EBNA3C deleted) increases the expression of LMP1 (Allday and 
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Farrell, 1994). Recently White et al. (2010) using microarrays reported that over 1000 
genes regulated by EBV, require one of the three EBNA3s. 
1.5.4. EBNA-LP 
Encoded by the leader mRNA sequence of EBNAs in a bicistronic message, EBNA-LP is a 
protein with repeats of 66 amino acids (the W1W2 domains) and a unique 45 amino acid C-
terminal sequence (the Y1Y2 domains) (Kief and Rickinson, 2007; Sample et al., 1986). 
Along with EBNA2, EBNA-LP induces the G0 to G1 transition of resting B cells (Sinclair 
et al., 1994).  EBNA-LP is also involved in co-up regulating the target genes of EBNA2, 
including LMP1 (Nitsche et al., 1997). Interactions of EBNA-LP with p53 and 
retinoblastoma protein (pRb) have also been demonstrated (Szekely et al., 1993). Although 
EBNA-LP is not essential for the immortalisation of the B cells, mutant EBV deleted for 
EBNA-LP shows an impaired ability to transform B cells. Moreover, deletion of W repeats 
(to 5 or less) also reduces the transforming ability of the virus (Tierney et al., 2011). 
1.5.5. LMP1 
LMP1 is considered to be the main transforming protein of EBV as it acts as a potent 
oncogene in several cell types in culture including B cells (Kaye et al., 1993; Wang et al., 
1985). In vivo, using LMP1 transgenic mice, the expression of LMP1 in the epithelial cells 
leads to the onset of early stage of epithelial hyperplasia and this can progress to neoplasia 
(Stevenson et al., 2005; Wilson et al., 1990). Under the control of an IgH enhancer, LMP1 
expression leads to the development of B cell neoplasia (Hannigan et al., 2011). 
Structurally, LMP1 resembles a tumour necrosis factor family member, CD40. The protein 
contains three main domains: 1) a short N-terminal cytoplasmic domain, 2) six 
transmembrane helices and 3) a long C-terminal domain which incorporates three 
functionally active regions termed C-terminal activating regions (CTAR) 1, 2 and 3 
(Eliopoulos and Young, 2001; Li and Chang, 2003). CTAR1 and CTAR2 interact with 
tumour necrosis factor receptor associated factors (TRAFs) and tumour necrosis factor-
receptor death domain proteins (TRADDs) respectively. Such interactions instigate several 
signalling pathways including the NFκB pathway (Huen et al., 1995), MAPK pathways 
(Eliopoulos et al., 1999) and P13K/Akt pathways (Dawson et al., 2003). Through these 
pathways, LMP1 deregulates the expression of multiple genes including EGFR (Kung et 
al., 2011) and EGFR ligand (Hannigan et al., 2007), apoptotic protein Bcl-2 (Henderson et 
al., 1991) and stimulates inflammatory cytokine production in LMP1 transgenic mice 
(Hannigan et al., 2010; 2011).  
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1.5.6. LMP2A/2B 
LMP2A and 2B are encoded by a single gene LMP2, which is intervened by the terminal 
repeat sequences, the point at which linear ends of EBV genome join to form an episome 
(Sample et al., 1989). Both genes are expressed simultaneously under the control of two 
promoters located 3kb apart. LMP2A and LMP2B are identical except for the presence of 
an additional 5’ exon in LMP2A giving it an additional 119 amino acids, N-terminal 
domain compared to LMP2B (Longnecker and Kieff, 1990). However, the 12 
transmembrane domains are common to both LMP2A and 2B. Analysis of EBV 
recombinant mutants deleted for LMP2 showed that both these proteins are not essential 
for B cell transformation (Longnecker et al., 1993a; 1993b; 2000). Two out of the eight 
tyrosine residues present at the N-terminal domain constitute a immunoreceptor, tyrosine-
based activation motif (ITAM), that play a central role in the proliferation and 
differentiation of lymphocytes by interacting with the protein kinases of Src and Syk 
families. It has been proposed that LMP2A can block normal B cell receptor (BCR) 
signalling by assembling the tyrosine kinase to its ITAM (Fruehling and Longnecker, 
1997). This finding is further supported by studies conducted using LMP2A transgenic 
mice. LMP2A expressing B cells from these transgenic mice survive without producing 
immunoglobulins suggesting that LMP2A may facilitate survival of B cells, even in the 
absence of essential BCR signalling suggesting that LMP2A can provide the survival 
signal that would otherwise be transduced by the BCR (Caldwell et al., 1998). 
1.5.7. EBERs 
The EBERs (EBER1 and EBER2) are non polyadenylated, non coding polIII RNAs, which 
along with EBNA1 are consistently expressed in all programmes of EBV latencies (with 
some exceptions like in GC). EBERs are amongst the most highly expressed viral genes in 
latency, therefore routinely used in the diagnosis of EBV infected cells (Chang et al., 
1992). Sequentially, EBERs are highly conserved among different EBV isolates and are 
thought to adopt a secondary structure conformation. The secondary structure contains 
stem loops which are suggested to interact with several proteins including protein kinase R 
(PKR) (Takada and Nanbo, 2001). Binding of EBERs with PKR is thought to inhibit 
interferon responses and in turn apoptosis, providing EBV with an arsenal to counter the 
host innate immune response (Nanbo et al., 2002). EBER expression in EBV negative 
Akata cell line results in partial restoration of tumourogenic phenotype of EBV+ Akata 
cells (Ruf et al., 2000). EBERs also confer resistance to apoptosis when expressed in 
intestinal epithelium cells, via blocking PKR activity (Nanbo et al., 2005). Moreover, 
EBER deleted mutant of EBV shows 100 fold reduced transforming ability as compared to 
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wild type (Yajima et al., 2005). Consistent with these observations, EBER1 expression in 
transgenic mice led to lymphoid hyperplasia ultimately followed by B cell malignancy 
(Repellin et al., 2010). Another study, based on recombinant viruses (either with EBER1 
or EBER2) suggests that the transforming ability of EBERs is due to EBER2 and not 
EBER1 (Wu et al., 2007).  
1.5.8. BamH1A region transcripts 
This region of the EBV genome encodes highly expressed RNAs termed BamH1A 
rightward transcripts or BARTs (Karran et al., 1992; Smith et al., 2000). During latent 
infection of EBV, 29 miRNAs are expressed from three clusters in the EBV genome, of 
these two clusters are made from BARTs (Edwards et al., 2008). Other protein coding 
transcripts from the same region include BARF0 and BARF1. BARF1 encodes a 31 kDa 
protein which was originally considered to be a lytic gene but also has been found to be 
expressed in NPC and GC (Decaussin et al., 2000, zur Hausen et al., 2000). Furthermore, 
BARF1 is a potential oncogene as its expression leads to the transformation of rodent 
fibroblasts in culture and it can induce expression of the antiapoptotic gene Bcl2 (Sheng et 
al., 2001).  
1.6. EBNA1 in depth 
EBNA1 is the only protein coding latent gene that is expressed in all latencies of EBV. 
EBNA1 was first described in fresh tumour biopsies of NPC (de The et al., 1973) and 
subsequently identified in many EBV infected tissues (Wright et al., 1975; Yamamoto et 
al., 1975). EBNA1 is an 88 kDa, 641 amino acid containing protein. More than one third 
of the protein is composed of a glycine and alanine repeats region, which were first 
identified using antibodies present in the human sera in 1983 by Hennessey and Kieff. 
EBNA1 is a pleiotropic protein and is involved in a variety of functions, including genome 
maintenance, transactivation, resistance to apoptosis and oncogenesis. The diversity in 
EBNA1 functions is primarily due to its ability to interact with several host and viral 
biomolecules (Figure 1.3; 1.4). 
1.6.1. The role of EBNA1 in genome replication and maintenance 
The main biological role of EBNA1 in the virus is to facilitate the non random segregation 
of viral genomes in latently infected cells. During latent EBV infection, the circular 
episome of the virus undergoes one round of bi directional replication per cell division. 
EBV replication in latent infection starts at unique region, oriP and while using only one 
viral protein, EBNA1, it relies heavily on the host replication machinery. oriP is composed  
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Figure 1.3. Binding partners and functions of EBNA1. The figure represents the 
pleiotropic nature of EBNA1 involved in a variety of functions including genome 
maintenance, transactivation and resistance to apoptosis owing to its binding with multiple 
host proteins as well as DNA and RNA.  
 
 
Figure 1.4. Protein interacting regions and domain distribution of EBNA1.  Schematic 
representation of the EBNA1 protein is shown. Different structural/functional domains are 
coloured differently and indicated. The horizontal bars represent the position and span of 
different protein binding regions on EBNA1 sequence. Note, EBNA1 interacts with 
multiple host proteins, binding region of only few are mapped and shown here. 
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of two functional elements: a Dyad symmetry (DS) element and a family of repeats (FR), 
situated 1kbp apart. The DS element contains 65bp central dyad symmetrical sequences 
flanked by 3 copies of a 9bp sequence (nonamers) at each end. The central dyad 
symmetrical region contains 2 of the 4 binding sites for EBNA1 and optimal replication of 
EBV episomes requires all four sites of EBNA1 interaction and the nonamers. Moreover, 
the space (3bp) between two adjacent EBNA1 binding sites is also crucial for effective 
replication of the viral genome. The FR repeats are 20 tandem copies of a 30 bp sequence, 
each of which contains an 18bp region for EBNA1 binding (Figure 1.5). Interaction of 
EBNA1 with both DS and FR is critical for EBV genome replication (Reismann et al., 
1985; reviewed in Frappier, 2012). Paradoxically, binding of EBNA1 with FR may also 
inhibit the replication by resisting the unwinding of DNA and movement of the replication 
fork, limiting replication to once/S phase (Dhar and Schildkraut, 1991).  
The co-crystallized structure of an EBNA1 C-terminal dimer with DNA has shown the 
presence of two important regions, a DNA recognition helix (461-503 a.a) that flanks the 
second dimerisation or core domain (504-604 a.a). Despite the limited sequence homology, 
the core domain of EBNA1 shares noticeable structural similarity with the dimerisation 
domain of the E2 protein of papilloma virus (Bochkarev et al., 1995; 1996). The EBNA1 
homodimer recognizes and binds to the 18bp pallindromic sequence present in DS and FR 
(Ambinder et al., 1990; Rawlins et al., 1985). This DNA-protein interaction is mediated by 
the C-terminal domain (459-603 a.a) of EBNA1. However, it is now increasingly evident 
that in addition to the C-terminal one third of the protein, N- terminal region of EBNA1 
also contribute to viral DNA replication and genome maintenance (Deng et al., 2005; 
Holowaty et al., 2003; Shire et al., 1999). Binding of EBNA1 with USP7 has been shown 
to increase its efficiency to bind with DNA in vitro. Depletion of cellular USP7 negatively 
affects the EBNA1 binding to oriP (Sarkari et al., 2009; 2010). Conversely, higher DNA 
replication activity has been shown in the presence of an EBNA1 mutant lacking the USP7 
binding region, suggesting that EBNA1-USP7 binding may negatively regulate viral DNA 
replication (Holowaty et al., 2003).  
EBV genome replication during latent infection also involves extensive recruitment of the 
host replication machinery (reviewed in Frappier, 2012). Studies have shown that the host 
cell origin recognition complex (ORC) and minichromosome maintenance (MCM) 
complex are recruited on the DS element at oriP, suggesting their role in EBV genome 
replication (Chaudhuri et al., 2001; Dhar et al., 2001). Consistent with this it has been 
demonstrated that cells having a mutation in ORC fail to stably replicate the EBV genome 
(Dhar et al., 2001). Recruitment of ORC to the DS region is mediated by EBNA1 via its  
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Figure 1.5. EBNA1 role in genome maintenance. Schematic representation of functional 
components of EBV genome maintenance is shown. To date, a scientific consensus is 
lacking regarding the molecular mechanism underlying non random partitioning of the 
EBV episome in dividing latently infected cells. Shown here are all the proposed 
mechanisms with the corresponding references. Inset: the structure of oriP is shown with 
both DS and FR repeat elements, the main DNA binding site of EBNA1. Genome 
maintenance role of EBNA1 is derived from its direct interaction with metaphase 
chromosome or indirect interaction with chromosome by EBP2, RNA, Brd4 and HMG2B 
as indicated. Surface topologies of the protein molecules are shown. Predicted models of 
EBP2 and EBNA1 (this study) are used to represent the surface of full length molecules. 
Partial structures of Brd4 (PDB id: 4HXP) and HMG2B (PDB id: 1J3C) are used to 
represent the respective proteins.  
Mushtaq Hussain, 2013  30 
interaction with RNA and/or Cdc6 protein (Moriyama et al., 2012; Norseen et al., 2008). 
As marking of the origin of replication is mediated by EBNA1, it has been proposed that 
assembly of ORC at the same position may serve some additional and/or different role in 
EBV genome replication (Frappier, 2012). The Minichromosome maintenance (MCM) 
complex is also recruited at the oriP via two accessory proteins, Cdc6 and Cdt1 and may 
undertake a helicase action in EBV episome replication (Dhar et al., 2001). Another 
cellular protein recruited at the oriP is telomere repeat binding factor 2 (TRF2), which 
interacts with the three nonamer repeats at DS mostly during the G1/S phase (Deng et al., 
2002). Although the N-terminal domain of TRF2 was shown to be supportive in order to 
recruit ORC to DS, its absolute requirement is still unclear (Atanasiu et al., 2006) as a later 
study by Moriyama et al., 2012 showed that EBNA1 mediated recruitment of ORC and 
Cdc6 at oriP is TRF2 independent. Another study has demonstrated that depletion or 
deletion of TRF2 advances the EBV episomal replication from late S to mid S phase, 
possibly by recruiting histone deacetylase (HDC) 1 and 2 (Zhou et al., 2009). TRF2 has 
also been shown to recruit ChK2 to DS during the G1/S phase (Zhou et al., 2010) and 
recombination proteins like MRE11 and NBS1 during S phase (Dheekollu et al., 2007). 
Telomere associated factors such as TRF1 also bind to the DS of oriP, however its role in 
viral genome replication is unclear. Two other proteins have also been found to be 
recruited to the DS: tankyrase poly (ADP-ribose) polymerase (TPP) and hARP (Deng et 
al., 2002; 2003b). TPP also directly binds to EBNA1 and this interaction negatively 
regulates DNA replication, as mutation in the TPP binding site of EBNA1 (Gly81 and 
Gly425) leads to an increase in oriP mediated DNA replication (Deng et al., 2005). By 
contrast depletion of hARP results in a decrease in oriP mediated EBV episome replication 
(Deng et al., 2003). Timeless (tim) and tipin are two other proteins which are recruited to 
oriP. Decrease oriP mediated replication and increased double strands breaks have been 
observed at oriP when tim protein is depleted from the cell. Additionally, both timeless 
and tipin are known for stabilizing replication forks at repetitive sequences (Dheekollu et 
al., 2011). EBNA1 also directly interacts with template activating factor Iβ (TAFIβ) via 
Gly-Arg region (325-376 a.a) of EBNA1 and recruits it to oriP. Recruitment of TAF1β 
negatively regulates viral DNA replication by assembling histone acetylase and HDA, 
which in turn modify the chromatin structure (Wang and Frappier, 2009).  
Although EBNA1 association with the viral episome has been explored in detail, the 
mechanism of EBNA1 association with host chromosomes, for effective segregation of the 
EBV genome, is still under debate (Figure 1.5). Nevertheless, based on observations taken 
from florescent microscopy, deletion mutants, immuno precipitation and biochemical 
fractionation, it seems that EBNA1 interacts with human chromosomes at AT rich regions 
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via the two EBNA1 Gly-Arg regions LR1 (33-89) and LR2 (328-378), therefore termed 
AT hooks. This interaction may be direct (Sears et al., 2004) or indirect (in later stages of 
cell cycle) by a nucleolus protein p40 or EBP2 (Kapoor et al., 2005; Nayyar et al., 2009; 
Shire et al., 1999; Wu et al., 2002). Replacement of LR1 and/or LR2 with a similar region 
from the high mobility group AT hook 1 protein, was as effective in the segregation of the 
EBV episome, supporting the idea of direct association of EBNA1 with human chromatin 
(Sears et al., 2004). By contrast, depletion of EBP2 (by silencing or dissociation by aurora 
kinase) notably decreases the association of EBNA1 with host chromosomes (Kapoor et 
al., 2005), supporting the idea that EBNA1 interacts with metaphase chromosome 
indirectly through EBP2. Similarly, colocalization of EBNA1 and EBP2 was observed on 
chromosomes from metaphase to telophase (Nayyar et al., 2009). Moreover, Jourdan et al. 
(2012) has demonstrated that the interaction of EBP2 and EBNA1 occurs during interphase 
and not in the later stages of mitosis. These authors purposed a non obligate loading role of 
EBP2, for EBNA1 association with metaphase chromosomes. In the same study an 
alternate binding partner, HMGB2, was proposed, for stabilizing the EBNA1-chromosome 
interaction. Adding further complexity is the observation that Braco-19, a G-quardi duplex 
RNA disruptor, also inhibits EBNA1 association with cellular chromosome (Norseen et al., 
2009), suggesting a role for RNA in EBNA1-chromosome association. Additionally, it has 
recently been shown that the relocalization of EBNA1 during the cell cycle (dispersed 
throughout nucleus to metaphase chromosomes) also depends on Gly-Ala repeat (GAr) 
length (Coppotelli et al., 2013). Finally, by using a reconstituted virus replication system in 
yeast and EBNA1 deletion mutation analysis, the direct physical interaction between 
EBNA1 and Brd4 was shown and an additional but dispensable mechanism for EBV 
episome tethering to the metaphase chromosome was proposed (Lin et al. 2008). 
Nevertheless, association of EBNA1 with metaphase chromosomes subsequently leads to 
the non random segregation of EBV episomes into the daughter cells, as the chromosomes 
move towards the opposite poles during anaphase (Figure 1.5).  
1.6.2. EBNA1 as transactivator 
EBNA1 acts as a transcriptional transactivator for both viral and cellular genes. Upon 
binding to FR in the EBV genome, EBNA1 mediates the transcription of several latent 
genes including LMP1 (Gahn and Sugden, 1995). Paradoxically, EBNA1 specific binding 
to viral promoter Qp has shown to negatively regulate its own transcription (Sample et al., 
1992; Sung et al., 1994). Although the molecular mechanism of EBNA1 transactivation 
activity is not clear, some details are available. For example EBNA1 binding to oriP may 
result in the loop formation between FR and DS and this structure has direct consequences 
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upon viral replication and latent gene transcription (Frappier and O’Donnell, 1991; Su et 
al., 1991). It may induce re-organization of the chromatin structure which results in the 
progressive recruitment of additional transcriptional machinery to the region (Niller and 
Minarovitis, 2012). Moreover, DNA looping may further be induced by binding partners of 
EBNA1, such as Brd4, PRMT5, TAF1 and NAF1 (Lin et al., 2008; Malik-Soni and 
Frappier, 2012; Wang and Frappier, 2009).  Additionally, a region between 64-89 a.a. in 
EBNA1 contains two strongly conserved cysteine residues which might bind with Zn. 
Substitutions at these cysteine residues or chelation of cellular zinc impairs the 
transactivation ability of EBNA1 (Aras et al., 2009).  
In addition to the viral episome, it is now widely established that EBNA1 specifically 
interacts with the host cellular DNA. This interaction may have consequences on the 
expression of cellular genes.  Using chromatin immunoprecipitation (ChIP) supported by 
promoter array and/or deep sequencing analyses, several cellular sites have been identified 
as targets for EBNA1 binding. Interestingly, these sites are diverse in terms of their 
sequence, thus unlike the viral sequence, a clear consensus is still lacking regarding the 
target sequence(s) in the human genome for EBNA1 binding (Canaan et al., 2009; Lu et 
al., 2010). Moreover, the functional significance of this interaction is elusive. For example, 
EBNA1 high affinity binding to FR like elements in the human genome has been 
demonstrated but without any evidence of ORC or MCM protein recruitment (d’Herouel et 
al., 2010; Lu et al., 2010). It is possible that lack of such recruitment is due to the 
requirement of a 21 bp span between two adjacent EBNA binding site for recruiting 
cellular proteins involved in replication (Bashaw and Yates, 2001). Similarly, binding with 
the FR like elements present on human chromosome 11 does not show any alteration in the 
transcriptional activity of the nearby genes (Lu et al., 2010). Consistent with these studies, 
cellular promoters to which EBNA1 shows an affinity, when cloned upstream of the 
luciferase gene, have not shown any alteration in transcription in the presence of EBNA1 
(Dresang et al., 2009). Conversely, exogenous expression of EBNA1 enhanced the 
transcription of several genes including survivin in the EBV negative BL cell lines DG75 
and BJAB. Decreased transcription has also been observed in a similar set of genes when 
EBNA1 is depleted in the EBV positive Raji cell line using siRNA (Lu et al., 2010; 
Canaan et al., 2009). Moreover, the presence of EBNA1 results in the two and four fold 
increase in the expression of ATF2 and c-Jun genes respectively in NPC cells (O’Neil et 
al., 2008).  
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1.6.3. EBNA1 as oncogene 
Given that EBNA1 is the only latent protein expressed in BL and is consistently expressed 
in all latency programmes of EBV, it has been speculated that EBNA1 may contribute to 
EBV associated oncogenesis. Considerable amount of evidences has been accumulated 
pointing to a direct role of EBNA1 in EBV associated oncogenesis. The first demonstration 
that EBNA1 might have oncogenic activity was made using transgenic mice (Wilson et al., 
1996; Wilson and Levine, 1992). These studies showed that two independent, EBNA1 
expressing transgenic mouse lines were predisposed to B-cell lymphoma. Although this 
finding was against the dogma at the time (and another group failed to show EBNA1 
mediated transgenic oncogenesis (Kang et al., 2001; 2005; 2008), numerous studies since 
then have pointed to EBNA1 having an oncogenic activity, particularly in increasing the 
cell survival. Increased immortalization has been observed in EBV infected B lymphocytes 
due to the presence of EBNA1 (Altmann et al., 2006; Humme et al., 2003). Additionally, 
expression of EBNA1 dominant negative mutants decreased cell survival and increased 
apoptosis in BL cells (Kennedy et al., 2003). In line with this, silencing of EBNA1 
increased the survival in BL and NPC cell lines (Hong et al., 2006; Yin et al., 2006). This 
was also found in vivo using EBNA1 expressing transgenic mice. EBNA1 lymphocytes 
showed a prolonged survival, but this was dependent in culture on the supplement of IL2.  
In the same study increased expression of bcl-XL and recombination activating genes 
(RAG 1 and 2) was also noticed (Tsimbouri et al., 2002). In another study a synergistic 
effect of Myc and EBNA1 leading to the early onset of the lymphomogenesis was observed 
in the transgenic system (Drotar et al., 2003). Furthermore, increased primary tumour 
formation and metastasis have been observed in response to EBNA1 expression in the 
HONE1 NPC cells (Sheu et al., 1996), breast cancer cells (Kaul et al., 2007) and gastric 
carcinoma cells (Cheng et al., 2010). 
At the molecular level, evidence to delineate the underlying mechanism of cell survival 
and consequently oncogenesis involving EBNA1 is accumulating. Among these are: 
destabilization of p53 (Holowaty et al., 2003; Saridakis et al., 2005), destabilization of 
promyelocytic leukemia (PML) nuclear bodies (Sivachandran et al., 2008; 2012), 
induction of reactive oxygen species (ROS) (Cao et al., 2012; Gruhne et al., 2009a) and  
modulation of signalling pathways (Wood et al., 2007; Valentine et al., 2010) (Figure 1.6). 
Direct binding between EBNA1 (436-450 a.a) with the MATH/TRAF domain of USP7 has 
been demonstrated in vitro (Holowaty et al., 2003; Saridakis et al., 2005). USP7, a 
deubiquitinase, removes the polyubiquitin chain from the key tumour suppressor protein 
p53, as well as its ubiquitin E3 ligase MDM2, thereby protecting both proteins from 
proteosomal degradation and promoting their stabilization (Li et al., 2004; Hu et al., 2006).  
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Figure 1.5. EBNA1 as an oncogene: Depiction of models, based on the studies suggesting 
the role of EBNA1 in cell survival and resistance to apoptosis. Surface topology of all 
protein and DNA molecules are shown and labelled. The predicted models of full length 
EBNA1 (cyan) and USP7 (brown) are used.  Full length structures of CK2 (purple and 
yellow PDBid: 1JWH), proteosome (dark purple; PDBid:1G65), ubiquitin (orange; 
PDBid:1AAR), survivin (brown; PDBid:4AON), NFkB (red; PDBid:1NFK), SMAD2 
(dark brown; PDBid: 1KHX), STAT1 (light green; PDBid: 1YVL), p53 (light purple; 
PDBid:1TUP) and NM23-H1(blue; PDBid: 3L7U) have been retrieved from RCSB protein 
data bank. PML (green; PDBid: 1BOR) is represented by their partially available structure. 
Short description between the EBNA1 and the associated proteins and the suggested 
outcome are indicated on the connecting arrows, coloured as partner molecule.  
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Biochemical and structural studies have demonstrated that all, EBNA1, MDM2 and p53 
compete for the same region for binding with USP7, however EBNA1 shows highest 
affinity amongst the three. As a consequence it has been proposed that during EBV 
infection, EBNA1 binds with USP7 and thus interferes with the otherwise tightly regulated 
ubiquitination/deubiquitination processes of p53; this dys-regulation leads to the 
proteosomal degradation of p53 (Hu et al., 2006; Li et al., 2004; Saridakis et al., 2005).  In 
vivo studies have also demonstrated that expression of EBNA1 in U20S (Saridakis et al., 
2005) and CNE2 NPC (Sivachandran et al., 2008) and GC cells (Sivachandran et al., 
2012a) results in the depletion of p53. Taken together these observations plausibly suggest 
that EBNA1 can disturb the steady state levels of p53 in the EBV infected cells to support 
cell survival. However, treatment of LCL with DNA damaging agents has led to p53 
mediated apoptosis (O’Nions et al., 2006) and p53 is intrinsically mutated in 50% of the 
BL cases but not in NPC (Schmitz et al., 2012). The role of EBNA1 in the cell survival 
could in part be explained by its interaction with PML nuclear bodies. PML nuclear bodies 
consist of nuclear proteins, which are involved in apoptosis and DNA repair (reviewed in 
Bernardi et al., 2007; Salomoni et al., 2012). EBNA1 preferentially interacts with one of 
the five human isoforms of PML, namely PMLIV. Additionally, the EBNA1 region 
defined (387-394) also directly interacts with the β regulatory subunit of casein kinase 2 
(CK2), which phosphorylates PML. CK2 mediated phosphorylation of PML signals for its 
ubiquitination and consequently proteosomal degradation (Scaglioni et al., 2006; 2008; 
Sivachandran et al., 2010). Moreover, EBNA1 expression in both GC and NPC results in 
the depletion of PML nuclear bodies (Sivachandran et al., 2008; 2012). Moreover, the 
EBNA1-USP7 interaction is thought to be important in this regard, but lacks clarity for the 
underlying molecular mechanism. However, some studies have demonstrated that USP7 
can induce the degradation of PML nuclear bodies, independently of its EBNA1 
interaction and its DUBs catalytic activity (Sarkari et al., 2011). 
Microarray analyses of Ad/Ah cells, with elevated expression of EBNA1, have shown 
perturbed expression of 162 genes compared to Ad/AH cells infected with a rEBV or in the 
C666-1 EBV-positive NPC cell line. Among these genes is STAT1, a protein with an 
established role in apoptosis mediated and independent cell death (Wood et al., 2007). In 
addition, microarray analyses comparing EBNA1 expressing transgenic B cells with 
controls, also shows elevated STAT expression (Tsimbouri and Wilson, unpublished data). 
Moreover, a potential EBNA1 binding site is located near the STAT1 transcription 
initiation site (Dresang et al., 2009). Similarly, the presence of EBNA1 in the Ad/Ah cells 
reduces the half life of SMAD2, an important mediator of TGFβ1 signalling, implicating 
EBNA1 in the interference of the TGFβ1 signalling cascade. Moreover, expression of βig-
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h3, a gene regulated by TGFβ1 signalling has been found to be reduced in the presence of 
EBNA1 (Wood et al., 2007). In support of this, another study using HL cells has also 
shown reduced turnover of SMAD2 and reduced expression of Protein Tyrosine Phosphate 
Receptor K (PTPRK) in the presence of EBNA1 (Flavell et al., 2008). It is also noteworthy 
that 15% and 20% of promoters of differentially expressed genes (in the presence of 
EBNA1) in Ad/Ah cells bear DNA binding motifs for NFκB (Valentine et al., 2010) and 
AP-1 (O’Neil et al., 2008) respectively. Further studies have revealed that EBNA1 can 
negatively affect NFκB activity by inhibiting its binding with DNA (Valentine et al., 
2010). Taken together, the data show that EBNA1 modulates certain signalling cascades, 
known for their role in cell survival and apoptosis.  
In BL cell lines, expression of EBNA1 increases the production of ROS and consequently 
genomic instability (Gruhne et al., 2009b). ROS exhibits many cellular effects, not least 
are genomic instability by DNA damage and induction of apoptosis (Avery, 2011). 
Similarly, in CNE2 cells, expression of EBNA1 results in the increased expression of 
Nox2 and production of ROS. Moreover, increased telomeric instability has been observed 
under the EBNA1 mediated production of ROS (Cao et al., 2012; Gruhne et al., 2009a,b; 
Kamranvar et al., 2011). This suggests that EBNA1 may cause genomic instability by 
increasing the production of ROS.  
EBNA1 also binds with cellular metastatic inhibitor Nm23-H1 through amino acids 65-89 
and the interaction is thought to impair the Nm23-H1 function. In agreement, increased 
cell migration has been observed in LCL in the presence of EBNA1 (Murakami et al., 
2005). Moreover, nucleoproteosomal analysis of NPC cells has shown increased level of 
Nm23-H1 and two other metastasis associated proteins namely, maspin and stathamin 1 in 
the presence of EBNA1 (Cao et al., 2012). In addition, increased expression of Nm23-H1 
has been correlated with increased expression of apoptotic genes such as caspases 3, 
caspases 9, Bcl-X and p53 (Choudhuri et al., 2010). Though details are still elusive, but the 
evidence suggest that by impairing the function of Nm23-H1 through direct binding, 
EBNA1 may decrease apoptosis in the EBV infected cells. Finally EBNA1 is also known 
to increase the expression of an anti apoptotic protein, survivin (Lu et al., 2011) which has 
a role in cell proliferation. 
In summary, the direct role of EBNA1 in cell survival and proliferation and conferring 
resistance to apoptosis and potentially oncogenesis is substantiated by a significant amount 
of evidence. This suggests that aside from its core function in the virus of genome 
maintenance, EBNA1 is very likely to be involved in the onset and/or progression of EBV 
associated cancers.  
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1.7. Ubiquitin Specific Proteases 
To undertake their biological roles, most proteins are required to adopt stable and 
functionally favourable structural conformations. The process of ubiquitination and 
deubiquitination plays a pivotal role in ensuring this structural stability, as well as enabling 
rapid removal of proteins that are no longer required within the cell (reviewed in Amerik 
and Hochstrasser, 2004; Komander et al., 2009; Peng et al., 2003). Ubiquitin tagging of a 
protein is mainly mediated by the sequential activities of three different ligases: E1, E2 and 
E3. Briefly, three main steps are involved in the molecular cascade of ubiquitination: first 
an energy mediated process leads to the linkage of two activated ubiquitin molecules to E1 
ligase, via thiol ester and adenylate linkages. Second, this thiol linked molecule is 
transferred to E2 ligase and finally the ubiquitin molecule is transferred from E2 to target 
protein by interacting with a substrate specific E3 ligase (reviewed in Pickart, 2001). As 
substrate specificity is mostly defined by the E3 ligases, it is not surprising that there are 
more variants of E3 ligases in comparison to E1 and E2 ligases. To date, over 650 
ubiquitinated proteins and over 600 E3 ligases have been identified using mass 
spectrometry and genome wide analysis respectively (Li et al., 2008; Meierhofer et al., 
2008). The diversity of E3 ligases is further augmented by the length of the ubiquitin chain 
attached to the substrate via isopeptide bonds between the carboxy terminus of Gly of the 
substrate protein and one of seven internal Lys residues (Lys6, Lys11, Lys27, Lys33, Lys 
48 and Lys63) of ubiquitin. However, considering the protein diversity in human proteome 
(from over 20,000 genes), many novel E3 ligases and target proteins may yet to be 
identified.  
Ubiquitination instigates the proteosomal degradation of redundant or improperly folded 
protein molecules. To counter balance this, properly folded ubiquitinated proteins get 
untagged by the activity of another set of proteins collectively referred as deubiquitinases 
(DUBs).  Around 100 DUBs have been identified so far which are catalytically active 
(Komander, 2010; Nijman et al., 2005b). DUBs are characterised into 5 different families, 
namely: Ubiquitin C-terminal hydrolases (UCHs), ubiquitin specific proteases (USPs), 
ovarian tumour proteases (OTUs), Josephins and JAB1/MPN/MOV34 metalloenzymes 
(JAMMs) (reviewed in Kommander et al., 2009). Of these five families, USPs stands 
distinct in terms of structural and functional diversity.  
To date over 50 USP paralogues in the human genome have been identified. The proteins 
encoded by these genes vary considerably in size and domain architecture (reviewed in 
Kommander et al., 2009). Akin to the other DUBs, the main function of USPs is to 
regulate their target protein turnover and this is mediated through the cysteine peptidase 
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activity of the C19 peptidase domain. Structurally, the peptidase domain of USPs consist 
of three subdomains referred to as palm, thumb and fingers of a hand, with catalytic sites 
positioned at the interface of all three subdomains. The main interaction between DUBs, 
(including USPs) and the ubiquitin molecule is established between the ubiquitin binding 
domain (UBD) of DUBs and Ile44 of ubiquitin (Zhu et al., 2007). Additionally, some USP 
domains are structurally disordered and adopt a functional folding upon interaction with 
ubiquitin (Awakumov et al., 2006; Hu et al., 2005; Reyes-Turcu et al., 2008). In addition 
to ubiquitin, at least 16 other proteins encoded by the human genome exhibit characteristic 
ubiquitin fold  collectively referred to as ubiquitin-like proteins for example SUMO 
protein, certain neuronal precursors and Interferon Stimulated Gene 15 (ISG15) 
(Hochstrasser, 2009). Upon interaction with the target protein, the ubiquitin molecule is 
identified by USPs from the unique stretch of 6 residues at the C-terminus of ubiquitin 
which differs from other ubiquitin-like molecules however, cross reactivity is not 
uncommon (Catic et al., 2007; Drag et al., 2008; Malakhov et al., 2002). Ubiquitin forms 
an isopeptide bond with its partner protein which differs from a conventional peptide bond 
on the basis of free rotation of bonds (Komander et al., 2009). USPs, are cysteine 
peptidases and exhibit isopeptidase activity to remove the attached ubiquitin. Cysteine 
dependent DUBs (like USPs) have a catalytic diad or triad of amino acids which 
mechanistically acts similar to the well studied plant cysteine peptidase, papain (Johnston 
et al., 1997; Storer and Menard, 1994). In short, the catalytic cysteine conducts a 
nucleophilic attack on the isopeptide bond and this requires lowering of the pKa of Cys, 
which is facilitated by a proximal polarized His residue. With few exceptions, polarization 
of His is further dependent on Asp or Asn alignment with the His. The catalysis is carried 
out by the hydrolysis of the acyl Cys intermediate which is formed by covalent association 
of the carboxyl group of ubiquitin with the enzyme. 
Although the main function of USPs in the cell is to maintain adequate levels of the 
functionally important proteins and to recycle the pool of free ubiquitin, an increasing body 
of evidence demonstrates that they are directly and indirectly involved in variety of 
different biological functions. Given the diversity of USPs it is difficult to list let alone 
describe all the biological roles of all USPs, however, the functional distribution of USPs is 
illustrated (Figure 1.7) and summarised below.  
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Figure 1.7.  USPs biological roles: Venn diagram depicting the distribution of USPs 
according to their functions as reported in the literature. For the sake of clarity some minor 
or relatively less established functions are not represented. Important functions are shown 
here (differently coloured) encircling the involved USPs.   
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1.7.1. The role of USPs in gene expression 
Eukaryotic genomic DNA is tightly wrapped around histones forming small nucleoprotein 
structures referred to as nucleosomes. Each nucleosome consists of a 146bp segment of 
DNA wrapped around an octamere of histone proteins. The tails of each histone molecule 
protrudes out of the nucleosome forming the target of several posttranslational 
modifications like methylation, acetylation, phosphorylation, sumolyation and 
ubiquitination (Strahl and Allis, 2000). These posttranslational modifications regulate 
chromatin structure which in turn regulate gene expression, DNA repair and chromosome 
condensation. Several E2 and E3 ubiquitin ligases are known to modify histones 
(Hammond-Martel et al., 2012).  Similarly, several DUBs (including USPs) have been 
identified opposing the actions of the ubiquitin ligase on histones. For instance USP3, 
USP7, USP12, USP16, USP21, USP22, USP36 and USP46 deubiquitinate either H2A, or 
H2B, or both which variably results in repression or activation of genes (Joo et al., 2007; 
2011; Nakagawa et al., 2008; Nicassio et al., 2007; Taillebourg et al., 2012; Zhang et al., 
2008;). Other gene regulatory mechanisms affected by USPs include: preventing the 
degradation of cytoplasmic mRNA by USP52 (Bett et al., 2013), USP39 involvement in 
the RNA processing  (Rios et al., 2011) and transcriptional negative feedback loop by 
USP8 (Luo et al., 2012). 
1.7.2. The role of USPs in apoptosis 
Several USPs have been reported to have a role in the molecular machinery of apoptosis. 
Most USPs are proapoptotic (USP8, USP10, USP15, USP28, USP47 and CYLD) however, 
some are anti apoptotic (USP2, USP9 and USP18) and some may have a dual role (USP7) 
(Ramakrishna et al., 2011). Proapoptotic activities of USPs are generally mediated by 
stabilizing proteins involved in programmed cell death, for example USP7 and USP10 
deubiquitinate p53, a key pro apoptotic protein (Li et al., 2004; Yuan et al., 2010). USP8 
deubiquitinates Nrdp1, a ubiquitin E3 ligase, responsible for the proteosomal degradation 
of apoptosis inhibitor, Baculoviral IAP Repeat Containing 6 (BIRC6), and consequently 
lead to the induction of apoptosis (Qiu et al., 2004). USP15 stabilizes procaspases-3 
leading to its dissociation from Skp, Cullin, F-box containing (SCF) complex to cause 
apoptotic cell death (Xu et al., 2009). USP28 stabilizes ChK2 and 23 BP1 (DNA damage 
response proteins) which regulate p53 mediated induction of proapoptotic genes (Zhang et 
al., 2006). CYLD stabilizes RIP1 which is essential for NF-kB activation (Wang et al., 
2008). The anti apoptotic property of USP2 is mediated by its ability to deubiquitinate fatty 
acid synthase (FAS) (Graner et al., 2004). Although the mechanistic details of how 
inhibition of FAS promote apoptosis is not clear, however, only it has been recently 
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demonstrated that the FAS upregulates an oncogenic protein, β catenin (Gelebart et al., 
2012). A pro apoptotic functioning of USP17 has been demonstrated; however the 
mechanistic details are elusive (Shin et al., 2006). USP7 stabilizes p53 and its ubiquitin 
ligase, MDM2, the proapoptotic role of USP7 is thought to be the result of tight regulation 
between these contrasting functions (Li et al., 2004). USP9X mediates its anti apoptotic 
activity by stabilizing apoptosis signal regulating kinase 1 (ASK1) and MCL1. MCL1 is a 
member of BCL2 family and normally required to ensure the survival of stem cells 
(Noguchi et al., 2008; van Delft et al., 2006). Antiapoptotic function of USP18 has also 
been demonstrated recently (Potu et al., 2010).   
1.7.3. The role of USPs in cancers 
Since cellular processes like DNA repair, mitosis and apoptosis are all affected through the 
molecular events of oncogenesis (Hoeijmakers, 2009; Hussain et al., 2009; Singh et al., 
2010), the involvement of several associated USPs with cancers is not surprising. Indeed 
the Oncomine database (Rhodes et al., 2004) shows that dysregulation of several USPs has 
been observed in different cancers. Though the molecular mechanisms of many of these 
associations are poorly understood, aberration in ubiquitin mediated degradation plays a 
central role in this regard. For example, premature truncation of CYLD translation due to 
germ line mutation (stop codon) has been associated with cylindromatosis and 
trichoepthelioma (Bignell et al., 2000; Massoumi et al., 2007; Poblete Gutierrez et al., 
2002). It has been demonstrated that CYLD is a negative regulator of the NF-kB signalling 
cascade, a pathway known for its oncogenic consequences (Baud et al., 2009). Similarly, 
over expression of USP16 due to chromosomal translocation at chromosome 17p13 has 
been found to be causative in many aneurysmal bone cysts (Oliveira et al., 2006). USP8 is 
another DUB implicated for its role in oncogenesis due to its role in regulating receptor 
tyrosine kinase (RTK) internalization and proteolytic degradation and consequently cell 
proliferation (McCullough et al., 2004; Row et al., 2006). USP9 stabilizes β-catenin and 
SMAD4 (important components of Wnt and TGFβ pathway respectively) suggesting its 
role in cellular proliferation and potentially oncogenesis (Dupont et al., 2009; Murray et 
al., 2004). USP3 and USP21 deubiquitinate histone subunits and the former may also be 
involved in DNA repair; both genes have been shown to be dysregulated in a variety of 
cancers (Oncomine database). As well as several other USPs (USP1, USP3 and USP28) 
are involved in DNA repair processes and thus their deregulation may be associated with 
cancer (Hussain et al., 2009).  
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1.8. Chitinase and chitinase like proteins 
Chitin, the linear polysaccharide of N-acetylglucosamine, is ranked second after cellulose 
in terms of abundance in nature. It serves as a structural component of many invertebrates 
including the exoskeleton of crustaceans and insects, shells and radulae of gastropods, the 
internal skeleton of cephalopods and the microfibrial sheet of parasitic nematodes. It is also 
a major constituent of fungal cell walls and in some cases it is found in structural elements 
of lower chordates and fishes such as Branchiostoma floridae and Paralipophrys trigloides 
respectively (Guerriero, 2012; Tharanathan and Kittur, 2003; Wagner et al., 1993; Weaver 
et al., 2011). Proteins required for the hydrolysis and/or remodelling of chitin are referred 
to as chitinases. They are found in all taxa of living organisms from bacteria to primates 
(Arakane and Muthukrishnan, 2010; Kasprzewska, 2003; Ohno et al., 1996).  
Chitinases are members of the glycoside hydrolases (GH) protein family which is one of 
the largest and most diverse group of proteins. They are classified into 14 clans and 133 
Carbohydrate-Active Enzyme database (CAZy) families on the basis of sequence and 
structural similarity, substrate specificity and catalytic mechanism (Cantarel et al., 2009). 
Chitinases are generally restricted to the GH18 and GH19 protein families and to a very 
limited extent are members of GH20 and GH48 families (Fujita et al., 2006; Kubota et al., 
2004). Chitinases of the GH18 family carry out their catalytic function by substrate 
assisted mechanism while GH19 enzymes employs single displacement or inverting 
mechanisms for catalysis (Brameld and Goddard, 1998; van Aalten et al., 2001). The 
difference in catalytic mechanism and structural features suggests independent 
evolutionary lineages for members of these families. Broadly, chitinases can also be 
classified as endo or exo chitinases. Endochitinases perform internal but random cleavage 
of the polymer, while exochitinases mainly act on terminal ends of branched and 
unbranched polymers (Dahiya et al., 2006). 
During the course of evolution, higher plants and vertebrates have replaced chitin by 
cellulose and hyaluronan respectively, yet plants and animals bear genes encoding active 
chitinases. Plant encoded chitinases are included in both GH18 and GH19 families of 
classes I, II and IV, where as animal encoded chitinases almost exclusively (except for 
some nematodes) are members of the GH18 family (Kasprzewska, 2003). All vertebrates 
(excluding some fishes) do not synthesize chitin and most species do not use chitin as a 
nutritional source. However, antifungal, antiprotozoal and antihelminthic properties have 
been attributed to human chitinases (Barone et al., 2003; Boot et al., 1998; 2001). 
Moreover, CHIA  is found associated with the pathophysiology of asthma (Zhu et al., 
2004) and others diseases involving immune dysfunctions (Lee, 2009; Sutherland et al., 
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2011). Therefore the presence of chitinases (particularly CHIT1 due to its elevated 
expression in macrophages in humans) is thought to be linked with immunity against chitin 
containing pathogens. 
Humans have three catalytically active chitinases, two endochitinases: namely 
chitotriosidase I (CHIT1) and acidic mammalian chitinase (AMCase or CHIA), and an 
exochitinase chitobiase (CTBS). In addition to this, humans also encode four sequentially 
and/or structurally related inactive chitinases termed chilectins (ChiLs).  These are CHIL1 
(aka: CHI3L1, YKL-40 and CGP-39), CHIL2 (aka: CHI3L2, YKL-39, CP-39), oviductin 
(OVGP1) and stabilin 1 interacting chitinase like protein (CHID1) (Kzhyshkowska et al., 
2006). These proteins lack catalytic activity due to substitution from a glutamic acid 
residue in the catalytic region of the protein but CHIL1 (at least) retains the ability to bind 
with chitin (Bussink et al., 2006; Houston et al., 2003). In mice, except for CHIL2, the 
other three ChiLs (CHIL1, OVGP1 and CHID1) are present. Intriguingly, an additional 
array of ChiLs has also been identified in mice:  Chil3 (aka: Chi3l3, YM1), Chil4 (aka: 
Chi3l4, YM2), Chil5 (aka: Chi3l7, Bclp2) and Chil6 (aka: basic YM, BYm) (Hussain and 
Wilson, 2013). Phylogenetic analyses have shown that OVGP1 and all murine ChiLs are 
evolutionary related to CHIA, while CHIL1 and CHIL2 result from gene duplications of 
ancestral CHIT1 (Bussink et al., 2007; Funkhouser and Aronson, 2007).  
Similar to active chitinases, studies have shown that most ChiLs are also involved in 
immunomodulation. For instance over expression of CHIL1 and in some cases also of 
CHIL2 has been reported in chronically inflamed tissues and in patients suffering from a 
variety of autoimmune disorders and cancers (reviewed in Coffman, 2008; Lee et al., 
2011). Additionally, expression of ChiLs has also been found to be elevated in animal 
models of  inflammatory diseases including allergy, asthma and cancer (Hannigan et al., 
2011; Qureshi et al., 2011; Zhao et al., 2007). Importantly, up-regulation of ChiLs has 
been observed in EBV associated Hodgkin’s lymphoma, breast cancer, gastric carcinoma 
and nasopharyngeal carcinoma (Biggar et al., 2008; reviewed in Ober and Chup, 2009). 
ChiLs are also up-regulated in LMP1 (EBV oncogene) transgenic mice (Hannigan et al., 
2007 Qureshi et al., 2011). Another chilectin, OVGP1 is normally expressed in the ovary 
and cervix and functions in fertilization and early embryo development (reviewed in Buhi 
et al., 2002; Lindsay et al., 1999; Yong et al., 2002). Like other ChiLs, elevated OVGP1 
expression has been observed in the inflammatory disorders, such as disendometriosis 
(Wang et al., 2009) and ovarian cancer (Maines-Banidiera et al., 2010).  
To date GH18 domain (39kDa) of two active chitinases of humans (CHIT1 and CHIA) and 
three human ChiLs CHIL1, CHIL2 and CHID1 have been structurally resolved by x-ray 
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crystallography (Fusetti et al., 2002; Houston et al., 2003; Meng et al., 2010; Olland et al., 
2009; Schimpl et al., 2012). In addition, structures of two other ChiLs, one from family 
bovidae termed BP40 and Chil3 from the mouse, have been resolved (Srivastava et al., 
2007; Sun et al., 2001). Structurally, all active chitinases and ChiLs contain a 39KDa 
GH18 homology domain which is composed of two sub-domains, a large triosephosphate 
isomerase (TIM) β barrel domain and a relatively small α+β domain (Figure 1.8). Based on 
the presence or absence of the latter, GH18 family chitinases are further classified into 
subfamily A or B respectively.  To date, all the known vertebrate GH18 homologues 
contain both the TIM barrel and the α+β domains and thus belong to family A. Distribution 
of family B chitinases is mostly restricted to bacteria (Suzuki et al., 2002; Watanabe et al., 
1993). The TIM barrel domain is comprised of a β barrel like structure which is composed 
of eight anti parallel β strands and eight α helices. This (α/β)8 fold has been found as a 
primary structural component of many catalytic proteins, varying greatly in terms of 
sequence identity and function (Nagano et al., 2002). In tertiary conformation, this TIM 
barrel (with little contribution from the α+β domain) forms a ligand binding cleft lined 
with the solvent exposed aromatic residues.  The catalytic site lies within this cleft of 
active chitinases, characterized by a DxDxE motif where Asp and Glu are required for the 
catalytic activity (Fusetti et al., 2002; Olland et al., 2009). These amino acids are replaced 
by Leu/Ile or Gln in different ChiLs (Sun et al., 2001; Houston et al., 2003). Recently, on 
the basis of primary sequence conservation, another sub domain has been identified as a 
chitinase insertion domain (CID), located between the 7th α helix and 7th β strand of the 
TIM barrel. Computational analyses have shown the importance of this domain in ligand 
binding affinity and specificity (Li et al., 2010).  In addition to the GH18 domain, another 
relatively small chitin binding domain, CBM14, has also been described at the C-terminal 
end of both active chitinases CHIT1 and CHIA. This domain is also present in many 
invertebrate chitinases and the CBM14 of CHTI1 has been shown to bind with insoluble 
(colloidal) chitin (Tjoelker et al., 2000). The C-terminal region of human OVGP1 instead 
consists of a long tail with patchy similarity to mucin-like proteins. The tail has no 
recognizable sequence similarity with CBM14 and predicted to be heavily glycosylated 
(Huang et al., 2012). Taken together, we have proposed that the phylogenetic relationship 
and subtle variations in the structures of vertebrate chitinase and ChiLs are the combined 
product of shared ancestry and independent evolution leading to their structural and 
functional divergence (Hussain and Wilson, 2013). 
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Figure 1.8. Structure of CHIL1. Ribbon structure of human CHIL1 (PDBid: INWU) is 
shown here with important functional regions indicated: TIM barrel domain (green), α+β 
domain (cyan) and ligand binding central cleft (pink). 
 
1.9. Aims and approaches of project 
1.9.1. Chapter 3. EBNA1 structure-function relationship 
The purpose of these studies was to develop and analyse a full length model of EBNA1 of 
human and other primate LCVs using in silico methodologies. Upon generating a plausible 
model, the full length structural conformation of an EBNA1 dimer of human and other 
primates LCVs was constructed. A further aim was to design and screen an inhibitory 
peptide using in silico molecular docking approach. Preliminary tests, to examine the 
efficiency of inhibitory peptide, were conducted using cell culture based assay.  
1.9.2. Chapter 4. EBNA1 protein-protein interactions 
The main aims of the chapter were to explore the utility and efficiency of peptide arrays for 
investigating the protein interactions of EBNA1. Modified peptide (alanine replacement 
and truncated peptide) arrays were used to explore the interaction sites at fine resolution.  
1.9.3. Chapter 5. Evolution of Ubiquitin Specific Proteases  
The aim of this work was to conduct extensive phylogenomic analyses of USP homologues 
in order to explore, the evolutionary time line of the diversification of USPs in animal 
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kingdom. USPs homologues from animals representing major evolutionary lineages were 
selected for the study. Special attention was paid to determine the origin, expansion and 
functional divergence of USPs in animals in general and vertebrates in particular. Genomic 
synteny analyses were incorporated into the study to explore the different mechanisms at 
work in the evolution of USPs. Any unresolved phylogenies of the homologues were 
assessed using evolutionary distance analysis. Expression patterns and protein interaction 
networks were compared to assess functional innovations paralleling USP expansion. 
1.9.4. Chapter 6. Phylogenomic studies of chitinase and chitinase like proteins 
The aim of this study was to determine the evolutionary history of the vertebrate 
Chitinases/ChiLs. A robust data mining of vertebrates GH18 family genes was carried out 
to examine the distribution of GH18 family members across different vertebrate lineages. 
Phylogenetic analyses were carried out to explore the evolutionary relationship of different 
GH18. Genomic synteny of GH18 family genes of selected vertebrates was compared to 
investigate the underlying mechanism of the expansion of GH18 family. Structurally 
unresolved GH18 family proteins (to complete the set of encoded proteins from paralogous 
genes) were modelled and assessed for their structural plausibility. Several structural 
features including ligand binding regions of the known and modelled structures of GH18 
proteins were compared to explore the structural and functional divergence of the proteins. 
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Chapter 2. Materials and Methods 
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2. Materials and Methods 
2.1. Buffers and reagents  
Unless mentioned otherwise, all buffers were made in dH2O 
2.1.1. General buffers 
PBS (Phosphate buffered saline) 
80mM Na2HPO4 
20mM NaH2PO4 
100mM NaCl 
PBST (PBS with Tween 20) 
80mM Na2HPO4 
20mM NaH2PO4 
100mM NaCl 
0.05% (v/v) Tween-20 
 
TBST (Tris-phosphate buffered saline 
with Tween 20) 
50mM Tris 
 
pH to 7.5 with HCl 
150mM NaCl 
0.05% (v/v) Tween-20 
 
 
2.1.2. Buffers and reagents used in nucleic acid procedures 
TE 
10mM Tris 
1mM EDTA 
pH to 7.5 with HCl 
TAE 
40mM Tris 
2mM EDTA 
20mM acetic acid 
10x DNA loading dye 
50% (v/v) glycerol 
50% (v/v) TE pH 7.2 
Trace of bromophenol blue 
Trace of xylene cyanol 
DEPC water 
0.1% (v/v) di ethyl pyrocarbonate in 
dH2O,  
Shaken vigorously and left over night,  
Autoclaved next day 
 
 
4M GT stock 
4M guanidinium thiocynate 
25mM sodium citrate pH7.0 
0.5% sarcosyl  
dissolved at 65
o
C in DEPC water 
MOPS 
20mM MOPS 
1mM EDTA 
5mM sodium acetate 
pH to 7.0 sodium hydroxide 
Solution D 
0.7% (w/v) β-mercaptoethanol in 4M GT 
stock  
RNA loading dye  
50% (w/v) glycerol 
0.1% (w/v) bromophenol blue 
0.1% (v/v) xylene cyanol 
50% (v/v) TE pH 7.5 
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RNA  loading buffer  
1xMOPS 
17.8% (v/v) formaldehyde 
50% (v/v) formamide 
Transformation Buffer 1: 
30mM potassium acetate 
100mM RbCl2 
10mM CaCl2.2H2O 
50mM MnCl2.4H2O 
15% (v/v) glycerol 
Set pH to 5.8 using 0.2 M acetic acid  
Volume made up to 200ml 
Filtered to sterile 
 
 
 
 
Transformation Buffer 2: 
10mM MOPS 
10mM RbCl2 
75mM CaCl2.2H2O 
15% (v/v) glycerol 
pH set to 6.5 with 0.2 M KOH 
Volume made up to 100ml 
Filtered to sterile 
2.1.3. Buffers and reagents used in protein related procedure 
Lysis buffer (for bacteria) 
360mM NaCl 
5mM imidazole (not included for bacteria 
with pGEX-6P-1 plasmid)  
Dissolved in 1xPBS 
Complete protease inhibitor 1 tablet/10 
ml (freshly added) 
Aprotinin 100µl/10 ml (freshly added) 
1mM DTT (freshly added) 
1mg/ml lysozyme* (freshly added) 
*(only added for lysis) 
Wash buffer-I (protein purification)  
360mM NaCl 
5mM imidazole (not included for bacteria 
with pGEX-6P-1 plasmid) 
Dissolved in 1xPBS 
set pH to 7.5 
 
 
 
Elution buffer (His tag protein 
purification)  
360mM NaCl 
250mM imidazole* 
Dissolved in 1xPBS 
set pH to 7.5 
Complete protease inhibitor 1 tablet/10 
ml (freshly added) 
Aprotinin 100µl/10 ml (freshly added) 
*For gradient purification in addition to 
250mM imidazole, buffer containing 
50mM, 100mM, 150mM, 200mM and 
300mM of imidazole were also prepared. 
Elution buffer (GST tag protein 
purification)  
10mM glutathione  
Dissolved in 1xPBS 
Wash buffer-II (protein purification) 
23 parts wash buffer-I 
2 parts elution buffer for His tag protein 
 
Mushtaq Hussain, 2013  50 
RIPA buffer 
150mM NaCl 
50mM tris-HCl pH7.5 
1% (v/v) triton X 
1% (w/v) deoxycholic acid 
0.1% SDS 
Aprotinin 100µ1/10ml (freshly added) 
Roche complete mini (protease inhibitor) 
1 tablet/10ml (freshly added) 
Protein loading dye 
7.5% (v/v) glycerol 
2.5% (v/v) β-mercaptoethanol 
2% (w/v) SDS 
50mM tris-HCl pH 6.8 
bromophenol blue (trace) 
Transfer buffer 
25mM tris 
92mM glycine 
pH to 8.3 with HCl 
20% (v/v) methanol 
Running buffer 
25mM tris 
190mM glycine 
0.1% (w/v) SDS 
Stripping buffer 
100mM β-mercaptoethanol 
2% (w/v) SDS 
62.5mM tris-HCl pH6.8 
Fixing solution  
50% (v/v) Methanol 
10%(v/v)  Acetic acid 
Staining solution  
50% (v/v) Methanol 
10% (v/v) Acetic acid 
0.05% (w/v) Comassie brilliant blue 
 
Destaining solution  
30% (v/v) Methanol 
10% (v/v) Acetic acid 
Blocking solution (western blot 
membrane) 
5% non fat milk (NFM) in 1xPBST 
Blocking solution (glass peptide array) 
5% Bovine Serum Albumin (BSA) in 
1xTBST 
Blocking solution (membrane peptide 
array) 
5% NFM  in 1xPBST 
Probing solution (glass peptide array) 
0.5% Bovine Serum Albumin (BSA) in 
1xTBST 
Probing solution (membrane peptide 
array) 
1% NFM  in 1xPBST 
Stripping solution (membrane peptide 
array) 
60mM Tris 
set pH to 6.8 with HCl 
20mM DTT 
2% (w/v) SDS 
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2.2. Chemical and reagents  
Table 2.1. Table of the chemicals used 
Chemicals Company Catalogue No. 
1kb DNA ladder Invitrogen 10787-01-8 
2-mercaptoethanol SIGMA-ALDRICH 6132-04-3 
40% bis/acrylamide gel solution BIORAD 161-0148 
Acetic acid BDH Labs 10001CU 
Agarose Invitrogen 16500-500 
Ammonium per sulphate (APS) SIGMA-ALDRICH A3678 
Ampicillin SIGMA-ALDRICH A9518 
Aprotinin SIGMA-ALDRICH A6012 
Biorad dye BIORAD 500-000-6 
Bovine serum albumin (BSA) SIGMA-ALDRICH A3311 
Chloramphenicol SIGMA-ALDRICH C0378 
Cobalt Slurry Thermo Scientific 89965 
Coomassie blue Koch Light Labs 88755 
DAPI SIGMA-ALDRICH D9542 
Deoxycholic acid SIGMA-ALDRICH D6750 
dNTPs Invitrogen 10297-018 
DTT SIGMA-ALDRICH D9779 
ECL detection kit GE health care RPN2209 
EDTA  SIGMA-ALDRICH 27285 
Glutathione sepharose fast flow GE health care 17-5132-01 
Glycerol Fisher-Scientific BP229-1 
Glycine Fisher-Scientific 56-40-6 
Guanidium thiocynate SIGMA-ALDRICH G9277 
Imidazole SIGMA-ALDRICH 15513 
IPTG Melford MB1008 
Isopropanol SIGMA-ALDRICH 24137 
Kanamycin SIGMA-ALDRICH K4378 
Methanol Fisher Chemical M/4000/PC17 
Miniprep plasmid extraction kit Qiagen 27104 
Midiprep plasmid extraction kit Qiagen 12143 
NaCl VWR International 27810-295 
Na2HPO4 VWR International 102494C 
NaH2PO4 Riedel-deHaen 04269 
NaOH Fisher Chemical S/4920/53 
Nickel Slurry Qiagen 1018244 
Oligo(dT)20 Primer Invitrogen 18418-020 
Phosphatase inhibitor Roche 04906837001 
Precision Plus Protein ladder BIORAD 161-0373 
Protease inhibitor Roche 11873580001 
QIA quick gel extraction kit Qiagen 28104 
QIA quick PCR purification kit Qiagen 28704 
Sarcosyl SIGMA-ALDRICH L5125 
SDS VWR International 442444H 
Sodium citrate Fisher Scientific 6132-04-3 
TEMED SIGMA-ALDRICH T9281 
Tris Fisher Scientific BP152-1 
Triton SIGMA-ALDRICH 57H0650 
Tween-20 SIGMA-ALDRICH P5927 
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2.3. Cell culture  
Table 2.2. Table of reagents used for cell culture 
Chemicals Company Catalogue No. 
Fetal Bovine Serum (FBS) SIGMA-ALDRICH F9665 
L-Glutamine  
(2% v/v of 200mM stock) 
SIGMA-ALDRICH G7513 
PBS GIBCO 14190-094 
Penicillin-Streptomycin solution 
(2% v/v of 200mM Stock) 
Lonza 17603E 
RPMI-1640 SIGMA-ALDRICH R0883 
Trypan blue (0.4% solution) SIGMA-ALDRICH T8154 
 
2.4. Enzymes  
Table 2.3. Table of the enzymes used 
Enzymes Company Catalogue No. 
BamHI New England Biolab R3136S 
EcoRI New England Biolab R3101S 
HindIII New England Biolab R3104S 
MMLV-Reverse transcriptase Invitrogen 14190-094 
Phusion high fidelity polymerase New England Biolab M0530S 
T4 DNA ligase Invitrogen 15224-017 
T4 DNA polymerase Invitrogen 18005-017 
RNase free DNAase Promega M6101 
XhoI New England Biolab R0146S 
 
2.5 . Antibodies 
Table 2.4. Table of the antibodies used  
Antibodies Dilutions  Supplier Cat.No 
IH4 1:20 Snudden et al., 1994 --- 
Aza2E8 1:200 Hearing et al., 1985 --- 
Rab 16-4 1:1000 Prof. J.M.  Middeldorp --- 
EBP2 1:1000 Santacurz sc-46314 
USP7 1:1000 Abcam ab4080 
Anti-goat-HRP 1:4000 Santacurz sc-2032 
Anti-mouse-HRP 1:4000 Santacurz sc-2031 
Anti-rabbit-HRP 1:4000 Santacurz sc-2030 
Anti-rat-HRP 1:4000 Santacurz sc-2032 
Anti 6x-His-HRP 1:4000 (western) 
1:6000 (slide 
peptide array) 
1:5000 
(membrane 
peptide array) 
Abcam ab1187 
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2.6. Cell lines 
Table 2.5. Table of the cell lines used 
Cell lines EBV status 
BJAB EBV negative 
B958 EBV positive 
BL2+ve EBV positive 
BL2-ve EBV negative 
BL30+ve EBV positive 
BL30-ve EBV negative 
BL70+ve EBV positive 
BL70-ve EBV negative 
IB4 EBV positive 
Namalwa EBV positive 
Raji EBV positive 
 
2.7. Primers  
All primers were purchased from Sigma Aldrich and presented in following tables 
Table 2.6. Table of the primers used  
Primers Direction Sequence 
EBP2FG Forward GATCTTGCTCGAGATGCTATTTAGTGTGTTCTG 
EBP2RG Reverse CTGACGGATCCGGCGAGATGGACACTCC 
EBP2FH Forward GTGCATAAGCTTGGCCACCATGGACACTCCCCCG 
EBP2RH Reverse GATCTGCTCGAGATGCTATTTAGTGTGTTCTG 
USP7F Forward GTGCATAAGCTTGATGAACCACCAGCAG 
USP7R Reverse GTGTGTCATATCTCGAGCAGCTTGGAAATCAGTTATG 
 
2.8. Plasmids 
2.8.1. pGEX-6P-1 
pGEX-6P-1 (GE Healthcare, 28-9546-48) is a 4.9Kbp bacterial expression plasmid which 
tags Glutathione S-Transferase to the N-terminal of the recombinant protein. The plasmid 
harbours ampicillin resistance gene for selection and the inserted gene expression is 
induced by isopropyl β D thiogalactopyranoside (IPTG) under tac promoter. BamHI and 
XhoI sites were used for cloning human EBP2 in the plasmid. 
2.8.2. pET-28c 
pET-28c (Novagen 69866-3) is a 5.3Kbp bacterial expression plasmid which tags 6-
histidine residues to the N-terminus of the recombinant protein. The plasmid harbours 
kanamycin resistance gene for selection and the inserted gene expression is induced by 
IPTG under T7 promoter. HindIII and XhoI sites were used for cloning human EBP2 and 
USP7 in the plasmid. 
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2.9. Peptides 
Dimerisation Inhibiting Peptides (DIP) designed and used in this study were synthesized 
and purchased from Cambridge Peptides.  
Table 2.7. Sequences of the peptides used  
Peptides Sequences 
DIP YGRKKRRQRRRFGMAPGPGPQPGPLR 
DIP-Flu YGRKKRRQRRRFGMAPGPGPQPGPLR-Flu* 
*Flourescein molecule is attached to the C-terminal of the peptide for microscopic studies 
2.10. Bacterial Strains 
2.10.1. Escherichia coli DH5α 
E.coli DH5α is an efficient bacterial strain for cloning, primarily because of the deletion in 
restriction endonucleases endA1 and hsdR17 genes. 
2.10.2. Escherichia coli BL21 star (DE3) 
Competent E.coli BL21 was purchased from Invitrogen (Cat#440049). The strain offers 
high mRNA and protein stability due to mutation in rne131, lon and OmpT genes. 
2.10.3. Escherichia coli Rosetta  2(DE3) plysS 
Competent E.coli Rosetta 2 was purchased from Novagen (Cat#714013). The strain is a 
derivative of BL21 strain with an additional plasmid encoding seven rare eukaryotic tRNA. 
  
2.11. Bacterial media   
2.11.1. LB  broth  
1% (w/v) tryptone  
0.5% (w/v) yeast extract 
1% (w/v) NaCl 
pH set to 7.5 by NaOH 
 
2.11.2. LB agar 
1% (w/v) Tryptone  
0.5% (w/v) Yeast extract 
1% (w/v) NaCl 
pH set to 7.5 by NaOH 
1.5% (w/v) Agar 
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2.12. Computation 
2.12.1. HP Pavilion g6 notebook PC 
Intel (R) Core (TM) i5 CPU 
M480 @2.67 Ghz 
RAM 4.00 GB  
Windows 7 64 bit 
Linux red hat (virtual) 
2.12.2. Mac OS X Version 10.6.2 
Intel Core 2 Duo 
3.06 Ghz 
RAM 8.00 GB  
Mac OS X Version 10.6.2 
 
2.12.3. Servers and Softwares  
Table 2.8. Table of softwares and server used 
Programmes 
/Server 
Main purpose References 
Swiss model Homology modelling Kiefer et al., 2009 
Modeller Homology modelling Eswar et al., 2006 
ITASSER Iterative multiple threading modelling Roy et al., 2010 
MOE Homology and ab initio modelling ChemComp 
ClusPro Molecular Docking Comeau et al., 2004 
SymmDock Molecular Docking Schneidman-Duhovny et 
al., 2005 
RCSB data base Protein structure retrieval Berman et al., 2000 
Fold Index Structure propensity estimation Prilusky et al., 2005 
MolProbity Structure assessment Chen et al., 2010 
Q mean square Structure assessment Benkert et al., 2009 
SPDB Viewer 
v4.0.2 
Structure assessment Johanson et al., 2012 
DS visualizer Protein structure visualization Accelrys  
POCASA 1.0 Cavity analysis Yu et al., 2010 
NCBI server Data mining and genomic synteny Wheeler et al., 2008 
Ensembl server Data mining and genomic synteny Flicek et al., 2013 
HMMER Data mining Finn et al., 2011 
UniProt server Data mining and domain identification  Margrane et al., 2011 
CDD server Domain identification Marchler-Bauer et al., 2011 
BioGPS Gene expression data Wu et al., 2009 
STRING 9.05 Protein interaction  Szklarczyk et al., 2011 
Clustal X Multiple sequence alignment Thompson et al., 1997 
Bioedit v 7.0.53 Multiple sequence alignment Hall, 1999 
CLC seq.viewer 
v5.1 
Multiple sequence alignment 
visualization 
CLC bio 
NetNGlyc 4.0 Prediction of N glycosylation sites www.cbs.dtu.dk 
NetOGlyc 4.0 Prediction of O glycosylation sites www.cbs.dtu.dk 
MEGA5.1 Phylogenetic analysis Tamura et al., 2011 
Fig tree Tree visualization tree.bio.ed.ac.uk 
Time tree Timeline for speciation events Hedges et al., 2006 
pDraw32.1.0 Plasmid drawing ACAclone 
Prismv4.0.C Graphs and statistical analysis GraphPad 
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2.13. DNA and RNA techniques 
2.13.1. RNA isolation 
RNA was isolated from Raji cell line according to the method by Chomczynski and Sacchi 
(1987). The cell pellet was suspended in 250µl of solution D by vortexing and pipetting. 
50µl of 2M sodium acetate was dispensed in the tube and after gentle vortexing, 500µl of 
phenol and 100µl of chloroform: isoamylalcohol (49:1) was added in the tube. The extract 
was mixed by inversion and vortexed for 10 seconds and was incubated on ice for 15 
minutes. The samples were centrifuged at 10,000g for 20 minutes at 4
o
C and the upper 
aqueous phase was gently transferred to a fresh tube. 500µl of prechilled isopropanol was 
added into extract and stored at -20
o
C over night to precipitate the RNA. Next day RNA 
was pelleted by centrifugation at 10,000g for 20 minutes at 4
o
C and the supernatant was 
removed. The pellet was resuspended in 300µl of solution D and 600µl of ethanol and 
stored at -20
o
C for 2 hours. The precipitated RNA was recollected by centrifugation at 
10,000g for 20 minutes at 4
o
C and the supernatant was discarded. The pellet was washed 
twice with 75% ethanol by centrifuging for 5 minutes at 10,000g between each wash. The 
supernatant was removed and pellet was allowed to air dry before dissolving in 100µl of 
DEPC water. 1µl of RNA sample was used to quantify the concentration of extracted RNA 
using nanodrop at 260nm and 280nm. 5µl of the sample was mixed with 15µl of RNA 
loading dye and heated at 68
o
C for 10 minutes. Finally, the samples were loaded in wells 
of 1% agarose gel (prepared in 1xTAE in DEPC water) to evaluate the quality of RNA.  
Sharp bands representing 28S, 18S and 5S rRNA reflect the presence of good quality 
RNA. 
2.13.2. RNA purification  
DNA contamination from RNA was removed using RQ1 RNase free DNase. 4µl of 
DNase, 6µl of 10x buffer was mixed and DEPC water was added to a total volume of 60µl. 
The reaction mixture was incubated for 1 hour at 37
o
C and subsequently the enzyme was 
inactivated by heating the mixture to 75
o
C for 10 minutes. DEPC water was added to make 
the total volume of 250µl, after which an equal volume (250µl) of phenol solution 
saturated with 0.1M citrate buffer was dispensed and mixed by inversion. The mixture was 
centrifuged at 14,000g for 2 minutes at room temperature and upper aqueous phase was 
removed and transferred to a new tube. 250µl of chloroform was added and mixed by 
inversion. The sample was centrifuged at 14,000g for 2 minutes at room temperature and 
the aqueous phase was transferred to a fresh tube. 625µl of ethanol and 24µl of 3M sodium 
acetate was dispensed and the mixture was stored at -20
o
C over night for precipitation. The 
RNA was pelleted by centrifugation at 14,000g for 30 minutes at 4
o
C and the supernatant 
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was removed. The pellet was washed with 1ml of 75% ethanol followed by centrifugation 
at 14,000g for 5minutes at 4
o
C. After discarding the supernatant, the pellet was airdried 
briefly and dissolved in 20µl of DEPC water and stored at -20
o
C. 
2.13.3. cDNA synthesis by Reverse Transcription (RT-PCR) 
The reaction mixture was prepared by mixing 5µg of DNase treated RNA, 1µl of oligodT 
and 6µl of DEPC water. The mixture was heated at 65
o
C for 5 minutes to denature any 
secondary structure of RNA and to allow annealing of oligodT to the mRNA. 4µl of 5x 
reaction buffer, 2µl of dNTP (20mM) and 1µl of reverse transcriptase was added to the 
positive reverse transcription (RT+ve) reaction mixture. To monitor the possibility of DNA 
contamination, a RT-ve reaction mixture was also prepared with similar composition 
except 1µl of reverse transcriptase was replaced by 1µl of DEPC water. The reaction 
mixture was incubated at 37
o
C for 1 hour and then enzyme was inactivated by heating at 
75
o
C for 15 minutes. This reverse transcribed cDNA mixture was then used to amplify the 
specific product by conventional PCR. 
2.13.4. Plasmid Isolation 
Miniprep Plasmid Isolation: Miniprep plasmid isolation was carried out using Qiagen 
miniprep plasmid extraction kit for verifying the clones (inserts) by restriction digest. 5ml 
overnight culture of bacteria containing cloned or vector plasmid was pelleted by 
centrifugation at 10,000g for 5 minutes. The bacterial pellet was suspended in 250µl of 
suspension buffer (P1) by rigorous vortexing. 250µl of lysis buffer (P2) was dispensed in 
the tube and was left at room temperature for 5 minutes after mixing by inversion. 350µl of 
neutralizing buffer (N3) was added, mixed by inversion and tube was centrifuged at 
15,000g for 10 minutes. The supernatant was transferred to a QIAprep spin column and 
centrifuged for 1 minute. The flow through was discarded and 500µl of binding buffer 
(PB) was dispensed over the bottom end of spin column before centrifugation for 1 minute. 
Flow through was discarded and column was washed by 750µl of wash buffer containing 
ethanol (PE). Flow through was discarded and tubes were centrifuged for one minute to 
remove any residual ethanol. The collection tube was replaced by a fresh eppendorf tube 
and 40µl of elution buffer (EB) was dispensed over the bottom end of column and 
centrifuged at 10,000g for one minute. The eluted plasmid was stored at -20
o
C till further 
use. 
Midiprep Plasmid Isolation: Qiagen plasmid midiprep protocol was used to obtain 
sufficient yield of the plasmids (require for cloning and/or sequencing). 100ml of the 
overnight culture of bacteria containing cloned or vector plasmid was pelleted by 10,000g 
for 15 minutes at 4
o
C. The bacterial pellet was suspended in 4ml of suspension buffer (P1) 
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by rigorous vortexing. 4ml of lysis buffer (P2) was dispensed in the tube and was left at 
room temperature for 5 minutes after mixing by inversion. 4ml of pre chilled neutralization 
buffer (P3) was added in the mixture and tube was incubated for 15 minutes on ice. The 
tube was centrifuged at 15,000g for 30 minutes at 4
o
C and the supernatant was transferred 
to fresh tube immediately and centrifuged again at 15,000g for 20 minutes at 4
o
C to 
remove any residual bacterial debris. QIAGEN-tip100 column was equilibrated by 4ml of 
equilibration buffer (QBT), passed by gravity flow. The supernatant was decanted in the 
pre-equilibrated column and allowed to pass through gravity flow. Washed the column 
twice with 10ml washing buffer (QC) and DNA was eluted by passing 5ml of elution 
buffer (QF) through the column. 3.5ml of isopropanol was added in the final flow through 
and centrifuged for 30 minutes at 4
o
C. The pelleted DNA was washed twice by 5ml of 
70% ethanol and after centrifugation the supernatant was discarded gently. The pellet was 
left for 10-15 minutes to air dry and DNA is dissolved in 1-1.5ml of 1xTE. 
2.13.5. Polymerase Chain Reaction (PCR) 
Target genes (EBP2 and USP7) were amplified using conventional PCR. The reaction 
mixture include: 5µl of reverse transcribed cDNA (EBP2) or 1µl (40-50ng) plasmid 
(pGEX-6P-1 EBP2 or pCI-neo Flag HAUSP (addgene 16655)) were mixed with 0.2µl of 
Phusion high fidelity polymerase, 4µl 5x polymerase buffer, 1µl dNTP (20mM), 1µl each 
of reverse and forward primers (10µM) and appropriate volume of autoclaved and filter 
sterile water to a total volume of 20µl. The PCR reaction was carried out for both RT+ve 
and RT-ve and plasmid DNA samples under following conditions. 
1. Initial denaturation at 95oC for 10 minutes 
2. Denaturation at 95oC  for 5 minutes 
3. Annealing  at 66oC for 5 minutes 
4. Amplification at 72oC for 3 minutes  
5. Final amplification/extension at 72oC for 10 minutes 
6. Cycles: From step 2 to step 4, 30 cycles 
All PCR reactions were loaded in 1% agarose gel and run in 1xTAE buffer and visualized 
for products (EBP2;1Kbp, USP7;3.3Kbp ) under UV. 
2.13.6. Purification of PCR products 
For cloning, PCR products of the gene of interest (EBP2 and USP7) were cleaned using 
Qiaquick PCR purification kit. 20µl of PCR product was mixed with 100µl of buffer PB 
and dispensed on the Qiaquick spin column. The column was centrifuged at 10,000g for 1 
minute and flow through was discarded. The column was then washed with 750µl of wash 
buffer (PE) and after centrifugation for 1 minute the flow through was discarded. The tubes 
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were centrifuged again to remove any residual ethanol (present in wash buffer) and the 
DNA was eluted by dispensing 40µl of the elution buffer (EB) over the bottom of spin 
column. The tube was centrifuged for 1 minute at 10,000g and the eluted DNA was stored 
at -20
o
C till further use. 
2.13.7. Preparation of competent cells 
A loop full glycerol stock of E.coli DH5α was inoculated in 20ml LB broth and incubated 
at 37
o
C over night in shaking conditions (200rpm). 100µl of the overnight culture was 
dispensed in 5ml of LB broth and incubated at 37
o
C under shaking (200rpm) till the OD 
reached at 0.3 at 550nm. Whole culture was transferred to 100ml of LB broth and 
incubated under the same condition till the OD reached between 0.4-0.5 at 550nm. The 
bacterial culture was divided into two equal halves and placed on ice for 5 minutes before 
centrifuging at 3000g for 5 minutes at 4
o
C. Supernatant was discarded and each bacterial 
pellet was suspended in 20ml of transformation buffer-I and placed on ice for 5 minutes. 
The cell suspension was centrifuged (3000g) for 5 minutes at 4
o
C and supernatant was 
discarded. Each bacterial pellet was resuspended in 5ml transformation buffer-II and 200µl 
of suspension was dispensed in separate pre autoclaved fresh tubes and immediately 
dropped into liquid nitrogen for snap freezing. The cells were stored at -80
o
C till further 
use. 
2.13.8. Cloning of human EBP2 and USP7 genes in expression vector 
Both cleaned PCR products and plasmid were digested to create sticky end for cloning. 
EBP2 was cloned both in pGEX-6P-1 and pET-28c expression vectors while USP7 was 
only cloned in pET-28c vector. Following reaction mixtures were used for digesting 
different plasmids and PCR products. 
 
Table 2.9. Reaction mixture for restriction digests 
Ingredients For cloning in pGEX-6P-1 For cloning in pET-28c 
EBP2 pGEX-6P-1 EBP2 USP7 pET-28c 
DNA 26µl 11µl 26µl 26µl 11µl 
BamHI 2µl 2µl -- -- -- 
XhoI 2µl 2µl 2µl 2µl 2µl 
HindIII -- -- 2µl 2µl 2µl 
10xbuffer 5µl 3µl 5µl 5µl 3µl 
dH2O 15µl 12µl 15µl 15µl 12µl 
Total 50µl 30µl 50µl 50µl 30µl 
 Incubated at 37
o
C over night 
BamH1 1µl 1µl -- -- -- 
XhoI 1µl 1µl 1µl 1µl 1µl 
HindIII -- -- 1µl 1µl 1µl 
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All mixtures were incubated at 37
o
C for overnight and on next day 1µl of respective 
restriction enzymes was added and incubated for further 2 hours at 37
o
C. Enzymes were 
then deactivated by heating at 65
o
C for 20 minutes. Appropriate amount of DNA loading 
dye was added into mixture and samples were electrophoresed in 1% agarose in 1xTAE. 
The desired size bands were cut and access gel was removed. DNA was extracted from the 
gel by QIAquick gel extraction kit. Briefly, one volume of gel (1gm~1ml) was mixed with 
3 volume of extraction buffer (QG) and sample was incubated at 50
o
C for 10 minutes on 
thermomixer at shaking. One gel volume of isopropanol was added in the tubes, mixed by 
inversion and decanted in QIAquick spin column. The column was centrifuged at 10,000g 
for 1 minute and flow through was discarded. 500µl of the QG buffer was added to the 
column and centrifuged at 10,000g for 1 minute. The flow through was discarded and 
750µl of wash buffer (PE) was dispensed in the column and centrifuged at 10,000g for 1 
minute. The filterate was discarded and column was centrifuged again for 1 minute to 
remove residual ethanol (present in PE). Finally the column was fixed on a fresh eppendorf 
tube and 30µl of elution buffer was added at the bottom of column and tube was 
centrifuged at 10,000g for 1 minute. 1µl of the eluted DNA was used to quantify the 
amount of DNA by nanodrop and remaining was stored at -20
o
C till further use.  
Finally the gel extract, restricted plasmid and inserts were mixed at molar ratio 1:3 
respectively by calculating the amount of the DNA required for insert against fixed amount 
of plasmid (vector) using following formula. 
                         
                                 
                  
 
                     
                     
 
Appropriate volume of insert and plasmid DNA was mixed with 1µl DNA ligase and 5µl 
of 5x ligation buffer to a total volume of 20µl. The reaction mixture was incubated at 16
o
C 
over night. Note; in the negative control insert DNA volume was replaced with equal 
volume of dH2O. Next day the ligation mixture was used to transform competent cells. 
2.13.9. Transformation of plasmids in bacteria. 
Competent cells (E.coli DH5α or E.coli BL21 or E.coli Rosetta 2) were thawed and 10ng 
of DNA (from ligation mixture) was added in the tube. The bacterial DNA mixture was left 
on ice for 30 minutes to allow DNA to stick to the surface of the bacteria. After incubation 
the tubes were gently placed in the water bath set at 42
o
C for 90 seconds after which tubes 
were promptly placed on ice for 1 minute. 200µl of prewarmed (37
o
C) LB broth was added 
to the bacterial suspension and incubated at 37
o
C on shaking for one hour. 100µl of the 
culture was inoculated on selective LB agar containing 50µg/ml ampicillin (for pGEX-6P-
1 selection) or 50µg/ml kanamycin (for pET-28c selection) of 50µg/ml each of 
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chloramphenicol and kanamycin (for Rosetta strain transformed with pET-28c plasmid). 
The inoculum was homogenously spread over the surface of plate and the plate was 
incubated at 37
o
C for overnight.  
2.13.10. Validation of cloning by colony PCR 
A small part of colony of a clone was picked from the selection media and added into 
master mixture (as defined in section 2.13.5). PCR was run using respective primers. At 
the end of the cycling, the amplicons were detected in 1% agarose gel.  
2.13.11. Validation of cloning by restriction digest 
The plasmids were extracted by miniprep Qiagen kit as described in section 2.13.4.  20µg 
of plasmid was digested by BamHI and XhoI (pGEX-6P-1) or HindIII and XhoI (pET-28c) 
at 37
o
C for 2 hours. The restriction enzymes were deactivated by heating at 65
o
C for 20 
minutes and samples were loaded in 1% agarose gel containing ethidium bromide to 
visualize the presence of inserts.  
2.13.12.Validation of cloning by DNA sequencing  
The cloned plasmids (extracted by Midiprep Qiagen, kit) were sent to source biosciences to 
validate the presence of the cloned gene and its sequence. 
2.13.12. Preservation of bacterial clones 
Bacterial clones, verified for the presence of inserts by colony PCR and restriction digest, 
were inoculated in 20ml LB broth supplemented with 50µg/ml ampicillin (pGEX-6P-1) or 
50µg/ml kanamycin (pET-28c) or 50µg/ml each of chloramphenicol and kanamycin (for 
E.coli Rosetta strain). The bacteria were incubated at 37
o
C under shaking condition over 
night. Next day 1ml of the bacterial culture was dispensed in 1ml of preservation media 
(2% (w/v) peptone, 40% (v/v) glycerol in water) in a screw cap tube and stored at -80
o
C.  
2.14. Protein techniques 
2.14.1. Protein extraction from cell lines 
250µl of RIPA buffer (supplemented with protease and phosphatase inhibitor) was added 
to cell pellet and the pellet was resuspended by pipetting and vortexing. After giving a 
brief (2-3 seconds) ultrasonic pulse to shear the genomic DNA, the extract was incubated 
on ice for 15 minutes. The extract was centrifuged at 14,000g for 3 minutes and clear 
supernatant was transferred to a fresh tube. This supernatant was again centrifuged at 
14,000g for 2 minutes to remove any remaining debris and clean supernatant was 
transferred to a fresh tube. 5µl of the supernatant was used to quantify the protein by 
Bradford assay and typically 50-100µg of the protein was mixed with appropriate amount 
of 4x protein loading dye, heated at 95
o
C for 5 minutes, cooled at room temperature. The 
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extracts were centrifuged to remove any insoluble material before loading onto 
polyacrylamide gel.  
2.14.2. Protein Expression in bacteria 
A loop full of glycerol stock was inoculated in 20ml of LB broth supplemented with 
appropriate antibiotic(s) at concentration of 50µg/ml. The inoculated broth was incubated 
at 37
o
C over night in shaking condition (200rpm). This starter culture was transferred to 
500ml of LB broth containing 50µg/ml concentration of ampicillin or kanamycin or each 
chloramphenicol+kanamycin (for p-GEX-6P-1 or pET-28C or Rosetta strain respectively) 
and incubated for 3 hours at 37
o
C under shaking condition (200rpm). After three hours 
500µl of IPTG (1M stock) was added in the culture and reincubated for overnight at 37
o
C 
under shaking condition. Next day cells were harvested by centrifugation at 10,000g for 30 
minutes and stored at -80
o
C till further use. 
2.14.3. Protein extraction from bacteria 
The bacterial pellet (500ml culture) was resuspended in 20ml of lysis buffer. Complete 
homogenous suspension was obtained by rigorous vortexing and incubated on ice for 10 
minutes. The cell suspension was sonicated thrice (while placed on ice) for 3 minutes with 
intervals of 1 minute. The cell suspension was centrifuged at 15,000g for 90 minutes at 
4
o
C. The clear supernatant was transferred to a fresh tube for further purification. 
2.14.4. Protein purification  
To purify the recombinant proteins from bacterial lysate 20ml of bacterial lysate was 
mixed with 500µl of Glutathione sepharose fast flow or Ni slurry (pre equilibrated with the 
appropriate bacterial lysis buffer) and incubated at 4
o
C overnight. Ni slurry is strongly 
cationic and binds strongly with the 6x his tag attached to the recombinant protein. The 
mixture then placed into columns and liquid was allowed to flow through. The settled 
beads were washed thrice with 20ml of wash buffer-I and twice with 20ml wash buffer-II. 
Typically five fractions were collected by adding 500µl of elution buffer containing 10mM 
glutathione (GST tagged protein) or 250mM imidazole (His tagged proteins), which 
replaced the target protein bound to slurry. In case of gradient purification two 500µl 
fractions were collected with each elution buffers of different concentrations of imidazole: 
50mM, 100mM, 150mM, 200mM, 250mM and 300mM. 5µl, 10µl and 40µl of the samples 
were separated for quantification, western blot and comassie blue gel staining respectively. 
All fractions were stored at -80
o
C till further use. 
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2.14.5. Protein quantification  
Protein quantification was done using the Bradford assay.  Bradford assay is a 
colourimetric assay in which dye binds to the protein and changes colour (Bradford, 1976). 
This colour change can then directly be measured by optical density (OD) which in turn is 
proportional to the protein concentration of the sample. For quantification of protein, a 
standard curve was prepared each time using solutions of known concentration of BSA: 1, 
2, 4, 8, 16µg to which, TE pH8.0 was added to a total volume of 800µl. To quantify 
protein in the samples, typically, 5µl of protein extract (for test) or RIPA or bacteria lysis 
buffer (blank) was added to 795µl of TE pH8.0. To each sample 200µl of Biorad dye was 
added and after immediate mixing the absorbance was noted at 595nm. A standard curve 
was plotted by placing absorbance values against the known concentration of BSA, which 
then used to quantify the unknown protein concentration of samples using their OD. 
2.14.6. Protein dialysis and concentration 
Selected protein fractions (typically 2
nd
 to 5
th
) were poured in amicon Ultra-4 centrifugal 
filter units of appropriate molecular weight cut-off (for USP7; 100kDa and for EBP2; 50 
and subsequently 30 kDa). After placing the samples, the units were centrifuged at 4000g 
at 4
o
C till volume of the sample was reduced to 250µl. The retentate was collected in a 
fresh tube and stored at -80
o
C till further use. 
2.14.7. SDS-Poly Acrylamide Gel Electrophoresis (SDS-PAGE) 
Polyacrylamide gel (10% resolving and 3% stacking) solution and was prepared as 
mentioned in table 2.10. The gel solution was poured in the assembled gel setting 
apparatus immediately after adding and mixing TEMED and 20% (w/v) APS solutions. A 
film of air barrier was overlaid on the gel solution by pouring little amount of water 
saturated butanol and the gel was allowed to polymerize for 30 minutes. Once resolving 
gel had polymerized, the butanol was decanted and washed thoroughly with dH2O to 
remove any residual butanol, subsequently an appropriate comb was inserted between the 
gel slab. Appropriate volume of TEMED and 20% (w/v) APS was added into stacking gel 
solution and poured immediately. The stacking gel was also allowed to polymerize for 30 
minutes. The gel was then placed in the electrophoresis apparatus and comb was removed 
gently. Wells formed were flushed thoroughly to remove any excess of polyacrylamide. 
The running buffer was poured in the gel apparatus and appropriate volumes of samples 
along with 10µl of protein ladder were loaded into desired wells. The samples were 
electrophoresed through gels at 200V for 3-4 hours. 
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Table 2.10. Composition of gels used in SDS-PAGE 
Reagent Stacking Gel (5%) Resolving Gel (10%) 
1.5M tris (pH8.8) ----- 12.5ml 
1.0M tris (pH6.8) 3.75ml ---- 
0.5M EDTA 60µl 100µl 
20% SDS 150µl 250µl 
20% APS 300µl 500µl 
TEMED 30µl 50µl 
dH20 21.96ml 27.22ml 
 
2.14.8. Coomassie staining 
To visualize the protein on acrylamide gel, gels were stained using comassie brilliant blue 
dye. The dye binds with protein and this complex stabilizes the anionic property of dye 
which in turn produces blue colour. The gels were fixed for 30 minutes in 50ml fixation 
solution at room temperature with gentle shaking. After fixation the solution is decanted 
gently and gels were stained in 50ml coomassie blue staining solution for an hour or till the 
whole gel turned blue. The gels were then destained using 50ml of destaining solution and 
later with dH2O over night at room temperature on gentle shaking. 
2.14.9. Western Blotting 
For western blot, the proteins were transferred from gel to ImmobilonTM-P 0.45µm 
membrane (Millipore) by electrophoresis at 1500mA, 4
o
C for 2 hours 20 minutes. After the 
transfer, the membrane was blocked using 40-50ml of blocking solution for 2 hours to over 
night at 4
o
C. After which the membrane was probed with appropriate specific antibodies 
with desired dilution in membrane probing buffer and incubated for 2 hours to over night 
at 4
o
C. If required (for instance anti His antibodies are HRP conjugated thus do not require 
secondary antibodies) washed the membrane with 1xPBST thrice for 10 minutes on 
shaking at 4
o
C and probed the membrane with appropriate dilution of secondary antibodies 
in the membrane probing buffer for 2 hours at 4
o
C. The membrane was washed thrice with 
1xPBST for 10 minutes on shaking at 4
o
C. The conjugated HRP was detected using ECL 
plus kit. The HRP conjugated enzyme oxidises the substrate (acridinium ester) in the 
detection kit and produces light (chemiluminescence). This resulting light is detected by 
autoradiography using X-ray films. The probed membrane was exposed to 8ml mixture of 
both reagents (1:1 ratio; provided in the ECL kit) for 45-60 seconds at room temperature. 
The membrane was then placed in the plastic bag and sealed. X-rays films were then 
placed over the membrane in the cassette for different time duration to get the appropriate 
impression of protein on the films. 
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2.14.10. Stripping of membrane 
Membrane, if required to be reprobed with the same or different antibody(ies), was 
stripped by incubating in the stripping buffer for 1 hour at 50
o
C in water bath. The stripped 
membrane was then blocked and probed as required after washing with 1xPBST three 
times for 10 minutes on shaker.  
2.14.11. Peptide synthesis 
Peptide libraries were synthesized by automatic SPOT synthesis (Kramer and Schneider-
Mergener, 1998) on Whatman 50 cellulose membrane support using Fmoc                        
(9-fluroel methoxycarbonyl) chemistry on Autospot Robot ASS222 peptide synthesizer 
(Invatis Bioanalytical Instruments AG, Cologene, Germany). Note, for glass slide array the 
peptides were synthesized separately and subsequently spotted on the sabstrum. Alanine-
scanning libraries were synthesized and spotted for the peptides showing positive reaction 
in the glass arrays and each residue with the peptide was sequentially changed to alanine or 
aspartate (if alanine is a natural residue). 
2.14.12. Peptide array probing and development 
Peptide array was blocked with the appropriate blocking solutions (different for membrane 
and slide array) for four hours at room temperature on gentle shaking. Note; membrane 
peptide array was rinsed with absolute ethanol before blocking. After blocking, the arrays 
were probed with specific antibodies (appropriate dilution) or proteins (appropriate 
concentration) in the appropriate probing buffer (different for membrane and slide array) 
for overnight at 4
o
C at gentle shaking. The array was washed thrice with 1xTBST for 10 
minutes and probed with the appropriate dilution of appropriate antibodies for two hours at 
room temperature on gentle shaking. Array was washed thrice with 1xTBST at room 
temperature for 10 minutes and developed in 2ml (for slide array) or 4 ml (for membrane 
array) mixture of ECL detection kit solutions (after probing with appropriate secondary 
antibodies if required) similarly as western blot. 
2.14.13. Stripping of the peptide array 
The membrane array was stripped by incubating the arrays in array stripping buffer (pre 
heated at 70
o
C) for 30 minutes. The array was washed twice with 1xTBST for 10 minutes 
at room temperature, blocked and reprobed after rinsing it with absolute ethanol as 
mentioned in section 2.14.12. 
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2.15. Cell culturing and related techniques 
2.15.1. Standard cell culturing conditions 
Suspension cell (B cell) lines were grown in RPMI 1640 medium, supplemented with 10% 
(v/v) fetal calf serum (FCS), 2% (v/v) penicillin/streptomycin (10,000 U/ml stock) solution 
and 2% (v/v) L-glutamine (200mM stock). All cell suspensions were incubated in vented 
flasks at 37
o
C and 5% CO2.   
2.15.2. Cell counting by trypan blue exclusion  
Trypan blue dye is used to count the number the viable cells. Trypan blue is a polar dye 
that can cross the cell membrane barrier of dead or dying (necrotic and apoptotic) cells but 
unable to pass through the living cell membrane. This property of dye than can be used to 
distinguish dead or dying cells (stained) from viable (unstained) cells. The cells were 
diluted in appropriate ratio (e.g. 1:10) with 0.4% solution of trypan blue. 10µl of this 
suspension was dispensed into haemocytometer chamber and viewed under the inverted 
microscope. All 4 x 16 chambers were counted for live (unstained) cells. Each sample was 
counted in triplicate and average count was deduced from it. The average count of the cells 
was placed in the following equation to deduce the number of cells/ml of the suspension. 
Number of cells/ml = (Total number of cells counted/4) X dilution factor  X 104 
2.15.3. Harvesting cell pellet 
Cells were centrifuged at 194g for 5 minutes and supernatant was decanted. The cells were 
suspended with appropriate volume (0.5-1.0ml) of cell culture grade PBS (per 1x10
6
 cells 
for suspension cells). The suspension was centrifuged again at 2000g for 5 minutes and 
supernatant was decanted. Residual PBS was removed gently by pipette and cells pellet 
were vortexed for a short time, after which pellets were snap frozen using liquid nitrogen 
and stored at -80
o
C.  
2.15.4. Freezing of viable cells  
A densely populated cell suspension was centrifuged at 194g for 5 minutes and supernatant 
was decanted. Cell pellet was resuspended in 5ml of cell culture grade PBS. Cell counting 
was performed and cells were centrifuged again at 194g for 5 minutes. PBS was decanted 
and cell pellet was resuspended in appropriate volume (based of cell density desired) of 
freezing medium (90% (v/v) FCS, 10% (v/v) DMSO). 1ml of this suspension was 
dispensed in screw cap vials and frozen slowly in an insulated box at -80
o
C for 1-2 days 
before being transferred to liquid nitrogen storage.  
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2.15.5. Thawing of viable cells 
To revive the stored cells, cells were thawed quickly at 37
o
C and resuspended in 10 ml of 
prepared (supplemented) and prewarmed RPMI 1640 medium. After 1-2 hours of 
incubation, the cells were centrifuged at 194g for 5 minutes and the supernatant was 
decanted. The cell pellet was resuspended in prewarmed RPMI 1640 medium and 
incubated at 37
o
C, 5% CO2. 
2.15.6. Treatment of peptides with different cell lines 
Cells were centrifuged at 200g for 5 minutes and resuspended in 3 ml of RPMI medium. 
Cells counts were carried out by trypan blue assay and 10
6
 cells were seeded in 6 well 
tissue culture plates. Inhibitor peptide (dissolved in cell culture grade PBS) was dispensed 
in all wells (to the final concentration of 25µM in 2 ml of the medium) while similar 
volume of only PBS was added in all control wells and the plate was left for 20 minutes at 
room temperature. RPMI 1640 medium was added in each well to a total volume of 2ml.  
After gentle rotation, plate was incubated at 37
o
C, 5%CO2. The 25µM of DIP (final 
concentration) was added in each test well for each of the 3 subsequent days. The 
experiment was run in triplicate. 
2.15.7. DAPI staining  
10µl of DAPI solution (300nM stock) was dispensed in 200µl of cell suspension and 
incubated at room temperature in dark for 2-3 minutes. Cells were centrifuged at 200g for  
30 seconds and supernatant was removed. Cells were resuspended in 200µl of tissue 
culture grade PBS and centrifuged again for 30 seconds. After decanting the supernatant 
same procedure of washing is repeated. Finally the cells were resuspended in 50µl of  
tissue culture grade PBS. 
2.15.8. Confocal microscopy 
The cells, treated with DIP-Flu and stained with DAPI, were dispensed on glass bottom 
culture dishes (MatTek Cat#P35G-0-10-C) and observed under confocal microscope (Zeiss 
LSM 510 Meta). Flu is a green florescein molecule which excites at 488nm wave length 
thereby its signal is best observed at FITC channel. On confocal microscopy, the DIP-Flu 
was visualized using Argon/2 laser (488nm) and DAPI stained nuclei were observed with 
laser diode (405nm). Images were taken at different magnifications and at different planes. 
2.16. Phylogenomics studies 
2.16.1. Datamining  
DNA and protein sequences were retrieved from NCBI (Wheeler et al., 2008) and 
ENSEMBL (Flicek et al., 2013) databases by BLASTing (blastn and blastp) against 
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humans protein or cDNA sequences under default parameters. Additionally, the BLAST 
search of the homologues was further strengthened using HMMER (Finn et al., 2011), 
which employ hidden Markov model for finding homologues. Full-length EBNA1 
sequences were retrieved from the UniProt database (http://www.uniprot.org/) (Magrane et 
al., 2011). To verify, each hit was reciprocally BLASTed against human genome. 
Moreover, in case of USPs, characteristic peptidase C19 domain of each homologue was 
also used to improve the search of their orthologues in selected species. In few cases where 
the complete cDNA sequences were not available, the predicted full coding sequence was 
compiled from the inferred exon structures provided on ENSEMBL. The list of sequences 
retrieved is provided with the organism names and accession numbers in Appendix I, IV 
and VI.   
2.16.2. Multiple sequence alignment 
Complete coding cDNA sequences (chitinase and ChiLs), full length proteins sequences 
(EBNA1) and peptidase C19 domain sequences (USPs) were aligned using CLUSTALX 
under default parameters (Thompson et al., 1997). Manual adjustment in the alignment 
(removing long unique indels) were made where necessary using Bioedit. For chitinases 
and ChiLs amino acid sequences representing each paralogue were also aligned using 
CLUSTALX after removing N-terminal signal sequences as identified by UniProt 
(Magrane et al., 2011). Where present, C-terminal tails (chitin binding domain of CHIT1 
and CHIA; mucin like tail of OVGP1) were also removed. The alignment files were 
visualized by CLC sequence viewer.  
2.16.3. Phylogenetic tree reconstruction 
All phylogenetic trees were reconstructed using the maximum likelihood method from 
cDNA (chitinases and ChiLs) or protein sequences (EBNA1 and USPs) employing the 
evolutionary model (mentioned in the legends of the respective trees) selected on the basis 
of least Bayesian Information Criterion (BIC) value using MEGA5.20 (Tamura et al., 
2011). Genes with incomplete/partial sequence were excluded from the analysis. Statistical 
support values were generated by 1000 bootstrap replicates. The consensus tree topology 
were developed using 50% majority rule. The substitution rate heterogeneity was 
incorporated by choosing Gamma distribution (based on the best fit model) to model 
difference in the evolutionary rates. The Nearest Neighbour Interchange heuristic method 
was selected to generate original trees. All phylogenetic trees of USPs family genes were 
rooted using bacterial (Candidatus amoebophilus asiaticus) protein bearing C19 domain 
whereas chitinase and ChiLs tree were variably rooted with homologues of Caenorhabditis 
elegans or Branchiostoma floridae as mentioned in the respective tree (figure) legends.  
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2.16.4. Evolutionary distance analyses 
To estimate the evolutionary distance between one gene and a selected group of genes 
(usually 5 or 6), all nucleotide/protein sequences for comparison were aligned using 
CLUSTALX and manually adjusted where necessary. The alignment file was converted 
into MEGA format and the pair wise evolutionary distance was calculated using the 
maximum composite likelihood method (Dessimoz and Gil, 2008). The nature of data 
distribution was identified by Kolmogroe Smirov test. The mean of the distances was 
calculated and compared for the statistical significance from the unpaired student t test 
(normal distribution) or Wilcoxon signed rank test (skewed distribution) using Prism 
v4.0c.  
2.16.5. Genomic synteny analyses 
Genomic synteny of the selected species was investigated by locating cDNA sequence of 
the homologues to the genomic maps provided by NCBI and Ensembl databases. BLAST 
and reciprocal BLAST search of sequences of the un-annotated genes adjacent to these 
sites were also carried out to explore any evolutionary relationship. 
2.16.6. Gene expression data  
Anatomical pattern of gene expression was assessed using BioGPS database (Wu et al., 
2009). BioGPS is an online public database which allows comparison of gene expression 
based on the high density oligonucleotide microarray experiments performed uniformly for 
79 human tissues.   
2.16.7. Protein network analyses 
Protein interaction network of USPs were assessed using STRINGv9.05 (Szklarczyk et al., 
2011). Unless stated otherwise, binding partners were with only high confidence threshold 
score of 0.7 were considered. The STRINGv9.05 database provides comprehensive 
coverage to both experimentally determined as well as predicted protein interactions of the 
query protein. The interaction map construction is primarily based on co expression, 
genomic context, highthrough put screening and reported empirical evidences.  
2.16.8. Glycosylation site prediction  
Potential glycosylation sites of the protein sequences were predicted using CBS servers 
(NetNglyc and NetOglyc) at a threshold value of 0.5.  
2.16.9. Protein domain identification  
Conserved Domain Database (CDD) of NCBI (Marchler-Baeur et al., 2009) and UniProt 
database were exploited to identify the protein domains and catalytically active sites in 
USPs. 
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2.17. Protein structure prediction  
2.17.1. Prediction of disordered regions of proteins 
Protein structural propensity was predicted using FoldIndex (Prilusky et al., 2005). 
FoldIndex is a method developed from charge-hydropathy plots (Uversky et al., 2000) by 
changing the arrangement of the basic equation and further improvised by incorporating 
the sliding window. In this study, sliding window of 10 residues was used to assess the 
protein structural propensities.   
2.17.2. Protein homology modelling 
Protein homology modelling was carried out using Modeller 9v8 (Eswar et al., 2006) and 
Swiss Model (Kiefer et al., 2009). Input for the template is provided manually using the 
best template(s) selected by PDB Blast search.  Human CHIA structure (PDBid: 3FXY) 
was selected as a template to model human OVGP1 and cow Chio. Similarly, murine 
specific ChiLs: Chil4, Chil5 and Chil6 were modelled using mouse Chil3 (PDBid: 1E9L). 
Other mouse homologues such as Chit1, Chia, Ovgp1, Chil1 and Chid1 were modelled 
using the already resolved structures of human orthologues: 1LQ0 (Chit1), 3FXY (Chia 
and Ovgp1), 1NWR (Chil1) and 3BXW (Chid1) respectively. Modeller constructed the 
protein models by satisfying the spatial restraints at both secondary structure elements and 
flexible loops (Sali and Blundell, 1993; Fiser et al., 2003). The final model selection was 
based on the normalized Discrete Optimized Molecule Energy (DOPE) score .  
2.17.3. Protein modelling using i-TASSER 
Protein models of full length EBNA1 of human and primates lymphocryptoviruses, DIP 
peptide, full length human CHIT1, CHIA, OVGP1, CTBS and mouse CTBS were 
developed using I-TASSER (Roy et al., 2010).  The protein primary sequences were input 
to the Itasser which employs multiple threading programs using replica exchange Monte-
Carlo simulation to construct structural models of the input. I-TASSER is a metaserver, 
which uses multiple threading programmes to get the large query coverage for templates 
and since 2007 to date it is the best ranked method for protein structure prediction in 
several benchmark studies (Battey et al., 2007; Cozetto et al., 2009; Zhang, 2009; 
predictioncenter.org/casp10/groups_analysis.cgi?type=server&tbm=on&tbm_hard=on&tb
mfm=on&fm=on&submit=Filter, 2013). In the beginning, I-TASSER conducts the 
position specific iterated BLAST (PSI-BLAST) to identify the evolutionary relative and to 
generate a sequence profile (Altschul et al., 1997). The sequence profile is then used to 
predict the secondary structure using PSI-PRED (Jones et al., 1999). Subsequently the 
query sequence, generated sequence profile and secondary structure prediction are 
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threaded to the PDB structure library using meta threading server LOMETS, which itself is 
a collection of seven threading programmes (Wu et al., 2007b). Each program in LOMETS 
finds the suitable template and ranks them on the basis of sequence and structural 
properties. The well aligned fragments are excised from the template while the unaligned 
regions of input sequence are modelled ab-initio (Wu et al., 2007a). In order to generate 
the full length EBNA1 model, I-TASSER automatically selected several fragment 
templates comprising: EBNA1 C-terminal dimer (1B3T); yeast fatty acid synthetase 
(2PFF), lipase (2Z8X), photosynthetic reaction centre (1C51), type A collagen (1YOF) and 
sineric 6-phosphoglucouronate dehydrogenase (2ZYD). Incase of CTBS, other known 
GH18 protein structures were selected: PDBid: 1VF8 (CHIL3), 1WB0, 1LQ0 (CHIT1), 
3ALF (Class V chitinase from Nicotinia tobaccum), 4AY1 (CHIL1), 3FXY (CHIA) 
whereas C-terminal tails of CHIT1, CHIA and OVGP1 were modelled ab-initio.  Cluster 
centroids were generated using replica exchange Monte-Carlo simulations (Zhang et al., 
2002) and by averaging all the clustered structure decoys. Subsequently steric clashes were 
removed and global topology of the clustered centroids was improved for the second round 
of simulation. The external constraints were gathered from the threading alignment and 
PDB structures that is closest to the clustered centroids. Finally REMO (Li and Zhang, 
2009) is employed to develop the full length structure of the query sequence based on the 
decoy generated in the second round of simulation. The models are ranked on the basis of 
C and TM score (Zhang, 2008; Zhang and Skolnick, 2004) to assess the similarity between 
the target protein model and known template structures. 
2.17.4. Protein modelling using Molecular Operating Environment (MOE) 
Models were also generated in MOE using the template 1B3T (with and without DNA) for 
homology modelling and ad hoc outgap modelling to similar fragments from PDB for the 
remainder of the sequence. An initial proposed partial geometry was copied from the 
template chains in the solved structure of 1B3T by using all coordinates where residue 
identity was conserved. Otherwise, only backbone coordinates were used. Based on this 
initial partial geometry, Boltzmann-weighted randomized modelling (Levitt, 1992) was 
employed with segment searching in PDB for regions that could not be mapped onto the 
initial partial geometry (Fechteler et al., 1995). Twenty-five models were constructed. On 
completion of segment addition, each model was energetically minimized in the AMBER-
99 force field (Wang et al., 2000). The highest-scoring intermediate model was then 
determined by the generalized Born/volume integral (GB/VI) methodology (Labute, 2008). 
All modelling using MOE was conducted by Dr. Derek Gatherer.  
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2.17.5. Structural assessments of models 
The models were assessed for their structural plausibility by generating Ramachandran 
plots and detecting bad angles using Molprobity (Chen et al., 2010). Additionally, 
normalized Q mean score were estimated for each model using Q mean server to assess the 
quality of models (Benkert et al., 2009). Normalized Q mean score is a method to derive 
the global and local error estimates independent to the protein length. The structural and 
spatial variability in the Cα back bone and orientation of ligand binding residues were 
assessed in terms of Root Mean Square Deviation (RMSD) by superimposing one structure 
over the other using Swiss-PdbViewer v4.0.2 (Johanson et al., 2012). All structures were 
visualized and electrostatic surface were generated using DS visualizer v3.5. 
2.17.6. Cavity analyses 
Protein cavity (ligand binding groove) volumes were calculated using POCASA 1.0 (Yu et 
al., 2010). Briefly, the program scans the protein in a 3D grid with 2.0Å probes for the 
cavities. When the search is completed the cavities are automatically displayed on the 
structure and ranked on the basis of volume (accumulation of the spherical probes). 
2.17.7. Molecular Docking  
Molecular docking was performed using SymmDock (Schneidman-Duhovny et al., 2005b) 
and ClusPro2.0 (Comeau et al., 2004) adopting both blind and directed (by providing 
interaction sites information) approaches. Symmdock is exploited to predict the EBNA1 
dimer conformation. The program exploits the local features of protein (input) to produce 
symmetric cyclic transformation at a given order n (for dimer; n=2). This symmetric cyclic 
transformation is later being exploited for clustering and finally to predict the dimer 
conformations of a given monomer (Schneidman-Duhovny et al., 2005b). Conformations 
are ranked on the basis of geometric score, desolvation energy (Zhang et al., 1997) and the 
interface area size. According to bench mark studies the near native conformation are 
usually found among the top 20 ranked predictions (Chen et al., 2003; Inbar et al., 2005). 
In this study we analysed first 20 ranked conformations of EBNA1 dimer and decision was 
made on the majority rule. ClusPro2.0 is currently the highest ranking algorithm for its 
reliability for the structural prediction of protein protein interaction (Kozakov et al., 2010) 
and it was used to predict the structural conformation of EBNA1-DIP interactions.  
ClusPro uses Fourier transform correlation technique based docking platforms; DOT and Z 
dock to predict the protein-protein interaction conformation. Scoring of the predicted 
conformation (depending on the platform) is based on pairwise shape complementarity 
(PSC), desolvation energy values and electrostatic values. The programme filters top 2000 
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docking simulations on the basis of pairwise binding site RMSD criterion to yield the final 
structure which is the further refined by applying CHARMM forcefield.  
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3. Results: EBNA1 Structure-Function Relationship 
3.1. Introduction 
Our understanding of EBNA1 structure is fragmented, as to date only the C-terminal 
portion of the protein, involved in DNA binding and dimerisation, has been structurally 
resolved (Bochkarev et al., 1995). The remaining one third of the protein which include 
glycine alanine repeat region (GAr domain) and glycine arginine rich regions (GR1 and 
GR2) and other host protein interacting regions have not been structurally resolved (Figure 
1.4). Given many of the EBNA1 functions such as transactivation, genome maintenance 
and conferring resistance to apoptosis are regulated with these regions; understanding the 
structural biology of these regions is of considerable significance. This chapter describes 
the structure-function relationship of EBNA1 encoded by EBV and other primate LCVs. In 
order to explore structural and/or functional divergence in EBNA1 of different LCVs, 
molecular models of EBNA1 protein for all LCVs were constructed and compared in the 
monomeric and dimeric conformations.  Based on the observations, a peptide (DIP) was 
proposed that could interfere with the EBNA1 dimer stability. In the present study the 
preliminary evaluation of the efficiency of DIP was evaluated.  
3.2. Phylogenetic analysis of EBNA1 
With the exception of the GAr region, EBNA1 shows limited sequence identity to any 
other proteins in the databases. However, several homologues of EBNA exist in different 
herpes viruses especially LCVs that infect primates. Several proteins were identified by 
textmining in rice (Oryzia sativa) and bacterium (Erwinia chrysanthemi) denoted as 
EBNA1, EBNA1-like or EBNA1-nuclear protein but with little or no sequence identity to 
herpesvirus EBNA1. Moreover, reciprocal BLAST did not show any relationship of these 
sequences with herpes viruses EBNA1.  
Since the GAr region is composed of a relatively simple stretch of residues, to improve the 
accuracy of the BLAST search, this region was deleted for the BLAST search. In total 8 
complete homologues were retrieved: 3 homologues from different strains of EBV and 
single homologues each from LCV infecting cynomolgus monkey (Macaca fasicularis), 
rhesus macaque (Macaca mulatta), baboon (genus Papio) and marmoset (Callithrix 
jacchus). These sequences are denoted as hu-EBNA1 (from EBV/HHV4), cy-EBNA1 
(from CyEBV), rh-EBNA1 (from CeHV15), ba-EBNA1 (from CeHV12) and ma-EBNA1 
(from CyEBV), rh-EBNA1 (from CeHV15), ba-EBNA1 (from CeHV12) and ma-EBNA1 
(from CalHV3). The reconstructed phylogenetic tree using these sequences revealed the 
separation of the single New World primate EBNA1 sequence (ma-EBNA1) from the Old 
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World primate virus sequences (Figure 3.1). Expectedly, human sequences were clustered 
together and other Old World primates sequences formed a distinct subclade. The overall 
tree topology resembles the extensive phylogenetic reconstruction based on the LCV 
glycoprotein B genes (Duellman et al., 2009).  
3.3. Multiple sequence alignment of EBNA1  
To compare the primary protein structure of EBNA1 homologues, primate LCVs EBNA1 
sequences were aligned, using EBNA1 of EBV B95-8 strain as the reference protein 
(Figure 3.2). The hu-EBNA1 sequences are the longest homologues of EBNA1 and show 
88% to 97% identity to each other. Identity between the Old World monkey LCV EBNA1 
is 35% to 46%, while ma-EBNA1, the shortest homologue of EBNA1, shows the limited 
identity with the other sequences (Table 3.1). The GAr of hu-EBNA1 spans over one third 
(90-324) of the total protein length and is predominantly composed of Gly and Ala 
residues (with the exception of Glu at position 273 and 274 in GD1 strain of human EBV). 
In comparison the GAr region of the Old World monkey LCVs is shorter and intervened 
by other residue (predominantly Ser and Val) while it is completely absent in EBNA1 of 
CalHV3 (Figure 3.2).  
The GAr region (where present) is flanked by Gly and Arg repeat regions (GR1 and GR2),  
which are present in EBNA1 homologues of all human and Old World monkey viruses, 
suggesting a conservation of function and reflecting their involvement in the viral genome 
replication, maintenance and transactivation. By contrast, ma-EBNA1 has only one GR 
region which shares higher sequence similarity with GR2 than GR1. Given that the GAr 
sequence is absent, a single GR region of ma-EBNA1 might reflect a domain that has not 
been cleaved by the GAr (Figure 3.1). A stretch of 10 amino acids (KRPSCIGCKG), just 
C-terminal to GR1 in hu-EBNA1 is strongly conserved in Old World primate LCVs 
EBNA1 suggesting conserved biological role, however, the region is absent from ma-
EBNA1. Two Cys residues in the N-terminal region of ma-EBNA1 (residues 38 and 43) 
aligned to Cys79 and Cys82 of hu-EBNA1 (Figure 3.2). These cysteines may perform a 
similar function to Cys79 and Cys82 in hu-EBNA1, within the highly conserved stretch in 
Old World primate virus EBNA1’s. 
The interaction sites for USP7 and CK2 on hu-EBNA1 are conserved in Old World 
monkey virus EBNA1 homologues. In particular, residues involved in intermolecular 
hydrogen bonding between EBNA1 and USP7 (EBNA1 Pro442, Glu444, Gly445 and Ser 
447) (Saridakis et al., 2005) are present at the corresponding position in EBNA1 of Old 
World monkey viruses. However, ma-EBNA1 did not show a similar sequence at the  
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Figure 3.1. Phylogenetic tree of EBNA1 homologues. The evolutionary history of 
primate LCV EBNA1 homologues was reconstructed using protein sequences and the 
maximum likelihood method with Whelan and Goldman replacement model (Whelan and 
Goldman, 2001). The consensus tree was developed with 1000 bootstrap replicates. One 
clade includes three EBV (HHV4) homologues of EBNA1 (huEBNA1). Non-human Old 
World monkey LCVs EBNA1 form a separate clade (herpes viruses of cynomolgus 
monkey (CyEBV), rhesus macaque (CeHV15) and baboon (CeHV12), while the marmoset 
CalHV3 EBNA1 homologue outgroups both clades. The domain organization of 
homologues is schematically represented on the right with protein length indicated in 
brackets. The predicted protein domains or sites are colour coded: purple: Gly, Arg repeat 
region (GR1 and GR2); yellow: GAr; orange: NLS; cyan: CK binding site; red: USP7 
binding site; green: DNA binding domain (core in dark green). 
 
 
 HHV4 
B958 
HHV4 
GD1 
HHV4 
AG876 
CEBV 
TsbB6 
CEBV 
SiIIA 
CeHV15 CeHV12 CalHV3 
B958  97 88 46 44 38 36 22 
GD1   87 46 43 38 36 22 
AG876    44 42 37 35 21 
TsbB6     90 54 47 21 
SiIIA      56 50 23 
CeHV15       59 25 
CeHV12        26 
CalHV3         
 
 
Table 3.1. Percentage identity of EBNA1 homologues. Sequence identities between 
different EBNA1 homologues are shown in percentages, based on the multiple sequence 
alignment. 
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Figure 3.2. Multiple sequence alignment of EBNA1 homologues. The protein sequence 
of EBNA1 homologues is shown with RasMol colour coding of the residues. The 
secondary structural elements (based on the composite model of EBNA1 of EBV-B95-8) 
are shown as cylinders (α helices) and arrows (β sheets). Important protein domains or 
interaction sites are represented by coloured horizontal bars: purple: GR1 and GR2, 
yellow: GAr, orange: NLS, cyan: CK2 binding site, red: USP7 binding site, green: DNA 
binding domain (core domain in dark green). Coloured dots above the sequences indicated 
critical residues of structural and/or functional importance: blue: predicted phosphorylation 
sites; pink: critical residues involved in USP7 binding; purple: dimerisation; green: DNA 
binding; orange: conserved Cys residues at N-terminal.  
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corresponding region or at any other position in the alignment. Compared to hu-EBNA1, 
an additional stretch of Ser at the CK2 binding site is present in the Old World monkey 
LCV EBNA1 homologues. At the aligned region in ma-EBNA1, several Ser/Pro residues 
are present, it is not clear if these could constitute a CK2 binding site. This implies that 
either both (USP7 and CK2) binding sites have been lost during the evolutionary course of 
New World Monkey virus or gained during Old World monkeys LCVs evolution. A 
sequentially conserved stretch of approximately 30 residues is present between CK2 and 
USP7 binding sites in EBNA1 homologues of Old World monkey viruses but absent in the 
hu-EBNA1 sequences. 
A single ubiquitination site on hu-EBNA1 (Lys477) was predicted, which is conserved in 
all the homologues. Six of the ten proposed phosphorylation sites of hu-EBNA1 (Duellman 
et al., 2009) are also conserved in primate virus homologues (Ser60, Ser62, Ser78, Ser365, 
Ser383, Ser393) (Figure 3.2). The nuclear localization signal sequence (NLS: 379-385, 
KRPRSPS) is fully conserved in all Old World monkey LCV EBNA1 homologues, while 
in ma-EBNA1 only the last four residues are present at the corresponding position in the 
alignment. A consensus NLS sequence (K, K/R, x, K/R) is also not present in ma-EBNA1, 
however RKxRxxxK towards the N-terminus or RKRxxxxR at the N-terminal end of the 
DNA binding region might function as a NLS. In ba-EBNA1 and rh-EBNA1, a conserved 
KKRRS within the LR1 homology region could serve as second NLS.  
The DNA binding and dimerisation domain (459-607) is the most sequentially conserved 
domain between the EBNA1 homologues (Figure 3.2). With few exceptions, residues 
shown for their involvement in DNA binding (Lys514, Thr515, Tyr518, Asn519, Arg521 
and Arg522) and dimerisation (Arg469, Tyr510, Arg532, Leu533, Phe541, Gly542, 
Pro553, Glu556, Tyr561, Val597, Ser599, Asp601, and Asp605) (Bochkarev et al., 1995) 
are highly conserved. Such retention of critical residues in this region suggests the 
structural and functional conservation between EBNA1 homologues of these primate 
viruses.  
3.4. EBNA1 monomeric model 
To understand the structural aspects of the EBNA1 biology, a full length model of the 
EBNA1 protein was constructed. First, the propensity of the protein molecules to adopt 
secondary or tertiary structure was explored by using FoldIndex web server. The 
FoldIndex analyses of EBNA1 homologues predicts that the N-terminal and central regions 
of the protein are unstructured or unfolded (Figure 3.3A). Conversely, the GAr domain is 
predicted to be folded and DNA binding and dimerisation domain yielded positive signals 
of structured conformation.  
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Figure 3.3. Structural propensity of EBNA1 homologues. EBNA1 protein sequences 
from the primate LCVs (as indicated) were used to predict the structural propensity by 
FoldIndex. The distribution of hydrophobic and charged residues across the protein length 
is shown by blue and pink lines (respectively). Potential disordered and ordered regions of 
protein are represented by negative (red) or positive (green) values (respectively). A 
simplified domain distribution is indicated as coloured bars above each plot: black: N-
terminal; brown: GAr; gold: GR2 and protein binding sites; pink: DNA binding and 
dimerisation. Numbers on X-axis correspond the length of the protein. (B) 
Ramachandran plots of EBNA1 modelled structures. The human and other primate 
LCV EBNA1 protein structure models (as indicated) were evaluated for dihedral angle 
distribution using Ramachandran plots. Residues in allowed and disallowed regions  are 
represented by green and pink spots (respectively). Generously and strictly allowed regions 
are depicted by fuchsia and cyan contour lines (respectively).  
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To construct the full length structural model of EBNA1 in silico, the hu-EBNA1 B95-8 
protein was screened for any structural similarities with deposited protein structures in the 
RCSB database using PDB BLAST. Apart from the resolved C-terminal portion of the 
EBNA1, none of the available structures thus identified alone or in combination, covered 
the query sequence to any extent. Therefore a combined approach was adopted to exploit 
the advantages of three programmes (I-TASSER, MOE and Modeller) of protein 
modelling. Over the last five years I-TASSER has been ranked first in the CASP (critical 
assessment of protein structure prediction) contest for protein structure prediction 
(Kryshtafovch et al., 2009).  I-TASSER employed homology modelling to model the C-
terminus of the query sequence using the resolved C-terminal domain of EBNA1 (1B3T) 
as a template. For structurally unresolved regions, I-TASSER searches the protein structure 
databases (primarily RCSB) for small regions of sequential and structural similarity and 
uses these fragments from multiple templates to model the aligned regions. Ab-initio 
modelling procedures are employed to model unaligned regions. Finally, I-TASSER 
assembles all fragments of predicted structure to generate thousands of models by iterative 
threading which are subsequently evaluated for the best fit. Homology modelling can also 
be conducted using MOE, which allows the placement of spatial constraints for 
heteroatoms or molecules (such as DNA). In order to exploit the advantage offered by both 
programmes, primary models were developed separately in I-TASSER and MOE using the 
structurally resolved region of EBNA1 (1B3T) as a template. The best models selected 
from each programme were then used as a template to construct composite models. The 
best composite model was then selected on the basis of dihedral bond angle ratio (89.5% in 
allowed region and additional 5.9% in the generously allowed region) (Figure 3.3B) and 
lowest free energy. Owing to the relative proportions of Gly and Pro compared to other 
residues, these values lie within acceptable limits of protein structure. As expected, the C-
terminal region (DNA binding and dimerisation domain) of the in silico model is nearly 
identical to the 1B3T crystal structure (RMSD deviation of 1.29Å) (Figure 3.4). 
The EBNA1 model predicts a helix (31-43) with GR1 (part of EBP2 and RNA binding 
region) (Figure 3.4). A conserved residue (Arg71 and to less extent Arg72) within LR1 
transactivation domain protrudes from the structure. The strong conservation and spatial 
position of the residue in the predicted structure suggests its biological importance. 
Consistent with the FoldIndex prediction, the GAr region forms multiple helices of 
variable length and the remainder of N-terminal region appears unstructured. Similarly, the 
central region (known for protein-protein interactions: EBP2 (residues: 325-476), CK2 
(residues: 399-395), USP7 (residues: 436-450)) is largely unstructured except for the 
presence of short parallel β sheets in GR2 (residues: 334-338, 348-351 and 370-374). 
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Figure 3.4. EBV EBNA1 composite model structure. A composite model of EBNA1 of 
EBV/B95-8, constructed using I-TASSER, MOE and Modeller is represented in (A-C), 
with 180
o
 rotation in horizontal plane (D-F). The model is shown in ribbon format (A, D) 
(with the structurally resolved portion boxed), electrostatic surface topology (B, E) and 
surface highlighting structurally and functionally important regions (C, F): yellow: GAr; 
purple: GR1 and GR2; pink surface: Arg71 and Arg72; cyan: CK2 interaction region; 
orange: NLS; red: USP7 binding site; light green and dark green: flanking region and core 
DNA binding and dimerisation domain respectively. Note the prehensile C-terminal tail 
curls back towards DNA binding region to form a ring (arrow in A).  Comparison of the C-
terminal region of the EBNA1 composite model and the resolved structure is shown in (G) 
& (H) with a horizontal rotation of 90
o
. The C-terminal region of the composite EBNA1 
model (cyan) is shown superimposed over a monomer retrieved from the structurally 
resolved template 1B3T (yellow) (RMSD value is 1.29Å). Note: the protruding proline rich 
loop is highlighted in (H).  
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The NLS region (residues: 381-385) is also modelled as disordered. Although the protein 
interacting region exhibits the characteristics of an intrinsically disordered region, it is 
possible that the region upon interacting with different partner proteins dynamically adopts 
alternate structural conformations. A proline rich region (residues 537-559) is highly 
conserved in all primate LCV EBNA1 homologues and forms a loop which protrudes in a 
different plane (Figure 3.4). Consistent with the FoldIndex prediction, the C-terminal tail 
(residues: 608-641) is largely unstructured in the predicted model except for two small 
helices. In the predicted model, the C-terminal tail curls back towards the DNA binding 
and dimerisation domain, making a ring-like conformation with a central hole (Figure 3.4).  
Comparison of primate LCV EBNA1 models with the hu-EBNA1 model shows clear 
structural similarity at the C-terminal DNA binding and dimerisation domain (Figure 3.5). 
Similarly, the C-terminal tail also curls back to the DNA binding region to form a loop 
with hole in the middle. However, the remaining portions of the modelled proteins show 
several differences with hu-EBNA1. The GR1 and GR2 domain become closer due to the 
reduction of GAr domain length in EBNA1 of non human primate LCVs. The GAr domain 
is absent and a longer α helix is predicted at the N-terminus of the ma-EBNA1 model. Both 
USP7 and EBP2 binding sites are relatively more unstructured (especially the latter) than 
in hu-EBNA1. By contrast, the CK2 binding region and the intervening sequence between 
CK2 and USP7 binding site, form β sheets, this is consistent with the FoldIndex prediction. 
The prominent Arg71 and to some extent Arg72 are not predicted to protrude in the 
primates LCV EBNA1 molecules except in the ba-EBNA1 model where only Arg71 shows 
an exteriorly located side chain.  
3.5. EBNA1 homodimer model 
Two approaches were used to construct in silico homodimer models of full length EBNA1: 
dimer homology modelling using MOE and dimer generation in SymmDock. In the former 
approach, the resolved EBNA1 C-terminal domain dimer (1B3T) was used as a template to 
construct a full length EBNA1 dimer with DNA (Figure 3.6). Spatial restraints (manually 
placed) allows incorporation of atomic coordinates of the DNA molecule (as available in 
1B3T) into the model and the resulting dimer model is highly similar to 1B3T in the C-
terminal region (RMSD=0.35Å). In this predicted dimer, the string of residues that 
connects C-terminal domain with the N-terminal region of the protein neatly occupies the 
major groove of the bound DNA (Figure 3.6). However, the N-terminal and C-terminal 
ends of the model predicted solely by MOE show several differences to the composite 
model (Figure 3.7). Moreover, the MOE monomers in the MOE predicted dimer are not 
symmetrical and show differences in the distribution of secondary structural elements. This  
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Figure 3.5. Primates LCV EBNA1 structures. Ribbon cartoons of different primate LCV 
EBNA1 monomers (as labelled) are shown in 180
o
 rotation in horizontal plane. Different 
regions are coloured differently to highlight structurally and/or functionally important 
regions as in Figure 3.4.  
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Figure 3.6. EBV EBNA1 MOE dimer model.  EBNA1 full length dimer as modelled in 
MOE is shown in ribbon format. The DNA binding region is shown in space filled 
topology. Note the string of residues sits in the major groove and connecting the N-
terminal and C-terminal regions of the protein.  
 
asymmetry of the monomers might result from the chance selection of different short PDB 
fragments for constructing the outgroup (N-terminal and C-terminal ends) modelling. 
Alternatively, the asymmetrical nature of DNA produce the asymmetry in the bound 
proteins modelled. 
In the second approach, an EBNA1 dimer was constructed using SymmDock providing the 
composite monomer model and the intermolecular contact points, as described for the 
resolved EBNA1 C-terminal dimer, as input. The top 20 predictions of SymmDock were 
evaluated and the best model was selected on the basis of lowest free energy. The selected 
model shows high similarity in the orientation of the DNA recognition and binding region 
to the resolved C-terminal domain dimer (Figure 3.8). The N-terminal portions of both 
monomers orient roughly perpendicular to the C-terminal DNA binding domain. The C-
terminal domains of the monomers of the SymmDock predicted dimer prediction are at a 
slightly altered angle to one another in comparison to 1B3T, resulting in a subtle widening 
of the β barrel (as compared to 1B3T) which is formed at the interface of the core domains  
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Figure 3.7. Distribution of structural elements on hu-EBNA1 models. The distribution 
of structural elements on the hu-EBNA1 as observed in the in silico models (maroon 
(composite model), blue (MOE models) and green (composite GAr deleted model)) are 
shown as cylinders (α helices) and arrows (β sheets). 
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Figure 3.8. EBV EBNA1 composite model dimer structure. (A) EBV B95-8 EBNA1 
composite dimer model is shown in the ribbon cartoon with the each monomer coloured 
brown or cyan. The C-terminal region associated with the DNA binding and 
homodimerisation is highlighted in a box, magnified and rotated by 90
o 
in the horizontal 
plane to show the central barrel (B) and viewed from the top to visualize protrusion of 
proline loop (C). Space filled topology of the monomers and dimers are shown in (D and 
E), illustrating the proline loop of each monomer: coloured green and red, corresponding 
to grey and purple monomers respectively.  
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of both monomers. The selected model shows noticeable congruencies with the resolved 
EBNA1 C-terminal dimer (1B3T) in the hydrogen bond pattern and over all topology 
(RMSD value 1.50Å) (Figure 3.8 and 3.9).  Five hydrogen bonds (Glu367-Arg368 x 2, 
Arg370-Ser368, Arg382-Asp455, Ser386-Asp455) lie between N-terminal residues in the 
SymmDock predicted dimer are not present in the resolved C-terminal DNA binding and 
dimerisation domain. Nine hydrogen bonds (Tyr510-Trp609, Tyr510-Phe610, Arg532-
Gly542, Leu533-Pro553, Ile558-Glu629 x 2, Tyr561-Trp609, Arg594-Pro608, Arg594-
Phe610) are located in the C-terminal region of the predicted dimer (Figure 3.9). The 
counter-part of some intermolecular hydrogen bond contacts differ between the resolved 
structure (1B3T) and the SymmDock dimer, for example Arg594-Asp605 bond found in 
1B3T is replaced with Arg594-Pro608 in the predicted dimer but of note, Pro608 was not 
present in the crystallized protein-DNA complex, therefore it is possible this contact in the 
1B3T may be artifactual. 
Interestingly, the protruding proline loop of one monomer slots into the hole between the 
C-terminal tail and the core domain of the other monomer (Figure 3.8). In the resolved 
structure the C-terminal tail (residues: 608-641) was not included thereby the significance 
of this conformation was not apparent. Although the C-terminal tail of the dimer predicted 
by MOE still encircles the proline loop to some extent it does not exhibit a complete ring. 
In total, based on the orientation of the proline rich loop in the predicted EBNA1 dimers, 
we propose that the protrusion of the proline rich loop of a monomer into another of its 
counter-part may render stability in the EBNA1 dimerisation. To evaluate this hypothesis, 
another dimer was constructed using SymmDock, using a monomer model deleted for the 
C-terminal region in question (deleting residues: 608-641). Of the top 20 best predictions, 
only 8 show the correct orientation of the two monomers to each other (in relation to the 
resolved C-terminal structure) as compared to 15/20 for the full length EBNA1 dimer 
predictions. Additionally, the best dimer shows poor values for geometry and free energy 
compared to the full length dimer, supporting the hypothesis that the C-terminal tail may 
be involved in dimer stabilisation.  
In comparison to the MOE predicted monomer and dimer, the composite model of EBNA1 
and SymmDock generated dimer give improved structural reliability scores. However, the 
SymmDock dimer shows spatial constraints at the location where DNA should interact 
with the C-terminal domain of the protein. Structurally, this region is predicted to be 
disordered in both models and FoldIndex analysis. Therefore it is likely that this region 
may be flexible and adjust its position during DNA interaction.  
Deletion of GAr of hu-EBNA1 facilitates increased expression of the protein in 
heterelogous systems, while retaining several of its functions including the ability to bind  
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Figure 3.9. Hydrogen bonds in EBNA1 composite dimer model. The intermolecular 
hydrogen bond pattern between the two EBNA1 monomers (cyan and brown) is shown. 
Residues involved in the bond formation are labelled with their respective positioning and 
hydrogen bonds are represented by black dashed line.   
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with DNA and genome maintenance. A composite GAr deleted model was generated by 
employing the same methodology as used in the construction of the full length EBNA1 
composite model. Subsequently the GAr deleted dimer was constructed using SymmDock. 
Consistent with the full length EBNA1 model, the GAr deleted dimer model also retains 
the same conformation of C-terminal DNA binding and dimerisation domain as found in 
1B3T. However, the C-terminal tail in the GAr deleted EBNA1 model is predicted to be 
structured and composed of a long α helix which forms a half ring (Figure 3.10). Exclusion 
of GAr in the model impacts the protein interacting region as both CK2 and USP7 binding 
regions forms short alpha helices. Interestingly, three hydrogen bonds that are found in the 
1B3T structure and absent or differently paired in the full length EBNA1 model (e.g. 
Arg469-Glu556) are present in the GAr deleted EBNA1 dimer (Table 3.2).  
Dimer models were also constructed from the EBNA1 monomers of non-human primate  
LCV using SymmDock (Figure 3.11). Given the regional distribution of sequence 
conservation, as expected in all cases the C-terminal domain participates in the 
dimerisation while the N-terminal half orients approximately perpendicular to the C-
terminal domain. However, some important differences were noted between the hu-
EBNA1 dimer and the other primate EBNA1 dimers, for example the β barrel of Old 
World monkey LCV EBNA1 structures is wider compared to hu-EBNA1. By contrast the 
β barrel of ma-EBNA1 dimer is similar to the hu-EBNA1 dimer in terms of symmetry of 
the interacting interface of the monomers. In summary, the modelled structures predict that 
homodimerisation of EBNA1 is a conserved structural characteristic that is retained in all 
primate LCV EBNA1 molecules.  
3.6. Zinc binding with EBNA1 homodimer  
Two conserved Cys residues in LR1 (Cys79 and Cys82) have been found to coordinate 
zinc to potentially facilitate interaction (linking) between EBNA1 dimers to form a homo-
multimeric complex at the repeated binding sites (the family of repeats, FR) at oriP (Aras 
et al., 2009). To explore this structurally, two zinc ions were introduced in the EBNA1 
dimer using MOE. Energy minimization (Amber forcefield 99) predicted the stable 
bonding between these two cysteines and the zinc ions (Figure 3.12), supporting this mode 
of linkage between the adjacent EBNA1 dimers while interacting with FR.  
3.7. Phosphorylation in EBNA1  
Several post translation modifications of the EBNA1 molecule have been reported, 
including phosphorylation of serine residues and methylation of arginine residues (Shire et 
al., 2006; Duellman et al., 2009). In order to explore this structurally, the composite model 
of EBNA1 was examined for the propensity of serine residues to undergo phosphorylation.  
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Figure 3.10. GAr deleted EBNA1 monomer and homodimer. The composite model of 
GAr deleted EBNA1 is shown in both ribbon format (A) and surface view (B). The boxed 
region (A) indicates the region which has been structurally resolved (in 1B3T). The surface 
topology images are colour coded to highlight structural and/or functional yellow: GAr; 
purple: GR1 and GR2; pink: Arg71 and Arg72; cyan: CK2 interaction region; orange: 
NLS; red: USP7 binding site; light green and dark green: flanking region and core DNA 
binding and dimerisation domain. The GAr deleted EBNA1 monomer model (A, B) was 
used to generate a dimer in SymmDock (C, D). Ribbon format views are shown with each 
monomer coloured cyan and brown (C). Monomers/proline rich loops in the surface 
topology view (D) are differently coloured: mauve/red and silver/green corresponding to 
purple and grey coloured monomer respectively.  
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No. 1B3T Full length model Gly/Ala deleted model 
1  NS Not found Lys313-Arg314 (x2) 
2  NS  Glu367-Arg368 (x2)  Not found 
3  NS  Arg370-Ser386  Not found 
4  NS  Arg382-Asp455  Not found 
5  NS  Ser386-Asp455  Not found 
6  Arg469-Glu556 (x2)  Not found Arg469-Glu556 
7  Tyr510-Asp605 Tyr510-Trp609  Tyr510-Asp605 
8  NS Tyr510-Phe610  Not found 
9  NF Not found Arg521-Pro553 (x2) 
10  Arg532-Gly542 (x2)  Arg532-Gly542 (x2)  Arg532-Met543 (x3) 
11  Arg532-Phe541  Not found Arg532-Gln550  
12  Leu533-Pro553  Leu533-Pro553  Not found 
13  Gly542-Pro607  Not found Not found 
14  NF Not found Ala544- Glu641 
15  NF Not found Arg555-Gly470 (x2) 
16  NF Ile558-Glu629 (x2)  Not found 
17  Tyr561-Tyr561  Tyr561-Trp609  Tyr561-Tyr561 
18  NF Not found Ala588-Asp625 
19  NF Not found Cys591-Asp625 
20 Arg594-Asp605  Arg594-Pro608  Not found 
21 NS Arg594-Phe610  Not found 
22 Thr596-Asp602 Not found Not found 
23 Val597-Asp601  Not found Not found 
24 Ser599-Ser599 Not found Not found 
 
Table 3.2. Hydrogen bond interactions in EBNA1 dimer. Comparison between inter-
residual hydrogen bonds of structurally resolved C-terminal EBNA1 dimer (1B3T) 
(residue 461-607), composite full length EBNA1 dimer (residues 1-641) and GAr deleted 
EBNA1 dimer (1-90; 327-641) are tabulated. Note, in the GAr deleted EBNA1 dimer, 
amino acids are numbered according to the full length protein.  
 
Out of the total 27 serine residues, present in EBNA1 of EBV-B95-8, 13 serines were 
predicted for their potential to undergo phosphorylation in the given composite model 
(Figure 3.13). Of these, only 3 serine residues (Ser60, Ser62 and Ser393) are consistent 
with the 10 reported phosphorylation sites (Duellman et al., 2009). It is important to note 
that most of the reported predicted sites are situated in the intrinsically disordered region of 
the molecule. Therefore, it is conceivable that the difference between the observed and 
predicted (structurally) phosphorylated sites could be due to the spatial restraints in the 
predicted model. Given the flexibility of these region it is possible that other sites 
(especially those of observed) will get phosphorylated.  
3.8. Structure of proposed Dimer Inhibitory Peptide (DIP) 
It was observed in all dimer predictions (described in section 3.5) that a protruding proline 
rich loop of each monomer slots into a hole (formed between the C-terminal tail and DNA  
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Figure 3.11. Primate LCVs EBNA1 dimers. Homodimers were constructed using 
SymmDock for each of the modelled (non-human) primate LCV EBNA1 homologues (as 
indicated). Monomers are coloured cyan or brown. Consistent with the hu-EBNA1, all 
primates LCVs EBNA1 dimerisation is mainly mediated by the C-terminal domain 
(boxed). The C-terminal regions of each predicted dimer are shown enlarged and rotated 
by 90
o
 in the horizontal plane.  
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Figure 3.12. Zn incorporation in the EBNA1 dimer model. Stable binding between a 
zinc ion (green) and Cys79 and Cys82 (red ball and stick) of each EBNA1 monomer is 
predicted in the dimer model, shown in ribbon format with 90
o 
rotation in the vertical plane 
between (A) and (B). (C) and (D) show enlarged images of these interactions as seen in 
(B).   
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Figure 3.13. Phosphorylation of EBNA1. Ribbon cartoon of EBNA1 protein model 
(composite) is shown where serine residues with a propensity to undergo phosphorylation 
are highlighted in red surface format.    
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binding region) of the other monomer. This consistent positioning of the proline loop in the 
proposed EBNA1 dimers may have a biological role in stabilising the dimer and could be 
exploited to design a disruptor. To investigate this possibility a small peptide (referred to 
as DIP) was designed by combining the TAT (YGRKKRRQRRR) sequence with the 
proline loop sequence (residues: Phe541-Arg555) at the N-terminal. The TAT sequence, 
found in the human immunodeficiency virus (HIV) TAT protein, is known for its ability to 
transport itself and linked sequence through cell and nuclear membrane (Ziegler et al., 
2005). As EBNA1 is a nuclear protein, therefore peptide/disruptor designed to disrupt any 
EBNA1 function (such as dimerisation) through direct physical interaction must cross the 
nucleic membrane barrier. Thus the TAT sequence was incorporated to drive the fusion 
peptide into the nucleus. The full peptide of 26 amino acids was modelled using I-
TASSER. In the in silico model of DIP, the N-terminal TAT sequence is predicted to form 
a helix while the proline loop shows a disordered conformation, consistent with that 
observed all EBNA1 monomer and dimer models (Figure 3.14). However, the 
intramolecular hydrogen bonds of the proline loop between DIP and the full length 
EBNA1 molecule differ, the number of predicted intramolecular hydrogen bonds were 
reduced from 7 (proline loop in native conformation) to 2 (proline loop in DIP). 
Importantly, 2 of 7 of these bonds in the proline loop of the full length EBNA1 model are 
present at turns (Gly548-Gly546; Gly546-Ala544) or between two limbs of the loop 
(Gln550-Met543). In contrast both hydrogen bonds (Gly542-Arg11; Leu554-Gly522) in 
the proline loop of the DIP model are formed at its terminal ends. It is possible that 
incorporation of the TAT peptide may influence the intramolecular interactions and 
topology of the proline loop in the DIP molecule or that taken out of context, it loses its 
configuration. 
3.9. Molecular docking of DIP with EBNA1 monomer 
To explore the potential binding orientation of DIP with the EBNA1 composite monomer, 
the DIP model was docked (blind i.e. without inputting required contacts) against the 
composite EBNA1 monomer model using ClusPro2.0 (Comeau et al., 2004). The top 10 
ranked simulations under balanced coefficient were examined for the position of DIP on 
the EBNA1 model and are collectively illustrated in Figure 3.15. The best or lowest 
docking score of balanced interaction mode is -1225.284 Kcal/mol and the highest is -979 
K cal/mol and the average score of docking energy center is 1081.4 Kcal/mol. In all 
docking simulations DIP was predicted to interact within or near to the potential target 
region (the central hole formed between the C-terminal tail and the DNA binding region) 
of the EBNA1 monomer. On the basis of orientation of the DIP to EBNA1, these  
Mushtaq Hussain, 2013  98 
 
 
 
Figure 3.14. Structural models of DIP and proline loop of full length EBNA1. Protein 
sequence (A) and predicted model (B) of DIP are shown where TAT and proline loop are 
coloured red and green respectively. The residue numbering of the proline loop is 
according to the full length EBNA1 sequence and indicated in (A). Amino acids are 
represented by grey lines and black dashed lines represent the hydrogen bonds between the 
residues indicated. Note the difference in the numbers of intramolecular hydrogen bonds in 
proline loop of DIP (B) and modelled structure of EBNA1 (C). 
 
 
Figure 3.15. Molecular docking of DIP with EBNA1 monomer. Molecular docking 
simulations were conducted using ClusPro2.0 and the top 10 docking simulations, ranked 
according to balanced coefficient, are shown here (A and B: 180
o
 rotation). DIP is 
represented in ribbon format while the EBNA1 composite monomer is represented in 
surface topology with 180
o
 rotation in the horizontal plane between the two images. Each 
of the 10 spatial positionings of DIP corresponds to a single simulation which are colour 
coded according to the rank: 1
st
 (purple); 2
nd 
(red); 3
rd
 (orange); 4
th
 (pink); 5
th
 (barn red); 
6
th
 (lemon); 7
th
 (yellow); 8
th
 (fuchsia); 9
th
 (amazon) and 10
th
 (green).  Note: All of the top 
10 ranked simulations place DIP at or within the proline loop hole of EBNA1. 
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interactions could be broadly classified into two different conformations: 1) penetrating or 
2) capping. Capping conformations (in which the DIP covers one side of the central hole) 
are slightly favoured over penetrating conformations (where dimer proline loop penetrates 
the central hole) with 60% and 40% ratio respectively (Figure 3.15). Given the docking 
simulations were undertaken without specifying the target region, the orientation of DIP on 
EBNA1 and associated energy values are encouraging. If DIP will associate with EBNA1 
in either orientation in vivo (penetrating or capping), it is expected to interrupt and/or 
hinder the protrusion of the proline loop (of another monomer) into the central hole of the 
1
st
 monomer, thereby inhibiting/destabilizing homodimer formation. 
3.10. DIP uptake 
Based on the in silico docking analysis of DIP with EBNA1, preliminary empirical study 
was designed to examine the effect of DIP on the EBNA1 dimerisation. First, DIP was 
synthesized with and without fluorescein (Flu) tag (DIP and DIP-Flu respectively). Various 
B cell lines (positive and negative for EBV; Table 2.5) were treated with 10µM DIP-flu 
and uptake and intracellular localization of the peptide were examined using confocal 
microscopy. After 20 minutes of peptide (DIP-Flu) treatment, the cell lines were stained 
with DAPI and examined by confocal microscopy (Figure 3.16). Amongst the observed 
fields, most cells of all cell lines have shown penetration of DIP. The DIP-Flu was mainly 
distributed in nucleus and in some cells accumulation of peptide in nucleoli was also 
noticed (Figure 3.16).  
3.11. EBNA1 expression in different cell lines 
In order to select the B cell line for the preliminary studies of DIP, EBNA1 expression in 
several B cell lines (Table 2.5) was assessed. Expression of the protein was examined by 
western blotting using 100µg of cell line lysate and probing with anti EBNA1 antibodies 
(IH4). Immuno blotting showed maximum expression of EBNA1 in Raji cell line and least 
expression was observed in BL30 (EBV positive) cell line. In comparison to Raji, much 
less expression of EBNA1 was observed in IB4, B958 and Namalwa (in decreasing order) 
(data not shown). In a separate experiment, EBNA1 expression was also assessed by 
comparing the lysates of 10
6
 cells of Raji, Namalwa and as negative control BL2 (EBV 
negative) (Figure 3.17). Higher expression of EBNA1 was observed in Raji cell lysate 
followed by Namalwa while BL2 (EBV negative) showed no band of protein at the 
corresponding size of EBNA1 when probed with IH4 antibodies (Figure 3.17). This is 
consistent with the earlier studies demonstrating the presence of only 2 integrated copies of 
EBV genome in each Namalwa cell (Ryan et al., 2004) compared to 50 to 60 EBV genome 
copies per Raji cell (Adams et al., 1973). Taking both cellular penetrations of DIP  
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Figure 3.16. Uptake of DIP-Flu in B cell lines. Several cell lines (as indicated) were 
treated with 10µM DIP-Flu peptide for 20 minutes and the cells were counter stained with 
DAPI. Cells were observed without fixation in different planes and fields of view. Images 
are representative of one field of view observed and were taken at different magnifications 
(for each cell line; top panel images (100x) and bottom panel images (600x) except Raji 
and B958 images were taken at 1200x) and with different contrasts as indicated.   
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Figure 3.17. EBNA1 expression in B cell lines. Cell lysate (10
6
 cells) of different B cell 
lines (as indicated) were probed with anti EBNA1 antibodies (IH4). The expected size of 
EBNA1 protein are indicated with red arrows. Note: the difference in the molecular weight 
of EBNA1 between Raji and Namalwa cell lines is due to the deletion of GAr domain in 
the former.  
 
and EBNA1 protein expression, Namalwa cells seems an adequate system for preliminary 
examination of the effect of DIP on the EBV infected cell. 
3.12. DIP inhibits cellular proliferation of Namalwa cell line.  
In order to explore that DIP inhibits the growth of the EBV dependent cell line, via 
disrupting essential EBNA1 function(s), Namalwa cell line was treated with 25µM DIP. 
To rule out any observed effect due to the cellular toxicity of the DIP, BL2 (EBV negative) 
cell line was also treated with the same concentration of DIP. The experiment was 
conducted in triplicate for four days and on each day cells were counted by trypan blue 
exclusion assay (Figure 3.18).  In another set of control, Namalwa and BL2 cell lines were 
grown in the absence of DIP. During the first two days, decline in the cell numbers were 
observed in all cell lines however, in the next 3 days, all cell lines recovered and started to 
proliferate, except DIP treated Namalwa cell line. No difference in the growth was  
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Figure 3.18. DIP effect on the EBV positive B cell growth. Namalwa and BL2 cells 
(10
6
) were treated 25µM of the DIP. Cells were counted over a four day period by trypan 
blue exclusion assay to assess the cellular proliferation. Each data point reflects the mean 
count of three replicates with vertical bars represent standard error of mean. Key: 
Namalwa cells treated with DIP (blue line; NT), Namalwa cells control (maroon line; NC), 
BL2 cells treated with DIP (green line; BT) and BL2 cells control (purple line; BC) 
observed between DIP treated and untreated BL2 cell lines. However, relatively slow 
growth was observed in DIP treated Namalwa cells compared to its respective negative 
control. On the final day (day 4) in the DIP treated Namalwa, most cells were dead while 
the untreated Namalwa still showed increase in the number of cells and the difference in 
the final count of cells in both (DIP treated and untreated Namalwa cells) was found to be 
statistically significant under student t test but not when Mann-Whitney test was employed. 
In total the data suggest that DIP may retard the proliferation of EBV positive Namalwa 
cell line and the continuous treatment of DIP led to the death of the Namalwa cells. As 
mentioned that this experiment is a preliminary investigation for evaluating the effect of 
DIP in EBV positive cell line and essentially require further studies (discussed latter) for 
further verification.  
3.13. Summary of findings 
 Marmoset LCV EBNA1 lacks several functional regions found in human EBV EBNA1, 
there are a split GR domain, the entire GAr domain and CK2 and USP7 binding sites. 
 The GAr region shows a sequential and structural increase in length in the EBNA1 of 
Old World Monkey LCVs from baboon to humans. 
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 The structural model of EBNA1 shows a strong alignment with the resolved C-terminal 
DNA binding and dimerisation region while the N-terminal region is largely composed 
of helices and unstructured loops. 
 The protein interaction sites in EBNA1are largely comprised of intrinsically disordered 
regions, which may allow EBNA1 to bind with multiple alternative partners. 
 The C-terminal tail of EBNA1 is composed of an unfolded loop which curls back to the 
DNA binding and dimerisation domain of the protein providing a hole for insertion of 
the loop of the interacting EBNA1 in the dimer. 
 EBNA1 models of primate LCVs are similar in over all topology and domain 
architecture (where present) to EBNA1 from human EBV. 
 It was possible to generate dimer models in SymmDock or MOE from the full length 
monomer models without any spatial restraints and intermolecular clashes. 
 Unlike the EBNA1 dimer constructed using MOE, a dimer model constructed using 
SymmDock showed spatial interference with a space likely to be occupied by DNA due 
to the occupancy of the loop constituting the partner proteins (EBP2, CK2 and USP7) 
binding sites. However, the dynamic nature of protein structure may allow flexibility in 
this region allowing it to change its spatial position and/or structure upon the interaction 
of EBNA1 with partner molecules, including DNA.  
 A plausible coordination between Zn2+ and two conserved cysteine residues (towards 
the N-terminus) was observed using the EBNA1 model, consistent with the multimeric 
complex formed by EBNA1. 
 We have hypothesized that the GAr region may mask the unstructured region of the 
EBNA1 protein to prevent its proteolytic degradation and consequent epitopic 
presentation.  
 In all EBNA1 dimer models generated, a conserved proline loop of one monomer 
protrudes into the space between the C-terminal tail and DNA binding and dimerisation 
domain of the other monomer, generating a dowel pin like joint. It is hypothesized 
herein that this joint may be involved in the stabilization of dimer conformation of 
EBNA1 and could be used as a therapeutic target. 
 A disruptor peptide (DIP) has been designed for this dowel pin like joint and blind 
molecular docking studies indicate that DIP may interact with the EBNA1 monomer in, 
or near the desired region.  
 Confocal microscopy experiments using fluorescent DIP showed good penetration of 
the peptide in all the B cell lines examined (both EBV+ve and EBV-ve). 
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 A cell proliferation assay showed growth inhibition in the EBV positive cell line 
(Namalwa) treated with DIP unlike an EBV-ve cell line, suggesting that DIP could 
potentially inhibit the growth of at least those EBV infected cells where survival 
depends upon the EBNA1 function. 
 
3.14. Discussion  
Comparison of EBNA1 sequences of primate LCVs were made to explore the evolutionary 
history of this viral gene. Additionally, in silico models of monomer and dimer 
conformation of full length of EBNA1 molecules of primate LCVs were generated and 
compared. Subsequently a possible dimerisation disruptor peptide was predicted by in 
silico means and preliminary empirical studies were conducted to evaluate these 
predictions.  
Evolution and protein domain divergence in EBNA1 of primate LCVs  
The phylogenetic analysis of EBNA1 homologues from related LCVs is in line with the 
evolutionary history of these viruses as inferred from the earlier analysis of DNA 
polymerase and glycoprotein B genes (Ehlers et al., 2010). It has been proposed that LCVs 
co-evolved with their respective host species (mostly primates) with some evidence of inter 
species transfer (Ehlers et al., 2010; Perelman et al., 2011).  The notable differences 
between ma-EBNA1 and hu-EBNA1 (outside the C-terminal DNA binding and 
dimerisation region) suggest sub-neo-functionalization occurred in the gene after the Old 
and New World primates split (43 MYA). Alternatively, the similarity between hu-EBNA1 
and other primates LCV EBNA1 is possibly an indicative of interspecies transfer.  
Owing to the strong conservation between the C-terminal domains of EBNA1 of primate 
LCVs, it is likely that there is mechanistic conservation also in homodimerisation and 
sequence specific DNA binding. Similarly, the LR1 and GR2 regions are also highly 
conserved in EBNA1 homologues of Old World primate LCVs. Unlike other EBNA1 
homologues, ma-EBNA1 has only one GR region, which shows similarity with GR2 in hu-
EBNA1. In the absence of a GAr region, this single GR region of ma-EBNA1 is located 
near the N-terminus of the protein. It is possible that this single GR domain represents the 
ancestral form of GR regions prior to the incorporation/emergence of the GAr domain in 
EBNA1. Deletion of LR1 from hu-EBNA1 adversely affects its transactivation function 
(Singh et al., 2009) and therefore ma-EBNA1 may differ with hu-EBNA1 in this respect. 
Both GR1 and GR2 regions of hu-EBNA1 are demonstrated to be involved in binding 
EBP2 and G-rich RNA and are required for stimulation of EBNA1 dependent viral genome 
replication, tethering to metaphase chromosomes and faithful segregation of viral genomes 
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in the dividing infected cells (Shire et al., 1999; Norseen et al., 2009; Shire et al., 2006). 
Sequence and structural similarities within these regions is indicative of functional 
conservation in viral genome propagation and segregation. A distinct NLS is absent from 
ma-EBNA1, however, it is possible that other regions with similarity to consensus NLS act 
in nuclear localization of ma-EBNA1.  
The USP7 binding site is highly conserved in the EBNA1 homologues of Old World 
monkey LCVs, and it seems likely that they interact with host USP7. The potential CK2 
binding site in Old World monkey LCVs EBNA1 is relatively long compared with hu-
EBNA1. This could suggest that the EBNA1 of non-human Old World monkey LCVs may 
interact with CK2 with different affinity. ma-EBNA1 lacks the GAr domain, USP7 binding 
site and possibly CK2 binding region as well. With the availability of more EBNA1 
sequences it would become clear whether or not these sites were acquired or lost together. 
Similar to EBV in humans, CalHV3 in marmoset is commonly associated with lymphoma. 
However, it can only immortalize marmoset B-cells after prolonged culture (Jenson et al., 
2002). Nevertheless, multiple differences in the genomes are present between CalHV3 and 
EBV, such as the polyproline tract of EBNA2, EBERs and viral IL10 are completely 
absent in CalHV3 (Rivailler et al., 2002).  
EBNA1 dimerisation and mutlimerisation in models 
In all of the compared EBNA1 models, a short proline rich string within the C-terminal 
domain is strongly conserved and forms a protruding loop, consistent with the resolved C-
terminal domain of hu-EBNA1. Interestingly, in all of the dimer models this region of each 
monomer inserts into the space between the C-terminal tail and core domain of other 
monomer, forming a “dowel pin joint” like interlocking structure. Additionally, a dimer 
model constructed using hu-EBNA1 monomer model with the C-terminal tail deleted, 
shows less favourable energy values, suggesting reduced stability compared to the full 
length dimer. As evident from the resolved C-terminal domain dimer, the C-terminal tail is 
not necessary for EBNA1 dimerisation; however, consistent in all EBNA1 dimers curling 
of the C-terminal tail of each monomer around the proline loop of other monomer suggests 
it may contribute to the stabilisation of the dimer. Importantly, this information could be 
exploited to design therapeutic molecules to disrupt EBNA1 dimerisation and thus 
associated functions. If these models are good representatives of the native conformation 
of EBNA1, then filling the space formed by the C-terminal tail or obstructing the proline 
loop to orient itself in the space, may preclude EBNA1 dimer formation.  
Incorporation of zinc ions into the dimer model predict stable bonding between the zinc 
and Cys79 and Cys82, located at the distal end of each N-terminal arm. This is consistent 
with the proposal of self association of EBNA1 dimers through zinc, when interacting with 
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FR. Furthermore, these residues along with zinc are required for cooperative 
transactivation (Aras et al., 2010). 
DNA binding with EBNA1 models 
The composite EBNA1 model shows good agreement with the structure propensity 
predictions and resolved C-terminal domain structure for EBNA1 gives improved 
Ramachandran plot values and QMEANnorm scores compared to other primary models. 
However, unlike the model generated using MOE, the composite model shows the 
presence of some residues in the space which should be occupied by the DNA (when 
bound) as observed in the co-crystal structure of the C-terminal EBNA1 dimer and DNA. 
Given that these residues reside within the unstructured region of the protein, they are 
likely to move away upon interaction with DNA, to allow DNA to bind with the EBNA1 
dimer. Therefore, it is proposed here that the composite model at present provides the best 
prediction of full length EBNA1 dimer conformation when not bound with DNA. It is 
possible to speculate that while interacting with DNA through the C-terminal domain, the 
unstructured strings of residues twist to provide space for DNA and in turn also move the 
N-terminal portion of the protein to adopt an angle in relation to C-terminus as found in 
dimer predicted by MOE.  
Protein interaction sites in EBNA1 are intrinsically disordered 
The known EBNA1-protein interaction sites (with EBP2, USP7 and CK2) are predicted to 
be unstructured in the in silico models. These unstructured regions in turn allow the protein 
molecule to adopt different conformational states at least in part, which could favour rapid 
association/dissociation, promiscuity in partner protein interactions and post translational 
modifications (Shire et al., 2006; Tompa, 2011). Proteins associated with signalling or 
transcriptional regulatory functions tend to contain intrinsically disordered regions perhaps 
to facilitate a greater repertoire of partner protein interactions (Babu et al., 2011). 
Similarly, EBNA1 interacts with multiple partners and in certain cases these binding sites 
overlap (e.g. with EBP2 and RNA) or present in the close proximity (CK2 and USP7 
binding regions). Thus, it is reasonable to suggest that EBNA1 may adopt different 
conformations upon interaction with different molecular partners and thereby, the 
predicted composite model represents the “resting shape” of the molecule that could attain 
different conformations upon binding with different molecules.  
The tumour suppressor protein p53 is an intrinsically disordered protein (IDP) (which also 
binds with USP7) and acts as a transcriptional regulator. Its tight regulation is mediated by 
efficient proteosomal degradation (ubiquitin dependent and independent) which is critical 
for the health of cell (Tsvetkov et al., 2009). It has been suggested that IDPs are 
susceptible to proteolytic degradation which are mostly mediated by the 20S proteosome 
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(Ubiquitin independent), hence to avoid degradation these disordered regions require to be 
masked (Tsvetkov et al., 2009; Gsponer et al., 2008). Interestingly, despite the predicted 
unstructured regions, EBNA1 is highly stable in B-cells (over 30 hours) (Tellam et al., 
2007), suggesting the possibility that these unstructured regions are being masked in some 
way. By contrast, cytotoxic T-cell recognition of the EBNA1 is largely mediated by the 
presentation of peptide, derived from the newly synthesized EBNA1 molecule (Fu et al., 
2004). These observations seem consistent with the predicted model of EBNA1 showing 
disordered regions which could be susceptible to proteolytic degradation immediately after 
synthesis. However, the observed stability of EBNA1 in B-cells could be due to rapid 
intermolecular complex formation, post translational modifications or possibly due to an 
intramolecular masking activity. It is tempting to speculate that the GAr domain could 
provide a possible masking region for the intrinsically disordered portions of the protein.  
The GAr domain is predicted to be structured by both FoldIndex and in the composite 
model. The latter predicts that the GAr region is mainly composed of α helices while the 
MOE constructed model predicted that the GAr domain may contain both α helices and β 
sheets. Earlier studies proposed that the GAr region may be composed of β sheets (Tellam 
et al., 2001), conversely, it has been demonstrated that Ala residues have a tendency to 
break β sheets and form α helices. Although Gly residues tend to break both secondary 
structure conformations (α helices and β sheets), in combination with Ala they strongly 
favour the α helical conformation (Fujiwara et al., 2012), supporting the prediction made 
by the composite EBNA1 model.  
Structural basis of GAr domain function in EBNA1 molecule 
The hu-EBNA1 GAr region has been demonstrated to render resistance to proteosomal 
degradation and inhibits self synthesis, which results in impaired immune responses to 
EBNA1 (Levitskaya et al., 1997; Yin et al., 2003). However, the length and purity of 
repeats has a substantial effect upon these actions. Little or no self synthesis inhibition was 
observed in case of rh-EBNA1 and ba-EBNA1 which contain relatively shorter and impure 
GAr (Tellam et al., 2007). Additionally, cytotoxic T-cells tend to recognize rh-EBNA1 
more efficiently compared to hu-EBNA1. Furthermore, in chimeric rh-EBNA1 in which 
the rh-EBNA1 GAr domain is substituted with its counterpart present in hu-EBNA1, 
impaired translation efficiency and endogenous processing was observed, suggesting 
involvement of the GAr domain of hu-EBNA1 in these functions (Tellam et al., 2007). It 
has been suggested that by stalling translation, the hu-GAr region reduces the synthesis of 
misfolded products thereby providing less epitopes for presentation by MHC (Yin et al., 
2003). This hypothesis could be extended on the basis of present studies. In addition to 
impairing self synthesis, it is also possible that the predicted structured region of hu-
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EBNA1 GAr domain may mask the disordered region of EBNA1 and in turn protect it 
from proteosomal degradation. Several observations are consistent with this proposal; (1) 
retarted translation might allow the GAr domain to fold independently and prior to whole 
protein folding thus inhibiting proteosomal degradation; (2) GAr masking the disordered 
regions would continue to prevent default degradation of the disordered region of the 
mature EBNA1 protein; (3) GAr mediated resistance to proteolytic degradation does not 
supersede ubiquitin mediated degradation; (4) This hypothesis accommodates both 
functions of the GAr domain: inhibiting translation and protection from the proteosomal 
degradation, as shown by hu-EBNA1 and would explain the observed differences between 
the functions of the hu-EBNA1 and both rh-EBNA1 and ba-EBNA1. It is possible that 
impure GAr domain sequence of Old World monkey LCV EBNA1, though unable to 
retard self synthesis may nevertheless efficiently mask the disordered region of the protein 
(Levitskaya et al., 1997). Finally, the proposed hypothesis also seems consistent with the 
evolutionary co-acquisition of the structurally disordered protein interaction sites (USP7 
and CK2) and possible masking region (GAr domain).  
An interesting comparison could be made between LANA1 of Kaposi’s sarcoma-
associated virus, which has central repeats (CR), shown to be responsible for immune 
evasion by inhibiting MHC-I mediated peptide presentation. However, unlike EBNA1, a 
separate subsection of repeats are involved in retarding the translation and inhibiting the 
processing of its potential epitopes (Kwun et al., 2011).  
EBNA1 dimerisation a potential drug target 
In all predicted EBNA1 dimers, the proline loop of one EBNA1 monomer slots into the 
central hole, formed between the C-terminal tail and DNA binding core domain of another 
monomer. Moreover, energy values of the full length dimers are more favourable 
compared to a dimer constructed using EBNA1 with a deleted C-terminal tail. This 
suggests a possible role of the proline loop and/or C-terminal tail in the stabilisation of the 
dimer. In view of these observations, a potential disruptor peptide was designed, the 
predicted model of which shows a similar topology to the counterpart region (proline loop) 
of full length EBNA1. However, it lacks a number of potentially critical hydrogen bonds 
compared to the native proline loop present in full length EBNA1 model. This relaxation in 
the structure is perhaps due to the absence of spatial constraints, offered by neighbouring 
residues in the full length protein. 
Other studies have successfully shown inhibition of EBNA3C interaction with different 
components of the cell cycle regulatory complex using a disruptor peptide (Knight et al., 
2006). Similarly EBNA2 interaction with DNA binding protein CBF1 has also been shown 
to be inhibited using a peptide derived from the interacting region of CBF1 (Farrell et al., 
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2004). Previously, virtual screening of the 90,000 low molecular weight potential 
inhibitors (non peptide) for EBNA1-DNA interaction have been reported, demonstrating 
3/90,000 of these compounds render reduction in the EBV genome copy numbers and 
inhibit transactivation function of EBNA1 in a Burkitt’s lymphoma cell line (Li et al., 
2010).  In the present study we have proposed a peptide to inhibit its homodimerisation and 
associated functions. This is the first time a disruptor peptide has been reported for the 
EBNA1 dimerisation. In molecular docking (blind) DIP interacts within or near the target 
regions (central hole and curling C-terminal tail). This reflects that the predicted peptide 
could possibly interfere with the interaction between two EBNA1 monomers by competing 
with the proline loop for the same site or region.  
Short stretch of basic amino acids, also termed protein transduction domain (PTD) have 
been identified as a carrier of linked cargo such as peptide, protein and nucleic acid into 
the cell. The TAT sequence, which is derived from the HIV TAT protein, is one such 
example of PTD (Futaki, 2002; Leifert et al., 2003). Treatment of different EBV positive 
and EBV negative cell lines with the DIP showed efficient intracellular and intranuclear 
penetration of the peptide. This reflects the efficiency of the TAT sequence as a carrier 
sequence for cellular transport and also demonstrating that the peptide could reach to the 
target area (in this case nucleus).   
Namalwa cell line harbours 2 integrated copies of EBV genome (Ryan et al., 2004) and to 
date no EBV negative variant has been known for this cell line. This may suggest that EBV 
genome is an integral part of Namalwa cell line and cell line may not survive or proliferate 
if the EBV genome has not been maintained properly. As mentioned, genome maintenance 
of EBV in the infected cells is regulated by EBNA1 dimer, therefore by  impairing or 
destabilizing the dimer formation of EBNA1 by DIP may halt the Namalwa cell 
proliferation which in turn may lead to their death by apoptosis. Consistently, treatment of 
DIP showed decline in the Namalwa cells viability compared to untreated and EBV 
negative BL2 cells. This suggests that DIP may have some intracellular effect on the 
viability of EBV positive cells at least in Namalwa. Which in light of its origin and 
molecular docking analyses may be due to its interaction with EBNA1. However, it is 
important to note that the effect of DIP is observed merely on the trypan blue exclusion 
assay which may suffer from observational bias and the cell line selected to examine the 
effect of DIP has least expression of EBNA1 protein. Therefore it is important to replicate 
the experiment by staining the cells using annexin V/ propium iodide and counting them 
using flow cytometry. Similarly, direct protein interaction assays could be conducted by 
immunoprecipitation EBNA1 or DIP from DIP treated Namalwa cell line. Using other cell 
lines with relatively higher expression of EBNA1 (such as Raji) may also facilitate to 
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optimize the dose required for the peptide to show any potential effect. Moreover, using 
cell lines with the negative variants of EBV such as BL2, BL30 or BL70, may also tells 
how efficiently DIP  (if it is)  can maintain the EBV genome over the period of treatment.  
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4. Results: EBNA1 Protein Protein Interactions 
4.1. Introduction 
Several functions of EBNA1 such as genome maintenance, conferring resistance to 
apoptosis and transactivation are attributed to its ability to interact with different host 
proteins. In this chapter, the interaction between EBNA1 and two of its partner proteins, 
EBP2 and USP7, were explored by peptide library array. Human genes encoding EBP2 
and USP7 were cloned into bacteria using bacterial protein expression vectors. The 
recombinant proteins were used as probes over a 25-mer EBNA1 array to explore their 
potential binding sites on EBNA1. To further resolve the binding regions, the proteins 
were used as probes over alanine substitution arrays of the binding site regions. 
Additionally, residues which have been proposed to be phosphorylated were modified 
accordingly on the arrays to unravel the effect of phosphorylation on binding.  
4.2. Validating the system 
In order to explore the EBNA1-partner protein interaction, peptide array technology was 
employed. Peptide arrays of EBNA1 were constructed by synthesizing a library of 25-mer 
peptides, each shifted along the protein sequence by 5 amino acids (from N-terminal to C-
terminal), covering the full length (641 residues) of EBNA1 using either small spots on 
glass slides or larger spots on cellulose membrane. Peptide synthesis and array spotting 
were conducted by our collaborators, Ruth MacLeod and Prof. George Baillie. Synthesis 
and sequential immobilization of the each peptide was conducted following the order of 
the EBNA1 protein sequence (Figure 4.1A). To verify the synthesis and efficacy of 
spotting of the peptides on the array, the arrays were probed with three different anti 
EBNA1 antibodies: Rabbit 16-4, rat IH4 and mouse Aza2E8. The binding of the antibodies 
on the EBNA1 peptide library was assessed using a western blot development like 
protocol, where positive binding appears as dark spots on the array. Probing of the EBNA1 
array with Rabbit 16-4 showed positive reaction at spots 76-83 which comprise residues: 
Arg376-Glu435 in EBNA1 sequence. This coincides with the known epitope (personal 
communication with Prof. J. M. Middeldorp) of this antibody (residues 394-420). Anti 
EBNA1 IH4 antibody bound to spots 85-88 on the EBNA1 array, which comprises 
residues Gly421 to Lys460, while Aza2E8 bound to spots 90-92, which correspond to 
residues Pro446 to Asn480 (Figure 4.2). The epitope of IH4 antibodies has been mapped 
around 407-450 amino acid on EBNA1 (Snudden et al., 1994) which fits well with its 
binding on EBNA1 peptide array. The epitope for Aza2E8 epitope is not known, however, 
due to its ability to impair the EBNA1-DNA interaction, it has been suggested to be within  
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Figure 4.1. Peptide Array. The primary protein sequence of EBNA1 (EBV B95-8) is 
shown in (A) where the residues in red, highlights the sequence in the first four spots on 
the array as indicated below (B). Each spot is composed of 25 amino acids with a 5 amino 
acids shift from N-terminal to C-terminal. The full map of EBNA1 array covering the full 
641 residues of the sequence in 125 spots of peptides is tabulated and shown in (C). The 
peptide sequences used are given in Appendix II. 
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Figure 4.2. Validation of Peptide Array. (A) Peptide arrays were probed with different 
anti-EBNA1 antibodies as indicated, dark spots on arrays shows the binding of respective 
antibodies. (B) Tabulated representation of the peptide array of EBNA1 is shown, 
indicating the peptides bound by each antibody: rabbit 16-4 (light green), IH4 (pink) and 
Aza2E8 (cyan). (C) The primary sequence of EBNA1 is shown where residues 
corresponding to the positive spots are highlighted as Rabbit 16-4 (light green), IH4 (pink) 
and Aza2E8 (cyan).  Light brown shows the overlapping peptide region of Rabbit 16-4 & 
IH4 binding. 
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or near to the EBNA1 DNA binding domain (Orlowski et al., 1990; Snudden et al., 1994) 
consistent with the observation with these arrays. In summary the binding pattern on the 
peptide array of the anti EBNA1 antibodies supports the reliability of the spotted peptides 
for their sequence and order which in turn shows the applicability of the arrays for 
EBNA1-partner protein interaction studies. 
4.3. EBNA1-EBP2 interaction 
4.3.1. Expression of human EBP2 in bacterial GST tag expression vector 
To investigate the EBNA1-EBP2 binding sites using EBNA1 peptide array, relatively pure 
EBP2 protein is required. Therefore, a cDNA of human EBP2 was amplified from the Raji 
cell line and cloned into the bacterial expression vector (pGEX-6P-1), incorporating a 
glutathione S-transferase tag at N-terminal of the recombinant protein (Appendix III). 
Clones were verified by colony PCR, restriction digest and DNA sequencing. The strain 
containing the EBP2 clone vector (denoted herein pEBP2gex) and empty vector (pGEX-
6P-1) were grown and induced with IPTG for the expression of the EBP2-GST fusion and 
GST proteins respectively. Bacterial growth was harvested after overnight incubation and 
pellets were lysed. Control (pGEX-6P-1) and test (pEBP2gex) bacterial lysates were then 
purified by affinity chromatography using glutathione sepharose beads. In total six 
fractions of 500µl were collected and stored at -80
o
C for subsequent use. Protein 
concentration of the fractions was measured using BIORAD assay. Aliquots of the 
fractions were assayed by SDS PAGE and bands were visualized using coomassie blue 
staining and western blotting using anti-GST antibodies (Figure 4.3). 
The comassie blue staining of the fractions of pEBP2gex, showed multiple bands including 
a band at around 61kDa, expected size of fusion protein (GST-EBP2). In addition, bands at 
approximately at around 35kDa and 45kDa were observed in the pEBP2gex samples. 
These may reflect that the fusion protein may have been degraded or translated with 
multiple truncations yielding the bands of small molecular weights (Figure 4.3). In the 
pGEX-6P-1 sample the predominant band was appeared at 26kDa, the expected size of 
GST protein. Both comassie blue stained gels and western blots reflect much lower level of 
expression of EBP2-GST fusion protein in comparison to alone GST protein (Figure 4.3). 
Nevertheless, the difference between the protein profile of pEBP2gex and pGEX-6P-1, 
suggests that fraction 3 and 4 of pEBP2gex may contain adequate amount of the 
recombinant protein that could be used for subsequent studies.  
4.3.2. Probing of EBP2-GST fusion protein on EBNA1 array 
In order to explore the binding site of EBP2 on EBNA1, EBNA1 peptide arrays were 
probed with ~10µg/ml of the EBP2-GST fusion protein (from fraction 4). As control,  
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Figure 4.3. Expression of recombinant human EBP2-GST in E.coli BL2. Recombinant 
protein (EBP2-GST) expression was assessed by SDS PAGE. (A): 70µl of each of six 500 
µl fractions (F1-F6) of affinity purified EBP2-GST were separated by 10% SDS-PAGE. 
Proteins were stained with comassie blue. Compared to (B) in which same volume of 
fractions from pGEX-6P-1 were assayed by SDS-PAGE and comassie staining, the 
pEBP2gex showed bands of the fusion protein (red arrow) whereas  fractions from pGEX-
6P-1 only showed bands with the expected size of GST (green arrow). (C) 20µl of each of 
six 500 µl fractions (F1-F6) of affinity purified EBP2-GST were separated by 10% SDS-
PAGE and western blotted. The blot was probed with antibodies to GST. Compared to (D) 
in which same volume of fractions from pGEX-6P-1 were assayed by SDS-PAGE and 
western blotted, the pEBP2gex showed bands of the fusion protein whereas  fractions from 
pGEX-6P-1 only showed bands with the expected size of GST. 
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another EBNA1 array was probed with same amount (~10µg/ml) of GST protein of 
fraction 2. Both arrays were then developed using anti GST and/or anti EBP2 antibodies 
(Figure 4.4). On the EBNA1 array, the EBP2-GST fusion protein binding was detected in 
three strings of spots: spots 5-11, spots 64-74 and spots 88-92, corresponding to the 
residues Ser21-Lys75, Gly316-Gly390 and Gln436-Asn480 respectively. Two of these 
bindings sites, Ser21-Lys70 and Gly321-Gly390, fit well with the previously reported 
EBP2 binding regions on EBNA1 (Shire et al., 1999; Nayyar et al., 2009). Highlighted in 
figure 4.4 are the strings of amino acids to which these peptide spots map, in the EBNA1 
sequence. Adjacent to the peptide which show strong binding are peptide spots which 
showed no or weak binding. Excluding the amino acids of these non-binding peptides 
(weak binding) provide a core binding region, referred to here as the “basic binding 
region” BBR (Figure 4.4). The BBR of each of the three sites are runs of glycine and 
arginine residues. Interestingly, the third site which shows relatively weak binding has not 
been found previously. However, the BBR sequence is GGRRK, again indicating the 
propensity of this protein to interact with the strings of glycine and arginine.  These results 
appeared to be consistent despite the array being probed with anti GST or anti EBP2 
antibodies (Figure 4.4), suggesting the positive spots may indeed reflect the novel binding 
region for the EBP2 on the EBNA1 molecule. However, probing of the EBNA1 array with 
GST protein alone showed weak binding to the peptide spots that overlap with those 
detected by EBP2-GST. Although compared to EBP2-GST fusion protein binding, the 
binding of GST to the EBNA1 peptide was very weak, it nevertheless raises questions over 
the reliability EBP2-GST results. To resolve this ambiguity it was decided to switch the 
vector system from GST-tag to His-tag for the partner protein expression in the subsequent 
studies.  
4.3.3. Expression of human EBP2 in bacterial His tag expression vector 
The human EBP2 cDNA was amplified from the pEBP2pgex vector by PCR using primers 
that incorporated HindIII and XhoI restriction sites in the DNA. The cDNA was then 
ligated into the pET-28c vector and transformed into both E.coli BL21(DE3) and E.coli 
Rosetta (DE3) strains which incorporate 6xHis tag at the N-terminal of the recombinant 
gene (Appendix III). The clones were verified by colony PCR, restriction digest and 
sequencing. Bacteria hosting pEBP2pET28 and pET-28c plasmids were grown and 
induced with IPTG and after overnight incubation, the bacterial pellets were harvested and 
lysed. The bacterial lysates were then purified by affinity chromatography using Ni beads. 
The fractions (5) of 500µl were collected and separated by SDS-PAGE to examine the 
quantity and quality of the protein by comassie blue staining and western blot (Figure 4.5).  
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Figure 4.4. EBNA1-EBP2-GST interaction. (A) EBNA1 peptide arrays were probed 
with 10µg (F3) of human EBP2-GST fusion protein and detected with anti-EBP2 or anti 
GST antibodies as indicated. Another array was probed with 10µg (F3) of GST protein and 
probed with anti-GST antibodies as indicated. The dark spots on the arrays reflect positive 
binding of the proteins. Note the difference in intensity of binding between EBP2-GST 
fusion protein and GST protein alone. A tabulated map of the peptide array is shown in 
(B), where cyan coloured boxes correspond to the basic binding region of the fusion 
protein. The primary sequence of EBNA1 is shown in (C) where residues corresponding to 
the BBR for EBP2 interactions are highlighted as cyan.  
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Figure 4.5. Expression of human EBP2 in E.coli BL2 and Rosetta strains. 
Recombinant protein (EBP2-6xHis) were assessed by coomassie blue gel staining (A) and 
western blot (B) of the 50µl of fractions (F1-F5), purified using 250mM imidazole from 
bacterial lysate of pEBP2pET28 and pET-28c (as indicated). Note the difference in the 
western blot profile of bacteria with EBP2 insert and bacteria with empty vector (B). 
Fractions eluted by varying the concentration of imidazole in the elution buffer (as 
indicated) were also examined using coomassie staining (C) and western blot (D). 
Fractions purified from lysate of E.coli Rosetta(DE3) strain containing pEBP2pET28 
bacterial lysate were also examined by comassie blue staining (E) and western blots (F). 
50µl and 10µl from each fraction were used for coomassie gel staining and western blots 
respectively. For western blots the membranes were probed with anti 6xHis HRP 
conjugated antibodies. The expected molecular weight (36kDa) of the recombinant protein 
(EBP2) is indicated by red arrows.  Key: M (molecular markers); F (fractions) and L 
(bacterial lysate). 
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Protein concentrations of the fractions were estimated by UV absorbance at 280nm. The 
expected molecular weight of recombinant EBP2-6xHis fusion protein is 36kDa (35kDa of 
EBP2+ 1kDa of 6xHis). Coomassie blue staining of the gel showed multiple bands of 
proteins in the different fractions from pEBP2pET28, including prominent bands between 
50-70kDa, at ~40kDa, at ~35kDa and at <35kDa. Except the two bands at ~40kDa and a 
single band at ~35kDa, corresponding fractions from pET-28c clone showed a similar 
profile on comassie blue staining (Figure 4.5A). The western blot (probed with anti-6xHis 
antibodies) of a parallel gel clearly distinguished the fractions of both clones 
(pEBP2pET28 and pET-28c), where prominent bands were observed in fractions from only 
bacteria containing EBP2 insert at ~35kDa (expected molecular size of EBP2) and between 
35-40kDa (Figure 4.5B), while no protein of same molecular weight was detected in 
fractions from pET-28c clone. This suggests that the ~35kDa protein observed in the 
bacteria with pEBP2pET28 plasmid was different from the protein of same molecular 
weight (as observed in the comassie blue stained gel of the respective fractions) in bacteria 
harbouring empty vector. Similarly, bands (reactive in the western blots; Figure 4.5B), at 
~40kDa was only observed in bacteria with recombinant plasmid (pEBP2pET28). These 
bands may possibly be of full length intact EBP2-6xHis and may have migrated differently 
on gel electrophoresis whereas <40kDa bands may reflect degradation products of the 
recombinant protein. Differential migration on the gel could be due to the post translational 
modification (glycosylation) of the recombinant protein in the bacterial cell.  The data 
show that complete purification was not achieved by affinity chromatography using a 
single concentration of imidazole (250mM) in the elution buffer. Therefore, the 
recombinant protein was purified from the bacterial lysate by using increasing 
concentrations of imidazole in the elution buffer (Figure 4.5C, 4.5D), this resulted in the 
separation of unwanted bands of 50-70kDa in early fractions (50-150mM imidazole), while 
bulk of recombinant EBP2-His was eluted in elution buffer containing 100-200mM of 
imidazole. Western blot of these fractions showed only one band at ~35kDa (expected 
molecular weight of EBP2) in fractions eluted with 100-200mM imidazole. Both the 
coomassie blue stained gel and the western blot showed a further degree of purification 
was achieved using imidazole gradient purification for recombinant EBP2 protein. In order 
to examine that the less than expected molecular weight (<35kDa) band is due to the 
interrupted translation of the recombinant protein (e.g. due to the codon bias), plasmid 
(pEBP2pET28) was transformed in the Rosetta (DE3) strain of E.coli. The protein was 
purified from the clone lysate by affinity chromatography as above. The same EBP2-His 
bands of 35kDa and 40kDa were produced in the Rosetta strain. This suggests that these 
proteins were not the result from the interrupted translation due to codon bias (Figure 4.5E, 
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4.5F). Given that the 6xHis tag is present at the N-terminus of the recombinant protein and 
these bands were not detected by western of fractions from pET-28c, it is reasonable to 
suggest that protein of <35kDa are indeed bacterial contaminant proteins.  
In total, from the comassie blue stained gel and western blot of the fractions, it is clear that 
the human EBP2 was successfully expressed in the bacteria using his tag expression 
vector. However, full purification of the recombinant protein was not achieved. 
Nevertheless the differences between the western blot profile of the fractions from 
pEBP2pET28 and pET-28c lysates suggest that some fractions of pEBP2pET28 clone 
(fraction 2/3 from non gradient purification; fractions 3A and 3B from gradient 
purification) are sufficiently pure by the western detection approach (which is used on the 
peptide array), therefore could be used for the subsequent EBNA1-EBP2 protein 
interaction studies.  
4.3.4. Probing of EBP2-His protein on the EBNA1 array 
EBNA1 glass arrays (analytical arrays) were probed with 7.5µg (30µl) of partially purified 
recombinant EBP2 protein obtained from fraction no. 2/3 (non gradient). As control, 
EBNA1 arrays were also probed with 7.5µg protein(s) from fraction 2 from pET-28c clone 
lysate. Both arrays were developed using anti-6xHis antibodies (Figure 4.6). Probing of 
recombinant EBP2-His protein on EBNA1 array showed binding at spots: 5-11; 64-74 and 
88-91, corresponding the residues: Ser21-Lys75; Gly316-Ser390 and Gln436-Leu485 
respectively. The first two binding regions matches well with the reported binding site for 
EBP2 interaction on EBNA1 (Shire et al., 1999; Nayyar et al., 2009) and the observations 
obtained by probing EBNA1 array with the EBP2-GST fusion protein (Figure 4.4). These 
binding sites resides within the two Gly-Arg rich regions of the EBNA1 protein termed 
GR-1 and GR-2 (Frappier and O’Donnel1, 1991; Mackey et al., 1995).  Also consistent 
with the fusion protein (EBP2-GST) probing, EBP2-His also showed binding to the same 
spots that correspond to the region previously unknown for EBP2 binding, Gln436-
Leu485, indicative of the presence of a potentially novel EBP2 binding region on EBNA1. 
The control (bacterial lysate) showed no binding on the EBNA1 arrays demonstrating that 
there is no cross reactivity of either the 6xHis tag or the anti-6xHis antibody with the 
EBNA1 peptide on the array (Figure 4.6). In addition, EBNA1 array probing with 
recombinant EBP2 protein from either fraction 2 (non gradient) or fraction 3 (gradient) 
produced identical results. 
In order to explore the EBP2 binding site, an alanine scan array was conducted using a 
membrane array (preparative array) (Figure 4.7). Peptides which had shown strong and 
consistent binding by EBP2 fusion protein were selected for this purpose. Briefly, peptide  
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Figure 4.6. Physical map of EBNA1-EBP2 interaction. (A) EBNA1 peptide arrays were 
probed with 7.5µg of recombinant human EBP2 protein and bacterial lysate as indicated.  
The arrays were developed using anti 6xHis antibodies. The dark spots on array indicate 
the positive binding of the proteins. (B) Tabulated representation of the peptide array of 
EBNA1, where cyan coloured boxes correspond to the binding region of the EBP2-His on 
the EBNA1 array. (C) The primary sequence of EBNA1 is shown where residues 
corresponding to the positive spots for EBP2 interactions  (representing BBR)  on array are 
highlighted in cyan.  
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(A)  
Peptide 8. 36-GDNHGRGRGRGRGRGGGRPGAPGGS-60 
Peptide 10. 46-GRGRGGGRPGAPGGSGSGPRHRDGV-70 
Peptide 70. 346-GRGGSGGRRGRGRERARGGSRERAR-370 
Peptide 73. 361-ARGGSRERARGRGRGRGEKRPRSPS-385 
Peptide 91. 451-RGQGDGGRRKKGGFGKHRGQGGSN-475 
 
(B) 
 
 
(C) 
 
 
Figure 4.7. Exploring critical residues involved in the EBNA1-EBP2 interaction. 
EBNA1 alanine scanning arrays for the EBP2 binding sites (A) were spotted and probed 
with 45µg (200µl) of recombinant human EBP2-His (B). Each peptide on the membrane is 
separated and shown in (C). The first spot in each row represent the unmodified peptide 
sequence spot as indicated. The following spots are the derivatives of the wild type 
sequence with successive amino acids substituted with Ala (or Asp in the case of Ala been 
present in wild type sequence). Peptides with one or more phosphorylated residue 
(superscript P) were also assayed. Ala scan of peptide 10 and 73 started from residue 60 
and 370 respectively (C).  The amino acids in blue and red indicate the decrease or 
increase in EBNA1-EBP2 binding due to the amino acid substitution respectively.  
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8 (corresponding residues: Gly36-Ser60), 10 (corresponding residues: Gly46-Val70), 
peptide 70 (corresponding residues: Gly346-Arg370), peptide 73 (corresponding residues: 
Ala361-Ser385) and peptide 91 (corresponding residues: Arg451-Asn475) were 
synthesized and spotted on the membrane array (An MRes student in the laboratory, Jin, 
contributed to the conducting this set of experiments). In addition to the wild type 
sequences, variants of each were also spotted with successive single amino acid 
substitutions to Ala (or Asp in case of Ala being present in the wild type sequence), from 
the N-terminus to C-terminus of the peptide (Figure 4.7). The array was probed with 45µg 
(200µl) of the recombinant EBP2 protein. In contrast to glass slide array, the peptide 8 
showed very weak binding with EBP2, however, on the alanine scan, Asp56Ala 
substitution yielded an increased signal for binding. Consistent with the glass array results, 
spot 10 (residues: Gly46-Val70) which also corresponds to the N-terminal EBP2 binding 
site (at GR1), showed strong binding.  Alanine scan of this site showed reduced binding 
with the Arg65Ala substitution and the binding was considerably reduced with the 
Asp68Ala substitution, indicative of the importance of these residues in EBNA1 N-
terminal binding of EBP2. Interestingly, significant improvement in the EBP2 binding was 
observed when either one or both serines in peptide 10 (Ser60 and Ser62) were replaced by 
their phosphorylated versions, suggesting that phosphorylation of serine may positively 
affects the binding of EBP2 with the N-terminus of EBNA1, however, it is important to 
note that both of these serines reside outside the reported N-terminal binding site for 
EBP2-His on EBNA1 (Shire et al., 1999). Similarly the Arg65 and Asp68 are also not 
included in the previously reported EBNA1 binding region for EBP2. Peptide 70, which 
corresponds to main EBP2 binding site (residues: Gly346-Arg370), on probing with EBP2 
showed strong binding. Peptide 70 and several of its derivatives showed a similar level of 
binding by EBP2-His as did peptide 10. However, substitutions at: Arg347Ala, Gly349Ala, 
Gly355Ala, Arg356Ala, Arg360Ala and Arg366Ala all reduced the EBP2-His interaction 
while substitutions at Glu359Ala and Glu367Ala nearly abolished EBP2-His interactions. 
The data suggest these may be the critical residues in the GR2 region of EBNA1 for 
binding with EBP2. In contrast to GR1 region, phosphorylation of Ser350 and Ser365 did 
not show any effect on EBP2-His interaction with the peptide. Although peptide 73 and 91 
(corresponding to the residues in the potentially novel site for EBP2 binding) showed 
nearly consistent binding on all EBNA1 glass arrays on probing with EBP2-His/EBP2-
GST, on the membrane array spots, the recombinant protein failed to show strong binding 
to the respective sequence spot and its alanine scan. An exception in this regard is the 
substitution, Lys379Ala, which noticeably improved the binding of EBP2 on the respective 
spot. Also incorporation of phosphorylated Ser365 and Ser385 on peptide 73 and Ser474 
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on peptide 91 enhanced the binding by EBP2 on the array compared to the unmodified 
peptide.  
The present peptide array approach supports the previous findings relating to the physical 
region on EBNA1 for EBP2 binding determined on the basis of deletion mutation and 
yeast two hybrid assays (Shire et al., 1999; Kappor et al., 2001; Nayyar et al., 2009). In 
addition, the data also points to certain key residues and possibly the involvement of post 
translation modification in EBNA1-EBP2 interactions.    
4.4. EBNA1-USP7 interaction 
4.4.1. Expression of human USP7 in bacterial His tag expression vector 
A human USP7 cDNA clone was obtained from Addgene. The cDNA was transferred to 
the pET-28c expression vector by PCR, incorporating HindIII and XhoI restriction sites  at 
5’ and 3’ ends respectively (Appendix III). This was transformed into E.coli BL21 (DE3) 
and E.coli Rosetta (DE3) strains. The clones were verified by colony PCR, restriction 
digest and sequencing. Bacteria containing pUSP7pET28 and pET-28c plasmids were 
grown and induced with IPTG at 37
o
C and after overnight incubation, the bacterial pellet 
was harvested and lysed. The bacterial lysate was then purified through affinity 
chromatography using Ni beads. Fractions of 500µl were collected and aliquots were 
electrophoresed to examine the quantity and quality of the protein by comassie staining 
and western blot (Figure 4.8). Protein concentrations of the fractions were estimated by 
UV absorbance at 280nm. The expected molecular weight of the recombinant USP7-His is 
129kDa (128kDa of USP7 + 1kDa 6xHis). Comassie blue gel staining of the fractions 
(from pUSP7pET28 containing bacteria) showed multiple bands, including prominent 
bands between 100kDa and 140kDa (expected molecular size of USP7), a band at 
approximately 75kDa, and two prominent bands at ~42kDa, and ~37kDa. The lysate of 
pET-28c clone was processed similarly and the comassie blue stained gel profile of the 
fractions showed a faint band at ~100kDa and bands at approximately ~70kDa, 68kDa, 
~35kDa and ~27kDa in fractions 1-3 (Figure 4.8A). Western blot of parallel gels showed 
reactivity with multiple bands present in the fractions of pUSP7pET28 (similar to those 
seen by comassie blue staining) insert while only bands <30kDa were detected in the 
fractions from pET-28c clone. In addition to the bands between 100kDa and 140kDa 
(expected molecular weight of USP7), low molecular weight bands were also observed in 
the fractions of lysate from pUSP7pET28 clone, especially between 70-100kDa, ~40kDa 
and between 40kDa and 35kDa, suggesting the possibility of truncated protein synthesis 
and/or degradation of recombinant protein (Figure 4.8B). The data show that the complete 
purification of the recombinant USP7 was not achieved by affinity chromatography 
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Figure 4.8. Expression of human USP7 in E.coli BL2 and Rosetta strains. 
Recombinant protein (USP7-His) was assessed by coomassie blue gel staining (A) and 
western blot (B) of the fractions (F1-F5) from BL2, purified using 250mM imidazole from 
lysates of pUSP7pET28 and pET-28c (as indicated). Note the difference in the western blot 
profile of bacteria with USP7 insert and bacteria with empty vector. Fractions eluted using 
elution buffer of different concentrations of imidazole (as indicated) were also examined 
using coomassie gel (C) and western blot (D). Fractions purified from the E.coli Rosetta 
strain containing pUSP7pET28 bacterial lysate were also examined by comassie blue 
staining (E) and western blots (F). 50µl and 10µl from each fraction were used for 
comassie blue gel staining and western blots respectively. For western blots the 
membranes were probed with anti 6xHis HRP conjugated antibodies. The expected 
molecular weight (129kDa) of the recombinant protein (USP7) is indicated by red arrows.  
Key: M (molecular markers); F (fractions) and L (bacterial lysate). 
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using a single concentration of imidazole (250mM) in the elution buffer. Therefore, the 
recombinant protein (USP7) was purified again using elution buffers with increasing 
concentrations of imidazole (Figure 4.8C, 4.5D).  Both comassie gel and western blot of 
the fractions obtained in this regard, showed no significant improvement in the purification 
of the recombinant USP7 as both expected and unexpected molecular weight protein bands 
appeared proportionally in all fractions eluted using 50mM to 300mM of imidazole. In 
order to investigate if the lower than expected molecular weight (<129kDa) bands result 
from interrupted protein synthesis (due to codon bias) of the recombinant protein, the same 
plasmid (pUSP7pET28) was transformed into the Rosetta strain (DE3) of E.coli. The 
protein from the clone lysate was purified by affinity chromatography. Both comassie blue 
stained gel and western blot showed some improvement in procuring the potentially full 
length recombinant USP7 as the bands between 35-40kDa became less intense without 
losing the intensity of bands between 100kDa and 140kDa (Figure 4.8E, 4.8F). In order to 
investigate if these fragments could be readily separated, extracts were subjected to size 
exclusion chromatography. Comassie blue gel staining (not shown) of the fractions showed 
that all the fragments appear to elute with the same profile and not according to their size 
by gel. This might reflect that the fragmented recombinant protein is structurally held 
together and only become separated at denaturation for separation by SDS-PAGE. 
In summary, from the comassie blue stained gel and western blot of the fractions, it is clear 
that the human USP7-His was successfully expressed in the bacteria. However, complete 
purification of the recombinant protein was not attained. Nevertheless the difference in the 
western blot profile of the fractions between the bacteria containing pUSP7pET28 and 
empty vector suggests some fractions (F2, F2A-F3B) from the bacteria hosting 
pUSP7pET28 plasmid could be used for the subsequent studies.  
4.4.2. Probing of USP7-His protein on the EBNA1 array 
EBNA1 glass arrays were probed with 20µg (22µl) of partially purified recombinant USP7 
protein from fraction no. 2 (from BL2 strain). As control, EBNA1 arrays were also probed 
with 20µg (50µl) from fraction 2 of lysate from bacteria containing empty vector. Both 
arrays were developed using anti-6xHis antibodies (Figure 4.9). Probing of the EBNA1 
array with recombinant USP7-His revealed strong binding to spots: 78, 80 and 87 
(particularly the latter) corresponding the residues: Ser386-Gly410; Arg396-Glu420 and 
Pro431-Asp455 respectively. The reported binding site for USP7 interaction on EBNA1 
ranges from Gln436 to Pro450 (Holowaty et al., 2003; Saridakis et al., 2005). This 
sequence can be completely found in peptide 86 to 88. The control fraction showed no  
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Figure 4.9. EBNA1-USP7 interaction. (A) EBNA1 peptide array was probed with 20µg 
of recombinant human USP7 protein and bacterial lysate as indicated.  The arrays were 
developed using anti 6xHis antibodies. The dark spots on array indicate the positive 
binding of the protein.   (B) Tabulated representation of the peptide array of EBNA1 where 
cyan coloured boxes correspond to the binding spots of the recombinant USP7 protein on 
the EBNA1 array. (C) The primary sequence of EBNA1 is shown where residues 
corresponding to the positive spots for USP7 interaction on array are highlighted as yellow 
(peptide 78) and cyan (peptide 87).  
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(A)   Peptide 87. 431-PGAIEQGPADDPGEGPSTGPRGQGD-455  
(B) 
 
(C) 
 
(D) 
 
                                                       (E)      
                                                                       
Figure 4.7. Critical residues involved in EBNA1-USP7 interaction. Alanine scan of the 
EBNA1 peptide 87 (A) was spotted and was probed with 125µg of recombinant human 
USP7 protein (B). The first spot in (C) represents the corresponding wild type sequence 
(peptide 87) spot as indicated. The following spots are the progenies of the peptide 87 
where single amino acid is substituted with Ala or Asp (in case of alanine present in the 
native sequence) in each spot as indicated. A peptide with phosphorylated Ser is also 
spotted on the array (indicated by superscript P).  Probing with the N-terminal and C-
terminal truncated peptides are shown in (D) and (E) with the spotted peptide indicated. 
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binding on the EBNA1 array reflecting the reliability of the approach (Figure 4.9).   
In order to further delineate the USP7 binding site on EBNA1, an alanine scan of peptide 
87 was generated and tested. For this purpose, wild type sequence (corresponding to the 
spot 87; Figure 4.10A) was spotted on the membrane array. In addition, to examine the 
effects of peptide selection, 3 spots, shifting this sequence each by one amino acid (i.e. 
87+1, 87+2 and 87+3) were spotted. Also, to compare this to spot 80 binding, peptide 80 
with each (in turn) of the tyrosine phosphorylated were included. Additionally, derivatives 
of the wild type peptide 87 sequence were included where each amino acid in turn was 
substituted with Ala (Asp in the case where Ala is present in the wild type sequence) from 
the N-terminal (Pro) to the C-terminal (Asp). To define the minimal region on EBNA1 for 
interaction with USP7, further derivatives of peptide 87 were synthesized and spotted 
sequentially truncating from the N-terminus and C-terminus one amino acid at a time. The 
complete set of the array was probed with 125µg (130µl) of the recombinant USP7-His 
protein (fraction 2 from BL2) and developed by probing anti His antibodies (Figure 
4.10B). On this array peptide 80 showed very weak binding (in comparison to peptide 87) 
and this was abolished when either of the tyrosines was phosphorylated. Shifting the frame 
of peptide 87 by one amino acid at a time gave weaker binding for 87+1 but good binding 
with 87+2 and 87+3, relative to peptide 87. Shifting by 5 amino acids either way (peptide 
86 or 88) showed only very weak binding on the original glass slide array. As expected a 
strong binding was observed for the unmodified peptide 87. The array showed that a 
substitution at Asp441Ala weakened the recombinant USP7-His binding with the EBNA1 
peptide whereas substitutions at Gly445Ala and Ser447Ala abolished the USP7-His 
interaction with the peptide. Additionally, phosphorylation at Ser447 also substantially 
decreased the binding of USP7 to the EBNA1 peptide compared to the unmodified peptide 
(Figure 4.10C).  N-terminal truncation of the peptide showed no effect upon USP7-His 
binding to the peptide from deletion of Pro431 to Ala438, however the binding 
significantly dropped upon the further deletion of Asp440 (Figure 4.10D). At the C-
terminal end, no effect on the interaction was observed through the successive deletion of 
Asp455 to Gly449 however, the further deletion of Thr448 reduced the binding and 
deletion of Ser447 completely abolished the peptide 87-USP7-His interaction (Figure 
4.10E). The data collectively shows that the minimal region that is important for the 
EBNA1-USP interaction spans from Asp440-Thr448 on the EBNA1 sequence. 
Furthermore Asp 441, Gly445 and Ser447 were identified as critical residues in this 
interaction with USP7. The minimal binding region peptide alone showed good binding, 
despite the reduced binding seen with peptides 87+1, 86 and 88, which all contain this 
sequence.  
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4.5. Summary of findings  
 Binding of anti-EBNA1 antibodies to the peptide array spots corresponding to the 
specific epitopic regions reflects the sequential specificity of EBNA1 on the array. 
 Binding of the EBNA1 epitope on the array with the conformation sensitive antibody 
(Aza2E8) suggests that the peptides on the array have atleast some correct structural 
attributes. 
 EBNA1 partner proteins, EBP2 and USP7, were successfully expressed as his tag 
fusions using a bacterial expression system, however absolute purification of the 
recombinant proteins would require an additional battery of protein purification 
techniques. Nevertheless, both recombinant proteins were detected on western blots 
suggesting that fractions obtained by purification could be exploited for peptide array 
studies. 
 Binding of recombinant EBP2 to EBNA1 arrays was consistent with the reported 
binding sites (GR1 and GR2 region). 
 A novel binding site of EBP2, downstream (~75 amino acids) to the GR2 region, was 
observed in the slide array but not in membrane array and this novel site is in close 
proximity to the GR2 region in the three dimensional model of EBNA1. 
 Substitutions of some positively charged residues or negatively charged residues of 
EBNA1 with hydrophobic residues, especially in the GR2 region increased or decreased 
the binding of recombinant EBP2 with the EBNA1 peptides (respectively). This 
suggests that electrostatic repulsion between the arginines of GR2 may negatively 
regulate the binding of EBP2 with EBNA1. 
 Phosphorylation of serine residues, especially in the GR1 region enhanced the binding 
of recombinant EBP2 to EBNA1 peptides, suggestive of the positive regulation of 
EBNA1-EBP2 binding by post translation modification. 
 Akin to EBP2, USP7 binding with the EBNA1 array was also consistent with the 
reported binding region. A novel binding site was only observed in the slide arrays.  
 An alanine scan of an EBNA1 peptide which interacts with USP7 revealed the minimal 
binding region required for this interaction and also highlighted critical residues in this 
intermolecular binding. 
 Phosphorylation of serine residues in the USP7 binding site of EBNA1 decreased the 
binding of recombinant USP7 suggesting that phosphorylation of the serine may 
negatively regulate the interaction.  
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4.6. Discussion 
Investigating protein protein interactions is central to developing a working understanding 
of biological systems. Peptide array represent a new methodology to study protein protein 
interactions in vitro. To date the method has been successfully employed in many studies 
such as studying the PDE4D5-β and arrestin interaction (Baillie et al., 2007), PAX protein 
interactions (Okada et al., 2012) and Argonuate-GW182 interactions (Pfaff et al., 2013). 
Despite being highly promiscuous in partner binding, this approach has not been used to 
explore the interaction of EBNA1 with its partner proteins. In the present study we 
explored the validity of this system for protein association studies of EBNA1.  
Structural conformations of EBNA1 peptides on array 
The binding of anti EBNA1 antibodies to their specific epitopes validates the EBNA1 
protein sequence on the peptide array (Figure 4.2). Of these, Aza2E8 binding with EBNA1 
has been suggested to be conformation sensitive (Hearing et al., 1985). Therefore binding 
of Aza2E8 to a 25-mer peptide on the peptide array suggests the presence of native 
structural conformation of peptides on the array. We do not know whether this observation 
could be generalized to the other peptides spotted on the array or limited to the spots where 
Aza2E8 binds. One way of evaluating would be to use a conformational sensitive set of 
antibodies that covers the full length of the EBNA1 molecule (but such a set is not 
available).  
Heterologous expression of EBNA1 partner proteins in bacteria 
For protein protein interaction studies using peptide array, partially purified protein is 
preferential for challenging the binding partner array. In this study, two human proteins, 
EBP2 and USP7 were expressed in E.coli BL2 using the bacterial expression vector 
(pGEX-6P-1 and pET-28c). Though both proteins were expressed successfully in the 
bacteria, complete purification was not achieved in either case. First in both cases, higher 
than expected molecular weight proteins were observed. These differences could be 
explained in terms of difference in the migration rate of the marker proteins and 
recombinant protein due to the presence of imidazole in the latter, which may resist the 
flow of current. Alternatively, it is not uncommon for protein to migrate differently from 
their expected size, due to conformational attributes. It is also possible that these proteins 
may be bacterial protein contaminants, however the respective size bands were not 
observed in comassie stained gel and western blot of the fractions of bacterial lysate from 
bacteria containing empty vector (pET-28c). Additionally, the gels of corresponding 
fractions were probed with the anti EBP2 and anti USP7 antibodies (data not shown) which 
supports their identity as EBP2 and USP7 respectively. This problem could be resolved by 
removing the imidazole from the fractions by dialysis, however, it may result in the 
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significant loss of the protein (possibly variably from each of the fractions). Additionally, 
mass spectrometric analyses of the proteins of unexpected size can reveal their true 
identity.  
Comassie blue staining and western blots of the fractions obtained from bacteria with 
EBP2 and USP7 inserts showed multiple small size (in comparison to expected) protein 
bands. In some cases similar sized bands were also observed in the comassie blue stained 
gel of the fractions from bacteria with empty vector which indicates that some small bands 
are due to the contamination with bacterial proteins during purification. However, none of 
those bands were found to be responsive to anti-His antibodies in western blotting. The 
small size bands (smaller than expected for recombinant proteins) detected are in Westerns 
blots are therefore either the degraded products of the recombinant protein or are the result 
of truncated protein synthesis. Although E.coli BL21 lacks many of the bacterial proteases 
it still has some proteases which could potentially be resistant to the enzyme inhibitors 
used in the lysis buffer and may degrade the recombinant protein before or after the lysis. 
As these human proteins (EBP2 and USP7) have been expressed in bacteria which lack the 
guidance machinery for protein folding (chaperone system), the recombinant proteins may 
have been misfolded. This misfolding of the recombinant protein may result in 
thermodynamic instability of the proteins, which in turn may promote their degradation 
despite the lack/inhibition of major proteolytic enzymes. In addition to lysozyme, 
sonication was used for the bacterial lysis which may also lead to the degradation of 
proteins due to the generation of heat. In the present study, both altering the sonication 
conditions and protease inhibitor composition and concentration did not make any 
noticeable impact on the purification profile of recombinant proteins (data not shown). 
Alternatively, it is possible that the expression of the recombinant protein was hampered 
due to the differences in the codon preferences between prokaryotes and humans. This 
negative effect on the heterelogous protein expression could be due to the translational 
frame shifting (Spanjaard and van Duin, 1988), premature termination of translation 
(Gerchman et al., 1994), amino acid misincorporation (Calderone et al., 1996) and in 
frame translational hop (Kane et al., 1992). The human EBP2 gene of 306 codons contains 
23 codons (7.5%) which are rare in bacteria, similarly, out of a total of 1103 codons of 
human UPS7, 77 codons (6.9%) are rare in the E. coli genome. The presence of these rare 
codons may interrupt the protein synthesis prematurely resulting in the production of small 
proteins which were observed in the comassie blue stained gels and western blots of the 
respective fractions. To address this possibility, the Rosetta DE3 strain of E.coli was used 
to express the recombinant proteins. In both cases a minor improvement was observed in 
expression and procurement of the full length recombinant proteins. This observation is 
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consistent with an earlier report, based on the assessment of 68 recombinant proteins, 
illustrating that recombinant proteins that express well in BL21(DE3) did not show any 
significant improvement in production when expressed in the Rosetta(DE3). Furthermore, 
in certain cases reduced expression of the recombinant protein was observed which 
otherwise expressed well in BL21(DE3) (Tegel et al., 2010). This is possibly due to the 
extrametabolic pressure in the Rosetta(DE3), which harbours an extra plasmid to encode 
and compensate for rare codon tRNAs. However, in the same study (Tegel et al., 2010), 
out of the 68 different recombinant proteins (encoded by genes with rare codons), some 
degree of improvement was observed in the procurement of the full length recombinant 
proteins (86% of the total tested for purity) when expressed in  Rosetta(DE3) as compared 
to when the same proteins were expressed in the BL21(DE3) (74% of the total tested for 
purity). This suggests that the effect of Rosetta strains to compensate for rare codon usage 
for heterelogous expression of proteins, differ with the specific protein. Additionally, a 
more pronounced negative effect was observed in the heterelogous expression of 
recombinant proteins when the rare codons are present at the 5’ end of the encoded gene 
(Kim et al., 2006). It was also found that attaching a long N-terminal tag or fusion protein 
could improve the expression and recovery of full length recombinant protein (Tegel et al., 
2010). Alternatively, purification could be enhanced by using an expression vector that 
fuses the 6xHis tag at the C-terminus of the recombinant protein, hence theoretically, 
allowing only the full length recombinant protein product to bind with the Ni beads. The 
purification strategy could be further enhanced by employing dedicated tools for protein 
purification such as reverse phase or ion exchange column chromatography. However, an 
advantage of the array system is that complete purification of the protein is not required, 
indeed a complex mixture can be used, so long as the detecting antibodies are specific.  
EBNA1-EBP2 interaction 
Probing of the EBNA1 peptide array with recombinant GST tagged or His tagged EBP2 
proteins showed nearly identical binding sites, binding to peptides incorporating GR1, 
GR2 and a new site represented by peptide 88 to 91 (BBR: Gly456-Lys460). Binding of 
EBP2 within GR1 and GR2 regions of EBNA1 has been previously demonstrated using the  
yeast two hybrid system and by co-immunoprecipitation studies (Shire et al., 1999; Kapoor 
and Frappier, 2003; Nayyar et al., 2009). Both GR regions are rich in glycine and arginine 
residues and are separated by a gly ala repeat of around 225 amino acids in the EBV 
EBNA1 sequence. The GR2 region of EBNA1 has been shown to have greater affinity for 
EBP2 interaction than GR1 and is critical (unlike GR1) for maintenance of the EBV 
episome (Nayyar et al., 2009). The interaction of EBP2-His with peptides 88 to 91 
(incorporated sequence Gln436-Leu485) has not been reported previously and in a 2 hybrid 
Mushtaq Hussain, 2013  135 
assay, deletion of this region along with C-terminal DNA binding region, did not show any 
noticeable effect on the EBNA1-EBP2 interaction (Shire et al., 1999). In contrast to GR1 
and GR2, this region is not particularly rich in Gly and Arg residues, however, a stretch of 
three positively charged residues, preceded with two glycine residues (Gly456-Lys460) is 
present within the BBR of this site. It is possible in the eukaryotic cell this site may remain 
concealed in the tertiary conformation of EBNA1 but once exposed (as in an EBNA1 
array) may form another interaction point between EBNA1 and EBP2.  Moreover, in the 
preparative array peptide 91 did not show positive binding of EBP2-His. This could be due 
to the difference in shape of the peptide spot between the arrays, which is convex in the 
case of glass array and flat in the preparative arrays, giving the former more surface area 
for contact. However, in the three dimensional model of EBNA1, the BBR of peptide 88 
and 91 (Arg451-Lys460) resides on a loop which is located proximal to the GR2 region 
(main EBP2 interaction site) (Figure 4.11). This suggests that the third site may be 
involved in binding with EBP2 in vivo. Sensitivity of the peptide array for the challenged 
protein relies on the purity and concentration of the spotted peptide (Volkmer et al., 2012). 
Given the purity of spotted peptide differs between analytical and preparative arrays, 
where the latter is less pure than the former, this may result in the observational differences 
in the binding partner interaction on the same sequence on those arrays. Additionally 
and/or alternatively, the possibility of difference in the secondary structure conformation of 
the peptides between the glass array and membrane array spot could also contribute in the 
observed differences. As recombinant protein expressed in the bacteria, which have less 
advance chaperone machinery to guide the protein folding, the recombinant protein 
molecules may adopt different structural conformation solely on the thermodynamic 
stability which in turn may produce observational variations within the same type or 
different type of arrays (analytical and preparative). However, these problems could be 
addressed by adopting rigorous control over the purity and concentration of the peptides 
and partner proteins. Secondly, expression of the recombinant proteins in eukaryotic cells 
especially of mammalian origin may also provide more control and may generate more 
consistent results on peptide arrays.  
On EBNA1 preparative array, spots corresponding to peptide 10 (Gly46-Val70) and 
peptide 70 (Gly346-Arg370) showed positive binding with EBP2-His. Alanine substitution 
of peptide 70 has shown that modification of certain residues weakens/abolished the 
binding of EBP2-His. Previously it has been observed that small deletions in the EBP2 
binding region did not affect the binding of EBP2 with EBNA1 nor the maintenance of its 
genome within the infected cells (Shire et al., 1999). Taken together, it is reasonable to 
propose that Glu359 to Glu368 (within peptide 70) may represent a candidate for the 
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minimal binding region on EBNA1 for its interaction with EBP2. This possibility could be 
evaluated by generating truncated peptides of this region and probing them with EBP2. 
Furthermore, a reciprocal array (EBP2 array probed with EBNA1 protein) could further 
highlight the interacting region for EBNA1 on the binding partner (EBP2). Replacement of 
Ala with Asp (Ala56 of peptide 8) improved the binding whereas replacing Glu359 and 
Glu367 (of peptide 70) with alanine almost abolished the EBP2-His interaction with the 
corresponding peptide spot. Similarly, replacement of lysine residue (Lys379 of peptide 
73) with alanine also improved the binding. Taken together these observations suggest the 
replacement of non polar or positively charged residues with negatively charged or 
hydrophobic amino acids enhances the binding of EBP2 to the peptides. Such substitutions 
may reduce the electrostatic and/or steric repulsion due to the abundance of positively 
charged residues (Arg) in the EBP2 binding regions. This is also consistent with the data 
which shows phosphorylation (which would introduce a negative charge) of Ser60, Ser62 
(incorporated in peptide 10) and Ser 475 (within peptide 91) improved the binding of 
EBP2-His with EBNA1, despite the observation that alanine substitution of these residues 
in their native peptide did not make any difference in the binding of the EBP2-His.  
 
 
Figure 4.11. EBNA1-EBP2 interaction. Surface topology of three dimensional model of 
EBNA1 is shown, where the GR2 region and the BBR (Gly456-Lys460) of third site 
(observed in this study) are highlighted with purple and red respectively.  
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It is possible that these post translational modification events may not be necessary for the 
EBNA1-EBP2 interaction however could enhance it. However, replacement of the 
positively charged arginine residues in turn, with alanine did not alter binding. However, it 
has been shown that arginine residues, particularly those present in the GR2 region, could 
be methylated and this contributes to localization of EBNA1 molecules within the cells 
(Shire et al., 2006). These post translational modifications of the EBNA1 molecule are 
mediated by PRMT1 and PRMT5 proteins and found to alter the intracellular localization 
of the EBNA1 molecule (Shire et al., 2006). Addition of methyl groups could alter the 
electrostatic properties and structural features of the binding region as well as the structure 
and the effect of these methylations on the EBP2 interaction remains to be evaluated. 
In summary, the data support previous reports in relation to the binding region of EBNA1 
for EBP2 (Shire et al., 1999; Kapoor et al., 2003; Nayyar et al., 2009) and also highlights a 
few potentially critical residues involved in this interaction. The data also show the 
possibility that phosphorylation of serines at the N-terminus may contribute to the binding 
of EBP2 at the GR1 region of EBNA1. However, because of some technological 
limitations, validation of these observations essentially requires additional biochemical and 
functional studies. For example EBP2 interacts with EBNA1 in its complexed form with 
viral DNA, which represents the dimer state of the molecule (Shire et al., 1999; Kapoor et 
al., 2003; Nayyar et al., 2009). The peptide array of EBNA1 reflects short segments of the 
EBNA1 sequence. The three dimensional conformation of EBNA1 under in vivo 
conditions may make some of these sites buried and not available for the partner protein 
interactions. Therefore further verification, using tools for investigating the protein protein 
interaction, is required to substantiate or refute the present findings. Moreover, EBP2 itself 
can form a homodimer (Tsujii et al., 2000) and the recombinant EBP2 may or may not be 
in the dimer state. Therefore expression of EBP2 in eukaryotic cells might provide a more 
suitable system for producing EBP2 molecules in near native conformation.  
EBNA1-USP7 interaction 
Probing EBNA1 peptide arrays with USP7-His protein showed strong binding of USP7 at 
peptide 87, supporting previous reports and highlighting the interacting region on EBNA1 
for USP7 interaction (Holowaty et al., 2003; Saridakis et al., 2005). Also consistent with 
the earlier studies, probing truncated peptides of EBNA1 with USP7-His demonstrated the 
minimal binding region spanning from Asp440 to Thr448, with Asp441, Gly 445 and 
Ser447 being most critical in establishing the EBNA1-USP7 interaction (Saridakis et al., 
2005). Although in the EBNA1 octapeptide (DPGEGPST) USP7 (MATH domain) 
complex no hydrogen bonds were observed between Gly445 and the MATH domain of  
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Figure 4.12. EBNA1-USP7 binding. The space filled image of EBNA1 octapeptide and 
USP7 MATH domain complex (PDBid; 2YY3; from Saridakis et al., 2005) is shown 
where the MATH domain is represented by purple surface while EBNA1 octapeptide is 
shown with cyan and green. The spatial position of the three critical EBNA1 residues 
(Asp441, GLy445 and Ser447) within is indicated.  Note the kink in the EBNA1 peptide at 
the Gly445 position.  
 
 
USP7, a close inspection of the atomic coordinates of this complex shows that Gly445 may 
provide essential flexibility for the peptide to curl and accommodate itself in the cavity of 
the USP7 MATH domain (Figure 4.12). This suggests that EBNA1 peptides may adopt at 
least some structural conformation on the array. Moreover, phosphorylation of Ser447 
reduces the binding of USP7 with the EBNA1 peptide. This serine was not found to be  
phosphorylated in the EBNA1 extracted from the BJAB cell line (Duellman et al., 2009). 
Consistent with this, our EBNA1 structural model, Ser447 did not show a propensity to be 
phosphorylated.  
EBNA1 interacts a variety of host proteins to carry out its biological role (Frappier, 2012; 
Smith and Sugden, 2013). To date many of these interactions have not been mapped on the 
EBNA1 sequence. In addition, the binding regions of EBNA1 have also not been mapped 
on its respective partner proteins. Owing to the binding of anti EBNA1 antibodies and 
recombinant proteins to the expected protein region on EBNA1 peptide array, it is 
reasonable to suggest that the present approach could be reliably used to map the binding 
sites of other potential and known interaction partners of EBNA1. The data gathered could 
direct the functional assessments of those intermolecular associations and could further be 
exploited for designing therapeutic interventions against EBNA1.  
 
MATH Asp441 
Gly445 
Ser447 
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Chapter 5. Evolution of Ubiquitin 
Specific Protease 
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5. Results: Evolution of Ubiquitin Specific Proteases 
5.1. Introduction 
Ubiquitination and deubiquitination play a major role in regulating the turnover of properly 
and improperly folded proteins in eukaryotic cells. This chapter describes the 
phylogenomic analysis of a family of deubiquitinating enzymes, Ubiquitin Specific 
Proteases (USPs). The diversity and phylogenetic relationship of the USP homologues 
were explored in representative species of different taxonomic lineages of animals ranging 
from protozoa to primates. Species were selected on the basis of their placement in the 
evolutionary tree of life and availability of the full genome sequence in the public 
databases. In addition, to resolve any ambiguous phylogenetic relationship of USP 
homologues, evolutionary distances between the sequences were estimated. In order to 
explore the gene expansion mechanisms at work, genomic syntenies of paralogues in 
humans were compared. Phylogenetic analyses of USPs were also compared with their 
gene expression profile, protein domain composition and protein interaction network to 
investigate the tissue specificity, protein domain promiscuity and molecular binding 
partners, which in turn reflects the functional divergence of the proteins. Although some 
USPs of humans have been characterized extensively for their structural and functional 
attributes (Komander et al., 2009), the evolutionary history of these genes remains largely 
unaddressed. To the best of my knowledge this study is the first account exploring the 
evolutionary history of USPs. Given the increasingly evident involvement of USPs in 
several human diseases including cancers, such a study holds value for both general and 
medical biology. 
5.2. Identification of paralogous groups  
The Ensembl paralogy prediction pipeline was used to collect the USP sequences encoded 
by the human genome. In total 86 homologues of USPs were identified in the human 
genome, which are divided into 16 paralogous groups (Table 5.1). Group 2 is the most 
densely populated, including 32 USP17 like genes (some of which are predicted as 
pseudogenes) in addition to USP2, USP8, USP50, USP21, USP36 and USP50. 
Interestingly, group 6 contains 21 paralogous genes, of which only USP6 contains a 
peptidase C19 domain, a characteristic domain present in all other USPs. This suggests that 
the paralogous relationship between USP6 and other members of group 6 (as indicated by 
the Ensembl) is mainly due to the presence of a TBC (Tre-2/Bub2/Cdc16) domain (found 
exclusively in the members of group 6).  
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Paralogous sets Members 
Group 1 USP1, USP12, USP35, USP38, USP46 
Group 2 USP2, USP8, USP17 (32 copies including intact orf and 
pseudogenes), USP21, USP36, USP42, USP50 
Group 3 USP3, USP16, USP20, USP22, USP33, USP44, USP45, USP49, 
USP51, USP27 
Group 4 USP4, USP11, USP15, USP19, USP31, USP32, USP43 
Group 5 USP5, USP13 
Group 6* USP6, USP6NL, TBC1D3(19X) 
Group 7 USP7, USP9X, USP9Y, USP18, USP24, USP34, USP40, USP41, 
USP47, USP48 
Group 8 USP10 
Group 9 USP14 
Group 10 USP25, USP28 
Group 11 USP26, USP29, USP37 
Group 12 USP30 
Group 13 USP39 
Group 14 USP52 
Group 15 USP53, USP54 
Group 16 CYLD 
 
Table 5.1. Paralogous groups of Ubiquitin Specific Peptidase. Shown here is the 
distribution of human USPs in 16 paralogous groups, as predicted by the Ensembl genome 
browser paralogy pipeline. Asterisk (*) denotes that except USP6 other homologues 
present in this group do not contain the characteristic peptidase C19 domain, which is 
present in all other USPs. The homologous/paralogous relationship between USP6 and 
other members of this group is thus based on the presence of a TBC domain. 
 
5.3. Distribution of USPs across the animal kingdom 
To investigate the distribution of USPs across the animal kingdom, protein sequences of 
full length human USP homologues and their corresponding C19 domain were BLASTed 
against the genomes of selected organisms (Table 5.2). Organisms were selected that are 
located at important transitional and/or speciation events in the evolutionary tree. Homo 
sapiens (Hs, human), Mus musculus (Mm, mouse), Bos taurus (Bt, cow) and Canis lupus 
familaris (Cf, dog) genomes were screened to represent the major lineages of eutherian 
mammals; representing primates, rodentia, cetartiodactyla and carnivora, respectively. 
Genomes of Monodelphis domestica (Md, opossum) and Ornithorhynchus ananitus (Oa, 
platypus) were explored as representatives of early divergent mammalian lineages, those of 
marsupial mammals and monotremata respectively. To represent the non mammalian 
vertebrates: reptiles, amphibians and fishes, genomes of Anolis carolinesis (Ac, lizard), 
Xenopus tropicalis (Xt, clawed toad) and Danio rerio (Dr, zebra fish), respectively, were 
screened. Ciona intestinalis (Ci, tunicate) was taken as a model for non vertebrate 
chordates. Strongylocentrotus purpuratus (Sp, sea urchin) reflects a non chordate 
deuterostome lineage which separated from the common ancestor with all other chordates                               
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Grps USP Hs Mm Bt Cf Md Oa Ac Xt Dr Ci Sp Dm Ce Hm Dd Cr 
1 1                 
12                 
46          
35         Lc        
38          
2 2                 
21                 
17                 
36                 
42          
8                 
50         Ga        
3 3                 
16                 
45          
20                 
33     Sh     
22                 
27                 
51   Ss              
44                 
49               
4 4               2  
15         Ga 
11          
31                 
43              
19                 
32                 
5 5                 
13          
6 6                 
7 7                 
9X         Ga        
9Y                 
24                 
34               2  
41                 
18                 
48                 
40                 
47         Ga        
8 10     Sh            
9 14                 
10 25     Sh            
28          
11 26                 
29   Bm              
37                 
12 30                 
13 39                 
14 52                 
15 53                 
54          
16 CYLD                 
Total 55 53 53 51 47 38 46 44 47 29 31 23 17 23 17 11 
Table 5.2. Distribution of USPs across the animal kingdom. The presence in the given 
genome of USP homologues, as identified by genomic BLAST of selected animals is 
indicated (shaded brown). The incomplete sequences with unclear orthologous relationship 
(hence not included in the analysis) are shaded green. The total number of genes (including 
USP homologues with C19 domains and excluding the multiple homologues of USP17) 
found in particular species are indicated in the last row. Also excluded are the plant USP 
homologues found in Dd and Cr. Genes detected in species (other than the species 
abbreviated in the row header, as indicated in the section 1.3) of the same 
taxonomic/evolutionary group are shown: B. mutus (Bm), L. chalumenae (Lc), S. harissi 
(Sh) and G. aculateus (Ga). The lack of clear orthology with human/vertebrate USP genes 
(probably reflecting the orthologues prior to duplication in vertebrate species) are 
represented by fused boxes. 
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around 740 million years ago. Drosophila melanogaster (Dm, fruit fly) and 
Caenorhabditis elegans (Ce, nematode) were used as representatives of protostomes. 
Hydra manipulata (Hm, hydra) and Dictyostelium discodium (Dd, slime mould) genomes 
provide information about the metazoa-protozoan split, which occurred more than 1100 
million years ago (MYA). While the genome of green algae, Chlamydomonas reinhardtii 
(Cr, chlamydomonas) was screened for USP homologues. Collectively with slime mould, it 
provides the information for the presence of USP homologues before plant-animal split 
(>1200 MYA). Where the orthologues could not be found in these species, BLAST search 
was extended to another species of the corresponding taxonomic lineage in order to 
generalize the observations. For example, the mouse, opossum, cow and dog genome 
BLAST search was expanded to Rattus rattus (Rr, rat), Sarcophilus harissi (Sh, Tasmanian 
devil) Sus scrofa (Ss, pig) and Ailuropoda melanoleuca (Am, panda) respectively. 
Similarly, Gasterosteus aculeatus (Ga, stickleback) and Latimera chalumenae (Lc, 
Coelacanth) were generally used for the zebra fish and Brachiostoma floridae (Bf, 
lancelet) genome was screened in place of tunicate genomes respectively. Only genes with 
the characteristic peptidase C19 domain were included in the analysis. Only one of the 
multiple homologues of USP17 (only found in eutherian mammals) was included to better 
reflect the long term evolutionary changes in the number of USP homologues across the 
animal kingdom (Table 5.2). 
In total, 55 paralogues of USPs (only including genes with the peptidase C19 domain), 
encoded by the human genome, were identified. With the exception of platypus, most of 
these homologues were traced back to zebra fish (Table 5.2). Two homologues (USP6 and 
USP41) were found only in humans and great apes (primate lineage). Several genes in 
vertebrates are annotated as USP6-N-terminal like (USP6NL), primarily due to the 
presence of a TBC domain at the N-terminus, but do not have a peptidase C19 domain. 
USP29 and USP51 orthologues were only found in humans, mice and cow/pig (of the 
species examined). BLAST results show that USP17, USP26 and USP27X homologues are 
restricted to eutherian mammals. The platypus genome BLAST shows the existence few 
USP homologues compared to human and zebra fish, indicative of extensive 
species/lineage specific gene loss in monotremes or incomplete genome assembly and/or 
annotation. Similarly, certain USP homologues (including USP46 and USP50, present in  
bony fishes and mammals) were not identified in the genome of clawed toad suggesting 
species/lineage specific gene loss. 
Taken together, the genome BLAST results demonstrate that the existing array of 
vertebrate USPs share deep evolutionary history, as orthologues of almost all of the human 
USPs exist in non mammalian vertebrates, including fish. Additionally, the total number of 
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USP homologues points to an extensive expansion of USPs in early vertebrates (Table 
5.2). In most cases, at least one paralogue of each group is present in protozoa. This 
suggests that the USP paralogous groups share a deep ancestral history which predates the 
protozoa-metazoan split. In order to explore the USP homologues in more distantly related 
lineages, the BLAST search was extended to chlamydomonas and microbial genomes. The 
algae chlamydomonas is a modern day representative of the ancestral root of plants and 
BLAST search revealed the presence of 13 USP homologues, of which 11 showed 
homology with the USPs found in different animal species. This suggests the presence of 
USP proteins in the common ancestor of plants and animals.  A BLAST search using the 
C19 protein domain sequence of all available microbial genomes in the databases provided 
only two positive hits (nearly identical homologues) in the bacterial species Candidatus 
amoebophilus asiaticus of phylum bacteriodes, indicative of a prokaryotic origin of USPs. 
However, given the breadth of microbial genomes examined, horizontal gene transfer 
offers a likely explanation for the presence of the peptidase C19 domain in microbes.  
5.4. Phylogenetic analyses of USPs 
The robustness of phylogenetic reconstruction of a gene family is heavily dependent on the 
accuracy of sequence alignment. As observed in the datamining, USP homologues in 
humans and other animals vary considerably in protein length and protein domain 
architecture. Thus in order to reconstruct the phylogenetic history of USPs, only the 
common peptidase C19 domain protein sequences were aligned. Similarly, to optimize the 
reliability of the tree, phylogenetic trees of each paralogous group were reconstructed 
separately from homologues of both vertebrates and non vertebrates (NV, including 
invertebrates and non vertebrate chordates) using the maximum likelihood method. NV 
homologues were included/excluded in the tree construction on the basis of BLAST and 
reciprocal BLAST score to the query sequence (human USP homologues). For 
reconstruction of evolutionary trees for each paralogous group, only those NV homologues 
were included which showed first ranked similarity (highest blast score and lowest e value) 
with any gene included in the respective paralogous group, in both BLAST and reciprocal 
BLAST. Trees were reconstructed with and without rooting with the C19 domain sequence 
of a protein from bacteria Candidatus amoebophilus asiaticus (YP003573189), one of the 
two (nearly identical) C19 domain bearing prokaryotic proteins. For clarity, the 
evolutionary relationship is described separately for each paralogous group. 
Group 1. Group 1 comprises five USP homologues: USP1, USP12, USP35, USP38 and 
USP46. In phylogenetic tree reconstruction, these paralogues form distinct clades of 
USP12/46, USP35/38 and USP1 (Figure 5.1).  
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Figure 5.1. Phylogenetic history of group 1 USP homologues. (A) A phylogenetic tree 
was reconstructed by the maximum likelihood method using C19 domain protein 
sequences,  adopting the Jones Taylor and Thornton model with gamma distribution and 
with some invariable sites (JTT+G+I) (Jones et al., 1992). All vertebrate homologues are 
annotated according to their orthologous relationship, whereas NV homologues are 
represented by the accession numbers. (B) Branch length format of the same tree is shown 
where all monophyletic clades are collapsed as indicated. Note the difference in the 
evolutionary rate between different branches.  
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Distinct homologue of this group was identified each in slime mould and chlamydomonas 
which shows orthology with the USP12/46 clade (100% bootstrap support) while other 
partial sequence of slime mould (XP645628) (found by the genome BLAST) shows 
similarity with the USP35/38 clade. This suggests a premetazoan origin of USP12/46 and 
USP35/38 ancestral genes. Single NV homologues (of several species examined) of 
USP12/46 and USP35/38 outgroup the two vertebrate specific subclades USP12 and 
USP46, USP35 and USP38 respectively, reflecting the expansion of these USPs prior to 
vertebrate divergence (parallel with timing of whole genome duplication events (1R and/or 
2R)) (Figure 5.1A). USP12/46 clade share ancestry with the USP1 clade which origin 
could be reliably placed at least with the emergence of coelomates, owing to the presence 
of fruit fly and sea urchin homologues in the respective clade. However, as it outgroup 
USP12/46 clade, it is possible that USP1 also has a premetazoan origin, but had lost in 
slime mould and hydra. Alternatively, as apparent from the branch lengths of USP1 
orthologues, the higher substitution rate may result in the outgrouping of this clade (Figure 
5.1B).  
Group 2. Group 2 includes seven USP paralogues (discounting the multiple homologues of 
USP17): USP2, USP8, USP17, USP21, USP36, USP42 and USP50. Phylogenetic 
reconstruction of the homologues reveals distinct clades of USP8/USP50, USP2/21 and 
USP17/36/42 (Figure 5.2).  
In genome BLAST, two homologues of this group were identified in chlamydomonas 
while one homologue was found in the slime mould, all groups with USP17/36/42 clade, 
reflecting the origin of this group at or before plant-animal divergence. Two homologues 
of hydra show orthologous relationships with USP8 (sharing ancestry with USP50) and 
USP17/36/42 clades and one partial sequence (XP004208370) of the organism shows 
similarity with USP2/21 clade. This suggests the divergence of USP8, USP17/36/42 and 
USP2/21 ancestral gene occurred in or at the common ancestor of metazoans. Interestingly, 
a fruit fly homologue joins the vertebrate USP2 subclade with relatively weak bootstrap 
support (44%) while a tunicate homologue forms an outgroup branch to both USP2 and 
USP21 subclades forming a single monophyletic clade (97% bootstrap support) (Figure 
5.2). The slightly off position of the fruit fly or tunicate sequence could be explained in 
terms of difference in substitution rate in either gene. Single NV homologues (except fruit 
fly NP608462) out group vertebrate specific USP2 and USP21 subclades, USP36 and 
USP42 sub clades, similarly the USP50 clade is constituted by only vertebrate 
homologues. This suggests expansion of these USPs with the origin of vertebrates. USP17 
homologues were only identified in eutherian mammals (of those examined) suggesting a 
recent origin of the genes despite outgrouping all the chordates USP36/42 homologues 
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Figure 5.2. Phylogenetic history of group 2 USP homologues. (A) A phylogenetic tree 
was reconstructed by the maximum likelihood method using C19 domain protein 
sequences,  adopting the Jones Taylor and Thornton model with Gamma distribution and 
with some invariable sites (JTT+G+I) (Jones et al., 1992). All vertebrate homologues are 
annotated according to their orthologous relationship, whereas NV homologues are 
represented by the accession numbers. (B) Branch length format of the same tree is shown 
where all monophyletic clades are collapsed as indicated. Differences in the branch length 
represent noticeable change in the substitution rate. (C) Graph shows the pair wise 
evolutionary distance between USP17 and USP36 (green) or USP17 and USP42 (pink). 
Large and small horizontal bars represent mean and standard error of mean respectively. 
The statistical significance of the difference in evolutionary distance was estimated by 
Wilxon signed rank test and the estimate of significance is indicated suggesting that 
USP17 is similar to USP42. 
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(Figure 5.2A), therefore contradicts the species evolutionary tree. The branch length of 
USP36/42/17 clade indicate faster evolution compared to other monophyletic clades of 
group 2 (Figure 5.2B), nevertheless the pair wise evolutionary distance comparison suggest 
the similarity between USP17 and USP42 (Figure 5.2C). With regard to USP17, there are 
32 homologues (nearly identical) encoded by the human genome and in a previous 
phylogenetic analysis of the USP17 subfamily, paralogues genes from each species form 
distinct clades from orthologues, which reflects intraspecies expansion of USP17 in 
different eutherian mammals (Burrows et al., 2010). For convenience, the C19 domain 
sequence of only the largest protein encoding homologue of USP17 from each species 
(where found) is considered in this analysis.  
Group 3. Group 3 comprises ten USP paralogues: USP3, USP16, USP20, USP22, USP27, 
USP33, USP44, USP45, USP49 and USP51. These paralogues form distinct clades in the 
tree with USP27 and USP51 grouping with USP22, a USP44/49 clade, a USP16/45 clade 
and a USP33/20 clade sharing ancestry with USP3 clade (Figure 5.3).   
One distinct homologue of slime mould was identified in this group which outgroups the 
USP16/45 clade, placing the origin of this group in the common ancestor of animalia. Four 
USP homologues of group 3 were identified in hydra, of these one aligns with 
USP22/51/27 clade which shares ancestry with USP44/49 clade, two others with USP3 and 
USP16/45, whereas one partial sequence (XP004206986) shows similarity with USP20/33 
clade (Figure 5.3). This suggests that the ancestral gene of group 3 had expanded to four 
genes at least by the emergence of the common ancestor of metazoans. These genes may 
have been present in the protozoan ancestor but since may have been lost from slime 
mould. The next evidence for expansion is the appearance of tunicate homologue of 
USP44/49 clade. Separation of two subclades is evident at the root of vertebrates for 
USP16 and USP45; USP44 and USP49 and USP33 and USP20. USP27 and USP51 
homologues were only found in some eutherian mammals suggesting a recent separation 
from USP22 (Figure 5.3).  
Group 4. Group 4 includes seven USP paralogues: USP4, USP11, USP15, USP19, USP31, 
USP32 and USP43. In the evolutionary tree USP4/11/15 group together to form a single 
monophyletic clade, USP31/43 forms a clade, whereas USP19 and USP32 individually 
forms two distinct clades (Figure 5.4).  
In chlamydomonas genome, only one homologue of group 4 USP was found which groups 
with USP4/5/11 clade suggesting the origin of this group before or at the common ancestor 
of animal and plant. Whereas two homologues of slime mould align with USP4/11/15 
clade, and one groups with USP32 clade, reflecting the premetazoan divergence within 
group 4. One hydra homologue shares shows lineal ancestry with USP4/11/15 clade  
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Figure 5.3. Phylogenetic history of group 3 USP homologues. (A) A phylogenetic tree 
was reconstructed by the maximum likelihood method using C19 domain protein 
sequences,  adopting the Jones Taylor and Thornton model with Gamma distribution and 
with some invariable sites (JTT+G+I) (Jones et al., 1992). All vertebrate homologues are 
annotated according to their orthologous relationship as found in studies, whereas NV 
homologues are represented by the accession numbers. (B) Branch length format of the 
same tree is shown; note the difference in the evolutionary rate (substitution rate) in 
different monophyletic clades. 
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Figure 5.4. Phylogenetic history of group 4 USP homologues. (A) A phylogenetic tree 
was reconstructed by the maximum likelihood method using C19 domain protein 
sequences, adopting the Jones Taylor and Thornton model with Gamma distribution (Jones 
et al., 1992). All vertebrate homologues are annotated according to their orthologous 
relationship, whereas NV homologues are represented by the accession numbers. (B) 
Branch length format of the same tree where all monophyletic clades are collapsed is 
shown.  
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whereas one groups with USP19 clade. A single partial sequence of hydra 
(XP00216354564) shows similarity with USP32 homologues in the BLAST search. This 
suggests that early expansion of group 4 USPs occurred prior to the divergence of 
metazoan resulting in the formation of USP4/11/15, USP32 and USP19 ancestral genes. 
Subsequent expansion in this group was observed in USP31/43 with orthologues present in 
vertebrates, tunicate, sea urchin and fruit fly. Single NV homologues (except slime mould) 
outgroup the vertebrate specific USP4, USP11 and USP15 subclades; USP31 and USP43 
subclades, indicative of vertebrate specific expansion of USPs (Figure 5.4).  
Group 5. Group 5 comprises two USP paralogues: USP5 and USP13. Vertebrates USP5 
and USP13 homologues form separate subclades in the phylogenetic tree and share lineal 
ancestry with one homologue of tunicate, sea urchin, fruit fly, nematode, hydra, slime 
mould and chlamydomonas (Figure 5.5A). This suggests the existence of a single ancestral 
gene in the common ancestor of plant and animals, which expanded into separate USP5 
and USP13 genes at the base of vertebrates. The branch length of both vertebrate specific 
USP5 and USP13 shows that since divergence both genes have evolved at different rate 
(Figure 5.5B). 
Group 7. Group 7 comprises nine USP paralogues: USP7, USP9 (X and Y), USP18, 
USP24, USP34, USP40, USP41, USP47 and USP41. All of these paralogues (except 
USP41) form distinct clades in the phylogenetic tree reconstruction (Figure 5.6A).  
BLAST results revealed existence of two USP homologues in the chlamydomonas 
showing homology with group 7 members. In phylogenetic reconstruction these 
homologues group with USP7 and USP48, suggesting pre animal-plant split origin and 
divergence of the group. In slime moulds five homologues of this group were identified 
which aligned with the USP7, USP34 (two homologues) USP40 and USP48, reflecting the 
expansion of USPs of group 7 prior to the origin of metazoans. Six USP homologues of 
hydra show similarity with group 7 paralogues and in the phylogenetic analysis, of which 
two align with USP7 and USP48. The remaining four show lineal ancestry with USP47 
(showing ancestry with USP40), USP34 (sharing ancestry with USP9 and USP24), USP24 
and USP9. A distinct clade of USP18/41 is populated with only vertebrates homologues 
representing the vertebrate specific expansion of the gene (Figure 5.6), however it out 
groups all other monophyletic clades of group 7, potentially due to the difference in the 
substitution rate (Figure 5.6B). The pairwise evolutionary distance between USP18/41 
clade and other paralogues of the group 7 was compared (Figure5.6C). In this comparison 
USP18 shows least distance to USP47 compared to any other USP of group7 and the 
difference between the least two (USP47 and USP48) is statistically significant 
(p<0.0001). This suggests that USP18 may have originated from USP47 but then diverged  
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Figure 5.5. Phylogenetic history of group 5 USP homologues. (A) A phylogenetic tree 
was reconstructed by the maximum likelihood method using C19 domain protein 
sequences, adopting the Jones Taylor and Thornton model with Gamma distribution and 
with some invariable sites (JTT+G+I) (Jones et al., 1992). All vertebrate homologues are 
annotated according to their orthologous relationship, whereas NV homologues are 
represented by the accession numbers. (B) Branch length format of the same tree where all 
monophyletic clades are collapsed as indicated.  
 
at different rate resulting in its off positioning in the phylogenetic reconstruction. USP9Y 
homologues share close ancestry with USP9X and only found in the eutherian mammals, 
indicative of recent expansion in the group 7 of USP. A USP homologue, USP41 found 
only in the humans and chimpanzee and clade with USP18 providing another evidence of 
recent expansion in the group 7 USP. 
Group 10. Group 10 includes two USP paralogues: USP25 and USP28. The evolutionary 
tree separates the vertebrates orthologues of USP25 and USP28 into separate subclades 
which share lineal ancestry with one homologue of tunicate, sea urchin and nematode 
worm pointing to the origin of the subclades before the divergence of bony fishes (Figure 
5.7).  
Group 11. Group 11 is composed of three USP paralogues: USP26, USP29 and USP37. 
The USP37 subclade includes all the compared vertebrate homologues and shares common 
ancestry with the subclades of USP26 and USP29, which include of eutherian mammals 
and of rodentia and primates respectively. This places the origin of USP26 and USP29 
from USP37 with the emergence of eutherian mammals and their separation at the 
common ancestor of rodentia and primates. All three subclades share a lineal ancestry with 
three NVs homologues of tunicate, sea urchin and hydra (Figure 5.12).  
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Figure 5.6. Phylogenetic history of group 7 USP homologues. (A) A phylogenetic tree 
was reconstructed by the maximum likelihood method using C19 domain protein 
sequences,  adopting the Jones Taylor and Thornton model with gamma distribution and 
with some invariable sites (JTT+G+I) (Jones et al., 1992). All vertebrate homologues are 
annotated according to their orthologous relationship as found in studies, whereas NV 
homologues are represented by the accession numbers. (B) Branch length format of the 
same tree is shown where all monophyletic clades are collapsed as indicated. (C) Graph 
shows the pair wise evolutionary distance between USP18 and other members of the group 
7. The difference between the least two evolutionary distances ((USP18 and USP47) and 
(USP18 and USP48)) suggests that USP18 is similar to USP47. 
 
 
 
 
 
Figure 5.7. Phylogenetic history of group 10 USP homologues. (A) A phylogenetic tree 
was reconstructed by the maximum likelihood method using C19 domain protein 
sequences,  adopting the Jones Taylor and Thornton model with gamma distribution and 
with some invariable sites (JTT+G+I) (Jones et al., 1992). All vertebrate homologues are 
annotated according to their orthologous relationship as found in studies, whereas NV 
homologues are represented by the accession numbers. Branch length format of the same is 
show in (B). 
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Figure 5.8. Phylogenetic history of group 11 USP homologues. (A) A phylogenetic tree 
was reconstructed by the maximum likelihood method using C19 domain protein 
sequences,  adopting the Jones Taylor and Thornton model with gamma distribution and 
with some invariable sites (JTT+G+I) (Jones et al., 1992). All vertebrate homologues are 
annotated according to their orthologous relationship, whereas NV homologues are 
represented by the accession numbers. Branch length format of the same tree is shown in 
(B). 
 
Group 15: Group 15 includes: USP53 and USP54. Vertebrate USP53 and USP54 form 
separate subclades in phylogenetic tree reconstruction and share a lineal ancestry with one 
homologue of tunicate, sea urchin and fruit fly (Figure 5.9) pointing to the separation of 
USP53 and USP54 at the root vertebrates from a single ancestral NV gene.  
 
 
Figure 5.9. Phylogenetic history of group 15 USP homologues. (A) A phylogenetic tree 
was reconstructed by the maximum likelihood method using C19 domain protein 
sequences,  adopting the Jones Taylor and Thornton model with gamma distribution and 
with some invariable sites (JTT+G+I) (Jones et al., 1992). All vertebrate homologues are 
annotated according to their orthologous relationship, whereas NV homologues are 
represented by the accession numbers. Branch length format of the same tree is shown in 
(B). 
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5.5. Genomic synteny reflects multiple mechanisms underlying expansion 
of USPs 
The extensive expansion of USPs in early vertebrates probably reflects the two whole 
genome duplication (WGD) events at the base of vertebrates. The resulting homologues 
are referred to as ohnologues (Wolfe, 2000). However, other mechanisms such as gene 
duplication, segmental duplication within chromosomes and gene domain acquisition may 
also have contributed to the expansion and diversification of these genes. To explore these 
possibilities, adjacent genomic regions of the human USP loci were compared (examining 
10 genes on either side) (Figure 5.10).  
Genome Duplication. Datamining and phylogenetic analyses presented in this study reflect 
the expansion of USPs at the origin of vertebrates, indicative of the expansion of USPs via 
WGD. Since WGD events generated duplicate copies of chromosomes harbouring 
identical copies of genes (at least initially), it is reasoned that many of the duplicates 
underwent gene death, mainly because of redundancy or neutral drift (Innan and 
Kordrashov, 2010). However, the genes retained (possibly due to functional divergence) in 
the organisms, despite being present on different chromosomes remains phylogenetically 
linked. Moreover, if not being subjected to genomic rearrangement, several of these genes 
have genes neighbours showing a syntenic relationship (having been duplicated by the 
same event). Several phylogenetically linked USP loci in the vertebrate lineage are 
associated with syntenic paralogues, for example in humans, USP12 and USP46 are 
present on chromosome 13q and 4q respectively and are neighboured by genes from three 
other evolutionary related families namely: Small Nucleolar RNA (SNORA), Ras like 
(RASL) and Ligand of Numb protein X (LNX). This situation result from the consequence 
of WGD.  Similarly, USP35 (chromosome 11q) and USP38 (chromosome 4q) are adjacent 
to genes encoding GRB2 associated Binding Proteins (GAB). USP2 and USP21 are 
present on chromosomes 1q and 15q respectively and both loci contain one homologue of 
an evolutionary related gene family Polio Virus Receptor Like protein (PVRL). Human 
USP36 and USP42 are present on chromosomes 17q and 7p respectively and adjacent to 
cytohesin encoding homologues. USP33 and USP20, present on chromosomes 1p and 9q 
respectively, are neighboured by Far Upstream Binding Protein (FUBP) homologues. Both 
members of group 5, USP5 and USP13, are present on different chromosomes (12p and 3q 
respectively) and flanked by Guanine Nucleotide Binding protein (GNB) homologues. 
Finally, in humans, USP53 and USP54 are present on chromosomes 4q and 10q 
respectively and are located downstream of three evolutionary related gene families, 
namely myozenin MYOZ), synaptopodin (SYNOP) and SEC24 family genes (SEC24).  
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Figure 5.10. Genomic Synteny of Human USPs homologues:  The genomic context of 
the human USP homologues is shown. The inferred evolutionary relationship is indicated 
at the left hand side with their respective paralogous group number. Syntenic genes are 
highlighted as yellow arrows while the USP homologues are represented with open arrows. 
The arrow direction corresponds to the direction of transcription with respect to the 
chromosome map. The gray dots indicate irrelevant or non syntenic genes to either side of 
the USP. The possible mechanism of genes expansion is represented by colour coded 
parenthesis to the right pink: potential WGD event (where syntenic evidence is present); 
gray: potential WGD events (where no syntenic evidence was found); orange: gene 
duplication; blue: segmental duplication; green: chromosomal conversion. Note, all genes 
of USP17* are not shown. 
 
 
Other USP paralogous pairs:  USP44/USP49, USP16/USP45, USP43/USP31, 
USP25/USP28 and a triplet USP4, USP11&USP15 showed a divergence in early 
vertebrates (according to the trees) and are present on different chromosomes. However, no 
syntenic paralogous gene (within 10 adjacent genes) was identified associated with these 
paralogous USPs. The absence of associated paralogous genomic synteny may reflect the 
extensive genomic rearrangement postdating WGD, or gene loss of the linked gene.  
Segmental duplication. Two gene pairs, USP27/USP51 and USP18/USP41 are 
phylogenetically linked, present on the same chromosomes and share syntenic regions 
(Figure 5.10). The USP27 and USP51 pair are specific to eutherian mammals and are 
present at different regions of same chromosome (Xp). Each gene is proximal to P Antigen 
family Genes (PAGE) and G Antigen family Genes (GAGE). Similarly, USP18 and 
USP41 are present at different regions of chromosome 22q and are proximal to Protein 
Phosphatase 1 Regulatory unit Pseudogenes (PPP1RP) and Gamma Glutamyltransferase 
Pseudogenes (GGT3P). The synteny shown by these USP pairs on the same chromosome 
strongly suggest extrachromosomal segmental duplication as the mechanism of expansion. 
Another interesting example in this connection is the presence of 32 copies of USP17 
genes and pseudogenes which are located on chromosomes 4p (23 copies) and 8p (9 
copies) in humans. The same scenario of multiple copies of USP17 gene exists in other 
eutherian mammals, including the mouse in which at least six intact orf and one 
pseudogenes of USP17 exists. Earlier phylogenetic analysis have shown that the 
paralogous based clustering in the USP17 gene family points to species specific extensive 
gene duplications and/or tandem segmental duplications, which lead to the formation of 
multiple copies of USP17 (Burrows et al., 2010). 
Gene duplication. USP50 has a vertebrate specific distribution and phylogenetically it is 
closely related to USP8. In humans the two genes are located head to head on chromosome 
Mushtaq Hussain, 2013  159 
15q suggesting to the origin of USP50 from a gene duplication of the ancestral gene, most 
likely similar to USP8 in early vertebrates. 
Chromosomal conversion. It is now widely accepted that the X and Y chromosome were 
the homologous autonomies and were converted into sex chromosomes after the 
monotremes-marsupial split (Grave et al., 2006; Lehn and Page, 1999). USP9X and 
USP9Y are phylogenetically related and present on Xp and Ya chromosomes respectively. 
Loci of the two genes are flanked by paralogues that include: DEAD box helicase 
(DDX3X), Calcium/Calmodulin dependent Serine protein Kinase (CASK) and MED14 
mediator complex subunit 14 (MED14) genes. This suggests the USP9Y and its proximal 
syntenic regions are among the few genes that have been retained in the Y chromosome 
since its existence.  
USP26 and USP29 are specific to eutherian mammals and shows close relationship with 
the USP37. However, the genomic synteny does not provide any evidence of gene or 
segmental duplication in relation to their origin. It is possible that these genes may have 
arisen due to the domain shuffling of USP37 or indeed by gene duplication and 
subsequently subjected to genetic rearrangement.  
Taken together, the data suggest that the genome duplication events contribute 
substantially to the expansion of USPs extant in humans today. In addition to this other 
mechanisms such as gene and intra chromosomal segmental duplications also lead to the 
origin of certain USPs. However, domain acquisition combined with serendipitous genetic 
rearrangement may provide alternative and perhaps counterintuitive explanation for the 
expansion of USPs especially at the root vertebrate. 
5.6. Protein domain promiscuity in USPs  
A protein domain can be broadly defined as a sequentially and/or structurally conserved 
region that can evolve, function or exist independently from the rest of the protein 
sequence. Protein domains occur either as a single entity within a coding sequence or in 
combinations and different permutations with the other domains, a feature referred to as 
“domain versatility” or “promiscuity” (Basu et al., 2008). In order to examine the protein 
structural and/or functional domain diversity of USPs, the protein sequences were assessed 
using the conserved domain database (CDD) and UniProt database (Figure 5.11 and Table 
5.3). For clarity, domain variations are described separately for each paralogous group.  
Group 1. Among the paralogues of group 1, USP12 and USP46 both have a C19G domain, 
supporting their close phylogenetic relationship, while USP38 and USP35 contain C19H. 
The C19 domains of USP35 and USP38 are both split into two, also reflecting their close 
phylogenetic relationship. Consistent with the phylogenetic studies, USP1 bears a C19O  
Mushtaq Hussain, 2013  160 
 
 
 
Mushtaq Hussain, 2013  161 
Figure 5.11. Protein domain distributions in human USPs. Schematic depiction of 
protein domains of the human USPs is shown. The length of each homologue is scaled 
according to the size of the protein and total amino acid length is indicated in bracket. The 
paralogous group number is indicated on the left. A key for the different protein domains 
and motifs is given on the right top.  The table inside the figure shows the similarity 
between the un typed C19 domains with the subtyped C19 domains. 
 
 
domain which is split into three in human orthologue.  
Group 2.  Two types of C19 domain are present in group 2 paralogues: C19R and C19E. 
The C19R domain (split into two except in USP50) was found in USP8, USP50, USP2 and 
USP21 while intact C19E was observed in USP17, USP36 and USP42. This C19 domain 
variation between the paralogues is in agreement with their phylogenetic relationship, as 
members with C19R and C19E are separated in the first dichotomy (excluding outgroup) 
of the tree. In addition to the C19 domain, other domains and functional sites are present in 
different paralogues of group 2. For example, USP8 contains a rhodanese domain and a 
domain of unknown function (DUF) which are absent in its phylogenetically closest 
paralogue, USP50. As described above, USP50 originated by gene duplication suggesting 
the additional domain and part of C19R were lost from the USP50 paralogue. Similarly, 
USP2, has an MDM4 binding site, absent from USP21 which instead has a nuclear 
localization signal. Proline, arginine and lysine rich sequences are present in USP42 which 
are not found in the closest paralogue USP36, while USP17 (closely related to 36/42) 
instead has a SUDS3 binding domain. 
Group 3. Group 3 is the most diverse group with respect to the variations in the C19 
domain. Consistent with the phylogenetic analysis, USP27, USP51 and USP22 all contain 
C19D domain while USP16 and USP45 have a split C19K domain. Similarly, USP33 and 
USP20 (phylogenetically more close than any other member of this group) contain a split 
C19R domain. Three paralogues of this group, USP44, USP49 and USP3 have un subtyped 
C19. Among those, USP44 and USP49 C19 domain asymmetrically split into two. By 
comparison, the C19 domain of USP3 is intact and phylogenetically it forms a distinct 
monophyletic clade suggesting that this is a different variant of the C19 domain. C19 
domains of these homologues (USP3, USP44 and USP49) show similarity with C19D type 
domain.  USP33 and USP20 (C19R) have two additional DUSP domains, this is in line 
with their close phylogenetic relationship. Interestingly, all paralogues of group 3 except 
USP27 (which is eutherian specific) contain a zinc finger domain, suggesting that this 
domain existed in the ancestral gene of group 3 before expansion.  
Group 4. All paralogues of group 4, except USP32, have a C19R domain which is split 
into two. The C19 domain of USP32 is split into three and is not subtyped in CDD. In 
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addition, USP32 contains three calcium binding (EF-hand) sites and a DUSP domain. 
USP4, USP11 and USP15, which may have expanded from a single lineal ancestral gene at 
the base of vertebrates, all contain a DUSP domain, suggesting the presence of the DUSP 
domain in the ancestral gene of all three paralogues. Additionally, USP4 contains two 
ubiquitin like domains, two zinc finger domains and nuclear localization and export 
sequences, which possibly reflect the domain and functional sites acquisition after gene 
expansion. USP19, which forms a separate monophyletic clade in the phylogenetic tree, 
also contains a zinc finger domain and two p23 like domains. The phylogenetically close 
paralogues, USP43 and USP31, have no additional domain except a stretch of proline and 
serine rich sequences in USP31.  
The presence of a C19R domain in some members of groups 2, 3 and 4 may be an 
indicative of a close evolutionary relationship between these groups than the other groups 
of USPs. Given the homologues of all these groups were found in slime mould, suggest 
that this division occurred before protozoa and metazoa split. 
Group 5. Both paralogues of group 5, USP5 and USP13, contain C19B domain (exclusive 
to this group) which is split into two and intervened by 2 UBA like domains. The 
paralogues also contain a zinc finger domain and the ORF size and domain structure are 
highly similar between the two genes supporting their close phylogenetic association. 
Group 6. USP6 is the sole member of group 6 which contains a C19 domain, which is split 
into three. Other non USP members of this group contain a TBC domain, which may form 
the basis of paralogous relationship between USP6 and other TBC domain containing 
proteins. As USP6 homologues are only present in primates, it suggests a relatively recent 
gene birth, with the acquisition of a C19 domain in the primate lineage. 
The C19 domain structure of USP6 bears a remarkable resemblance to that of USP32. 
Therefore in order to explore their relatedness, USP6 was included in the phylogenetic tree 
of group4. The USP6 C19 domain clusters in the USP32 clade (Figure 5.12A). Thus it 
seems likely that USP6 arose in a primate lineage (leading to the greater apes) through the 
acquisition of a USP32 C19 domain into a TBC encoding gene.  
Group 7. Paralogues of group 7 encode some of the largest in terms of protein length. Most 
of them contain an intact C19C domain (split only USP40), the only exception in this 
regard is USP48 and USP18/USP41 which contain C19L and un subtyped C19 domains 
respectively and are more distantly related to others in the group, however, C19 domain of 
USP18/41 shows similarity with C19C.   USP7 is unique among all USPs in containing a 
MATH domain and a herpes virus transactivator, ICP0 binding site. MATH domain 
interacts with the EBV oncogenic protein EBNA and the tumour suppressor protein, p53. 
The phylogenetically related USP40 and USP47 contain none of these additional domains. 
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Figure 5.12. Phylogenetic relationship between paralogous groups of USPs. The 
phylogenetic trees were reconstructed using the maximum likelihood method and 
employing JTT+G (A) or JTT+G+I (B) evolutionary model. The phylogenetic trees show 
the relationship between paralogous group 4 and group 6 (A) and group 2 and group 8 (B). 
The orthologues of group 6 and group 8 are indicated with red lines while homologues of 
group 2 and group 4 are coloured black.  
 
none of these additional domains. USP34 is the largest among all USPs examined but 
interestingly contains only C19C domain. Other uncharacterized or unidentified functional 
sites or domains could be present in this and other USPs particularly USP24, USP9X and 
USPY which are also large, however USP24 does have UBA domain in it. The USP48 has 
three DUSP domains and one DUF domain and formed a separate clade in the 
phylogenetic analysis.  
Group 8. The C19 domain of USP10, the only member of group 8, is intact and 
unsubtyped. The protein contains a binding site for p53 protein towards the N-terminus. 
The domain show similarity with C19E subtype, a domain also found among members of 
group 2. To examine it further, a composite tree was developed using homologues of group 
2 and group 8 (Figure 5.11B). In this phylogenetic reconstruction, this group cluster with 
USP36/45 suggesting the close evolutionary relationship between group 2 and group 8. 
Group 9. The only member of this group is USP14, which exclusively contains a C19A 
domain and a DUF domain.  
Group 10.  USP25 and USP28 are the two paralogues comprising the group 10, both 
containing C19I domains which are split into two and both also contain a UIM interaction 
site, supporting their close phylogenetic relationship. However, USP25 has an additional 
DUSP domain and SUMO interaction site reflecting acquisition or loss of new functional 
sites in the gene after duplication. 
Group 11. USP26, USP29 and USP37, the members of group 11, each contain an un 
subtyped C19 domain which is either intact (USP37) or split into two (USP26) or three 
(USP29) regions. USP37 also contains three destruction box domain (D-box), and UIM 
interaction sites.  Given the species distribution of USP26 and USP29, limited to eutherian 
mammals, while orthologues of USP37 were observed in all vertebrates, this suggests the 
loss of some functional sites in USP26 and USP29 after expansion of ancestral USP37 
gene.  
Group 12. USP30 is the single member of group 12 containing a C19F domain (exclusive 
to this group) which is split into three segments.  
Group 13.  Group 13 contains only one member, USP39, which has peptidase C19M 
domain with an additional DUSP domain within the C19 sequences and an arginine rich 
region at the N-terminus. 
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Group 14. USP52 is present in all vertebrates and a nonvertebrate examined and contains a 
C19P domain, which is split into two regions. In addition it contains PAN2 and WD40 
domain sequences. These domains are unique to USP52 among the human USPs. 
Group 15. Two paralogues of group 15, USP53 and USP54 contain an un subtyped C19 
domain without any additional domain. The two proteins differ in their length which may 
reflect the structural and/or functional differences between these proteins, and the C19 
domain of USP54 has lost the N-terminal peptidase active site.  
Group 16. CYLD is the only member of this group, contains exclusively a C19N domain 
with three CAP-GLY domains.  
In summary, the C19 domain and domain structure of the USPs show broad agreement 
with the phylogenetic analysis, where closely related paralogues have the same C19 
domain subtype. The variation in the additional domains (other than C19) between the 
paralogues reflects the functional divergence between the USPs.  
It has been proposed that protein architectural complexity is correlated with organismal 
complexity (Koonin et al., 2002; Vogel et al., 2004). To explore this proposition and  
to investigate the evolutionary history of the domain distribution, domain combinations of 
USPs were examined in selected species using InterPro, CDD and UniProt databases. The 
domain distribution is tabulated according to the species in which they were identified 
(Table 5.3). USP homologues of slime mould and chlamydomonas were investigated for 
their domain distribution. Chlamydomonas (11 USPs) and slime mould (17 USPs) are 
unicellular organisms and serve as models for the ancestral lineages of plants and animals 
respectively. Of the 16 C19 subtypes (excluding unclassified) in humans, 9 are present in 
both chlamydomonas and slime mould, namely: C19G (USP12&USP46 of group 1), C19E 
(USP17, USP36 and USP42 of group 2), C19R (group 2, 3 and 4), C19B (group 5), C19C 
(group 7), C19L (USP48 of group 7) C19A (group 9), C19M (group 13) and C19P (group 
14). This observation is consistent with the datamining and phylogenomic analysis 
suggesting the origin of most USP paralogous groups before the divergence of animals and 
plants. In addition, combinations of domains: C19A+DUF (USP14), C19C+MATH 
(USP7), C19B+Zf+UBA (USP5, USP13) and C19P+PAN2 (USP52) were observed 
amongst the USP homologues of both slime mould and chlamydomonas, supporting the 
orthologous relationship observed in the C19 domain based phylogenetic analysis between 
these genes and their corresponding counterparts in vertebrates including humans. Unlike 
chlamydomonas, 2 additional C19 domains were observed in slime mould; C19H (USP35 
& USP38 of group 1) and C19 K (USP16&USP45 of group 3). Additionally, 4 further 
domain combinations were found namely: WD40+C19P+PAN2 (USP52), USP19R+DUSP 
(group3,4), C19C+MATH+ICP0 (USP7), and C19L+DUSPx3 (USP48) in the USP 
 
 
Table 5.3. Origin and distribution of domains and domains combinations associated with USPs. InterPro, CDD and UniProt databases were 
employed to screen the domains present in USP homologues of selected species. The yellow boxes indicate the domain identified in the respective 
orthologues of USPs. Different combinations of domains are indicated in the boxes. The abbreviations of the domains are indicated in figure  5.11. 
C19 Cr Dd Hm Ce/Dm Sp Ci Vertebrates Eutheria Primates 
C19A DUF DUF DUF DUF DUF DUF DUF DUF DUF 
C19B UBAx1+Zf UBAx2+Zf UBAx2+Zf UBAx2+Zf UBAx2+Zf UBAx2+Zf UBAx2+Zf UBAx2+Zf UBAx2+Zf 
C19C MATH MATH+ICP0 
 
MATH+ICP0 
UBA 
MATH+ICP0 
UBA 
MATH+ICP0 
UBA 
MATH+ICP0 
 
MATH+ICP0 
UBA 
MATH+ICP0 
UBA 
MATH+ICP0 
UBA 
C19D   Zf Zf Zf Zf Zf Zf Zf 
C19E        SUDS3 SUDS3 
C19F          
C19G          
C19H          
C19I       UBA UBA UBA 
C19K    Zf Zf  Zf Zf Zf 
C19L Cyclase DUSPx3 ? ? DUSPx3+UBA DUSPx3+UBA DUSPx3+UBA DUSPx3+UBA DUSPx3+UBA 
C19M Zf Zf Zf Zf Zf Zf Zf Zf Zf 
C19N    CAP-GLY CAP-GLYx3 CAP-GLYx3 CAP-GLYx3 CAP-GLYx3 CAP-GLYx3 
C19O          
C19P PAN2 PAN2+WD40 PAN2+WD40 PAN2+WD40 PAN2+WD40 PAN2+WD40 PAN2+WD40 PAN2+WD40 PAN2+WD40 
C19R  DUSP ? DUSP 
DUSPx2 
DUF+Rhodanese 
EF-hand 
DUSP 
DUSPx2 
DUF+Rhodanese 
EF-hand 
P23like    
DUSP 
DUSPx2 
DUF+Rhodanese 
EF-hand 
P23like     
DUSP 
Zf+DUSPx2 
DUF+Rhodanese 
EF-hand 
P23like 
MDM4 
DUSP+UbX2 
DUSP 
Zf+DUSPx2 
DUF+Rhodanese 
EF-hand 
P23like    
MDM4  
DUSP+UbX2 
DUSP 
Zf+DUSPx2 
DUF+Rhodanese 
EF-hand 
P23like  
MDM4  
DUSP+UbX2 
C19? (44/49)      Zf Zf Zf Zf 
C19?(6)         TBC 
C19?(18/41)          
C19?(10)          
C19? 
(26/27/37) 
    DBOX 
UIM interaction 
DBOX 
UIM interaction 
DBOX 
UIM interaction 
DBOX 
UIM interaction 
DBOX 
UIM interaction 
C19? 
(53/54) 
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homologues of slime mould, suggesting a premetazoan origin of most USP paralogous 
groups.  
In the animal lineage the first major transition happened with the emergence of metazoans 
around 1184MYA. In this analysis two domain combinations (including the new C19D 
variant) were observed in the USP homologues of hydra. These are: C19C+UBA and 
C19D+Zf, found in USP24 and USP22, respectively. Both these additional domains (other 
than C19) pre-exist in different USP homologues in slime mould. USP homologues in the 
fruit fly, in addition to the already existing domain combinations (as found in 
representatives of early branches of the tree), have 3 new variants of C19, C19O (USP1), 
C19F (USP30) and C19N (CYLD), and 5 new domain combinations were found which 
persist in higher organisms, C19R+DUF+Rhodanese (USP8), C19N+CAP-GLY (CYLD), 
C19R+DUSPx2 (USP33/20), C19R+DUF+EF-hand (USP3), C19K+Zf (USP16/45). This 
suggests an increase in the domain permutations occurred with the origin of coelomates. 
The sea urchin genome encodes 31 USP homologues, of which three new domain 
arrangements were observed: p23+C19R (USP19), DUSPx3+UBA+C19L (USP48) and 
CAP-GLYx3+C19N. These combinations are also found in higher organisms. 
Additionally, a domain combination of C19?+DBOX+UIM interaction was also first 
observed in the sea urchin homologue of contains three calcium binding (EF-hand) sites 
and DUSP domain. Among the additional domains p23, DBOX and the UIM interaction 
site, were not identified in any USP homologue of organisms whose lineage emerged 
before the divergence of deuterostomes, indicating a further increase in the domain 
complexity as organismal complexity increases from protostomes to deuterostomes. 
However, the increment in the CAP-GLY (CYLD) is most likely the result of internal 
domain duplication.  
In chordates (specifically the tunicate examined here) no significant increase in the domain 
combinations was observed compared to earlier organisms, the only novelty observed is an 
emergence of a variant (un subtyped) of C19 domain (USP44/49) with zinc finger. 
However, unsubtyped C19 domain of USP44/49 show the greatest similarity to C19D 
(found also in USPs of group 3). New domain arrangements that emerged with the origin 
of vertebrates include: C19I+UBA (USP25), C19R+MDM4 (USP2) C19R+DUSP+Ubx2 
(USP4) and C19R+DUSPx2+Zf (USP20&USP33). Further, two new domain 
combinations, C19D+SUDS3 (USP17) and C19+TBC (USP6) appeared with the origin of 
eutherian mammals and primates respectively.  
Taken together, similarities in domain arrangements between non vertebrates and the 
vertebrate USPs supports their phylogenetic relationship. C19 domain variations and 
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domain combinations in USPs increase across the animal lineages especially in species 
reflecting the important transitional stages of speciation. This mirrors the increase in 
molecular complexity from early unicellular eukaryotes to primates.  
5.7. Structural similarities of peptidase C19 domain 
In order to compare the structure of the different peptidase C19 subtypes, the structures of 
several USPs were retrieved from the RCSB protein databank. Primary and tertiary 
structure alignments were developed and quantified in terms of sequence identity in 
percentage and root mean square deviation (RMSD) of the structures in Å (Table 5.4; 5.5; 
Figure 5.14). Despite limited primary sequence identity (6%-36%) between the peptidase 
C19 domains analysed (Table 5.4), Cα backbone superimposition of the domains shows 
considerable similarity between the structures in the core architecture (RMSD values range 
from 1.02Å to 2.09Å, Table 5.5). Structurally, the C19 domain is composed of three 
subdomains termed the palm, thumb and fingers (Hu et al., 2002). The C19 domain 
structures have the same characteristic sub-domains with nearly identical distribution of 
the secondary structural elements. The only exception is the C19 domain of CYLD in 
which all subdomains are shorter than those of the other paralogues. This strong 
conservation of the domain and subdomain architecture reflects the common ancestral 
origin of the C19 domain as well as conserved enzymatic action (Figure 5.14). 
 USP2 
(C19R) 
USP4 
(C19R) 
USP5 
(C19B) 
USP7 
(C19C) 
USP14 
(C19A) 
USP4 40%     
USP5 16% 16%    
USP7 20% 18% 13%   
USP14 17% 18% 14% 18%  
CYLD 9% 8% 9% 9% 7% 
Table 5.4. Sequence similarity between the selected C19 domains. Multiple amino acid 
sequence alignment of the peptidase C19 domains of the indicated human USP paralogues 
(of which structures are known) were constructed using ClustalX and the amino acid 
identities between these are shown. 
 USP2 
(C19R) 
USP4 
(C19R) 
USP5 
(C19B) 
USP7 
(C19C) 
USP14 
(C19A) 
USP4 1.02     
USP5 1.10 1.32    
USP7 1.31 1.36 1.27   
USP14 1.28 1.20 1.27 1.35  
CYLD 2.09 1.64 2.09 1.64 1.66 
 
Table 5.5. Structural comparison between selected C19 domains. Protein structures of 
the indicated human USPs were retrieved from the RCSB database, only the C19 domains 
were extracted from the atomic coordinates. Structures were superimposed and variations 
in Cα back bone were measured in terms of RMSD values in Å.  
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Figure 5.13. Multiple sequence alignment of C19 domain. Primary sequences of C19 
domain (of those which are structured) are aligned using CLUSTALX. the amino acids are 
colour coded according to RASMOL convention. The bars over the top of the alignment 
represent different structural regions as observed in the USP7 C19 domain (PDBid; 1F1Z): 
green (thumb), red (fingers) and blue (palm).  
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Figure 5.14. Structural comparison of C19 domains. Ribbon diagrams of C19 domain 
structure of the indicated human USPs (retrieved from the RCSB database) are shown. The 
characteristic subdomains of the C19 domain are shown: fingers (red), palm (cyan) and 
thumb (green). Note: the shortening of all the subdomains in CYLD compared to other 
structures. PDBids are indicated in brackets.  
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5.8. Gene expression profile of USPs in human 
The observed expansion and subsequent retention of USPs across the animal lineages 
could be the function of extensive novelties in organs and tissue, that is concurrent with the 
evolution of taxonomic lineages examined in this study. Thus to explore the tissue 
specificity of different human encoded USPs, the BIOGPS database was used to note the 
expression pattern of those proteins in different anatomical regions of the body. BIOGPS is 
a public database that is built upon the information acquired from RNAs derived from 79 
human tissues (Su et al., 2004). The relative quantity of gene specific RNA in the 
examined tissue is inferred as a measure of gene expression and the data is presented in 
graph, where bars represent the relative expression of the query gene, however this does 
not necessarily reflect the protein levels.  For clarity the observations are tabulated in Table 
5.6, where genes are categorized on the basis of relative level of expression. In total, 
relatively high levels of USP expression was noticed in tissues associated with the immune 
system, vasculature and nervous system. For example the data show that USP1 is 
expressed at 10 fold higher levels than the average USP1 level in CD34 cells. The CD34 
(cluster of differentiation 34) molecule belongs to a family of single pass transmembrane 
sialomucin that is expressed on hematopoietic stem cells and vascular associated cells 
(Nielsen and McNagny, 2008) and certain cancer cell types (Casey et al., 2006; Ney et al., 
2007; Nielsen and McNagny, 2008; Somasiri et al., 2004). USP1 plays a central role in the 
post translational regulation of proteins involved in Fanconi anaemia pathway for DNA 
repair (Murai et al., 2011; Nijman et al., 2005a) and translesion synthesis (Huang et al., 
2004). USP3 shows more than 10 fold higher expression in CD33+ myeloid cells and 
CD14+ monocytes compared to mean expression in the examined tissues. To date the best 
characterized function of USP3 is its ability to deubiquitinate histones (H2A and H2B) 
which in turn facilitates the progression of the cell cycle (Nicassio et al., 2007). However, 
the functional relevance of high levels of USP3 in myeloid cells and monocytes is not 
known. USP7 RNA is found at highest level (more than 10 fold) in CD71+ early erythroid 
cells to the average level of expression among the 79 tissues examined. USP7 is a 
multifunctional protein and it is widely known for its role in the regulation of the tumour 
suppressor protein p53 and PML bodies (Hu et al., 2006), as well as transcription coupled 
nucleotide excision repair (Schwertman et al., 2013). CYLD, the only member of group 
16, is expressed at more than 10 fold and 3 fold above average in CD4+Tcells and 
CD8+Tcells respectively. This is consistent with its role in the regulation of T cell 
development and function (Reissig et al., 2012).  
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Table 5.6. Gene expression profile of human USPs. The Gene expression profile of 
human USPs was retrieved from BIOGPS. Cells and tissues are coloured according to the 
systems and/or associated functions. Expression level is shown in comparison to the 
average (of tissues analysed) and categorised as >10x, >3x or >Median. Key: Immune 
system (green), vasculature (red) and nervous system (blue), glands (pink), reproductive 
(brown), others (light brown).  
 
 
 
 
GRPs USPs Gene Expression 
>10x >3x >Median 
1 1 CD34 CD71EE, CD105+EC, 721BLB, CD19B, BDCA4DC, CD56+NK Testis 
12 0 CD71EE, Colon, Pineal Night (PN), Pineal Day (PD), Pre-Frontal 
Cortex (PFC) 
CD105+EC 
46 0 Amygdala (AMY) PN,PD, Retina 
35 ND ND ND 
38 ND ND ND 
2 2 0 0 0 
21 0 CD34+ CD4T, CD8T 
8 0 PN, PD, CD19B, BDCA4DC CD4T, CD8T, Thyroid 
50 0 0 Skin 
36 0 CD19B, BDCA4DC CD4T, CD8T, Heart 
42 0 0 0 
17 0 0 Heart, Liver, Pancreas 
3 3 CD33My 
CD14Mo 
CD4T, CD8T, CD56NK, CD19B, BDCA4DC, 721BLB 0 
33 0 PN, PD, AMY, PFC CD4T, CD8T, CD19B, 
BDCA4DC, Hypothalamus, 
Thyroid 
20 CD8T CD71EE, CD4T, CD56+NK 0 
16 0 CD33My, CD19B, BDCA4DC, CD56+NK, 721BLB 0 
45 0 0 0 
44 0 721BLB Testis 
49 0 0 Heart, Trigeminal ganglion 
(TGG), Parietal lobe, Super 
Cervical Ganglion (SCG) 
22 0 0 Heart, TGG 
51 0 0 0 
27 0 SCG 0 
4 4 0 CD56+NK CD34+ 
15 CD71EE CD105+EC, CD14Mo 0 
11 0 PN, PD, PFC, Temporal Lobe, Hypothalamus Retina, Olfactory Lobe 
32 0 CD33My, Testis CD71EE 
19 0 TGG 0 
43 0 -- 0 
31 0 0 TGG, Testis 
5 5 0 0 721BLB 
13 Skeletal 
Muscles 
PN, 721BLB 0 
6 6 0 Testis 0 
7 7 CD71EE CD105+EE, 721BLB, CD19B, CD56+NK, CD33My, CD14M PN, PD, PFC 
47 0 CD56+NK, CD4T, CD8T, PFC 0 
40 0 0 Prostate 
34 0 0 PFC, SCG, Pons, Prostate 
24 0 0 CD4T, SCG 
9X 0 721BLB PN, AMY 
9Y 0 PN, PD 0 
48 0 TGG, SCG 0 
18 0 721BLB 0 
41 0 0 0 
8 10 0 0 721BLB, BDCA4DC 
9 14 0 CD34+, 721BLB, AMY, PFC, Prostate 0 
10 25 0 721BLB, BDCA4DC, CD4T, CD8T, CD56+NK, CD33My, Testis 0 
28 CD56NK 0 0 
11 26 0 0 0 
29 0 0 0 
37 0 0 0 
12 30 0 0 0 
13 39 0 0 CD34+, CD105+EC, 721BLB 
14 52 0 721BLB, CD4T, CD8T CD34+ 
15 53 0 0 Heart 
54 0 0 0 
16 CYLD CD4T CD8T, PD, PN PFC 
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Several gene pairs that segregated at the root of vertebrate divergence from a single lineal 
ancestral gene show difference in their tissue expression pattern in humans. For example, 
USP12 shows higher than the tissue average expression in immature erythroid cells 
(CD71+EE) and in pineal gland tissue, while USP46 (the closest paralogue of USP12) 
shows highest RNA abundance in the amygdala, part of the limbic system in the brain 
modulating  behavioural responses (Amunts et al., 2005). Interestingly, it has been recently 
observed that USP46 knockout mice behave differently compared to wild type mice in 
response to antidepressant drug, Nitrazepam (Imai et al., 2012), indicative of concurrent 
presence of tissue specificity and functional divergence between USP12 and USP46. 
Similarly, USP2 is expressed almost uniformly in all the examined tissues while >3 fold 
higher expression of its closest paralogue USP21 was observed in hematopoietic stem cells 
(CD34+). USP33 and USP20 are phylogenetically the closest paralogues of group 3, the 
former is expressed predominantly in tissues of the nervous system and the latter in cells 
involved in the cell mediated immunity (T cells). Despite the difference in tissue specific 
expression patterns USP20 and USP33 show functional similarities as both are associated 
with recycling of β adrenergic receptor (Berthouze et al., 2009). Similarly, the expression 
patterns of USP4, USP11 and USP15 of group 4 differ, where USP4 and USP15 are 
predominantly expressed in the vasculature and/or immune related cells, whereas higher 
expression of USP11 was observed in different regions of the central nervous system. 
Interestingly, USP4 and USP11 negatively regulate TNFα induced NFκB activation (Fan et 
al., 2011; Sun et al., 2010), by contrast USP15 promotes TGFβ cell signalling, which can 
support oncogenesis (Eichhorn et al., 2012), suggesting functional differences between 
these closely related paralogues. USP5 and USP13 are the two paralogues of group 5, 
where USP5 is almost uniformly expressed in the compared tissues whereas USP13 shows 
>10 fold average expression in skeletal muscle. Though a role of USP13 has been 
demonstrated in cell proliferation and regulation of gene expression (Zhao et al., 2011), the 
direct physiological relevance of significantly high expression of USP13 in skeletal muscle 
is unknown.  
The data indicate that many USPs are expressed in cells with an immune related function 
and several others in cells of the nervous system and vasculature. Interestingly, the USPs 
which emerged at the origin of vertebrates also demonstrate divergence in their tissue 
specific expression and molecular functions, showing a lack of redundancy and hence 
providing an explanation for their retention. 
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5.9. Protein interaction network analyses of USPs 
In order to further our investigation regarding the functional divergence of USPs, each 
human USP was explored using STRINGv9.1 data (Table 5.7). STRING is a public 
database that provides information regarding known and predicted, direct (physical) or 
indirect (functional) protein-protein interactions. STRING retrieves the protein-protein 
association information from four different sources: genomic context, high throughput 
screening, co-expression and previous knowledge (text mining) (Franceschini et al., 2013). 
The server offers several levels of statistical robustness from relaxed to highest confidence. 
In this study, associations with only high confidence score (>0.7) are considered. 
As reflected by association with ubiquitin C (UBC), regulation of protein turn over 
appeared as a common feature for almost all USPs. Other common associations detected 
by the protein network analysis are the association of USPs with proteins involved in DNA 
repair. For example, USP1 association was observed with FANC1, FANCD2 and ATAD5, 
which are important components of the DNA damage response and replication (Lee et al., 
2013; Murai et al., 2011). Similarly, association between KIAA1530 (UVS SA) and 
BRCA with USP7 was found, both these USP partner proteins are involved in nucleotide 
excision repair response (Deng et al., 2003a; Schewertman et al., 2013). Another common 
feature to which most USPs seems to be associated with is regulation of gene expression, 
for example, association of many USPs was identified with multiple components of the 
STAGA complex, which is a chromatin acetylating transcription co-activator (Martinez et 
al., 2001). Similarly association of USP7 was observed with several ubiquitin ligases 
(including RING1) and the chromatin binding factor (ATXN1), reflecting its role in the 
regulation of gene expression. Many USPs were also found to be associated with 
molecules that are connected with apoptosis. Among these, several apoptosis associated 
factors such as p53 and FOXO4 associate with USP7. Similarly, another paralogue of 
group 7, USP9X, establishes a network with proteins involved in apoptosis. This is 
consistent with empirical observations as these and many USPs are known to contribute in 
the regulation of several key factors of apoptosis (Ramakrishna et al., 2011).   
Several phylogenetically close paralogues show differences in the known and predicted 
binding/associated partners, which in turn reflect their functional divergence. For example 
USP20 and USP33, the closest paralogues of group 3, differ in their network analysis. 
USP20 establishes a network with molecule involved in gene regulation and angiogenesis 
(ERG) (Birdsey et al., 2012) while USP33 associates with proteins involved in the 
development of the nervous system such as ROBO1 (Long et al., 2004) and DIO2 (Guo et 
al., 2004). USP25 and USP28 are the only two paralogues of group 10, and they differ in 
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GRPs USPs Partner Proteins 
1 1 UBC, WDR48, FANCD2, FANCI, ATAD5, ZBTB352 
12 WDR20, WDR48, DMWD 
46 WDR20, WDR48, UBC, PHLPP1, DMWD 
35 NDA 
38 NDA 
2 2 UBC, UBA52, FASN 
21 UBB, UBC, UBA52, RIPK1, KCTD13, KCTD10, BTBD9 
8 UBC, UBB, UBA52, RNF41, RNF128, DNAJB6, BIRC6, OTUB1, KIF23, EGFR, AKT1, EPS15, GRB2, 
STAMs, CHMP1A, CHMP4C, C10orf2, C18orf2 
50 IMP5 
36 UBC, CDK4, DNAH14, DNAH5, DNAH12, DNAH19, DYNC1H1 
42 NDA 
17 SUDS3 
3 3 UBC, EIF3CL, H2A, H2B  
33 VHL, ATG3, ROBO1, DIO2, OS9, ARRB2 
20 VHL, USP16, ERG 
16 UBC, USP20, FUCA1, MARK1, MARK2, MARK3, MARK4, PRKC1 
45 NDA 
44 NDA 
49 PPT1 
22 UBC, KAT2A, KAT2B, TRRAP, ATXNL3, ENY2, STAGA-Trans-HAT Complex, SAP130, Sin3A, FAM48A, 
H2A, H2B 
51 NDA 
27 NDA 
4 4 UBC, SART3, GRP, RB1, PRPF3, LSM2  
15 UBB, UBC, UBA52, PSMD7, UCHL5, GRP, SART3, LSM2, SMAD7, TGFβR1, TGFβR2, TGFβ1 
11 UBC, USP7, BRCA2, WRNIP1, TCEAL1, CBX8 
32 NDA 
19 UBC, BIRC2 
43 NDA 
31 NDA 
5 5 UBC, UBA52 
13 UBC, UFDIL, SERPINCI, G6PD 
6 6 NDA 
7 7 UBC,UBA52, USP11, UHRF11, PSMA complex, PSMB complex, KIAA1530, BRCA1, p53, FOXO4, DAP6, 
MDM2, MDM4, DAXX, TRAF6,  GMPS, DNMT1, CLSPN, PPMIG, RING1, RNF2, C14orf2, RNF220, SRF, 
BMI1, ATXN1,  TSPYL4 
47 FBXL3, FBXL15, FBXO2, FBXL7, SCF-complex, SARS2  
40 NDA 
34 NDA 
24 UBC 
9X UBC, ITCH, BIRC5, MCL1, HUWE1, TMEM49, MTOR, NUAK1, MLLT4, CTNNB1, MARK4 
9Y NDA 
48 Lys6-D, PRUNE 
18 ISG15, IFNAR2 
41 NDA 
8 10 UBC,G3BP1, SNX3, CFTR 
9 14 UBC, UBA52, PSMA complex, PSMB complex, PSMD complex, ERG, CASP1, CDKL2, KIR2DL3, CD68 
10 25 UBC, SUMO2, SUMO3, KLH13, MYBC1 
 28 UBC, SUMO2, FBXW7,TP53BP1, CLSPN, MDC1, MYC 
11 26 NDA 
 29 NDA 
 37 NDA 
12 30 NDA 
13 39 UBC, SART3, SLC25A4 
14 52 PAN3 
15 53 NDA 
 54 CHMP2A, CHMP4A, CHMP6 
16 CYLD UBC, HDAC6, PLK1, TRAF2, TRAF6, RIPK, SQSTM1, TRAIP, OPTN, IKBkG, IKBkE, BCL3, TBK1, 
DVL1, DDX58, LCK 
Key: Protein turnover, DNA repair, Transcription, Cell cycle and division, Apoptosis, G protein signalling, Embryogenesis, General 
metabolism, TNF signalling, Channel protein, ER trafficking and protein degradation, EGFR signalling, TGFβ signalling, Unknown 
function, Cilliary motility, Protein synthesis, Cytoskeleton, RNA processing, NFkB signalling, Cell adhesion, WNT signalling, 
Immunity, Musculature, NDA: no data available 
Table 5.7. Known and/or predicted protein binding partners of human USPs. Partner 
protein interactions of USPs were examined using STRING v9.0. USP partner proteins 
predicted with a high confidence level (>0.7) are included. Interacting molecules are 
coloured differently according to the main associated functions (see key). USP paralogue 
boxes are shaded: (light brown) vertebrate specific, (light blue) mammalian specific and 
primate specific (light green). Abbreviations of all molecules are provided in Appendix V. 
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their association in the protein network analysis. USP25 is found associated with KLH13, a 
protein involved in cytokinesis (Sumara et al., 2007) while USP28 establishes a network 
with CLSPN which is associated with the DNA damage response in the cell cycle 
(Bassermann et al., 2008).  
In total, the differences in the protein network of USPs demonstrate the 
subfunctionalization between distantly and closely related USP paralogues. Despite 
retaining the core function of regulating protein turnover, these genes contribute to a 
variety of functions, reflected by the diversity of their molecular partners.  
5.10. Summary of findings 
 In total 55 paralogues of USPs are encoded by the human genome (excluding multiple 
paralogues of USP17), of these, most homologues are present in all the vertebrates 
examined. Some exceptions in this regard are USP6 and USP41 (present only in greater 
apes), USP17, USP51, USP26 and USP29 (present only in eutherian mammals). 
 The Ensembl paralogy pipeline divides all human USP homologues into 16 paralogous 
groups and in most cases homologues of at least one paralogue from each group were 
found in slime mould and/or chlamydomonas suggesting a deep ancestral root of these 
USP homologues.  
 Only two homologues of C19 domain containing proteins were identified in bacteria 
(Candidatus amoebophilus asiaticus), out of the >4500 prokaryotic genomes examined. 
This might suggest these have been acquired by horizontal gene transfer from 
eukaryotes to prokaryotes.  
 C19 domain based phylogenetic reconstruction and data mining demonstrated a rapid 
expansion of the USPs genes at the base of the vertebrate tree.  
 Genomic synteny of certain closely related paralogues points to the role of the whole 
genome duplication in the expansion of many vertebrate specific USPs.  
 The origin of many eutherian specific USPs could be explained as a result of intra 
chromosomal segmental duplication. 
 USPs paralogues of most organisms show a noticeable variation in the domain 
architecture and protein length. 
 The domain architecture tends to be conserved between the orthologues of most USPs, 
supporting the idea that the C19 domain based phylogeny represents the evolutionary 
relationship of the full length gene.  
 An increment in the domain combinations in the USP proteins was observed with the 
increase in organism complexity. 
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 Despite the sequence variation, strong structural conservation between the C19 
peptidase domains of different USPs reflects common ancestry and functionality.  
 The retention of the many USPs paralogues and/or ohnologues could be explained in 
terms of the divergence in the tissue specificity and functionality as observed by the 
comparison of expression data and protein association network.  
 The origin of certain USPs is parallel to the origin of the substrate or partner protein and 
associated molecular pathways. 
5.11. Discussion  
The phylogenomic analyses of the USPs conducted here delineates time points in relation 
to the origin of different USP homologues in animal lineages and point to the underlying 
mechanisms of their expansion and subsequent retention. 
Origin of USPs 
Datamining and phylogenetic analyses show that at least one homologue of nearly all the 
USP paralogous groups existed in slime mould (protozoa), which indicate that the last 
common ancestor of animalia (including protozoa and metazoa) had at least one 
antecedental gene of most of the paralogous groups of USPs. From these expansion and 
diversification at different speciation points lead to the formation of the extant array of 
USPs in humans. Interestingly, 11 peptidase C19 domain containing proteins are present in 
chlamydomonas and showing orthologous relationship with paralogues of group 1, 2, 4, 5, 
7, 8, 9, 13 and 14. This suggests the origin of respective USP groups before the animal-
plant split. The number of USP homologues increases from chlamydomonas (green algae) 
to Arabidopsis thaliana (eudicot), suggesting the possible convergent expansion of USPs 
in plants and animal kingdom. It is of great interest for evolutionary studies to explore the 
potential array of USPs present in the common ancestor of all eukaryotes by comparing 
plant and animals USPs. However, given the 2,738 million years of independent evolution, 
difference in the nucleotide substitution rate (Buckley and Cunningham, 2002) and 
variable gene death (Roy et al., 2009), such an endeavour demands an extensive 
phylogenetic analysis beyond this study. Out of over 4,500 bacterial and archaeal genomes 
screened, the presence of the C19 domain in only one bacterial species (Candidatus 
amoebophilus asiaticus) is surprising. Intriguingly, C. Amoebophilus asiaticus is an 
obligate intracellular symbiont of amoeba (Schmitz-Esser et al., 2008), this raises the 
possibility that C19 domain may have been acquired as a result of horizontal gene transfer 
(HGT) from the eukaryotic cell (amoeba) and not originated in the prokaryotic genome. 
Alternatively, the peptidase C19 domain had indeed originated in the prokaryotes and 
nearly all bacterial species had lost it after the prokaryote eukaryote split. However, the 
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genome sequence analysis of C. Amoebophilus asiaticus shows the presence of over 50 
foreign genes in the bacterial genome which also include two genes that share 27% 
sequence identity with ubiquitin carboxyl terminal hydrolase of Trichomonas vaginalis, a 
protozoan (Schimitz-Esser et al., 2010). This strongly supports the bacteria may have 
acquired the C19 domain as result of horizontal gene transfer. This brings a caveat in the 
phylogenetic analysis as all trees were rooted using C. Amoebophilus asiaticus C19 
domain sequence. However, in all trees the sequence automatically rooted out from the 
homologues found in eukaryotes. Additionally, the unrooted trees also retained the 
topology observed in the rooted trees. 
Structural similarities indicate the common ancestry  
Owing to the limited number of structural folds and strict evolutionary constraints on the 
folding pattern, protein structures are often considered as better evolutionary markers than 
the gene or protein sequences, especially to explore distant ancestral relationships 
(Agarwal et al., 2009; Liu et al., 2004; Scheeff and Bourne, 2005). Thereby, strong 
structural conservation in a protein reflects common ancestry despite the lack of support 
from traditional sequence based approaches (Agarwal et al., 2009; Scheeff and Bourne, 
2005). Comparison of the six C19 domains (examined here) revealed strong structural 
similarities between the peptidase C19 domains of USPs regardless of their association 
with different paralogous groups. This reflects that different variants of the C19 domain 
may have evolved from a common ancestor, however, over time, the sequences diverged 
considerably but with limited effect on the overall domain architecture. Alternatively, the 
possibility that these structures developed through convergent evolution cannot be 
completely discounted (Bukhari and Caetano-Anolles, 2013; Tomii et al., 2012).  
Origin of USP paralogous groups  
The phylogenetic analysis reveals that nearly all USP paralogous groups emerged before 
the origin of metazoa. Exceptions in this regard are the USP paralogous groups 6, 10, 11, 
12, 15 and 16, which incorporate relatively few USP homologues (1-3). Among those, the 
origin of groups 10, 12, 15 and 16 is placed with the origin of coelomates (nearly 1000 
MYA). One homologue of group 11 (comprising USP26,29,37) was identified in hydra 
and the others coelomates suggesting its origin lies in the common ancestor of metazoans. 
USP6 (group 6) is composed of two protein domains, a TBC domain and C19. Only 
homologues found in humans, chimpanzee and gorilla possess both domains, while 
homologues found in all other animals have only the TBC domain. This suggests a recent 
acquisition of the C19 domain in the common ancestor of great apes probably from USP32 
(based on the phylogenetic analysis).  Similarly, CYLD (the only human USP homologue 
of group 16) is comprised of two protein domains: CAP-GLY and C19N. The CAP-GLY 
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domain was identified in genes of both slime mould and hydra but without a C19 domain. 
This points to the origin of CYLD by domain acquisition with the origin of coelomates.  
Owing to the very low sequence identity between the members of different paralogous 
groups, sequence based phylogeny (by composite tree reconstruction of all USPs) lacks 
resolution (data not shown). However, the evolutionary relationship between different USP 
paralogous groups could be investigated using structural based phylogenetic 
methodologies. In addition some clues have been gathered from individual species trees, 
which points to a common ancestry for group 2, 3 and 4. Similarly group 1 and 7 show 
some linkage patterns as do groups 5 and 10. 
Birth and death of USPs in metazoa and role of whole genome duplications; Model of 
USPs Evolution 
Given the extent of sequence divergence between USP paralogues, the potential gene loss 
in the species analysed and the species bias represented in the sequenced genomes, it is 
difficult to develop a reliable composite phylogeny of all paralogous USP groups together. 
Therefore phylogenetic trees were reconstructed separately for each paralogous group 
using the C19 domain and based on their topology, and the distribution of vertebrate and 
non vertebrate homologues, a model tree has schematically drawn (Figure 5.15). Although 
the data indicate that most USP paralogous groups originated before the protozoan-
metazoan split (1184 MYA) and/or possibly before animal-plant split (1369 MYA), genes 
within several paralogous groups underwent subsequent expansion at different time points 
particularly during the emergence of coelomates and vertebrates. The latter time is also 
marked for the proposed two whole genome duplication events occurred between the 
divergence the vertebrates and chordate-vertebrate split (722 MYA) (Ohno et al., 1970; 
Holland et al., 1994). It has been proposed that the first whole genome duplication event 
(1R) occurred between the divergence chordates and divergence of jawless fishes while the 
second whole genome duplication event (2R) happened between jawless fishes and bony 
fishes (Escriva et al., 2002; Kuraku et al., 2009). Moreover, after the fish-tetrapod split, the 
common ancestor of ray finned fishes (400 MYA) also underwent a whole genome 
duplication event (3R) (Amores et al., 1998; Postlethwait et al., 1998). If the genes 
produced via these genome duplication events (referred to as ohnologues) survived during 
the course of evolution, each of such duplication events would have resulted in the 2 fold 
increase in the number of antecedental genes, thereby 4 and 8 copies of USPs would be 
present in tetrapods and fishes respectively, against each lineal ancestral gene. However, 
consistent to the  “Birth and Death” model of gene evolution (Nei and Rooney, 2005),  
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Figure 5.15. Model for evolution of USPs in animalia. Evolutionary relationship of 
USPs were explored using the maximum and likelihood method. The tree is manually 
redrawn to collate the informations gathered by the phylogenetic reconstructions of 
individual paralogous groups regarding distribution of the vertebrate and nonvertebrate 
homologues in the tree. Branches corresponding to each gene is coloured differently to 
represent their associated paralogous group and drawn to scale with estimated evolutionary 
timeline (shown below). Major taxonomic association of the animals are shown below. The 
light bar represents to the evolutionary period where two events of whole genome 
duplications have been proposed. Organisms are abbreviated as defined in section 5.3.  
 
neutral drift in evolution quickly eliminated most of the duplicated paralogues due to 
redundancy. Alternatively, the daughter genes could undergo the process of fixation which 
leads to the sub-functionalization and/or neo-functionalization (Innan and Kondrashov, 
2010). In agreement, the present phylogenomic analyses are indicative of a “Birth and 
Death” patterns of evolution in the USP genes. More than half of the potential USP 
ohnologues which emerged after 1R/2R have succumbed to gene death in vertebrates, 
whereas the remainder underwent a process of fixation and preservation in the population. 
Genome analysis of lancelet (Branchiostoma floridae) has also shown that only one quarter 
of the duplicated paralogues retained in the human gene families and much smaller fraction 
of these are ohnologues (Putnam et al., 2008). Although the proposed 3R event occurred in 
the common ancestor of ray finned fishes, no evidence of additional USPs was found 
among the fish genomes, suggesting extensive gene death in USP ohnologues generated by 
the fish specific WGD. A similar extent of gene death was observed through the 
phylogenetic analysis of the GATA gene family, where despite the retention of ohnologues 
originating from 1R/2R, all teleosts fishes have lost all the ohnologues which had emerged 
as a result of 3R (Gillis et al., 2009). Conversely, in GH18 family genes, evidence for the 
relics of 3R have been presented (discussed in chapter 6) (Hussain and Wilson, 2013). 
Nevertheless, phylogenetic reconstruction shows 13 pairs of vertebrate specific USP 
homologues  (including the triplet of USP4, USP11 and USP15) share a lineal ancestry 
with a single non vertebrate gene. Out of these, the genomic loci of 7 pairs of 
phylogenetically linked genes exhibit other paralogous gene pairs in their proximity. 
Furthermore, based on paralogous chromosomes regions determined in the human genome, 
relics of both WGDs have been partially mapped (Dehal and Boore, 2005; Nakatani et al., 
2007), only four of the vertebrate specific USPs map to these regions which include: 
USP36/42, USP20/33, USP4/11/15 and USP5/13. Both these observations (presence of 
paralogons and position of the genes on human genome) support the model of USP gene 
expansion in early vertebrates via whole genome duplication events. It is noteworthy that 
paralogons of USPs are discontinuous in nature as in many cases non paralogous genes 
disrupt the stretch of paralogous genes. Additionally, 5 vertebrate specific and 
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phylogenetically linked USP gene pairs shows no syntenic support in connection to WGDs 
in the compared region and with the loci mapped for WGD while one pair USP8/50 likely 
to be originated by gene duplication. These observations may be due to the limit placed in 
this comparison of 10 genes on each side of the locus. However, the same threshold 10 
genes was found suitable in the previous studies using a proximate gene pair method for 
identifying true syntenic regions which had arisen by WGD (Panopulo et al., 2003; Hufton 
et al., 2008). Alternatively and perhaps more likely, the lack of synteny among the 
vertebrate specific USP pairs is the result of extensive post WGD gene death and/or 
genomic rearrangement, thereby losing the genomic synteny, as proposed by Nakatani et al 
(2007) and Hufton et al (2008). Moreover, it is suggested that the WGD events themselves 
increased the rate of genomic rearrangement (Otto, 2007), however, later studies have 
shown no cause and effect correlation between WGDs and genomic rearrangements but 
instead demonstrated an increased rate of synteny loss in early tetrapod lineages (Huffton 
et al. 2008). Counterintuitively, existence of USP paralogons could also be inferred as a 
result of large scale segmental duplication in the ancestral genome followed by genetic 
rearrangement over time. Finally, as it is assumed that the genome duplication events 
occurred between the emergence of chordates and early vertebrates, inclusion of 
homologues from organisms that reflect this time frame, such as cartilaginous fishes (once 
the genomic assembly is available) and lamprey, may further refine the timeline for the 
expansion of USPs at the root of vertebrates. 
Examining these limited number of species revealed no evidence of expansion in USPs 
with the origin of mammals however, some paralogues originated after the marsupial-
eutherian split (162 MYA). In this regard one interesting case is of USP17, where multiple 
homologues are arranged on human chromosome 4p and 8q. A previous phylogenetic 
study by Burrows et al., (2010) demonstrated the clustering of USP17 paralogues in a 
single clade, suggesting that these duplications happened after the speciation events in the 
eutherian mammals. However, given the relatively recent gene expansion of USP17, it is 
possible that the gene sequences, especially of the C19 domain, have not diverged enough 
to distinguish between paralogues and orthologues. It has been suggested that most 
breakpoints in the human and mouse genomes occur close to tandem gene duplications or 
large segmental duplications (Armengol et al., 2005). Hence it is tempting to speculate that 
the tandem duplication of USP17 lead to chromosomal breakage and relocation, resulting 
in the presence of USP17 homologues on the two chromosomes (4p and 8q). 9 out of 32 
copies of USP17 homologues are either catalytically inactive or exist as pseudogenes. 
Similarly, two human USPs, USP50 and USP54, are also catalytically inactive. However, 
Mushtaq Hussain, 2013  183 
USP50 is catalytically active in all vertebrates examined except human suggesting that loss 
of the enzymatic activity in USP50 is relatively a recent evolutionary event.  
With phylogenetic support present, homologues adjacently located on a chromosome can 
be the product of gene duplication (Hussain and Wilson, 2013; Cridland et al., 2012). 
Among the USPs, except for USP17 homologues (eutherian specific) USP8 & USP50 
(vertebrate specific), which are located adjacent on a single chromosome, no other USP 
pairs are proximally present indicating a limited role of gene duplication in the expansion 
of USPs in vertebrates. Some of the USP genes such as USP18&USP41 and USP27&51 
are phylogenetically linked and found on different but paralogous regions of the same 
chromosome, suggesting these pairs of genes originated via segmental duplication. It is 
interesting to note that most of those genes have limited distribution in eutherian mammals 
(USP27, USP51) or two species of primates: human and chimpanzee (USP41). Of note, 
earlier observations have shown an increased proportion of interspersed segmental 
duplications within the genomes of humans and great apes (Marques-Bonet et al., 2009; 
Zhou and Mishra, 2005) compared to other mammals. Though segmental duplication is 
generally associated with the genomic instability (Emanuel and Shaikh, 2001) recently it 
has been shown to underlie the emergence of promoters for LRRC37 gene family (Bekpen 
et al., 2012), suggesting segmental duplication has also contributed in the expansion of 
other gene families. 
In summary, the USP gene family has undergone extensive expansion at the root of the 
vertebrates and limited expansion with the origin of eutherian mammals and great apes. 
Several genetic forces such as genome duplication, segmental duplication, gene duplication 
and domain acquisition have contributed at different time points in the expansion of the 
USPs in the extant vertebrates and eutherian mammals.  
Conflict between gene tree and species tree 
Given the considerable sequential divergence among the USPs, it is not surprising that 
positioning of certain branches and nodes in the phylogenetic reconstructions are not super 
imposable upon the established species tree. Discordances between multigene trees and the 
species tree are not uncommon in phylogenetic analyses (Degnan and Rosenberg, 2006; 
2009; Nichols, 2001).  Discordances between the species and gene trees, also termed 
anomalous gene trees; (AGT; Degnan and Rosenberg, 2006; 2009) are more evident in 
paralogues with limited distribution. For instance USP17 homologues are only present in 
eutherian mammals and yet it outgroups vertebrate USP36 and USP42 in a single 
monophyletic clade (Figure 5.3). Similarly, the arrangement of the orthologues with in 
clade/subclades also deviates from the established speciation events. Several explanations 
could be proposed to account for these inconsistencies: 1) extensive loss of the gene causes 
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the misplacement of the clade or subclades that deviate from the established speciation 
events; 2) bias in the available and/or analysed genome sequences of animals (more 
mammalian genomes have been sequenced/analysed than other taxonomic lineages); 3) 
loss of phylogenetic signals (less informative substitutions) because of the usage of limited 
sequence length  (for example C19 domain sequences instead of full gene sequences); 4) 
heterogeneity in the substitution rate between the compared homologues. 5) AGT can also 
result from the fast adaptive radiation resulting in divergence in rapid succession.   
Peptidase C19 is the only domain that is consistently present in other wise highly divergent 
USPs. Moreover, for multidomains proteins, conserved domain sequences are often 
employed successfully to examine the evolutionary history of the corresponding genes 
(Alvarez-Venegas and Avramova, 2012; Rojas et al., 2012). This and the observation 
obtained from the phylogenetic analysis (most clades with >90% bootstrap value) suggests 
that C19 domain sequence provides sufficient informative signal to reconstruct the 
phylogenetic relationship of USPs. Finally variation in the nucleotide substitution rate, as 
reflected by the branch length of individual clades within the tree and rapid adaptive 
radiation could be accounted to reason the AGT in the present phylogenetic 
reconstructions.   
Domain diversity and organismal complexity 
Protein domains are considered as a distinct evolutionary unit and it has been suggested 
that multidomain architectures reflect organismal complexity (Konnin et al., 2002; Vogel 
et al., 2004). However, other lines of evidence suggest that domain promiscuity is 
independent of complexity of the organisms and similar multidomain architecture could 
evolved convergently, independent of the evolutionary position of the organism (Forslund 
et al., 2008). The domain analysis of USP homologues in species associated with key 
phylogenetic points demonstrates a trend of incremental complexity. While retaining the 
inherited domain conformations, new variants of peptidase C19 domain and domain 
combinations arose in USPs during the transition from a simpler form to relatively more 
complex form.  Most domains combinations (such as MATH-C19C-ICP0 and WD40-
C19P-PAN2 etc) are stably inherited from protozoa to primates. This strong conservation 
in domain combinations between orthologues suggests a functional conservation of USPs 
orthologues across animal lineages. By contrast, the domain versatility between paralogues 
reflects functional divergence. Biological mechanisms leading to the generation of new 
domains or domain combinations are not fully understood. However, processes such as 
gene fusion and loss/gain of protein domains or shuffling of protein domains are often 
proposed as major contributing factors in this regard (Bork, 1991; Chothia and Gerstein, 
1997). Moreover, progressive folds do evolve over time in domains, resulting in the 
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variations within the protein domains and even origin of new domains (Grishin, 2001; 
Scheef and Bourne, 2005). 
Although domain combinations among most USP orthologues remains fixed throughout 
the evolutionary history, there are a few exceptions in this regard. For example the 
rhodanese domain and domain of unknown function (DUF) are present in all orthologues 
of USP8 except of hydra (XP002164031) which points to their acquisition in the USPs in 
early coelomates. However, the rhodanese domain is frequently found in other proteins of 
bacteria, fungi and plants (reviewed in Bordo and Bork, 2002), demonstrating the 
prokaryotic origin of the domain and likely subsequent assembly (via domain acquisition) 
into USP8 in the common ancestor of coelomates. Alternatively, the domain could have 
been present in the ancestral USP8 and subsequently lost in hydra after its divergence from 
the common ancestor. Typically, the rhodanese domain is catalytically active and 
composed of two identically folded sub-domains with very weak (13%-21%) sequence 
identity (Bordo et al., 2000). In USP8 orthologues, only the N-terminal half of the domain 
is present which lacks the catalytic activity and has been shown to interact with the E3 
ligase NRDP1 (Avvakumov et al., 2006). Given that this sub domain is also absent in the 
USP8 orthologue in hydra, it is reasonable to suggest that USP8 orthologue may be 
functionally different from USP8 of other species. Similarly, Zn finger domain (Zf)  are 
not present in slime mould and NV orthologues  of USP16,45 and USP20,33 suggesting 
the origin of the DNA binding capacity of these proteins emerged with coelomates and 
vertebrates respectively. In certain orthologues C19 associated domains appeared to have 
duplicated over time during the evolution of animals. For instance the CYLD orthologue in 
fruit fly (NM164910) carries a single CAP-GLY with a C19N domain, whereas in all other 
deuterostome orthologues of CYLD there are 3 CAP-GLYdomains along with C19N, 
suggesting domain duplication occurred. The CAP-GLY domain is an 80 residue long 
protein module which is involved in microtubule organization and transportation of 
vesicles and organelles (Steinmetz and Akhmanova, 2008).  Since the CYLD orthologue of 
fruit fly and USP19 orthologues of NV deuterostomes are yet to be functionally 
characterized, the significance of this domain duplication is not known. However, it is 
suggested to be a common feature in protein evolution (Nacher et al., 2010).  
As Zf, UBA, DUSP and peptidase C19R domains (not mutually exclusive) are present in 
USPs of different paralogous groups, this indicates that domain combinations could be 
emerged several times. Alternatively it may indicate distant shared ancestry between those 
paralogous groups. 
In summary, the phylogenomic and domain distribution analysis show the stable transition 
of multidomain architectures from the ancestral lineages (represented by slime mould) to 
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the primates (humans), which reflect functional conservation between the orthologues. 
Moreover, domain comparison of USPs homologues shows an increase in the domain 
combination paralleling organismal complexity. Finally, it is important to note that USP 
proteins in humans show considerable variation in length and most of the protein regions 
are not annotated for any structural or biological significance.  
USPs evolution and functional divergence 
The retention of duplicated genes in an organism is indicative of functional divergence 
which in turn is reflected by domain diversity, expression profile and partner protein 
interaction of the corresponding genes (Innan and Kondrashov, 2010; Lynch and Conery, 
2000).  
Homologues found in slime mould include: USP12, USP46, USP36, USP7, USP16, 
USP15, USP47, USP40, USP5, USP10, USP14, USP39, USP48 and USP52. Most USPs 
present in protozoa are associated with core eukaryotic functions such as DNA repair 
(USP7, USP47 etc) (Parson et al., 2012; Sarasin, 2012), RNA processing (USP39, USP52) 
(Bett et al., 2013; Rios et al., 2011) and cell division (USP39 and USP16) (van Leuken et 
al., 2008; Joo et al., 2007). All of these functions have shown considerable transition as 
life evolved from prokaryotes to eukaryotes. Parallel origin of these USPs with eukaryotic 
cells implicates the role of USPs in the evolution of complex molecular machinery in 
eukaryotes. 
Lineal ancestry of many human USPs were traced back prior to the origin of vertebrates. 
Molecular partners of these USP homologues suggest that most of the homologues that had 
originated with the origin of metazoans are associated with DNA repair, cell division, 
induction of apoptosis and cell cycle control. For example USP22 and USP3 deubiquitinate 
H2A and H2B and contribute in the cell cycle progression (Zhang et al., 2008), USP37 
once phosphorylated with CDK2 results in the increased stability of cyclin A which in turn 
facilitate G1/S transition (Huang et al., 2011). Earlier datamining studies have shown 
molecular mechanisms that regulate cell cycle evolve considerably throughout animal and 
plants evolution (Cross et al., 2011; de Lichtenberg et al., 2007).  
USP34 and USP9 origin is contemporaneous with the emergence of the associated 
molecular pathways in metazoans. USP34 deubiquitinates axin, a key molecule of Wnt/β-
catenin which in turn facilitates β catenin mediated transcription (Lui et al., 2011). Wnt 
pathway is important in cell proliferation and development and first discovered in fruit fly 
(Baker et al., 1987). No homologues of Wnt have been detected in the protozoa, plants and 
bacteria however, 14 homologues were identified in the cnidarians suggesting the point of 
the origin of this pathway (Kusserow et al., 2005). Similar to the Wnt pathway, TGFβ 
pathway is also metazoan specific (Huminiecki et al., 2009) and human USP9X has been 
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reported to stabilize SMAD4, one of the key modulatour of TGFβ pathway (Dupont et al., 
2009). Considering the contemporaneous origin of Wnt and TGFβ pathways and the 
associated USPs suggest the possibility of co-evolution of molecular pathways and their 
associated USPs.  
Ohnologues generated as a result of WGDs, differ in their expression profile and molecular 
partners (Table 5.5 and 5.6).  Expression profile in humans suggests ubiquitous expression 
of USP2 but elevated expression of USP21 in immune related cells. Both genes are 
antagonist in their functions as USP2 induces cell proliferation by stabilizing MDM2 
resulting in the degradation p53 (Stevenson et al., 2007) while USP21 inhibits the cell 
growth by its interaction with NEDD8 (Gong et al., 2000). Another such example is 
USP20 and USP33, USP20 expression has been observed mostly in the immune related 
cells while elevated expression of USP33 was observed in the nervous system. Despite the 
similarity in the domain organization USP20 is involved in the endocytosis whereas 
USP33 has been shown essential for axon guidance (Yuasa-Kawada, 2009) and centriole 
biogenesis (Li et al., 2013) potentially by its interaction with ROBO1 and centriolar 
protein CP110 respectively. Similarly USP4, USP11 and USP15 emergence is parallel to 
the emergence of vertebrates.  Though expression pattern of USP4 and USP15 are similar 
and mostly concentrated to immune cells, USP11 expressed at high levels in different parts 
of nervous system.  
At present, functions of many USPs (especially vertebrate specific) are poorly understood 
or not elucidated at all. The present study highlights the important evolutionary events and 
mechanisms resulting in the extant array of these important proteins in vertebrates 
including humans. However, more insights could be gained by the structural comparison of 
full range of C19 domains of different USPs (once available) to resolve the ambiguous 
paralogous relationship. Functional innovation among different USPs though being 
reflected by domain composition, gene expression and molecular partners, nevertheless, 
studies on the selection pressure across the length of proteins may also provide useful 
information in this regard. Studies in this connection are underway in our research team.    
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6. Results: Phylogenomic studies of vertebrates 
chitinases and chitinase like proteins  
6.1. Introduction 
This chapter describes the structural phylogenomic analysis of the GH18 family 
homologues in vertebrates. The study includes the robust datamining of GH18 homologues 
in nearly all vertebrates whose genome sequence is available in public databases to explore 
the diversity and expansion of the genes across different vertebrate lineages. We applied 
the maximum likelihood method to reconstruct the phylogenetic relationship of GH18 
homologues using cDNA sequences of vertebrates available on databases to explore the 
evolutionary relationship of vertebrate GH18 genes. Genome syntenies of vertebrates 
GH18 genes were also compared to investigate the underlying mechanism of GH18 gene 
expansion in vertebrates. The study presented here is published recently (Hussain and 
Wilson, 2013) and it not only helped to resolve some existing annotation issues of ChiLs 
but proposed novel paralogues in the vertebrate GH18 family. In addition, to explore the 
structural and in turn functional diversity of the proteins, protein sequence alignments and 
structural models of paralogous GH18 proteins were constructed and examined for the 
differences in functionally important residues and regions respectively.  
6.2. Datamining  
Two public databases, NCBI and Ensembl were extensively surveyed for GH18 family 
genes in mammals and other chordates. BLAST searches for GH18 family members were 
undertaken against the databases as well as against the genomes of the sequenced 
organisms. In total 388 vertebrate GH18 homologues were identified after excluding mis-
annotations, duplicates and pseudogenes (Appendix VI).  GH18 homologues were 
identified across 45 species of mammals covering 35 families and 17 orders. Homologues 
were found in three marsupials (opossum, Tasmanian devil and wallaby) and a monotreme 
(duckbill platypus), reflecting early evolutionary branches in the mammalian lineage. 
Relatively, fewer GH18 homologues were detected among non mammalian vertebrates 
such as reptile, bird, amphibian and fishes (respectively). As a representative of early 
vertebrates, sequences (chid1 and chitinases, respectively from sea lamprey and Arctic 
lamprey) from lampreys were found and included in the analysis. Digging more into the 
evolutionary past of vertebrates, genomic BLAST revealed one GH18 chitinase homologue 
in tunicate (urochordate) and two in lancelet (cephalochordate). Homologues from both 
sequences were incorporated in the subsequent phylogenetic analysis. 
Mushtaq Hussain, 2013  190 
With few exceptions, both active chitinase, CHIT1 and CHIA homologues were found in 
most of the mammalian species examined. Additional CHIA-like homologues were 
identified in some species namely: cow, marmoset, bush baby, Tasmanian devil and 
opossum (Table.6.1). Like CHIT1 and CHIA, two ChiLs, CHIL1 and OVGP1 were also 
found well distributed among different mammalian lineages ranging from monotremes to 
primates. Consistent with the previous studies (Bussink et al., 2007; Srivastava et al., 
2007), a gene identified as secretory glycoprotein 40 (BP40) was found exclusively among 
the members of family bovidae sharing 92% identity with CHIL1. Although CHIL1 is 
physically mapped in the cow and pig genomes, no separate locus for BP40 has been 
identified yet.  Therefore the presence of both paralogues could be inferred as a result of 
species specific duplication of CHIL1 or alternatively, a single paralogue with sequencing 
errors or allelic variations.   In contrast to CHIL1, CHIL2 was found to have a limited 
distribution across mammalian lineages. Except primates, homologues of CHIL2 were 
found to have limited distribution in different mammalian lineages. An additional array of 
ChiLs was observed in at least three species of family muridae. The mouse (as the best 
characterized genome) encodes Chil3, Chil4, Chil5 and Chil6. In the literature (Bussink et 
al., 2007) previously predicted mouse Chil5 and Chil6 pseudogenes have now been 
resolved as a single pseudogene annotated as Gm6552 in the databases. Another finding 
through datamining was the detection of partial CHIL2 orthologues in kangaroo rat 
(ENDORT00000003888), a member of rodent order which was previously thought to have 
lost the CHIL2 gene through evolution (Bussink et al., 2007). BLASTp search showed that 
the gene has 84% sequence identity with human CHIL2 (e value=0.0). This may suggest 
that the loss of CHIL2 in many rodents probably occurred after diverging from the most 
recent common ancestor of the order. 
Chitinase genes were found in all non mammalian vertebrates examined; fishes in 
particular have multiple genes annotated as novel genes and showing high sequence 
identity with the chitinases and having catalytic motif. Surprisingly, anole lizard (reptile) 
does bear a ChiLs homologue. Despite showing the identical sequence and genomic 
location, the gene is differently annotated as CHIL1 and CHIL2 in NCBI and Ensembl 
databases respectively. Multiple active chitinases and ChiLs have been described among 
invertebrates especially arthropods (Huang et al., 2012). Genes annotated as oviductins are 
found in some arthropods, however, they showed no domain or sequence similarity with 
the mammalian OVGP1; rather they were found more similar (37% amino acid identity of 
deer tick (Ixodes scapularis) to human ovochymase, a serine protease. Similarly, fruit fly 
imaginal disc growth factor genes are also ChiLs, however, none of those genes were 
identified in the BLAST search using vertebrate GH18 homologues.  
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1 2 3 4 5 6 
Mammalia 
Placental Mammals 
Afrosoricida 
Echinops telfairi  hedgehog Tenericidae              
Carnivora 
Ailuropoda melanoleuca giant panda Ursidae             
Canis familiaris dog Canidae             
Felis catus cat Felidae             
Cetartiodactyla 
Bos taurus cow Bovidae  2 1 2         
Bubalis bubalis water buffalo Bovidae             
Capra hircus goat Bovidae             
Ovis aries sheep Bovidae             
Sus scrofa pig Bovidae             
Tursipos truncatus dolphin Delphinidae             
Vicugna picas alpaca Camelidae             
Chiroptera 
Myotis lucifugus microbat Vespertilionidae  2   2        
Pteropus vampyrus megabat Pteropodidae             
Euliptophyla 
Erinaceus europaeus hedgehog Erinaceidae             
Sorex araneus shrew Soricidae             
Hyracoidea 
Procavia capensis rock hyrax Procaviidae             
Lagomorpha 
Ochotona princeps Am. pika Ochotonidae             
Oryctolagus cuniculus rabbit Leporidae             
Perisodactyla 
Equus caballus horse Equidae  ?           
Primates 
Callithrix  jacchus marmoset Callitrichidae  2           
Gorilla gorilla gorilla Hominidae             
Homo sapiens human Hominidae   *          
Macaca mulatta macaque Cercopithecidae             
Microcebus murnus mouse lemur Cheirogaleidae             
Nomascus leucogenys gibbon  Hylobatidae             
Otolemur garnettii bush baby Galagidae  3           
Pan troglodytes chimpanzee Hominidae             
Papio Anubis baboon Cercopithecidae             
Pongo abelli orangutan Hominidae             
Tarsius syrichta tarsier Tarsiidae             
Proboscidea 
Loxodonta africana Af. elephant Elephantidae             
Rodentia 
Cavia procellus guinea pig Caviinae             
Cricetulus griseus Ch. hamster Cricetidae             
Dipodomys ordii kangaroo rat Heteromyidae      ?       
Mesocricetus auratus golden hamster Cricetidae             
Mus musculus mouse Muridae             
Rattus novergicus rat Muridae             
Spermophilus 
tridecemlineatus 
squirrel Sciruidae             
Scadentia 
Tupaia belangari tree shrew Tupaiidae             
Xenarthra 
Chleopus hoffmani two toed sloth Megalonychidae             
Dasypus novemcintus armadillo Dasypodidae             
Marsupials Mammals 
Dasyuromorphia 
Sarcophilus harrissi  Tas. devil Dasyuridae  3           
Didelphimorphia 
Monodelphis domestica grey opossum  Didelphidae  3 2          
Diprotodontia 
Macropus eugenii wallaby  Macropodidae             
Cont... 
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1 2 3 4 5  6 
Mammalia 
Egg Laying Mammals 
Monotremata  
Ornithorhyncus ananitus platypus  Ornithorhyncidae 3            
Aves 
Galliformes 
Gallus gallus chicken Phasianidae  3           
Meleagris gallopova turkey Phasianidae  3           
Passiriformes 
Taeniopygia guttata zebra finch Estrilididae  3           
Reptilia 
Squamata 
Anolis carolinensis anole lizard Poluchrotidae ? 3 3 ?         
Pelodiscus  sinensis Chinese turtle Trionychidae   3 ?         
Amphibia 
Anura 
Bufo japonicum Jap.toad Bufonidae             
Rana catesbeiana bullfrog Ranidae             
Xenopus topicalis clawed frog Pipidae  2           
Xenopus laevis Af. frog Pipidae              
Pisces 
Beloniformes 
Oryzias latipes medaka Adrianichthyidea 2  3          
Coelancanthiformes 
Latimera chalumnae Coelacanth Latimeridae  2           
Gardiformes 
Gadus morhua cod Gadidae   3 5          
Gasterosterioformes 
Gasterosteus aculeatus stickleback Gasterosteidae  2 4          
Salmoniformes 
Oncorhyncus mykiss trout Salmonidae   2          
Cypriniformes 
Danio rerio zebra fish Cyprinidae   3         2 
Perciformes 
Oreochromis niloticus   3            
Tetradontiformes  
Takifugu rubripes fugu  Tetradontidae   4          
Tetradon nigrovidis puffer fish Tetradontidae   2          
Hyperoartia 
Petromyzoniformes  
Lethenteron japonicum Arctic lamprey Petromtyzontidae            
Petromyzon marinus sea lamprey Petromtyzontidae             
 
Table 6.1. Distribution of GH18 homologues in vertebrates. The distribution of GH18 
homologues currently identified amongst vertebrate species is shown (shaded cells). 
Absence or not yet identified genes are represented by blank cells.The number within the 
cells indicates the number of genes identified. The orthologous identification is based on 
the phylogenetic analysis conducted herein (described later). The newly identified 
(discussed later) CHIO group is also included. (?) indicates where a partial 
gene/unresolved has been identified. 
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Single genes encoding the exochitinase CTBS and ChiL CHID1 are present in most of the 
species examined (Table 6.1) and homologues were also observed in most organisms 
including plants, fungi and slime moulds.  
6.3. Three evolutionary groups of vertebrate GH18 homologues  
To advance the understanding of vertebrate GH18 gene family evolution, maximum 
likelihood trees were generated using the complete cDNA sequences of nearly all the 
available GH18 homologues of vertebrates and chordates. In order to root the tree, GH18 
chitinase sequence of Serratia marscens chitinase was included. The phylogenetic tree 
revealed multiple clades reflecting multiple paralogous groups (Figure 6.1). Mainly, three 
observations could be gathered from the tree topology. First the tree shows separation of 
vertebrates GH18 homologues into two halves separated by the chordates GH18 
homologues. On one side two clades of CHID1 and CTBS are present while on the other 
side both endo chitinases and associated ChiLs are present which indicates that three  
major evolutionary groups separated before the origin of vertebrates (Figure 6.1).  
Excluding CTBS and CHID1, other expanded vertebrates GH18 homologues share lineal 
ancestry with GH18 homologues of non vertebrates chordates. Although both CTBS and 
CHID1 are retained as single gene per species (except in zebra fish where two homologues 
of CHID1 were noticed) the remaining GH18 homologues have expanded extensively in 
vertebrates especially within mammalian lineages. The limited homology (<30%) between 
CHID1, CTBS and the other GH18 homologues could account for instability in the 
alignment (especially at the phylogenetically important data points) and evidenced by low 
bootstrap support in the tree. Consequently, to improve the accuracy of prediction of the 
phylogenetic relationship of vertebrate GH18 homologues, another tree was constructed 
excluding CTBS and CHID1 sequences. 
6.4. The expanding vertebrate GH18 homologues  
Excluding CTBS and CHID1 genes, a maximum likelihood tree was reconstructed from 
nearly all available vertebrate GH18 homologues and rooted with the lancelet chitinase 
sequences (Figure 6.2). The tree reveals two major groups named here CHIT and CHIA 
super clades. Both super clades are further divided into smaller clades of active chitinases 
and ChiLs. The CHIT super clade includes one active chitinase (CHIT1) and two ChiLs: 
CHIL1 and CHIL2.  The anole lizard ChiL is annotated in the Ensembl and NCBI 
databases as chi3l2 and chi3l1 respectively, clusters with the mammalian CHIL2 clade 
with a high bootstrap support (97%). In support to this, this ChiL shows a shorter 
evolutionary distance to mammalian CHIL2 homologues than to CHIL1 (Figure 6.3A). 
This study indicates two separate events of gene duplications, but in a different order  
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Figure 6.1. Phylogenetic tree of vertebrates GH18 homologues. Phylogenetic tree of 
GH18 homologues of chordates was constructed using the maximum likelihood method. 
The tree is shown in collapsed (A) and expanded format (B). The tree is rooted with the S. 
marcescens chitinase homologue and support values obtained by 1000 bootstrap replicates 
are shown. Clades and subclades are coloured differently to represent known and 
potentially new paralogues. The green arrow in (A) indicates the branches of non 
vertebrate chordate GH18 homologues suggesting separation of the CTBS and CHID1 
from other vertebrate GH18 homologues predates origin of the chordates. 
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Figure 6.2. Phylogenetic tree of expanding vertebrate GH18 homologues. Phylogenetic 
tree of GH18 homologues (excluding CTBS and CHID1) of chordates was reconstructed 
using the maximum likelihood method employing the General Time Reversible (GTR) 
model with 1000 boot strap replicates. The tree is rooted with B. floridae GH18 
homologues.  Clades and subclades are coloured differently to represent known and 
potentially new paralogues. The tree is shown in both branch length (left) and topology 
format (right). The clades at the root are generally supported with high boot strap values 
(>90%). Note the two clades of fish GH18 homologues (pink) and new paralogous clade 
(CHIO).  
 
 
 
 
Figure 6.3. Evolutionary distance analysis of selected GH18 homologues. Evolutionary 
distances of selected GH18 homologues were estimated using the maximum composite 
likelihood method. The data distribution and statistical significance were tested using the 
Kolmogorov-Smirnov and the Wilcoxon tests respectively (p values are shown in red). 
Error bars indicate standard error of mean (SEM). (A) Anolis lizard chil2 evolutionary 
distance is compared with CHIL1 and CHIL2 homologues of selected mammalian species 
(human, chimpanzee, marmoset, rhesus monkey, pig, cow and opossum). (B) Evolutionary 
distance of homologues of CHIT1, CHIL1 and CHIL2 from the same species were 
compared in pairs (as indicated). (C) Evolutionary distance of clawed toad NM00105790 
(chit1) was compared against CHIT1 and CHIA homologues of human, baboon, orangutan, 
rhesus monkey, pig, panda, rat, hamsters and opossum. (D) Evolutionary distance of CHIO 
homologues were compared against all homologues (included in Figure 6.2) of CHIA and 
OVGP1. 
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(Bussink et al., 2007; Funkhouser and Aronson, 2007) leading to the emergence of ChiLs 
where CHIL2 origin predating the CHIL1. To support this notion, evolutionary distances 
of comparable orthologues of CHIT1, CHIL1 and CHIL2 were estimated (Fig.6.3B).  This 
comparison indicates that the evolutionary distance between CHIT1 and CHIL1 is 
significantly smaller in comparison to CHIT1 and CHIL2. Moreover, the distance between 
CHIL2 and CHIL1 is significantly (p<0.0001) larger than CHIL1 and CHIT1. Taken 
together these data indicate that the CHIL2 ancestor emerged prior to the reptilian-
mammals split and CHIL1 emerged later from a gene duplication of ancestral CHIT1 
before the diversification of mammals. 
Unlike the CHIT1 clade, which is comprised of only mammalian homologues, the CHIA 
clade, contains one representative of reptile, bird, amphibian and fish with 98% bootstrap 
support. This would suggest that there has been an extensive gene loss of CHIT1 
homologues in the non mammalian vertebrates. Like the CHIT super clade, the CHIA 
super clade also includes ChiLs: OVGP1 and the rodentia specific Chils. These ChiLs form 
separate clades with high bootstrap support, 97% for rodentia specific chilectins and 86% 
for OVGP1 (99% excluding platypus Ovgp1). Rodentia Chils form a separate cluster 
within the CHIA clade which points to a recent evolutionary origin from rodentia Chia. 
The gene currently annotated as rat Chi3l4 clusters with the mouse Chil5 (100% bootstrap 
support) suggesting an orthologous relationship between these two homologues.  Between 
the CHIA and OVGP1 clades two relatively sparsely populated clades are present referred 
to as CHIO and fish chio/chia herein (Figure 6.2). The CHIO clade contains representative 
of genes from a reptile, an amphibian and mammals (opossum and cow) and is statistically 
(99%) supported as monophyletic excluding one (XM003220376) of the two Anolis 
homologues within this clade. The CHIO clade also contains a clawed toad homologue 
(NM001056792) which is annotated as chit1 in both NCBI and Ensembl databases. This 
misnomer has led to the impression in earlier studies (Bussink et al., 2007) that duplication 
leading to CHIA and CHIT1 occurred at the common ancestor of tetrapods. However, 
phylogenetic reconstruction based on increased taxa does not support this idea as clawed 
toad “chit1” (NM001056792) does not cluster with the CHIT1 clade or CHIT super clade, 
rather it joins the separate monophyletic CHIO clade within the CHIA superclade. 
Furthermore, evolutionary distance analysis also showed the same homologue of clawed 
toad is statistically closer (p=0.0024) to CHIA as compared to CHIT1 (Figure 6.3C). 
Although CHIO representatives form a distinct clade in between CHIA and OVGP1 but 
the presence of DXDXE motif suggests they are potentially active chitinases. Evolutionary  
distance analysis also indicates that CHIO genes are more closely related (p<0.001) to 
CHIA than OVGP1 (Figure 6.3D). Another smaller clade, in between OVGP1 and CHIA is 
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of fishes GH18 homologues (90% bootstrap support) which are annotated as CHIA-like or 
novel gene in NCBI and ENSEMBL respectively. The presence of a DXDXE motif in all 
the representatives (except stickle back ENSGACT00000016635) suggest they are active 
chitinases.  Three fish and one lamprey GH18 homologues with two discrete branches are 
present at the base of both super clades which raises two possibilities, one that these fish 
genes (at least those of bony fishes) are CHIT1 orthologues but cannot yet be reliably 
placed because of the weak phylogenetic signals. Alternatively, it is possible that these 
homologues are the lineal common ancestor of all the vertebrate CHIT1 and CHIA genes 
as suggested in earlier studies (Funkhouser and Aronson, 2007; Huang et al., 2012). 
However, the presence of bony fish GH18 homologues in the CHIA super clade and more 
specifically CHIA clade support the former inference.  
To explore if outgroup (lancelet chitinases) biases on the tree topology two separate 
phylogenetic trees were reconstructed excluding lancelet and lamprey genes (Figure 6.4A) 
and rooted with a more ancestral GH18 homologue of nematode worm and including all 
the chordates GH18 homologues (Figure 6.4B). The fish homologues change location in 
the tree demonstrating a lack of resolution in determining their evolutionary history. 
Despite this the overall topology of the tree remains intact with high boot strap support, 
indicating the stability of the tree. In the tree devoid of both lancelet and lamprey 
chitinases, fish GH18 homologues (with the notable exception of stickleback chia) are 
present at the base of both CHIA and CHIT super clades forming two distinct clades of fish 
chio/chia and fish chit1. Whereas in the tree rooted with the nematode worm homologue, 
the fish chio/chia clade is present at the base of CHIA superclade and fish chit1 clade is 
situated at the base of both CHIT and CHIA superclades.  
Considering the data of all trees together it appears that CHIL1 and CHIL2 arose from 
separate duplication events. In addition a new paralogous group, CHIO has been identified.  
6.5. Novel paralogues of vertebrates GH18 family 
Data mining has shown multiple CHIA like genes in several mammals and non 
mammalian vertebrates. Some of these genes form a discrete clade, resolving between 
CHIA and OVGP1 clades and referred here as CHIO. To explore these sequences further, 
separate phylogenetic trees were reconstructed including all CHIA like genes selected 
OVGP1 orthologues with lamprey chitinase and lancelet chitinases to root the tree (Figure 
6.5). The tree shows one major clade of CHIA from orthologues ranging from fishes to 
mammals with strong bootstrap support (99%). However, this major clade is intervened by 
at least two other groups, which reflect the known speciation events (Bininda-Emonds et 
al., 2007). For example a new clade referred to as CHIAII contain two primate  
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Figure 6.4. Phylogenetic relationship of vertebrate GH18 homologues. Two different 
phylogenetic trees were reconstructed using the maximum likelihood method and 
employing GTR model of nucleotide substitution by excluding lancelet and lamprey (A) 
and including tunicate and nematode worm GH18 homologues (B) in the taxa included in 
the Fig.6.2. The Clades are coloured differently to represent the paralogous relationship. 
Note the swapping of relative position in the trees of the fish GH18 compared to the tree 
shown in Fig. 6.2. Also note, stickle back chia remains in the CHIA clade in both trees. 
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Figure 6.5. Evolutionary tree of vertebrate CHIA super clade genes. The evolutionary 
history of the CHIA superclade was reconstructed using all available complete mammalian 
CHIA related genes and selected OVGP1 homologues as well sequences from 
representatives of fish species. The tree was reconstructed using the maximum likelihood 
method using the GTR model of nucleotide substitution with 1000 bootstrap replicates and 
rooted with B. floridae chitinase genes. Different paralogous clades are labelled including 
three newly identified paralogues i.e. CHIA-II, CHIA-III and CHIO. 
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homologues (bush baby and marmoset), and is located between the Chia of carnivores and 
primates. Similarly, a CHIAIII clade includes homologues from fish to mammals, located 
in the tree between clawed toad and stickleback chia. In addition to this the rodentia 
specific Chils clearly show common ancestry with rodentia Chia suggesting their recent 
origin. All CHIA clades collectively share a common ancestry with the CHIO clade (91% 
bootstrap support) which is populated by three mammalian homologues (2 of opossum and 
1 of cow), one amphibian sequence clawed toad (NM00105792; database annotation chit1) 
and five reptilian sequences (3 of anole lizard and 2 of Chinese soft shell turtle). Finally, 
both CHIO and CHIA clades share common ancestry with the other GH18 homologues of 
fishes. Both OVGP1 and potential fish chit1 form separate and distinct clades from CHIAs 
and CHIO. In addition to the newly identified paralogous clades (CHIAII, CHIAIII and 
CHIO), some additional species specific duplications in chia were observed in opossum, 
anole lizard and chicken (Figure 6.5). Further genomic BLAST search also revealed the 
presence of three pseudogenes in humans. To investigate the evolutionary relationship of 
these pseudogenes, the CHIA phylogenetic tree was reconstructed incorporating the human 
pseudogenes (Figure 6.6). The tree suggests that relics of all three novel paralogues 
(CHIA-II, CHIA-III and CHIO) are present in the human as pseudogenes, providing 
evidence of extensive gene death of GH18 members across the mammalian lineage. It 
might be expected that pseudogenes would show long branches because of higher 
nucleotide substitution rates due to possible loss of selection pressure. However, these 3 
human pseudogenes do not show long branches and do not greatly distort the tree 
topology. 
Collectively, the data demonstrate that the CHIA ancestral genes have undergone extensive 
gene duplication events followed by extensive gene death in many examined mammalian 
lineages during the evolutionary course. At least two duplication events could be aligned 
before the emergence of mammals giving rise to CHIO/OVGP1 and CHIA-III. Another 
duplication event may have occurred in the common ancestor of primates giving birth to 
CHIA-II. Consistent with the birth and death model of gene evolution, three human 
pseudogenes (and three from macaque, Appendix VI) reflect death of genes in each of the 
three newly identified paralogous groups. 
6.6. Fish paralogues of vertebrate GH18 
To examine the proximal time line for the birth and diversification of CHIT1/CHIA and 
CHIA/CHIO clades, fish sequences were investigated in more detail. Therefore, a 
phylogeny of fish GH18 homologues was reconstructed using the maximum likelihood 
method including two mammalian CHIA (Figure 6.7). The tree composed of 4 distinct  
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Figure 6.6. Phylogenetic relationship of human pseudogenes with CHIA superclade 
genes. The evolutionary tree of CHIA super-clade homologues was reconstructed using all 
available complete mammalian CHIA related genes, human pseudogenes and selected 
OVGP1 homologues as well sequences from representatives of fishes. The tree was 
reconstructed using the maximum likelihood method employing the GTR model of 
nucleotide substitution with 1000 bootstrap replicates and rooted with lancelet chitinase 
genes. Different paralogues clades are labelled including three newly identified paralogues 
i.e. CHIA-II, CHIA-III and CHIO. Note the placement of human pseudo genes in all three 
of the newly identified paralogous clades.  
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Figure 6.7. Evolutionary relationship Fish GH18 homologues. The phylogenetic tree of 
fish GH18 homologues (excluding CTBS and CHID1) was reconstructed using the 
maximum likelihood method using the GTR model with 1000 bootstrap replicates. Four 
distinct phyletic clades are coloured differently namely CHIA and clade I-III. Clade I and 
II are potential homologues of CHIO while homologues in clade III are potentially the fish 
representatives of CHIT1. 
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phyletic groups. First acting as an outgroup of the CHIA clades is a clade of 7 genes 
(clade-III; 99% bootstrap support) belonging to GH18 homologues of medaka, zebrafish, 
Nile tilapia and stickle back. This separation is consistent with the hypothesis that these 
genes may be CHIT1 orthologues. Three fish sequences, two from stickleback and one 
from trout, formed a clade with mammalian CHIA (CHIA clade; 99% bootstrap support) 
strongly supporting the orthologous relationship of these homologues with the mammalian 
CHIA. Most of the remaining fish GH18 homologues occupied two distinct phyletic 
groups (clade-I and clade-II) between the CHIA clade and clade-III, with evidence of 
further duplications in several species. Four fish homologues did not cluster with any of 
designated clades namely: stickleback ENSGACT00000015229, medaka XM00343878, 
zebrafish ENSDRT00000111829 (forming outgroup of CladeI and Clade II) and pufferfish 
ENSTNIT00000002465.  
Consistent with all the data is that the duplication event giving rise to the ancestral CHIT1 
and CHIA, and probably CHIO as well, occurred prior to the divergence of bony fishes.   
6.6. Genomic synteny reflects the phylogeny  
The phylogenetic relationship of chitinases and ChiLs is recapitulated in the chromosomal 
location and gene order of these genes (Figure 6.8). The distantly related CTBS and 
CHID1 genes are not chromosomally linked to other GH18 homologues in any of the 
vertebrate species examined. The Chia related ChiLs, OVGP1 and rodentia specific Chils 
are located in the proximity of the CHIA genes in the analysed organisms. Similarly, 
CHIL1 and CHIT1 are consistently present next to each other. Interestingly, CHIL2 which 
showed a close evolutionary relationship with CHIT1 in the phylogenetic analysis was 
found genomically linked with CHIA. This observation points to the birth of this paralogue 
predating the genetic rearrangement event that physically separated the CHIT1 and CHIA 
loci, while CHIL1 could have arisen subsequent to this separation or been carried with 
CHIT1. Interestingly, these genes are all present in close proximity within same 
chromosome in the anole lizard. This points to the physical separation of CHIT1 and CHIA 
genes seen in mammals, post dating reptilian mammalian split. In fishes, though multiple 
GH18 homologues were found, many of them have not been fully mapped on their 
respective genomes. However, the homologues in fishes are generally distributed on two 
different chromosomes which could suggest that they are the product of fish specific whole 
genome duplication. Moreover, in stickle back and zebra fish, homologues associated with 
three different phyletic clades (CHIA, cladeI/II and clade III) have been physically mapped 
on the same chromosomes, which indicate that at least two of gene duplication events may  
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Figure 6.8. Genomic synteny of vertebrate GH18 homologous. The chromosomal 
locations of Chi/ChiL genes of representative vertebrate species are depicted. Arrow heads 
correspond to the direction of transcription. Genes are coloured in relation to phylogenetic 
clades. Human pseudogenes, as shown from left to right are RP11-165H20.4, RP11-
165H20.1 and RP5-1125M8.5 and in mouse Gm6522. Where genes are not annotated the 
last four numbers of the accession number have been used. 
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have occurred prior to the divergence of fishes. It is interesting to note that among fishes, 
the GH18 homologues are flanked with genes that are homologous of those flanking both 
CHIT1 and CHIA in human. For instance, one side of the predicted CHIT1 orthologoues 
(ENSORLT00000013259 on chromosome 5) of medaka, genes lie CNTN2 and NAFSc 
which were found in the proximity of human CHIT1. On the other side of the fish genes lie 
CDC40 and SLC2A1, homologous to those seems at the human CHIA locus. This 
observation supports the idea that the physical separation of the CHIT1 and CHIA loci 
seen in mammals had not occurred prior to the divergence of fish.  
On the basis of the cumulative phylogenomic analyses, it seems likely that the ancestral 
chitinase gene underwent two duplication events leading to the formation of CHIA, CHIO 
and CHIT1 prior to the divergence of bony fish. Most of the further gene duplications have 
occurred in the recent common ancestral lineage of all mammals or some specific families 
(rodentia and bovidae) leading to the formation of an array of ChiLs. However, one such 
event of duplication in ancestral CHIT1 has occurred prior to the origin of mammals (in 
reptiles) resulting in the birth of CHIL2. 
6.7. The tale of the OVGP1 tail 
While OVGP1 orthologues show common ancestry with CHIA and CHIO and the gene has 
the GH18 homology domain, the C-terminal region of mammalian OVGP1 is quite 
different from mammalian CHIA C-terminal chitin binding domain (CBM14). In fact the 
extended C-terminal region of OVGP1 shares a patchy sequence similarity with mucin like 
proteins and previously reported as heavily glycosylated (Buhi et al., 2002).  N and O 
linked glycosylation sites on proteins were predicted using CBS NetNglyc and NetOglyc 
servers respectively. The threshold value has been set at 0.5 at which 96% accuracy is 
expected, however some sites may be missed. Asn is the target residue for N-linked 
glycosylation with Asn-X-Ser/Thru as a consensus site, whereas O-linked glycosylation 
occurs on Ser or Thru residues in a context dependent manner. In silico prediction showed 
that most mammalian OVGP1 sequences with an extended C-terminal tail have multiple 
glycosylation sites in comparison to CHIA (Fig.6.9). Extensive glycosylation could 
contribute to the increased stability and viscosity of the protein and could also provide 
additional ligand binding sites. The OVGP1 C-terminal region showed considerable 
variation across mammalian species in terms of length and glycosylation sites, suggesting 
that variation/retention in the number of glycosylation sties may have acted as a selection 
force in the evolution of OVGP1 orthologues. No distinct OVGP1 orthologue was 
identified in the non mammalian vertebrates, however CHIO orthologues of anole lizard, 
clawed toad and stickle back, despite having the catalytic motif (DXDXE), have  
Mushtaq Hussain, 2013  207 
 
 
Figure 6.9. OVGP1 glycosylation. Schematic representation of OVGP1 or CHIO (where 
OVGP1 is not found) from several species of different vertebrates are shown. The length 
of the horizontal rectangle is scaled corresponding to the polypeptide length (indicated at 
the right of each). Human CHIA is shown at the top with GH18 domain highlighted in 
light green and CBM14 domain in yellow. N and O glycosylation sites (predicted using 
CBS servers NetNglyc and NetOglyc respectively) are shown with red and blue bars 
respectively. The presence of the catalytic motif is represented by a star. The sequences of 
horse (E.caballus) and shrew (T.bellangari) have gaps and hence glycosylation sites were 
not predicted. 
 
comparable number of glycosylation sites compared to most mammalian OVGP1, 
suggesting CHIO orthologues exhibit intermediate characteristics of CHIA (presence of 
catalytic motif) and OVGP1 (highly glycosylated tail). 
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6.8. Multiple sequence alignment of vertebrates GH18 proteins  
In order to explore the similarities and differences in primary structure of the mammalian 
GH18 proteins, multiple amino acid sequence alignments (excluding CTBS and CHID1) 
were constructed by selecting one representative from each paralogue (Figure 6.10; Table 
6.2). For convenience, herein the amino acids positions of compared proteins are indicated 
with reference of human CHIT1. The catalytic site residues and cleft lining aromatic 
residues are conserved to varying degree in the human and mouse GH18 proteins (Table 
6.2).  Among the important observations gathered: the catalytic active sites between 
residues 115-119 (DXDXE) is strongly conserved in both known active chitinases (CHIA 
and CHIT1) and the newly identified paralogue (CHIO). However, in CTBS, Asp115 is 
substituted with Asn102. With the exception of the complete substitution of Glu119 in all 
ChiLs, Asp115 and Asp117 are variably substituted among the compared homologues 
(Table 6.2). The ligand binding cavity of chitinases and ChiLs is lined with the aromatic 
residues (Fusetti et al., 2002; Houston et al., 2003; Olland et al., 2009; Schimpl et al., 
2012). These residues are largely conserved among all the compared paralogues. For 
example Tyr/Phe191, Tyr/Phe246 and Trp337 were found strictly conserved across all 
chitinases and ChiLs. Trp10 is conserved in all homologues except Chil7 where Val 
substituted it at the corresponding position. Among paralogues, Trp197 is only substituted 
with different residues in three mouse ChiLs. Tyr169 has been reported as a residue lining 
the ligand binding cavity of CHIT1 (Fusetti et al., 2002), however in the sequence 
alignment it did not reveal any noticeable pattern of conservation. Trp78 is also conserved 
except in CHIL2 and Chil7 where it is replaced by Tyr and Arg respectively. Tyr13 and 
Trp50 were also appeared conserved in all active chitinases, CHIL1 and BP40.  
In mammalian CHIA, a strictly conserved triad of three residues; Arg124, His187 and 
His248 have been attributed to its optimal activity in acidic pH (Olland et al., 2009).  The 
triad is completely conserved between mouse and human orthologues of CHIA (Table 6.2). 
In addition, Arg124 is conserved in most homologues except CHIT1, CHIL2, Chil8, CTBS 
and CHID1. His 187 is completely unique to CHIA whereas His248 is only conserved in 
CHIA, CHIL2 and murine specific Chils except Chil5. Previously, it has been proposed 
that CHIL1 may bind with the heparin (Fusetti et al., 2003) owing to the presence of a 
positively charged residue cluster (GRRDKQH) in the region: 122-128. In CHIL2 the 
corresponding region is less basic and contains only two positively charge residues, Lys 
and His at the corresponding positions. While in the other chitinases and chilectins this 
region lacks conservation. Since CHID1 and CTBS have evolved as separate GH18 gene 
lineages and share very low sequence identity with other GH18 homologues (17% and 9% 
respectively with human CHIT1), to attain maximum accuracy in the alignment of  
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Figure 6.10. Multiple sequence alignment of GH18 proteins. A multiple sequence 
alignment of GH18 proteins (one per paralogue excluding CTBS and CHID1) is shown. 
The N-terminal leader sequence and C-terminal extension (where present) were removed. 
Secondary structure with reference to human CHIT1 structure (PDB id: 1LQ0) is 
schematized using purple cylinders (α helices) and arrows (β strands) at the top of each 
respective row. Catalytic site residues are indicated with red filled circles whereas aromatic 
residues aligning the ligand binding groove are indicated by green filled circles. All 
sequences are of human origin except Chio and BP40 from cow and Chil3, Chil4, Chil5 
and Chil6 from mouse. 
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Figure 6.11. Multiple sequence alignment of CHIT1, CTBS and CHID1.  A multiple 
sequence alignment of human CHIT1, CTBS and CHID1 is shown. The N terminal leader 
sequence was removed and the secondary structure with reference to the CHIT1 structure 
(PDB id: 1LQ0) is delineated using purple cylinders (α helices) and arrows (β strands). 
Catalytic site residues are represented with red filled circles and aromatic residues aligning 
the ligand binding groove are represented by green filled circles 
Proteins Catalytic 
Residues 
Aromatic Residues  
(Lining the ligand binding groove) 
Residue for 
Optimal 
acidic pI 
CHIT1 D115 D117 E119 W10 Y13 F37 W50 W78 Y169 Y191 W197 Y246 W337 Q124 N187 R248 
Chit1* D115 D117 E119 W10 Y13 F37 H50 W78 L169 Y191 L197 Y246 W335 R124 N187 R248 
CHIA D115 D117 E119 W10 Y13 F37 W50 W78 N169 Y191 W197 Y246 W338 R124 H187 H248 
Chia* D115 D117 E119 W10 Y13 F37 W50 W78 N169 Y191 W197 Y246 W339 R124 H187 H248 
CHIO D116 D118 E120 W10 Y13 F37 W50 W79 S170 Y194 W200 Y249 W339 R125 S190 R251 
OVGP1 D116 F118 L120 W10 S13 F37 L50 W79 I170 Y192 W198 Y242 W334 R125 N188 R244 
Ovgp1* D116 F118 L120 W10 S13 F37 L50 W79 I170 Y192 W198 Y242 W334 R125 N188 R244 
CHIL1 D115 A117 L119 W10 Y13 F37 W50 W78 T163 Y185 W191 F240 W331 R124 S181 R242 
Chil1* D116 A118 L120 W10 Y13 F37 W51 W79 A164 Y186 W192 F241 W332 R125 N182 K243 
BP40 D115 A117 L119 W10 Y13 F37 W50 W78 A165 Y185 W191 F239 W330 R124 S181 R241 
CHIL2 D115 S117 I119 W10 D13 F37 K50 Y78 M166 F186 W192 Y243 W334 K124 N182 H245 
Chil3 N115 D117 Q119 W10 D13 F37 E50 W78 V169 Y191 K197 Y246 W339 R124 Q187 H248 
Chil4 N115 D117 Q119 W10 D13 F37 E50 W78 V169 Y191 K197 Y246 W339 R124 Q187 H248 
Chil5 N115 D117 Q119 V10 N13 F37 M50 R78 T169 Y191 Q197 Y246 W339 R124 Q187 Q248 
Chil6 N115 A117 Q119 W10 H13 F37 R50 W78 T169 Y191 W197 Y246 W339 Y124 Q187 H248 
CTBS N102 D104 E106 -- -- F23 W37 -- N148 Y171 W178 Y216 W316 L111 F167 Y218 
Ctbs* N102 D104 E106 -- -- F23 W37 -- R148 Y171 W178 Y216 W316 S111 F167 Y218 
CHID1 V171 E173 W175 W69 -- -- -- -- F222 Y242 W258 Y283 W361 -- S238 S283 
Chid1* V171 E173 W715 W69 -- -- -- -- F222 Y241 W258 Y283 W361 -- S238 D286 
Table 6.2. Amino acids conservation of GH18 proteins. The table shows the conserved 
residues in different mammalian GH18 homologues on the basis of multiple sequence 
alignment and/or structural alignment. Residues at three functionally important regions 
namely, catalytic active sties, ligand binding groove aromatic residues and residues 
important for optimum acidic pI were compared. Conserved residues with reference to 
human CHIT1 and/or CHIA  are shaded. Mouse orthologues are indicated by (*). 
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functionally important amino acids, CTBS and CHID1 proteins were examined 
independently using a structural alignment with human CHIT1 (Figure 6.11 and Table 
6.2). This suggests the presence of catalytic activity in at least CTBS. Additionally, 
structural conservation of residues lining the ligand binding groove is mainly restricted to 
the last four residues (Y191, W197, Y246 and W337) which are present at the C-terminal 
region of both CTBS and CHID1. 
The data not only show the absence of the catalytic motifs and the catalytic activity in the 
ChiLs but also provide information about the differences in the amino acid composition of 
the ligand binding cleft, suggesting differences in ligand specificity. Additionally, it is 
important to note that amino acids present at the proximity of cleft lining residue (except 
Trp337) vary considerably between the compared sequences. Such differences may affect 
the orientation of side chains of important aromatic residues and consequently alter the size 
and shape of the cavity. 
6.9. Structure of chitinases and chitinase like proteins  
In order to examine the effect of sequential conservation and variations on the three 
dimensional conformation of the human and mouse GH18 proteins, the structurally 
unresolved human and mouse chitinases and ChiLs, were modelled. Models of human 
OVGP1 and CTBS, mouse Chit1, Chia, Ovgp1, Chil1, Chil4, Chil7, Chil8, Ctbs and Chid1 
and cow Chio (the latter not present in human and mouse) were developed using the 
closest available templates (for mouse Chils; PDBid 1VF8 , for human OVGP1; PDBid 
3FXY, human CTBS; PDBid 3XY, 1LQ0 , cow Chio; PDBid 3FXY) based on the 
maximum primary sequence identity or multiple threading in the case of CTBS and full 
length CHIT1 and CHIA. The final models were selected on the basis of minimized DOPE 
and structural constraints. Ramachandran plot analyses of the selected models show that 
more than 98% of the residues of the modelled structures were present in the allowed 
region, supporting the structural plausibility of the molecular models (Figure 6.12). 
Moreover, Q mean scores of all selected models range between the acceptable limits of 
0.0-1.0. The vertebrate GH18 proteins are typically composed of two structural domains: a 
core domain which adopts a TIM barrel (β/α)8 conformation and a relatively small second 
domain, situated between β7 and α7 called the α+β domain (Sun et al., 2001; Fusetti et al., 
2002; Olland et al., 2009; Houston et al., 2003; Meng et al., 2010). Evaluation of all the 
modelled structures revealed that both domains are present in nearly identical spatial 
positions in relation to the known structures (Figure 6.13). In order to further examine the 
structural similarities, all the modelled and structured mammalian chitinases and ChiLs 
were superimposed in two sets: one set comprising all the structures with the exception of 
CTBS and CHID1 and the second set include CHIT1, CTBS and CHID1. 
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Figure 6.12. Ramachandran plots of modelled GH18 proteins. Ramachandran plot 
analyses of the modelled proteins were conducted using Molprobity server. The X and Y 
axis of each plot represent phi and psi angle respectively. Each black dot is the 
representation of the position of an amino acid with reference to the ratio of phi and psi 
angles. Light blue contour margins indicate the strictly allowed region while dark blue 
contour lines represent the generously allowed regions in the plot. Note all models are 
from the mouse sequences except Chio (from cow) and OVGP1 (from humans).  
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Additionally, mouse Chit1, Chia, Ovp1, Chil1, Ctbs and Chid1 were individually 
superimposed over the respective human orthologues (Figure 6.14). In set 1, 
superimposition of molecules showed that there is considerable conservation, not only in 
the Cα backbone architecture (RMSD values <0.5), but also in the distribution and spatial 
positioning of the secondary structural elements. The only exception in this regard was the 
modelled structure of cow Chio, where two small loops (Lys173-Ile176 and Thr257-
Pro264) did not coincide with the loops of other molecules at the corresponding position 
(Figure 6.13 A&B). Conserved cysteine residues which form disulphide bonds in CHIT1, 
Cys5-Cys30 and Cys286-Cys349 were observed in all the structured and modelled 
proteins. Two overlapping antigenic epitopes described for CHIL1 (Pro238-Glu250 and 
Arg242-Gly252) (Boots et al., 2007) occupy the same spatial positions and structural 
conformation (β8) in all the compared proteins. By comparison, CHIT1, CTBS and CHID1 
tertiary structure superimposition revealed variation in the spatial arrangement of both the 
Cα backbone and secondary structural elements (Figure 6.13 C&D). Nevertheless, the 
overall topologies of the proteins are highly similar in terms of arrangement and 
positioning of domains (TIM barrel and α+β). Superposition of the mouse models over the 
respective human orthologues did not reveal any substantial differences in the 
conformation and spatial positioning of the secondary structural elements indicating high 
structural conservation between orthologues (Figure 6.14). For the mammalian chitinase 
and CHILs proteins where resolved structures are available, only the 39kDa GH18 region 
(including the TIM barrel and α+β domain) has been resolved, while the C-terminal tails of 
CHIT, CHIA and full length OVGP1 have not been structured. In order to explore the 
contribution of this domain to the structure, full length models of these proteins were 
generated (Figure 6.15).  The models reveal that these C terminal extensions (CBM14 in 
case of CHIT1 and CHIA; Mucin like tail in OVGP1) form spatially discreet structurally 
unfolded loops. In the case of CHIT1 and CHIA the tails runs at 90
o 
to the active site 
groove “Scorpion like” and it can be imagined how this might contribute to the binding of 
a chitin chain, perhaps even guiding it into the active site groove, In the case of OVGP1, 
the tail extends from the rear (fish like) of the protein (in relation to the active site groove). 
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Figure 6.13. Superimposition of GH18 Proteins Structures. The resolved and modelled 
proteins have been superimposed over each other in two sets. The first set includes a 
human, mouse (except Chil1 and nearly identical murine Chil4, 5 and 6) and cow 
representatives of each of the mammalian GH18 paralogous proteins, excluding CTBS and 
CHID1 (A&B). The second set shows the superimposition of human CHIT1, CTBS and 
CHID1 (C&D). Superimposition of the Cα back bone is shown in A and C, while B and D 
show the secondary structure superimposition. Each molecule is coloured differently: 
human CHIT1 (purple), human CHIA (red), cow CHIO (orange), human CHIL1 (blue), 
cow BP40 (light blue), human CHIL2 (green), human OVGP1 (yellow), mouse Chil3 
(brown), human CTBS (light green) and human CHID1 (sea green). Note variation in the 
Cα backbone and secondary structure in C and D (CHIT1, CTBS and CHID1) in 
comparison to A and B (all GH18 homologues excluding CTBS and CHID1). The 
differently placed cow Chio is shown in blue (Lys173-Ile176) and red (Thr257-Pro264) 
arrows.  
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Figure 6.14. Superposition of human and mouse orthologues. Ribbon diagrams of 
human and mouse GH18 homologues were superimposed according to their orthologous 
relationship. Human models are differently coloured while all mouse homologues are 
coloured cyan. 
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Figure 6.15. Full length models of human CHIT1, CHIA and OVGP1. Ribbon 
diagrams and electrostatic surface models of full length human CHIT1, CHIA and OVGP1 
are shown. Full length models were developed by I-TASSER, where the GH18 domain 
was constructed using the corresponding templates while the C-terminal region is mostly 
developed by ab initio modelling.   
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6.10. Variations in ligand binding grooves of different GH18 paralogues. 
Although strong structural similarities reflect the shared ancestry of the mammalian GH18 
proteins, it provides limited insights for understanding the ligand specificity of these 
paralogues. To explore this further, the biophysical and structural characteristics of the 
ligand binding cavities were compared. To identify the potential cavities, the protein 
examined  using POCASA 1.0. The program scans the protein surface in a 3D grid and by 
placing spherical probes (radius 2.0Å) in cavities it delineates the dimensions and depth of 
potential ligand binding cavities and ranks them according to volume (i.e. the number of 
accumulated probes (Table 6.3; Figure 6.16). Consistent with earlier studies (Fusetti et al., 
2002; Houston et al., 2003; Olland et al., 2009; Meng et al., 2010) the central cleft was 
detected in all the modelled structures, pointing to a similar ligand binding region. 
However, estimation of cavity volume revealed considerable variation in the size, shape 
and depth of these grooves. Among the expected GH18 the largest ligand binding groove 
was observed in human CHIT1 followed by human CHIL1 and mouse Chil3 and 4. 
Intriguingly, despite the close evolutionary relationship of BP40 with CHIL1 the cleft 
(groove) volume of BP40 is notably (1.5 times) smaller (358Å
3
) than human and mouse 
CHIL1 (543Å
3 
and 575Å
3 
respectively). Conversely, despite the distant evolutionary 
relationship of CHIL2 with CHIA their ligand binding clefts are of similar volume (431Å
3
 
and 426Å
3 
respectively). Active groove of mice shows a smaller volume then human 
CHIT1, but is similar in size to the groove volume of Chia of both species (Table 6.3; 
Figure 6.16). Mouse and human CHID1 reveal the smallest groove of the molecules 
examined, with other cavities on the surface having greater volume. The groove cavities of 
CTBS is amongst the largest (1164Å) observed in human GH18 proteins. The cavity opens 
out to a greater degree than the other molecule at lower end of the groove (as visualized in 
figure 6.16).  
The shape of the ligand binding region generally defines the nature and type of ligand that 
binds to the protein. Despite the similarity in the volumes of the grooves between CHIT1, 
CHIL1 and Chil3, the shape of their cavities differs considerably. The central groove of 
CHIT1 and CHIL1 runs down the length of the molecule giving it a tunnel like appearance. 
Similarly, the shape of CHIA, CHIL2 and Chio also appears to be elongated and tunnel 
like in appearance suggesting that these proteins can bind with an oligomeric 
(carbohydrate) moiety. The ligand binding cleft of Chil6 appears irregular in shape. By 
comparison, the Chil5 central cleft shape shows more resemblance to the antecedent 
homologue CHIA (Fig 6.16). This suggests that the different rodentia specific chilectins 
may have different ligand specificity. Interestingly, the central ligand binding groove of the 
active chitinase CTBS is different from CHIT1, CHIA and CHIO, with a wide and  
Mushtaq Hussain, 2013  218 
Protein PDB ID Volume (Å
3
) 
Human 
Volume (Å
3
) 
Mouse 
CHIT1 1LQ0 644 472 
CHIA 3FXY 426 474 
Chio* (3FXY) 364 --- 
OVGP1* (3FXY) 378 343 
CHIL1 1NWU 543 575 
BP40 2ESC 135 --- 
CHIL2 4AY1 431 --- 
Chil3 1VF8 --- 551 
Chil4 (1VF8) --- 473 
Chil5* (1VF8) --- 403 
Chil6* (1VF8) --- 389 
CTBS* (3FXY, 1LQ0) 1164 500 
CHID1 3BXW 34 29 
 
Table 6.3. Volume of Ligand Binding Grooves. PDB coordinates of all structured and 
modelled (*) proteins were submitted to POCASA 1.0 in order to estimate the volume of 
the central ligand binding groove with 2Å (radius) spherical probes. PDB ids of the 
structurally known GH18 molecules or templates used to model the unresolved proteins are 
given. 
 
 
irregular shape which possibly reflects its exo chitinase catalytic activity. The central cleft 
cavities of human and mouse orthologues are similar to each other. As mentioned earlier 
CHIL1 and BP40 evolved by the duplication of a common ancestor but the ligand binding 
groove of BP40 is smaller than CHIL1 and ranked as third largest as compared to other 
cavities present in the same protein. The first (177Å
3
) and second (157Å
3
) ranked cavities 
are present near the start (α9) and end of the α+β domain (between β10 and β11) respectively. 
Similarly, the central groove of CHID1 was also ranked as smallest among the potential 
cavities. An electrostatic surface analysis revealed that interiorly, the central cavity is 
hydrophobic in nature in all GH18 homologues except in CTBS where two of polar 
residues (Arg and Asn) were found buried inside the ligand binding groove (Figure 6.17).  
Additionally half of the rim around the central binding groove is relatively enriched with 
polar residues, which may define the orientation of the ligand. Comparison between the 
mouse homologues with the comparable human GH18 proteins did not show any 
significant differences in the shape and electrostatic surface (Figure 6.18). This points the 
similarities in ligand specificity and potentially functions between the compared 
orthologues. 
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Figure 6.16. Volume of Ligand Binding Groove. PDB coordinates of all structured and 
modelled GH18 homologues were submitted to POCASA 1.0 to evaluate the volume of 
potential ligand binding grooves with 1Å spherical probes. The protein molecules are 
represented with green ribbon while the density of probes are coloured as light blue, light 
green, pink and yellow in decreasing order of volume of cavities.  
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Figure 6.17. Electrostatic surface of the ligand binding groove. The electrostatic surface 
of the ligand binding groove as visualized by DS visualizer 3.5 is shown here. Red and 
blue refers to the negatively and positively charged residues respectively. Note the 
irregular margins of the cleft in Chil3, Chil6, OVGP1, CTBS and CHID1. Also to note, the 
division (compartmentalization) of the central groove into smaller pockets in the case of 
BP40 and Chil6.  
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Figure 6.18. Electrostatic surface of ligand binding cavities of mouse GH18 proteins. 
Electrostatic surface of ligand binding groove as visualized by DS visualizer 3.5 is shown 
here. Red and blue refers to the negatively and positively charged residues respectively. 
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The ligand binding grooves of the resolved GH18 homologues are lined with solvent 
exposed aromatic residues (Sun et al., 2001; Fusetti et al., 2002; Houston et al., 2003; 
Olland et al., 2009). Superimposition of these aromatic amino acids revealed significant 
similarities in the spatial orientation of these residues between different proteins (Figure 
6.19). However, some notable differences were observed, for instance Trp78 of CHIL1 and 
BP40 and Trp197 of CHIL1 showed a different orientation in comparison to the other 
proteins. Although Trp337 is completely conserved in all the compared proteins, it is 
slightly tilted in case of Chil3 and Chil4 molecules. Similar comparison of CHIT1 with 
CTBS and CHID (Figure 6.20) did not demonstrate such similarities in the orientation of 
the lining residues, with the exception of Tyr191, Trp197, Tyr246 and Trp339. 
Taken together the variations in shape and size of the ligand binding cleft, and the polarity 
and orientation of aromatic residues indicates that there is likely to be differences in the 
ligand binding specificity among different mammalian GH18 paralogues. Such differences 
in the active sites will reflect new and/or additional functional role(s) among vertebrate 
chitinases and ChiLs since their evolution from the ancestral gene.  
6.11. Summary of findings 
 The human genome encodes seven members of the GH18 protein family, these include 
three active chitinases (CHIT1, CHIA and CTBS) and four chitinase like proteins or 
chilectins (CHIL1, CHIL2, OVGP1 and CHID1). 
 Phylogenetic analyses demonstrated three major evolutionary lineages of GH18 proteins 
which diverged prior to the origin of vertebrates, leading to the formation of CHID1, 
CTBS and other GH18 homologues. 
 At the base of the vertebrate tree, extensive expansion of the GH18 genes (excluding 
CTBS and CHID1) were observed leading to the formation of ancestral CHIT1, CHIA 
and CHIO (a newly identified paralogue in this study). 
 The CHIT1 ancestral gene duplicated before the reptilian-mammalian split and again at 
the root of mammals leading to formation of two chilectins CHIL2 and CHIL1 
respectively. 
 The CHIA ancestral gene duplicated extensively in vertebrates leading to the formation 
of two active chitinases at the root of vertebrates and one at the base of primate 
divergence. 
 With the origin of mammals the CHIA ancestral gene duplicated to form a chilectin, 
OVGP1, and in family muridae additional array of chilectins.  
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 Synteny analyses of human and other vertebrate genomes recapitulate the phylogenetic 
association observed for the genes, where CHIA and CHIT1 related genes are closely 
linked. The only exception in this regard is the proximity of chil2 to chia, reflecting a 
genomic arrangement prior to the physical separation of the chia and chit1 ancestors in 
mammals. 
 Several GH18 protein encoding genes were identified in the fishes. With the exception 
of a few CHIA orthologues, the orthologous relationship of most homologues is 
ambiguous. A separate phylogenomic analysis suggested that these are potentially 
members of CHIT1 and CHIO groups. Additionally, relics of the fish specific genome 
duplication were also observed.  
 Potential relics of gene “death” as pseudogenes of CHIA and CHIO were found in the 
human genome.   
 Structurally, all GH18 homologues (human and mouse) are strongly conserved, 
comprising two distinct protein domains, a TIM barrel and α+β domain. 
 The CBM14 tail of CHIT1 and CHIA and highly glycosylated tail of OVGP1 are 
predicted to be unstructured. 
 Differences in the volume and shape of the central cleft were observed in different 
GH18 paralogues, which may determine the size and nature of the ligand for the 
proteins. The data suggest that in contrast to human chilectins, mouse Chil3 and Chil4 
and bovine BP40, may not be able to bind with oligomeric carbohydrate moieties.   
 
6.12. Discussion  
Multiple gene duplications and a differential rate of gene death across species lineages 
provide obstacles in inferring the evolutionary history of gene families (Roy, 2009). 
Moreover, inaccurate gene annotation may further confound the issue (Bidartondo, 2008; 
Demuth and Hahn, 2009). Hence a combined approach of data mining, phylogenetics and 
comparison of genomic synteny can provide a better resolution to not only annotate the 
gene sequences but also to identify the relationship of gene families with reasonable 
accuracy. In the present study we have exploited all three approaches to understand the 
phylogenetic relationship of GH18 family members in the vertebrate lineage. Our analyses 
presents a more detailed view of the evolutionary dynamics of chitinase and ChiLs in 
vertebrate. In addition more paralogues within the family were identified. The data provide 
an improved time line approximation for the expansion of GH18 family genes in 
vertebrates. In an investigation to explore the variability in the protein structure and ligand  
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Figure 6.19. Superimposition of the aromatic residues lining ligand binding grooves. 
Aromatic residues of GH18 proteins (excluding Chil4, CTBS and CHID1) lining the ligand 
binding groove were superimposed. In the inset magnified view of Trp337 superimposition 
is shown with all murine chilectins (Chil3, Chil4, Chil5 and Chil6) with human CHIL1. 
Note the tilt in the side chain of Trp337 in Chil3 and Chil4 in comparison to the other 
chitinases and ChiLs. Key: CHIT1 (purple), CHIA (red), OVGP1 (light green), CHIL1 
(blue), CHIL2 (green) BP40 (light blue) and Chil3 (maroon). 
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Figure 6.20. Superimposition of the aromatic residues lining ligand binding groove. 
CHIT (purple), CTBS (green) and CHID1 (cyan) aromatic residues lining the ligand 
binding groove were superimposed. Residues are numbered according to the CHIT1. 
 
specificity, protein models and resolved structures of mammalian human, mouse and cow 
GH18 proteins were compared. 
Evolution of GH18 proteins in vertebrates 
The inferred evolutionary history is based on all the GH18 homologues of vertebrates and 
chordates revealed an early separation of CHID1 and CTBS from other GH18 genes, 
including homologues of lamprey, lancelet and tunicate, into separate clades. The tree 
indicated that CHID1 and CTBS shared a common ancestor to other GH18 genes, before 
the origin of chordates. Both CTBS and CHID1 genes were detected in almost all the 
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vertebrates analysed, however with little evidence of gene death or gene birth in extant 
vertebrates. This sustained presence suggests that their functional role is vital for the 
organism’s physiology. In contrast to CTBS and CHID1, other GH18 family members 
have undergone extensive gene expansion in the vertebrate lineage. 
The present study is in agreement with the earlier studies (Bussink et al., 2007; Funkhouser 
and Aronson, 2007) in demonstrating a duplication event that lead to the formation of two 
active chitinases, ancestral CHIA and CHIT1. Both genes subsequently underwent multiple 
episodes of gene duplication that lead to the formation of additional chitinases and ChiL 
genes. Previously it has been suggested that this initial duplication occurred in early 
tetrapods with the evolution of CHIA paralleling the development of an acidic stomach 
(Bussink et al., 2007). However this study points to an event that occurred considerably 
earlier, before the divergence of bony fishes. Furthermore, this ancestral CHIA gene 
underwent multiple gene duplication events at different time points, in the evolutionary 
scale, of these at least two duplication events predate the divergence of bony fishes.   
It is now widely established that two rounds of whole genome duplications referred to as 
1R and 2R occurred before the divergence of chordates and vertebrates respectively. After 
these duplications, extensive gene loss and genomic rearrangements had occurred (Holland 
et al., 1994; Putnam et al., 2008; Hufton et al., 2008). Genome maps of the last common 
chordate ancestor have been reconstructed and signature regions of 1R and 2R have been 
determined in different vertebrate chromosomes including human (Nakatani et al, 2007). 
Considering that the time of the gene duplication event that lead to the formation of the 
CHIT1 and CHIA ancestor predates the divergence of bony fishes, it is possible that the 
birth of CHIT1 and CHIA results from 1R or 2R. However, a comparison of the human 
CHIT1 and CHIA loci (chromosome 1 p and q arm respectively) with the proposed regions 
of 1R or 2R signature indicates otherwise suggesting this duplication event was 
independent of 1R and 2R. Therefore the simplest explanation is that the duplication 
leading to the formation of the CHIT1 and CHIA ancestors had occurred after 2R and 
before the divergence of bony fishes. Homologous sequences from the cartilaginous fishes 
(sharks and rays) once available may increase the precision of these estimates.  
Orthology and paralogy of fish GH18 homologues 
In comparison to mammalian and fishes GH18 sequences, fewer homologues are available 
from intermediate vertebrates (amphibian, birds and reptiles). Either for this reason or due 
to concerted evolution of fish sequences it was not possible to clearly establish the 
orthology of most fish homologues. However, some homologues unambiguously align to 
the CHIA clades (both CHIA1 and CHIA3). It is possible that fish homologues that are 
present at the base of the CHIA and CHIT1 superclades are CHIT1. Similarly, the distinct 
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fish clades which are variably positioned within or at the base of the CHIA superclade may 
be CHIO genes. It is conceivable that both potential fish CHIT1 and CHIO may have 
undergone concerted evolution followed by the heterologous recombination and unequal 
cross over (Dover, 1982; Pinhal et al., 2011). This can result in the loss of the phylogenetic 
signal, to give ambiguous results in the trees. 
Two distinct clades of potential fish CHIO sequences point towards the telost specific 
genome duplication (3R) which occurred around 350 mya (Meyer et al., 2005). Gene 
synteny analysis also strengthens this idea as paralogues present in the two chio clades are 
located on different chromosomes and at least in one case (medaka) these two chromosome 
are proposed to result from 3R (Nakatani et al., 2007). It has been suggested that most 
duplicated genes which arose as a result of whole genome duplications (1R, 2R or 3R) died 
out because of the redundancy (Lynch and Conery, 2000). However, duplicated genes of 
CHIA/CHIO and to some extent CHIT1 resulting from 3R persist in many of the compared 
extant fishes. This expansion followed by retention of genes could be explained in terms of 
evolutionary pressure for example provided by the high chitin containing diet (molluscs 
and crustaceans) (Fines et al., 2009), fungal pathogen in an aqueous environment and for 
some developmental necessities (Wagner et al., 1993). 
Evolution of CHIA in vertebrates 
Multiple gene duplications occurred in ancestral CHIA giving rise to CHIO, CHIAII and 
CHIAIII as well as OVGP1 and an array of ChiLs in family muridae. Of these the origin of  
CHIAII probably occurred at the base of primate lineage, while CHIAIII ancestor arose 
before the divergence of the bony fishes. In the human genome relics of both paralogues 
are present as pseudogenes. Duplication of ancestral CHIA in the family muridae resulted 
in the emergence of Chils which further duplicated to produce an array of Chils in mouse 
and rat. The underlying reason of this expansion is difficult to assess however, given the 
immune related function of Chil3 (Sutherland et al., 2011) it is reasonable to speculate that 
a rapidly evolving immune system may provide the suitable selection pressure for the 
emergence and retention of murine specific chilectins.  
One of the most interesting observations of the phylogenetic analysis is the presence of an 
additional clade at the base of CHIA group, populated with amphibian, reptilian and 
mammalian sequences. We hypothesize that the gene duplication in ancestral CHIA to give 
rise to CHIO paralogues occurred before the divergence the bony fishes. From the 
topology of the phylogenetic trees it appears that the duplication of ancestral CHIA which 
resulted in the emergence of the OVGP1 paralogue, occurred before the divergence of 
bony fishes. However, no clear orthologue of OVGP1 was detected in any non mammalian 
vertebrate. This raises two possibilities that either OVGP1 indeed arose before the 
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divergence of bony fishes and that all non mammalian vertebrates lost the OVGP1 gene, or 
the difference in the nucleotide substitution rate of OVGP1, compounded with the data bias 
(fewer non mammalian sequences) make the emergence of OVGP1 appear earlier than in 
the case. Indeed, the branch length of the OVGP1 suggests a relatively fast evolutionary 
rate in comparison to CHIA, resulting in the more distinct phylogenetic signals. OVGP1 is 
involved in fertilization and early embryonic development (Buhi et al., 2002) and 
accelerated rates of evolution have been observed in other genes (ZP2, ZP3, ADAMs2 and 
ADAMs32) associated with reproductive physiology (Swanson et al., 2001), therefore a 
later origin of OVGP1 than the tree suggest is plausible. The CHIO clade shows common 
ancestry with either CHIA and OVGP1, depending on the out group used (lancelet  and 
nematode worm). Therefore based on the current evidence we propose that an initial 
duplication in the ancestral CHIA gave rise to the ancestor of CHIO and OVGP1 which 
then duplicated to form each gene, followed by faster OVGP1 evolution in mammals to 
give it a distinct clade topology.  
Evolution of CHIT1 in vertebrates 
The CHIT1 superclade shows that two main duplication event gave rise to the orthologues 
of extant CHIT1, CHIL1 and CHIL2. It was earlier proposed that gene duplication of 
ancestral CHIT1 resulted in the origin of CHIT1 and precursor of both ChiLs (Bussink et 
al., 2007; Funkhouser and Aronson, 2007). In contrast to this, the presented 
phylogenomics analyses indicate the first gene duplication event gave rise to CHIL2 and 
later another duplication in the CHIT1 gave birth to CHIL1. Furthermore the presence of 
the CHIL2 orthologue in the anole lizard points that this duplication event occurred prior to 
the origin of mammals.  
In mammals, CHIT1 and CHIA are either present on different chromosomes or different 
arms of same chromosome with CHIL2 present in the proximity of CHIA and CHIL1 
neighbouring CHIT1. Intriguingly, this physical separation is not evident in case of anole 
lizard as the CHIT1 homologue (partial sequence) is present next to CHIL2 in the animal. 
This observation suggests that the rearrangement of the CHIT1 gene occurred between the 
split of reptiles and mammals, before the diversification of the latter. As CHIL2 genes 
were identified in few mammalian species in comparison to CHIL1, it is possible that the 
function of CHIL2 has been taken over by CHIL1 rendering CHIL2 redundant and as a 
result CHIL2 is gradually being lost. Alternatively, in rodentia, the additional array of 
ChiLs may have evolved to replace the function of CHIL2  (Figure 6.21).  
The information gathered from all phylogenomic analyses collectively suggest that genes 
of family GH18 have taken three evolutionary lineages before the emergence of vertebrates 
namely CHID1, CTBS and ancestral endochitinase. In the vertebrate lineage the ancestral 
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Figure 6.21. Composite model of evolution of vertebrate chitinases and chilectins. A 
schematic representation of gene duplication events (excluding most species specific 
duplications) leading to the mammalian Chi/ChiL genes is shown. The branch lengths are 
approximated to a time line (at bottom) showing million years ago (mya) (Bininda-Emonds 
et al., 2007). The loss of catalytic activity is shown by cross. Whole genome duplication 
events, 1R, 2R and 3R are indicated as red blue and green circles. 
 
 
chitinase underwent extensive expansion which had lead to the emergence of CHIT1 and 
CHIA ancestors before the diversification of bony fishes around 450mya. Ancestral CHIA 
again underwent two events of gene duplication resulting in the birth of CHIA-III and 
CHIO/OVGP1 before the origin of tetrapods. Extensive gene death happened in both of 
these paralogues and relics of gene death are present in the form of pseudogenes in at least 
two primate species (human and macaque). Subsequently only one ChiL, CHIL2 arose in 
the common ancestor of reptiles and mammals (330mya) as a result of duplication of 
ancestral CHIT1. Two other ChiLs namely, OVGP1 and CHIL1 are the result of gene 
duplication of CHIA/CHIO and CHIT1 respectively which occurred before the divergence 
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of mammalian lineages (166mya). In comparison to CHIL1 and OVGP1, CHIL2 
underwent extensive gene loss in many mammalian lineages. Moreover, in some 
mammalian lineage GH18 genes underwent further gene expansion, such as in family 
muridae where duplication of CHIA resulted in the birth of an array of rodentia specific 
ChiLs and in family bovidae where duplication of CHIL1 gave rise to BP40.  
Comparing the evolutionary history of genes to the structure function relationship of the 
encoded proteins provides insights into the underlying reasons in the expansion, 
diversification and retention of genes. For this purpose, the protein structure of selected 
examples was compared. 
Structural conservation and potential ligands of GH18 paralogues  
All the structured and modelled chitinases and ChiLs proteins share considerable similarity 
in their scaffolding. Without exception all of them exhibit distinct TIM barrel and α+β 
domains. This strong conservation in the overall structure and domain distribution reflects 
their common evolutionary origin. However, subtle differences in the potential ligand 
binding sites suggest functional innovations (neo/sub functionalization) during the 
evolution of GH18 proteins. Despite the strong tertiary structure conservation substitutions 
in the catalytic sites, variations in the amino acid composition, size and shape of the ligand 
binding groove indicate that not all chilectins could bind with oligomeric carbohydrate 
moieties of the same length. For instance the relatively irregular groove, combined with the 
loss of critical aromatic residues in mouse specific Chil3, suggests different ligand 
specificity to Chil1. Indeed, consistent with the unpublished data from our lab that showed 
that mouse Chil1 binds tightly with chitin beads while Chil3 and Chil4 showed relatively 
weak binding and readily dissociated from chitin beads in washing. This observation is in 
agreement with the earlier studies by Houston et al., 2003 and Tsai et al., 2004 which 
demonstrated poor binding of Chil3 with oligomeric carbohydrate ligands. In addition to 
the difference in the shape of the cavity it is possible that difference in the orientation of 
Trp339 between Chil1 and Chil3 may be a contributing factor in this regard because of its 
profound importance in ligand binding (Fusseti et al., 2002). A similar explanation could 
be extended to other closely related rodentia specific chilectins, Chil4 and Chil6 owing to 
the high amino acid identity (95% and 85% respectively) and structural similarity with 
Chil3.  However, Chil3 and Chil4 differ in their expression pattern, as Chil3 has been 
found highly expressed in erythroblasts and bone marrow, whereas Chil4 expression has 
been noted in parotid gland and chondrocytes. This raises a possibility that these mouse 
specific ChiLs shares functional similarity but perform their role in different tissues or cell 
types. In contrast to other rodentia specific chilectins, the amino acid identity and ligand 
binding groove shape of Chil7 is more similar to Chia, suggesting that it may interact with 
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a polymeric carbohydrate moiety. Although, CHIL1 and CHIL2 share a common 
evolutionary origin, out of 10 aromatic residues, 4 residues (lining ligand binding cleft) are 
substituted in CHIL2 and 2 of these substitutions are non iso-functional. Moreover, the 
expression patterns of CHIL1 and CHIL2 show different tissue specificity as in humans 
CHIL1 is predominantly expressed bone marrow, uterus and retina, while elevated 
expression of CHIL2 has been found in thymus and adipocytes (Hruz et al., 2008). 
Considering, that structural and nutritional consumption of chitin is very limited in 
mammals and especially not known in humans, it has been proposed that human GH18 
proteins may interact with the other carbohydrate moieties. Among these heparin sulphate, 
heparan sulphate and hyaluronic acid are frequently considered as most likely candidates. 
These sugars may serve as linking bridges between proteins, especially for the proteins 
which are involved in growth and proliferation (Plazinski and Knys-Dzieciuch, 2012; 
Schlessinger et al., 2000).  Although, to date, no direct empirical evidence has been 
demonstrated in this regard, functional studies of ChiLs suggest that they may interact with 
the several glycoproteins via their carbohydrate moieties. One such possibility is the 
binding of ChiLs with syndecan-1, a major cell surface proteoglycan, via its heparan 
sulphate linkage. This binding along with integrin αvβ3 leads to the phosphorylation of 
focal adhesion kinase (FAK). Phosphorylated FAK in turn leads to the activation 
(phosphorylation) of mitogen activated protein (MAP) kinase (Erk), phosphotidyl inositol 
3 kinase (PI3K) and Akt Kinase. These molecular events instigate cell migration 
(transcytosis), proliferation, survival and angiogenesis, producing a supportive 
environment for oncogenesis (Alexopoulou et al., 2007; Shao et al. 2009). Indeed elevated 
expression of ChiLs has been reported in several cancers in humans (Coffman, 2008; Zhu 
et al., 2012a&b) and mouse models (Qureshi et al., 2011). Studies have been shown that 
syndecan-1 and MAPK mediated molecular events are involved in the tissue modelling 
(Peretti et al., 2008). Thus it is conceivable that these molecular events explain the 
underlying molecular basis of ChiLs role in the tissue remodelling (Johansen et al., 1997). 
Since heparan sulphate is negatively charged molecule, the binding protein is expected to 
possess strong positively charged residues at the binding site (Esko and Selleck, 2002). On 
ChiLs this cluster is present separately to the central ligand binding groove which implies 
that central characteristic cleft of humans ChiLs may not be involved in their cellular 
proliferation and tissue remodelling function. Further supporting this notion is the 
involvement of BP40 in tissue remodelling in mammary gland tissues in members of 
family bovidae (Srivastava et al., 2007). BP40 is a bovidae specific chilectin and despite 
the close relationship with ChiL1 it has a distinct central ligand binding cleft to CHIL1 but 
identitical potential heparin binding sites.  Moreover, BP40 is unable to bind with a chitin 
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tetramere (Kumar et al., 2007) and protein binding propensity has also been proposed for it 
(Mohanty et al., 2003). Taking both phylogenetic and structural data into account, it is 
conceivable that this probable heparin binding site on CHIL1 is in transition between neo 
to subfunctionalization (He and Zhang, 2005) since its origin in mammals. Comparing the 
same regions among different orthologues of CHIL1 may provide a signature for the 
ongoing evolution.  
OVGP1 plays a role in fertilization and early embryonic development (Buhi, 2002). Cell 
surfaces of both mammalian ova and sperm are coated with different glycoproteins (Batova 
et al., 1998; Bauskin et al., 1999) and these are involved in establishing interactions 
between gametes during fertilization (Clark, 2013; Gupta et al., 2012). Therefore it is 
possible that OVGP1 coats mammalian gametes by binding with their surface 
glycoproteins via the carbohydrate moieties. Indeed co-incubation of human sperm 
(Boatman and Magnoni, 1995) and ovum (Martus et al., 1998) with OVGP1 increases 
sperm binding and penetration. Moreover, the presence of a mucin-like highly glycosylated 
C-terminal tail in OVGP1 further contributes to sperm viability (Satoh et al., 1995). This 
may suggests that OVGP1 along with its tail may have evolved for its new environment 
and function. However, it is not yet understood how the interaction of OVGP1 with 
gametes and zygote biologically affect the fertilization and early embryonic development. 
Moreover, studies conducted using Ovgp1 null mice (-/-) suggest that it is not essential for 
fertilization (Araki et al., 2003).  
CHIT1 and CHIA share a common progenitor and are known to bind and hydrolyze chitin 
oligomers (Fusetti et al., 2002; Olland et al., 2009), but they are expressed in different 
tissues. Human CHIT1 is expressed in macrophages while CHIA largely restricted to the 
stomach. The exochitinase, CTBS, cavity is noticeably wide in comparison to other GH18 
active chitinases, which may reflect its different mechanism of chitinase activity. However, 
the ligand binding specificity and functions of human and other mammalian CTBS, is not 
known. Among all the compared chilectins, CHID1 has the smallest central cavity volume, 
however it does have larger cavities separate from the central cleft; nevertheless binding 
with the carbohydrate moieties (preferably monomeric) and lipopolysaccharides with less 
selectivity has been reported for the protein. It has also been proposed that this binding 
between CHID1 and lipopolysaccharide may neutralize the endotoxin of the invading 
bacterial pathogens (Meng et al., 2010). 
Finally, due to an irregularly shaped central cleft, interaction with oligomeric 
carbohydrates may not be feasible for certain ChiLs (Chil3, Chil4, Chil6, BP40, CHID1 
and OVGP1). However, binding with shorter carbohydrate moieties may be possible. 
Hyaluronic acid (HA) serves as a structural analogue of invertebrate chitin in vertebrates 
Mushtaq Hussain, 2013  233 
and its synthesis requires short chito-oligosacchrides (Semino et al., 1996; Meyer et al., 
1996). Additionally, the biological function of HA in tissue remodelling, inflammation and 
embryogenesis (Lee et al., 2000) over-laps with some of the functions proposed or known 
for Chil3 (Nio et al., 2004), BP40 (Srivastava et al., 2007), CHID1 (Meng et al., 2010) and 
OVGP1 (Buhi et al., 2002). Therefore it is tempting to speculate that these proteins 
undertake their tasks due to their involvement in the HA synthesis. 
No significant sequential or structural differences have been observed between the 
compared orthologues of human and mouse GH18 proteins, suggesting functional 
similarity between the orthologous proteins. However, several of the orthologues show 
different tissue specific expression between the species. For example in mouse, Chia 
inhibits chitin induced inflammation and contributes to Th2 mediated adaptive immunity in 
the lungs (Zhu et al., 2004; Reese et al., 2007). However, unlike mouse, in humans CHIT1 
not CHIA is the major chitinase in the lungs (Boot et al., 2005). 
Taken together, the expansion and diversification of GH18 proteins in vertebrates is 
followed by acquiring tissue specificity and adopting subtle structural variations. This in 
turn may allow the proteins to optimize additional functions from the ancestral protein or 
result in a change in function. This evolution and potential change in the ligand binding 
specificity was paralleled with the extensive anatomical and physiological changes in 
vertebrates, especially in the mammalian immune system and reproductive system. Given 
the accounts of involvement of chitinases and ChiLs in the immune response it is 
reasonable to assume that change in the ligand specificity may have played some role for 
chitinase and chitinase like protein to adopt new role(s) in adaptive immune physiology. 
This study does not identify the natural ligands of the chitinases and ChiLs  and previous 
experimental studies in this regard are inconclusive. However, it demonstrates that 
different chitinases and ChiLs may have different ligand specificity and points towards 
possible candidates. Further studies, like molecular docking, co-immuno precipitation, 
affinity purification and co crystallization with potential ligands, will provide more insight 
in this regard.  
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7. Building Bridges 
Without the current advances in bioinformatics, many new fields of study such as “Systems 
Biology” and “Comparative Genomics” would largely remain a dream. In view of the 
2013 Nobel Prize in chemistry going to computational chemistry, the importance of 
bioinformatics has clearly been recognized. This thesis deals with the application of some 
of the many bioinformatics tools to understand the structure-function relationship of the 
EBV encoded protein, EBNA1, and the evolution of two gene families, USPs and GH18.  
Reliability of Protein Molecular Modelling  
Protein-protein interactions are one of the hallmarks of biological complexity in living 
organisms. Molecular modelling of EBNA1 not only provides insights into the structural 
evolution of the molecule in different LCVs but also provide an indication of how EBNA1 
might bind to multiple partners. However, the efficiency and consistency of prediction 
made by protein modelling tools varies considerably. Protein homology modelling 
algorithms have become significantly refined and have been more consistent in their 
predictions in recent years. Protein structural models showing an RMSD value of <2.0Å 
compared with the template, typically fulfil high structural requirements (including 
dihedral angle ratio, plausible angles, thermodynamic stability etc) and can be reliably used 
for molecular docking studies to explore ligand specificities and virtual drug screening 
(Ekins et al., 2007; Zhang et al., 2009).  
Unlike homology modelling, the ab initio and iterative threading alignment methodologies 
for protein modelling show inconsistencies in their predictions. Discrepancies in the 
structural prediction are primarily due to the acquisition of evolutionary unrelated 
templates with marginal and/or fragmented sequence similarity with the query sequence, as 
seen in the predictions made by I-TASSER and MOE for the N-terminal half of EBNA1. 
Under these conditions, the RMSD values between the model and templates are irrelevant 
because of the possible misorientiation of loops and tails. However, the core region of the 
model may be correct. Despite this, approaches such as TM score can be used for 
evaluating models constructed in the absence suitable templates. TM scoring is mainly 
based on large distance between atoms of template(s) and models thus it is more sensitive 
to global topology than local structural errors. Therefore, the N-terminal half of EBNA1 
and C-terminal tail of selected GH18 proteins, which were modelled using non 
homologous proteins, may contain local errors; however their TM values are within 
acceptable limits (3-4). Both TM scoring and Ramachandran Plot analysis suggest that 
EBNA1 models could be used to predict the global conformation of the molecules. 
Moreover due to the structural conservation between proteins sharing the same domains, 
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the models could be used to identify domain boundaries and family and superfamily 
assignment (Malmstrom et al., 2007; Zhang et al., 2006). The presence of intrinsically 
unstructured regions (as observed in EBNA1) in a protein sequence may also contribute to 
the uncertainty in the prediction and spatial placement of loops and coils (Liu et al., 2009). 
The accurate prediction of loops is still a problem for computational modelling of the 
protein structures (Roy et al., 2010). Given that protein-protein interactions are dynamic 
and often involve conformational changes in the binding partners, such ambiguities limit 
the subsequent investigation using molecular docking (Goh et al., 2004; Zacharias, 2010).  
Pitfalls of Phylogenomic Studies 
Phylogenomic analyses are an important component of bioinformatic studies. The 
application of such studies ranges from unravelling the evolutionary history of a gene and 
of a species (Bininda-Emonds et al., 2007; Yang, 2013) to develop an understanding of 
molecular networks (Soyer and Malley, 2013) and even drug designing (Brown and Auger, 
2011; Wang et al. 2013). In this thesis, phylogenetic relationships and the underlying 
evolutionary mechanisms of two gene families, USPs and GH18, have been investigated. 
All phylogenetic analyses are statistical in nature (Kumar et al., 2011) and as a result the 
inference of the trees depends on sample size, methods employed for their reconstruction 
and the numerical values in support. At present, maximum likelihood and bayesian 
posterior probability are the two most frequently adopted methodologies to infer the 
phylogenetic relationship between genes, species and gene families. However neither of 
these methods is completely perfect and can be affected by sequence composition and 
sample size (Yang and Rannala, 2012). 
For practical convenience, sequences from representative species of the important 
speciation events were analysed to infer the evolutionary history of the very distantly 
related and extensively diversified USP gene family. Conversely, GH18 genes in 
vertebrates started to diversify with the origin of vertebrates and later with the emergence 
of mammals and rodents, therefore all available vertebrate sequences were included in the 
phylogenetic analysis of the GH18 gene family. Subject to the variable selection pressure 
and historical extent of divergence, occasionally sequences at the roots of clades could be 
difficult to infer with reasonable certitude potentially due to difficulty in the alignment. 
Additionally lacking in the sequence data, post speciation gene death can also lead to the 
misplacement of clades with respect to speciation events as seen in paralogous group 7 of 
USPs. These issues can be overcome or the tree approximated, by considering the 
biological context. 
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Future perspectives 
Typically docking programmes use scoring criteria, based on desolvation energy, 
hydrophobicity and electrostatic residues of challenged residues, to predict orientation of 
partner molecules during interaction (Ritchi, 2008; Tovchigrechko and Vasker, 2006). 
However, the solution predicted using these scoring criteria are still a subject of debate. 
Incorporation of other bioinformatic and empirical analysis such as sequence conservation 
and protein interaction data retrieved from peptide array and other protein interaction 
assays could improve the selection of a correct native conformation of interacting protein 
molecules. 
At present, a maximum length of 25 amino acids for each peptide could be spotted on an 
array, since the coupling efficiency drops after 12 amino acids. Given the possibility of 
structural properties of peptide (as observed by probing anti EBNA1 antibodies on EBNA1 
array), attempts are required to spot the full structural and/or functional domain (as marked 
by sequence conservation and structural modelling) sequence on a single spot. This may 
rectify the potential structural variabilities between the spotted peptides and in turn result 
in improved consistencies of the peptide array data.  
In this study the ClustalX programme was used to construct multiple sequence alignment. 
Nevertheless other alignment tools such as T-coffee (slower but relatively more accurate 
than ClustalX) could be used to achieve more accuracy in the alignment (Notredame et al., 
2000). In addition, phylogeny aware sequence alignment tools could be explored for 
example PRANK (Loytynoja and Goldman, 2008), PAGAN (Loytynoja et al., 2012) and 
ProGraphMSA (Szalkowski, 2012) to improve the sequence alignments (most of these 
programmes are either computationally extensive or not available at the onset of the 
present study). Using these alignment tools may in turn improve the tree construction. 
Presently, MEGAv5.2 attempts to resolve the ambiguous branch positioning of the taxa in 
tree with some success by invoking a branch swap filter. Branch swap filter improves the 
stringency of the tree with respect to branch length and likelihood by altering the order of 
branches. Other parallel analyses, like evolutionary distance estimation, comparison of 
genomic synteny and protein domain architecture, provide important biological 
information to resolve ambiguities in the phylogenetic analysis. Additionally, the use of 
other efficient alternative methodologies for phylogenetic tree reconstruction (such as 
Bayesian based phylogeny) could also be informative in developing a holistic and more 
general conclusion (Anisimova et al., 2013). Finally combining the phylogeny with the 
structural features of molecules, as undertaken for EBNA1, USPs and GH18 family 
proteins, is also useful to extend the phylogenetic observations to functional inference for 
the genes.  
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A database called TimeTree has been established which provides the time line of 
speciation events during the course of eukaryotic evolution based on paleontological and 
phylogenetic information (Hedges et al., 2006). Recently, another database (BioName) has 
been developed to provide the evolutionary history of taxa based on text minining (Page, 
2013). It would be of great value to develop a data base for the phylogenetic trees of genes 
and gene families where researchers can deposit their trees for comparison with other trees 
developed in other relevant studies and with the protein family trees present in different 
databases. Subsequently an algorithm could be designed to develop the consensus 
evolutionary relationship between orthologues and paralogues. This in turn will provide 
useful and readily available evolutionary information about different genes and gene 
families to users, especially to those who are working in other fields of life sciences where 
the phylogenomic information of molecules is relevant, but not the major objective of 
work.  
As extensive genome sequencing projects are underway and new advances in computer 
technologies and bioinformatics are regularly reported, the present study is by no means 
complete. However, it provides new insights for the experimental and computational 
biologists to verify and further expand upon, which will eventually complete the bridges in 
our current understanding of structural, functional and evolutionary aspects of these genes 
and proteins.  
As Carl Sagan famously put in his last interview on 27
th
 May 1996. 
“Science is more than a body of knowledge. It is a way of thinking; a way of skeptically 
interrogating the universe with a fine understanding of human fallibility” 
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Appendix I. Accession number of EBNA1 sequences 
No. Annotation UniProt Acession Numbers 
1 EBNA1 from EBV GD1 P03211 
2 EBNA1 from EBV B958 Q3KSS4 
3 EBNA1 from EBV AG876 Q1HVF7 
4 EBNA1 from CyEBV TsBB6 Q9IPQ9 
5 EBNA1 from CyEBV SiIIA Q9IPQ8 
6 EBNA1 from CeHV15 O91332 
7 EBNA1 from CeHV12 Q80890 
8 EBNA1 from CalHV3 Q993H1 
 
Appendix II. Peptide array sequences (analytical array) 
Spot No. Sequence Start End 
1 M-S-D-E-G-P-G-T-G-P-G-N-G-L-G-E-K-G-D-T-S-G-P-E-G 1 25 
2 P-G-T-G-P-G-N-G-L-G-E-K-G-D-T-S-G-P-E-G-S-G-G-S-G 6 30 
3 G-N-G-L-G-E-K-G-D-T-S-G-P-E-G-S-G-G-S-G-P-Q-R-R-G 11 35 
4 E-K-G-D-T-S-G-P-E-G-S-G-G-S-G-P-Q-R-R-G-G-D-N-H-G 16 40 
5 S-G-P-E-G-S-G-G-S-G-P-Q-R-R-G-G-D-N-H-G-R-G-R-G-R 21 45 
6 S-G-G-S-G-P-Q-R-R-G-G-D-N-H-G-R-G-R-G-R-G-R-G-R-G 26 50 
7 P-Q-R-R-G-G-D-N-H-G-R-G-R-G-R-G-R-G-R-G-G-G-R-P-G 31 55 
8 G-D-N-H-G-R-G-R-G-R-G-R-G-R-G-G-G-R-P-G-A-P-G-G-S 36 60 
9 R-G-R-G-R-G-R-G-R-G-G-G-R-P-G-A-P-G-G-S-G-S-G-P-R 41 65 
10 G-R-G-R-G-G-G-R-P-G-A-P-G-G-S-G-S-G-P-R-H-R-D-G-V 46 70 
11 G-G-R-P-G-A-P-G-G-S-G-S-G-P-R-H-R-D-G-V-R-R-P-Q-K 51 75 
12 A-P-G-G-S-G-S-G-P-R-H-R-D-G-V-R-R-P-Q-K-R-P-S-C-I 56 80 
13 G-S-G-P-R-H-R-D-G-V-R-R-P-Q-K-R-P-S-C-I-G-C-K-G-T 61 85 
14 H-R-D-G-V-R-R-P-Q-K-R-P-S-C-I-G-C-K-G-T-H-G-G-T-G 66 90 
15 R-R-P-Q-K-R-P-S-C-I-G-C-K-G-T-H-G-G-T-G-A-G-A-G-A 71 95 
16 R-P-S-C-I-G-C-K-G-T-H-G-G-T-G-A-G-A-G-A-G-G-A-G-A 76 100 
17 G-C-K-G-T-H-G-G-T-G-A-G-A-G-A-G-G-A-G-A-G-G-A-G-A 81 105 
18 H-G-G-T-G-A-G-A-G-A-G-G-A-G-A-G-G-A-G-A-G-G-G-A-G 86 110 
19 A-G-A-G-A-G-G-A-G-A-G-G-A-G-A-G-G-G-A-G-A-G-G-G-A 91 115 
20 G-G-A-G-A-G-G-A-G-A-G-G-G-A-G-A-G-G-G-A-G-G-A-G-G 96 120 
21 G-G-A-G-A-G-G-G-A-G-A-G-G-G-A-G-G-A-G-G-A-G-G-A-G 101 125 
22 G-G-G-A-G-A-G-G-G-A-G-G-A-G-G-A-G-G-A-G-A-G-G-G-A 106 130 
23 A-G-G-G-A-G-G-A-G-G-A-G-G-A-G-A-G-G-G-A-G-A-G-G-G 111 135 
24 G-G-A-G-G-A-G-G-A-G-A-G-G-G-A-G-A-G-G-G-A-G-G-A-G 116 140 
25 A-G-G-A-G-A-G-G-G-A-G-A-G-G-G-A-G-G-A-G-G-A-G-A-G 121 145 
26 A-G-G-G-A-G-A-G-G-G-A-G-G-A-G-G-A-G-A-G-G-G-A-G-A 126 150 
27 G-A-G-G-G-A-G-G-A-G-G-A-G-A-G-G-G-A-G-A-G-G-G-A-G 131 155 
28 A-G-G-A-G-G-A-G-A-G-G-G-A-G-A-G-G-G-A-G-G-A-G-A-G 136 160 
29 G-A-G-A-G-G-G-A-G-A-G-G-G-A-G-G-A-G-A-G-G-G-A-G-G 141 165 
30 G-G-A-G-A-G-G-G-A-G-G-A-G-A-G-G-G-A-G-G-A-G-G-A-G 146 170 
31 G-G-G-A-G-G-A-G-A-G-G-G-A-G-G-A-G-G-A-G-A-G-G-G-A 151 175 
32 G-A-G-A-G-G-G-A-G-G-A-G-G-A-G-A-G-G-G-A-G-A-G-G-G 156 180 
33 G-G-A-G-G-A-G-G-A-G-A-G-G-G-A-G-A-G-G-G-A-G-G-A-G 161 185 
34 A-G-G-A-G-A-G-G-G-A-G-A-G-G-G-A-G-G-A-G-A-G-G-G-A 166 190 
35 A-G-G-G-A-G-A-G-G-G-A-G-G-A-G-A-G-G-G-A-G-G-A-G-G 171 195 
36 G-A-G-G-G-A-G-G-A-G-A-G-G-G-A-G-G-A-G-G-A-G-A-G-G 176 200 
37 A-G-G-A-G-A-G-G-G-A-G-G-A-G-G-A-G-A-G-G-G-A-G-A-G 181 205 
38 A-G-G-G-A-G-G-A-G-G-A-G-A-G-G-G-A-G-A-G-G-A-G-G-A 186 210 
39 G-G-A-G-G-A-G-A-G-G-G-A-G-A-G-G-A-G-G-A-G-G-A-G-A 191 215 
40 A-G-A-G-G-G-A-G-A-G-G-A-G-G-A-G-G-A-G-A-G-G-A-G-A 196 220 
41 G-A-G-A-G-G-A-G-G-A-G-G-A-G-A-G-G-A-G-A-G-G-G-A-G 201 225 
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42 G-A-G-G-A-G-G-A-G-A-G-G-A-G-A-G-G-G-A-G-G-A-G-G-A 206 230 
43 G-G-A-G-A-G-G-A-G-A-G-G-G-A-G-G-A-G-G-A-G-A-G-G-A 211 235 
44 G-G-A-G-A-G-G-G-A-G-G-A-G-G-A-G-A-G-G-A-G-A-G-G-A 216 240 
45 G-G-G-A-G-G-A-G-G-A-G-A-G-G-A-G-A-G-G-A-G-A-G-G-A 221 245 
46 G-A-G-G-A-G-A-G-G-A-G-A-G-G-A-G-A-G-G-A-G-A-G-G-A 226 250 
47 G-A-G-G-A-G-A-G-G-A-G-A-G-G-A-G-A-G-G-A-G-G-A-G-A 231 255 
48 G-A-G-G-A-G-A-G-G-A-G-A-G-G-A-G-G-A-G-A-G-G-A-G-G 236 260 
49 G-A-G-G-A-G-A-G-G-A-G-G-A-G-A-G-G-A-G-G-A-G-A-G-G 241 265 
50 G-A-G-G-A-G-G-A-G-A-G-G-A-G-G-A-G-A-G-G-A-G-G-A-G 246 270 
51 G-G-A-G-A-G-G-A-G-G-A-G-A-G-G-A-G-G-A-G-A-G-G-G-A 251 275 
52 G-G-A-G-G-A-G-A-G-G-A-G-G-A-G-A-G-G-G-A-G-G-A-G-A 256 280 
53 A-G-A-G-G-A-G-G-A-G-A-G-G-G-A-G-G-A-G-A-G-G-G-A-G 261 285 
54 A-G-G-A-G-A-G-G-G-A-G-G-A-G-A-G-G-G-A-G-G-A-G-A-G 266 290 
55 A-G-G-G-A-G-G-A-G-A-G-G-G-A-G-G-A-G-A-G-G-A-G-G-A 271 295 
56 G-G-A-G-A-G-G-G-A-G-G-A-G-A-G-G-A-G-G-A-G-A-G-G-A 276 300 
57 G-G-G-A-G-G-A-G-A-G-G-A-G-G-A-G-A-G-G-A-G-G-A-G-A 281 305 
58 G-A-G-A-G-G-A-G-G-A-G-A-G-G-A-G-G-A-G-A-G-G-A-G-G 286 310 
59 G-A-G-G-A-G-A-G-G-A-G-G-A-G-A-G-G-A-G-G-A-G-A-G-G 291 315 
60 G-A-G-G-A-G-G-A-G-A-G-G-A-G-G-A-G-A-G-G-G-A-G-A-G 296 320 
61 G-G-A-G-A-G-G-A-G-G-A-G-A-G-G-G-A-G-A-G-G-A-G-A-G 301 325 
62 G-G-A-G-G-A-G-A-G-G-G-A-G-A-G-G-A-G-A-G-G-G-G-R-G 306 330 
63 A-G-A-G-G-G-A-G-A-G-G-A-G-A-G-G-G-G-R-G-R-G-G-S-G 311 335 
64 G-A-G-A-G-G-A-G-A-G-G-G-G-R-G-R-G-G-S-G-G-R-G-R-G 316 340 
65 G-A-G-A-G-G-G-G-R-G-R-G-G-S-G-G-R-G-R-G-G-S-G-G-R 321 345 
66 G-G-G-R-G-R-G-G-S-G-G-R-G-R-G-G-S-G-G-R-G-R-G-G-S 326 350 
67 R-G-G-S-G-G-R-G-R-G-G-S-G-G-R-G-R-G-G-S-G-G-R-R-G 331 355 
68 G-R-G-R-G-G-S-G-G-R-G-R-G-G-S-G-G-R-R-G-R-G-R-E-R 336 360 
69 G-S-G-G-R-G-R-G-G-S-G-G-R-R-G-R-G-R-E-R-A-R-G-G-S 341 365 
70 G-R-G-G-S-G-G-R-R-G-R-G-R-E-R-A-R-G-G-S-R-E-R-A-R 346 370 
71 G-G-R-R-G-R-G-R-E-R-A-R-G-G-S-R-E-R-A-R-G-R-G-R-G 351 375 
72 R-G-R-E-R-A-R-G-G-S-R-E-R-A-R-G-R-G-R-G-R-G-E-K-R 356 380 
73 A-R-G-G-S-R-E-R-A-R-G-R-G-R-G-R-G-E-K-R-P-R-S-P-S 361 385 
74 R-E-R-A-R-G-R-G-R-G-R-G-E-K-R-P-R-S-P-S-S-Q-S-S-S 366 390 
75 G-R-G-R-G-R-G-E-K-R-P-R-S-P-S-S-Q-S-S-S-S-G-S-P-P 371 395 
76 R-G-E-K-R-P-R-S-P-S-S-Q-S-S-S-S-G-S-P-P-R-R-P-P-P 376 400 
77 P-R-S-P-S-S-Q-S-S-S-S-G-S-P-P-R-R-P-P-P-G-R-R-P-F 381 405 
78 S-Q-S-S-S-S-G-S-P-P-R-R-P-P-P-G-R-R-P-F-F-H-P-V-G 386 410 
79 S-G-S-P-P-R-R-P-P-P-G-R-R-P-F-F-H-P-V-G-E-A-D-Y-F 391 415 
80 R-R-P-P-P-G-R-R-P-F-F-H-P-V-G-E-A-D-Y-F-E-Y-H-Q-E 396 420 
81 G-R-R-P-F-F-H-P-V-G-E-A-D-Y-F-E-Y-H-Q-E-G-G-P-D-G 401 425 
82 F-H-P-V-G-E-A-D-Y-F-E-Y-H-Q-E-G-G-P-D-G-E-P-D-V-P 406 430 
83 E-A-D-Y-F-E-Y-H-Q-E-G-G-P-D-G-E-P-D-V-P-P-G-A-I-E 411 435 
84 E-Y-H-Q-E-G-G-P-D-G-E-P-D-V-P-P-G-A-I-E-Q-G-P-A-D 416 440 
85 G-G-P-D-G-E-P-D-V-P-P-G-A-I-E-Q-G-P-A-D-D-P-G-E-G 421 445 
86 E-P-D-V-P-P-G-A-I-E-Q-G-P-A-D-D-P-G-E-G-P-S-T-G-P 426 450 
87 P-G-A-I-E-Q-G-P-A-D-D-P-G-E-G-P-S-T-G-P-R-G-Q-G-D 431 455 
88 Q-G-P-A-D-D-P-G-E-G-P-S-T-G-P-R-G-Q-G-D-G-G-R-R-K 436 460 
89 D-P-G-E-G-P-S-T-G-P-R-G-Q-G-D-G-G-R-R-K-K-G-G-W-F 441 465 
90 P-S-T-G-P-R-G-Q-G-D-G-G-R-R-K-K-G-G-W-F-G-K-H-R-G 446 470 
91 R-G-Q-G-D-G-G-R-R-K-K-G-G-W-F-G-K-H-R-G-Q-G-G-S-N 451 475 
92 G-G-R-R-K-K-G-G-W-F-G-K-H-R-G-Q-G-G-S-N-P-K-F-E-N 456 480 
93 K-G-G-W-F-G-K-H-R-G-Q-G-G-S-N-P-K-F-E-N-I-A-E-G-L 461 485 
94 G-K-H-R-G-Q-G-G-S-N-P-K-F-E-N-I-A-E-G-L-R-A-L-L-A 466 490 
95 Q-G-G-S-N-P-K-F-E-N-I-A-E-G-L-R-A-L-L-A-R-S-H-V-E 471 495 
96 P-K-F-E-N-I-A-E-G-L-R-A-L-L-A-R-S-H-V-E-R-T-T-D-E 476 500 
97 I-A-E-G-L-R-A-L-L-A-R-S-H-V-E-R-T-T-D-E-G-T-W-V-A 481 505 
98 R-A-L-L-A-R-S-H-V-E-R-T-T-D-E-G-T-W-V-A-G-V-F-V-Y 486 510 
99 R-S-H-V-E-R-T-T-D-E-G-T-W-V-A-G-V-F-V-Y-G-G-S-K-T 491 515 
100 R-T-T-D-E-G-T-W-V-A-G-V-F-V-Y-G-G-S-K-T-S-L-Y-N-L 496 520 
101 G-T-W-V-A-G-V-F-V-Y-G-G-S-K-T-S-L-Y-N-L-R-R-G-T-A 501 525 
102 G-V-F-V-Y-G-G-S-K-T-S-L-Y-N-L-R-R-G-T-A-L-A-I-P-Q 506 530 
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103 G-G-S-K-T-S-L-Y-N-L-R-R-G-T-A-L-A-I-P-Q-C-R-L-T-P 511 535 
104 S-L-Y-N-L-R-R-G-T-A-L-A-I-P-Q-C-R-L-T-P-L-S-R-L-P 516 540 
105 R-R-G-T-A-L-A-I-P-Q-C-R-L-T-P-L-S-R-L-P-F-G-M-A-P 521 545 
106 L-A-I-P-Q-C-R-L-T-P-L-S-R-L-P-F-G-M-A-P-G-P-G-P-Q 526 550 
107 C-R-L-T-P-L-S-R-L-P-F-G-M-A-P-G-P-G-P-Q-P-G-P-L-R 531 555 
108 L-S-R-L-P-F-G-M-A-P-G-P-G-P-Q-P-G-P-L-R-E-S-I-V-C 536 560 
109 F-G-M-A-P-G-P-G-P-Q-P-G-P-L-R-E-S-I-V-C-Y-F-M-V-F 541 565 
110 G-P-G-P-Q-P-G-P-L-R-E-S-I-V-C-Y-F-M-V-F-L-Q-T-H-I 546 570 
111 P-G-P-L-R-E-S-I-V-C-Y-F-M-V-F-L-Q-T-H-I-F-A-E-V-L 551 575 
112 E-S-I-V-C-Y-F-M-V-F-L-Q-T-H-I-F-A-E-V-L-K-D-A-I-K 556 580 
113 Y-F-M-V-F-L-Q-T-H-I-F-A-E-V-L-K-D-A-I-K-D-L-V-M-T 561 585 
114 L-Q-T-H-I-F-A-E-V-L-K-D-A-I-K-D-L-V-M-T-K-P-A-P-T 566 590 
115 F-A-E-V-L-K-D-A-I-K-D-L-V-M-T-K-P-A-P-T-C-N-I-R-V 571 595 
116 K-D-A-I-K-D-L-V-M-T-K-P-A-P-T-C-N-I-R-V-T-V-C-S-F 576 600 
117 D-L-V-M-T-K-P-A-P-T-C-N-I-R-V-T-V-C-S-F-D-D-G-V-D 581 605 
118 K-P-A-P-T-C-N-I-R-V-T-V-C-S-F-D-D-G-V-D-L-P-P-W-F 586 610 
119 C-N-I-R-V-T-V-C-S-F-D-D-G-V-D-L-P-P-W-F-P-P-M-V-E 591 615 
120 T-V-C-S-F-D-D-G-V-D-L-P-P-W-F-P-P-M-V-E-G-A-A-A-E 596 620 
121 D-D-G-V-D-L-P-P-W-F-P-P-M-V-E-G-A-A-A-E-G-D-D-G-D 601 625 
122 L-P-P-W-F-P-P-M-V-E-G-A-A-A-E-G-D-D-G-D-D-G-D-E-G 606 630 
123 P-P-M-V-E-G-A-A-A-E-G-D-D-G-D-D-G-D-E-G-G-D-G-D-E 611 635 
124 G-A-A-A-E-G-D-D-G-D-D-G-D-E-G-G-D-G-D-E-G-E-E-G-Q 616 640 
125 A-A-A-E-G-D-D-G-D-D-G-D-E-G-G-D-G-D-E-G-E-E-G-Q-E 621 645 
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Appendix III. Plasmid Maps 
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Appendix IV. Accession number of USPs 
Homo sapiens  Mus musculus 
No. Accession 
No. 
Given 
Annotation 
Proposed 
Annotation 
No. Accession No. Given 
Annotation 
Proposed 
Annotation 
1 AAH50525 USP1 USP1 1 AAH20007 Usp1 Usp1 
2 AAH02955 USP2 USP2 2 AAH17517 Usp2 Usp2 
3 AAH18113 USP3 USP3 3 EDL26123 Usp3 Usp3 
4 AAI25131 USP4 USP4 4 EDL21282 Usp4 Usp4 
5 EAW88724 USP5 USP5 5 AAH66993 Usp5 Usp5 
6 XP005256902 USP6 USP6 6 NP001003918 Usp7 Usp7 
7 NP003461 USP7 USP7 7 AAH50947 Usp8 Usp8 
8 AAI10591 USP8 USP8 8 P70398 Usp9x Usp9x 
9 XP005272732 USP9X USP9X 9 NP_683745 Usp9y Usp9y 
10 EAW91608 USP9Y USP9Y 10 EDL11619 Usp10 Usp10 
11 AAH00263 USP10 USP10 11 EDL00740 Usp11 Usp11 
12 AAI40850 USP11 USP11 12 AAH68136 Usp12 Usp12 
13 AAH26072 USP12 USP12 13 AAH90999 Usp13 Usp13 
14 AAH16146 USP13 USP13 14 AAH05571 Usp14 Usp14 
15 AAH03556 USP14 USP14 15 AAH50042 Usp15 Usp15 
16 EAW97104 USP15 USP15 16 AAH03278 Usp16 Usp16 
17 EAX09927 USP16 USP16 17 NP001243902 Usp17 Usp17 
18 NP958804 USP17 USP17 18 AAI38578 Usp18 Usp18 
19 AAH14896 USP18 USP18 19 AAH60613 Usp19 Usp19 
20 AAI46753 USP19 USP19 20 AAH79674 Usp20 Usp20 
21 XP005251722 USP20 USP20 21 NP038947 Usp21 Usp21 
22 AAH90946 USP21 USP21 22 AAH80737 Usp22 Usp22 
23 NP_056091 USP22 USP22 23 NP899048 Usp24 Usp24 
24 NP056121 USP24 USP24 24 AAH48171 Usp25 Usp25 
25 AAH75792 USP25 USP25 25 AAK31949 Usp26 Usp26 
26 AAK31972 USP26 USP26 26 NP062334 Usp27 Usp27 
27 NP001138545 USP27 USP27 27 AAH88733 Usp28 Usp28 
28 ACA06098 USP28 USP28 28 NP067298 Usp29 Usp29 
29 NP065954 USP29 USP29 29 NP001028374 Usp30 Usp30 
30 CAE51936 USP30 USP30 30 NP001028345 Usp31 Usp31 
31 CAE51935 USP31 USP31 31 NP001025105 Usp32 Usp32 
32 NP115971 USP32 USP32 32 EDL11924 Usp33 Usp33 
33 EAX06371 USP33 USP33 33 NP001177330 Usp34 Usp34 
34 NP055524 USP34 USP34 34 NP001170883 Usp35 Usp35 
35 CAE51937 USP35 USP35 35 NP001028700 Usp36 Usp36 
36 AAH71582 USP36 USP36 36 AAI39092 Usp37 Usp37 
37 AAI33010 USP37 USP37 37 AAH54404 Usp38 Usp38 
38 AAH68975 USP38 USP38 38 AAH26983 Usp39 Usp39 
39 EAW99490 USP39 USP39 39 NP001185502 Usp40 Us40 
40 XP005246145 USP40 USP40 40 AAI37853 Usp42 Usp42 
41 Q3LFD5 USP41 USP41 41 NP776115 Usp43 Usp43 
42 CAE53097 USP42 USP42 42 NP001193780 Usp44 Usp44 
43 AAI44042 USP43 USP43 43 AAH27768 Usp45 Usp45 
44 AAH30704 USP44 USP44 44 AAH39916 Usp46 Usp46 
45 CAE47746 USP45 USP45 45 NP796223 Usp47 Usp47 
46 AAH37574 USP46 USP46 46 NP570949 Usp48 Usp48 
47 XP005253054 USP47 USP47 47 AAH60712 Usp49 Usp49 
48 XP005246063 USP48 USP48 48 AAH61020 Usp50 Usp50 
49 CAE51939 USP49 USP49 49 NP001131019 Usp51 Usp51 
50 CAE47745 USP50 USP50 50 AAH75686 Usp52 Usp52 
51 CAE47750 USP51 USP51 51 AAI32340 Usp53 Usp53 
52 NP001120932 USP52 USP52 52 NP084456 Usp54 Usp54 
53 XP005263130 USP53 USP53 53 NP775545 Cyld Cyld 
54 NP689799 USP54 USP54 
55 XP005255868 CYLD CYLD 
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Bos taurus  Canis lupus familaris 
No. Accession No. Given 
Annotation 
Proposed 
Annotation 
No. Accession No. Given 
Annotation 
Proposed 
Annotation 
1 XP005899914 Usp1 Usp1 1 XP852320 Usp1 Usp1 
2 AAI12867 Usp2 Usp2 2 XP852320 Usp2 Usp2 
3 XP005211741 Usp3 Usp3 3 XP544715 Usp3 Usp3 
4 DAA16901 Usp4 Usp4 4 XP003432923 Usp4 Usp4 
5 NP001178985 Usp5 Usp5 5 XP543845 Usp5 Usp5 
6 XP005904435 Usp7 Usp7 6 XP005621615 Usp7 Usp7 
7 NP001069594 Usp8 Usp8 7 XP535474 Usp8 Usp8 
8 XP002700252 Usp9x Usp9x 8 XP005642140 Usp9x Usp9x 
9 NP001138981 Usp9y Usp9y 9 AGS47768 Usp9y Usp9y 
10 DAA20297 Usp10 Usp10 10 XP005620940 Usp10 Usp10 
11 XP005228137 Usp11 Usp11 11 NP001183969 Usp11 Usp11 
12 ABQ13036 Usp12 Usp12 12 XP543159 Usp12 Usp12 
13 DAA33286 Usp13 Usp13 13 XP003434175 Usp13 Usp13 
14 AAI22667 Usp14 Usp14 14 XP537306 Usp14 Usp14 
15 AAI05522 Usp15 Usp15 15 XP849935 Usp15 Usp15 
16 AAI23862 Usp16 Usp16 16 XP848330 Usp16 Usp16 
17 XP005196582 Usp17 Usp17 17 XP854031 Usp17 Usp17 
18 DAA29462 Usp18 Usp18 18 XP005637457 Usp18 Usp18 
19 XP005196535 Usp19 Usp19 19 XP005632614 Usp19 Usp19 
20 DAA24140 Usp20 Usp20 20 XP005625298 Usp20 Usp20 
21 AAI05489 Usp21 Usp21 21 XP536136 Usp21 Usp21 
22 DAA18687 Usp22 Usp22 22 XP005620237 Usp22 Usp22 
23 DAA31228 Usp24 Usp24 23 XP005620394 Usp24 Usp24 
24 DAA33643 Usp25 Usp25 24 XP535562 Usp25 Usp25 
25 DAA13384 Usp26 Usp26 25 XP005641887 Usp26 Usp26 
26 NP001138547 Usp27 Usp27 26 ENSCAFG00
000015958 
Usp27 Usp27 
27 DAA22406 Usp28 Usp28 27 XP005619814 Usp28 Usp28 
28 XP005911409 Usp29 Usp29 28 XP005636387 Usp30 Usp30 
29 DAA20724 Usp30 Usp30 29 XP005622126 Usp31 Usp31 
30 XP002703139 Usp31 Usp31 30 XP537710 Usp32 Usp32 
31 DAA19082 Usp32 Usp32 31 XP005622106 Usp33 Usp33 
32 DAA31326 Usp33 Usp33 32 XP005626192 Usp34 Usp34 
33 DAA24665 Usp34 Usp34 33 XP542286 Usp35 Usp35 
34 XP002699105 Usp35 Usp35 34 XP005624096 Usp36 Usp36 
35 XP580726 Usp36 Usp36 35 XP545643 Usp37 Usp37 
36 DAA32431 Usp37 Usp37 36 XP533279 Usp38 Usp38 
37 DAA20849 Usp38 Usp38 37 XP532977 Usp39 Usp39 
38 DAA24597 Usp39 Usp39 38 XP005635930 Usp40 Us40 
39 DAA30943 Usp40 Us40 39 XP005621173 Usp42 Usp42 
40 XP005225215 Usp42 Usp42 40 XP005620104 Usp43 Usp43 
41 DAA18798 Usp43 Usp43 41 XP532654 Usp44 Usp44 
42 XP005206168 Usp44 Usp44 42 XP539054 Usp45 Usp45 
43 XP005210908 Usp45 Usp45 43 XP005628243 Usp46 Usp46 
44 NP001179373 Usp46 Usp46 44 XP005633729 Usp47 Usp47 
45 NP001230219 Usp47 Usp47 45 XP535372 Usp48 Usp48 
46 XP003581941 Usp48 Usp48 46 XP532134 Usp49 Usp49 
47 XP005192988 Usp49 Usp49 47 XP850913 Usp50 Usp50 
48 NP001073699 Usp50 Usp50 48 XP531635 Usp52 Usp52 
49 XP005206706 Usp52 Usp52 49 XP005639380 Usp53 Usp53 
50 XP003582353 Usp53 Usp53 50 XP005619079 Usp54 Usp54 
51 XP003588038 Usp54 Usp54 51 XP005617624 Cyld Cyld 
52 XP005218740 Cyld Cyld 
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Monodelphis domesticus  Ornithorhynchus anatinus 
No. Accession No. Given 
Annotation 
Proposed 
Annotation 
No. Accession No. Given 
Annotation 
Proposed 
Annotation 
1 XP001380891 Usp1 Usp1 8 ENSOANG00
000003109 
Usp11 Usp11 
2 XP001380891 Usp2 Usp2 9 XP001519444 Usp12 Usp12 
3 XP001366252 Usp3 Usp3 10 XP001519267 Usp14 Usp14 
4 XP001367947 Usp4 Usp4 11 XP001519648 Usp15 Usp15 
5 XP001370137 Usp5 Usp5 12 XP003430360 Usp19 Usp19 
6 XP003341676 Usp7 Usp7 13 XP001507999 Usp20 Usp20 
7 XP001370028 Usp8 Usp8 14 XP001511206 Usp22 Usp22 
8 XP001366553 Usp9 Usp9 15 XP001514451 Usp25 Usp25 
9 XP001371319 Usp11 Usp11 16 XP001518118 Usp28 Usp28 
10 XP001376012 Usp12 Usp12 17 XP001508127 Usp30 Usp30 
11 XP001368216 Usp13 Usp13 18 XP001509900 Usp31 Usp31 
12 XP001367917 Usp14 Usp14 19 XP001510553 Usp32 Usp32 
13 XP001363243 Usp15 Usp15 20 XP001507122 Usp33 Usp33 
14 XP001373230 Usp16 Usp16 21 XP001512478 Usp34 Usp34 
15 XP001374147 Usp18 Usp18 22 XP001520693 Usp36 Usp36 
16 XP001367829 Usp19 Usp19 23 XP001515367 Usp37 Usp37 
17 XP001364410 Usp20 Usp20 24 XP001513216 Usp38 Usp38 
18 XP001371948 Usp21 Usp21 25 XP001518784 Usp39 Usp39 
19 XP001370855 Usp22 Usp22 26 XP001510790 Usp40 Usp40 
20 XP003340143 Usp24 Usp24 27 ENSOANG00
000003278 
Usp42 Usp42 
21 XP001381253 Usp28 Usp28 28 XP001510004 --- Usp44 
22 XP003342245 Usp30 Usp30 29 XP001506389 Usp45 Usp45 
23 XP001377884 Usp31 Usp31 30 XP001515746 Usp46 Usp46 
24 ENSMODG00
000014128 
Usp32 Usp32 31 XP001511271 Usp47 Usp47 
25 XP001382154 Usp34 Usp34 32 XP001510634 Usp48 Usp48 
26 XP003340998 Usp35 Usp35 33 XP001518088 Usp49 Usp49 
27 XP001371102 Usp36 Usp36 34 XP001506997 Usp50 Usp50 
28 XP001365238 Usp37 Usp37 35 XP001513697 Usp52 Usp52 
29 XP001367345 Usp38 Usp38 36 XP001512481 Usp53 Usp53 
30 XP001363937 Usp39 Usp39 37 XP001520353 Usp54 Usp54 
31 XP001376325 Usp40 Us40 38 XP003430149 Cyld Cyld 
32 XP001377522 Usp42 Usp42 Anolis carolinensis 
33 XP003340388 Usp43 Usp43 No. Accession No. Given 
Annotation 
Proposed 
Annotation 
34 XP001367818 Usp44 Usp44 1 XP003220186 usp1 usp1 
35 XP001367818 Usp45 Usp45 2 XP003229751 usp2 usp2 
36 XP001371592 Usp46 Usp46 3 XP003228123 usp3 usp3 
37 XP001379670 Usp47 Usp47 4 XP003217654 usp4 usp4 
38 XP001377884 Usp48 Usp48 5 XP003227153 usp5 usp5 
39 XP001379917 Usp49 Usp49 6 XP003224810 usp7 usp7 
40 XP001380549 Usp50 Usp50 7 XP003220426 usp8 usp8 
41 XP001371690 Usp53 Usp53 8 XP003218990 FAF-X usp9 
42 XP001364881 Usp54 Usp54 9 XP003228345 usp10 usp10 
43 XP001363603 Cyld Cyld 10 ENSACAG00
000004813 
usp11 usp11 
Ornithorhynchus anatinus 
No. Accession No. Given 
Annotation 
Proposed 
Annotation 
11 XP003225554 usp12 usp12 
1 XP001514295 Usp2 Usp2 12 XP003218164 usp13 usp13 
2 XP003429803 Usp3 Usp3 13 XP003219701 usp14 usp14 
3 XP001505377 Usp4 Usp4 14 XP003221229 ups15 ups15 
4 XP001506396 Usp7 Usp7 15 XP003219113 usp16 usp16 
5 XP001507996 Usp8 Usp8 16 XP003220892 usp18 usp18 
6 XP003430712 Faf-X Usp9 17 XP003217915 usp19 usp19 
7 XP001510486 Usp10 Usp10 18 XP003230291 usp20 usp20 
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Anolis carolinensis Xenopus tropicalis 
No. Accession No. Given 
Annotation 
Proposed 
Annotation 
No. Accession No. Given 
Annotation 
Proposed 
Annotation 
19 ENSACAG00
000004099 
usp21 usp21 26 NP001016228 usp33 usp33 
20 XP003226563 usp22 usp22 27 XP002939554 usp34 usp34 
21 XP003220199 usp24 usp24 28 XP002936594 usp35 usp35 
22 XP003219106 usp25 usp25 29 XP004916402 usp36 usp36 
23 XP003226222 usp28 usp28 30 XP004917686 usp37 usp37 
24 ENSACAG00
000025026 
usp30 usp30 31 XP004911187 usp38 usp38 
25 XP003229499 usp31 usp31 32 XP004912614 usp39 usp39 
26 XP003226642 usp32 usp32 33 XP002932051 usp40 usp40 
27 XP003223123 usp33 usp33 34 XP004918037 usp42 usp42 
28 XP003227816 usp34 usp34 35 XP004918792 usp43 usp43 
29 XP003226021 usp35 usp35 36 NP001072389 usp44 usp44 
30 XP003217171 usp36 usp36 37 NP001011153 usp45 usp45 
31 G1KAT4 usp37 usp37 38 NP001106637 usp46 usp46 
32 XP003221712 usp38 usp38 39 NP001090710 usp47 usp47 
33 XP003228282 usp39 usp39 40 NP001120167 usp48 usp48 
34 XP003215223 usp40 usp40 41 XP002933022 usp49 usp49 
35 XP003227691 usp42 usp42 42 XP004911946 usp52 usp52 
36 XP003217208 usp43 usp43 43 XP002934301 usp53 usp53 
37 XP003221118 usp44 usp44 44 XP002935811 usp54 usp54 
38 XP003215560 usp45 usp45 45 NP001116960 cyld cyld 
39 XP003225359 usp46 usp46 Danio rerio 
40 XP003224231 usp47 usp47  NP955873 usp1 usp1 
41 XP003230296 usp48 usp48  XP001337596 usp2 usp2 
42 XP003220426 usp49 usp49  NP001186800 usp3 usp3 
43 XP003228929 usp50 usp50  XP002662556 usp4 usp4 
44 XP003216988 usp52 usp52  XP005173535 usp5 usp5 
45 XP003221824 usp53 usp53  XP005164014 usp7 usp7 
46 XP003223182 usp54 usp54  XP005170811 usp8 usp8 
Xenopus tropicalis  NP001070917 faf-x usp9 
1 NP001072581 usp1 usp1  XP685621 usp10 usp10 
2 NP001135522 usp2 usp2  XP002663119 usp11 usp11 
3 NP001006783 usp3 usp3  NP001077025 usp12 usp12 
4 XP002936515 usp4 usp4  XP005165987 usp13 usp13 
5 NP001116956 usp5 usp5  NP956267 usp14 usp14 
6 XP002939495 usp7 usp7  XP002667650 usp15 usp15 
7 XP004912670 usp8 usp8  NP001139569 usp16 usp16 
8 ENSXETG000
00015489 
usp9 usp9  XP002661398 usp18 usp18 
9 NP001006761 usp10 usp10  XP005162175 usp19 usp19 
10 XP002941584 usp12 usp12  NP957281 usp20 usp20 
11 XP002931622 usp13 usp13  XP692003 usp21 usp21 
12 NP001005641 usp14 usp14  NP001038713 usp22 usp22 
13 NP001121498 usp15 usp15  XP005170208 usp24 usp24 
14 NP001072158 usp16 usp16  NP001001886 usp25 usp25 
15 XP004912551 usp18 usp18  XP001920096 usp28 usp28 
16 NP001072879 usp19 usp19  XP005165213 usp30 usp30 
17 NP001090641 usp20 usp20  XP005164285 usp31 usp31 
18 XP002942482 usp21 usp21  XP005157663 usp32 usp32 
19 NP001192175 usp22 usp22  NP998392 usp33 usp33 
20 XP002931653 usp24 usp24  XP002660609 usp34 usp34 
21 NP001039152 usp25 usp25  XP688241 usp36 usp36 
22 XP002937867 usp28 usp28  XP005169174 usp37 usp37 
23 ENSXETG000
00022301 
usp30 usp30  XP003197722 usp38 usp38 
24 XP002932037 usp31 usp31  NP001073539 usp39 usp39 
25 XP002933869 usp32 usp32  XP001921353 usp40 usp40 
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Danio rerio Strongylocentrotus purpuratus 
No. Accession No. Given 
Annotation 
Proposed 
Annotation 
No. Accession No. Given 
Annotation 
Proposed 
Annotation 
 XP005169521 usp42 usp42  XP790411 usp16 usp16/45 
 NP001082871 usp43 usp43  XP003723365 usp19 usp19 
 NP956551 usp44 usp44  XP792380 usp20 usp20/33 
 XP005158432 usp45 usp45  XP003728926 usp20 usp20 
 NP001231910 usp46 usp46  XP786312 usp22 usp22 
 NP001093619 usp47 usp47  XP796637 usp24 usp24 
 XP005172974 usp48 usp48  XP003723638 usp25 usp25/28 
 NP001038361 usp49 usp49  XP785002 usp30 usp30 
 XP001920000 usp52 usp52  XP798688 usp31 usp31/43 
 XP005171014 usp53 usp53  XP003726385 usp32 usp32 
 XP005156922 usp54 usp54  XP790530 usp34 usp34 
 XP684817 cyld cyld  XP003731526 ---- usp36/42 
 XP001334225 usp64e usp64e  XP001179436 ---- usp36/42 
 XP003198930 usp17 usp37  XP795476 usp36 usp36/42 
Ciona intestinalis  XP003725936 usp37 usp37 
 XP002129026 usp2 usp2/21  XP001178896 usp38 usp35/38 
 XP002128421 --- usp4/11/15  XP001185686 usp39 usp39 
 XP002122471 usp5 usp5/13  XP782883 usp40 usp40 
 XP004225844 usp7 usp7  XP792596 usp44 usp44/49 
 XP002126339 --- usp8  XP003728913 usp44 usp44/49 
 XP002123585 faf-x usp9  XP001200360 usp47 usp47 
 XP002120858 usp10 usp10  XP782863 usp47 usp47 
 XP002120616 usp12 usp12/46  XP791204 usp48 usp48 
 XP002126675 usp14 usp14  XP790587 usp52 usp52 
 XP004226714 usp16 usp16/45  XP781136 --- usp53/54 
 NP001071926 znf usp19  XP782657 ----- cyld 
 XP002124776 usp20 usp20/33  XP003726771 cyld cyld 
 XP004225789 usp22 usp22  XP788815 --- usp4/11/15 
 XP002123370 usp25 usp25/28 Drosophila melanogaster 
 XP002131158 usp30 usp30 1 NP733282 cg15817 usp1 
 XP002120550 usp31  usp31/43 2 NP608462 cg14619 usp2/21 
 XP002125579 usp32 usp32 3 NP647773 cg12082 usp5/13 
 XP002124833 usp33 usp20/33 4 NP572779 usp7 usp7 
 XP002127053 usp36 usp36/42 5 NP650948 ubpy usp8 
 XP002127688 usp37 usp37 6 NP524612 fat facets usp9 
 XP002124170 usp38 usp35/38 7 NP728554 cg32479 usp10 
 XP002123896 usp39 usp39 8 NP651099 cg7023 usp12/46 
 XP002121238 usp40 usp40 9 NP609377 cg5384 usp14 
 NP001041464 znf usp44/49 10 NP572220 cg4165 usp16/45 
 XP002128614 usp45 usp16/45 11 NP610943 cg8494 usp20 
 XP002122214 usp47 usp47 12 NP524140 non stop usp22 
 XP002121467 usp48 usp48 13 NP572274 cg3016 usp30 
 XP002122964 usp52 usp52 14 NP611959 cg30421 usp31 
 XP002120975 usp54 usp53/54 15 NP649153 cg8334 usp32 
 XP002131459 cyld cyld 16 NP651275 cg5794 usp34 
Strongylocentrotus purpuratus 17 NP610784 cg8830 usp35/38 
 XP782306 usp1 usp1 18 NP729092 scrawny usp36 
 XP003728306 usp2 usp2 19 Np573334 cg7288 usp39 
 XP781718 usp3 usp3 20 NP996001 64e usp47 
 XP003725951 usp4/11/15 usp4/11/15 21 NP610427 cg8232 usp52 
 XP796964 usp5/13 usp5/13 22 Np570018 cg2662 usp53/54 
 XP780569 usp7 usp7 23 NP723554 cyld cyld 
 XP784858 usp8 usp8 Caenorhabditis elegans 
 XP003723719 usp9 usp9 1 NP493434 usp3 usp3 
 XP794239 usp10 usp10 2 NP501035 h34c03 usp4 
 XP783431 usp12 usp12/46 3 NP491765 usp5 usp5/13 
 XP786966 usp14 usp14 4 NP505825 math-33 usp7 
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Caenorahbidtis elegans Dictyostelium discoideum  
No. Accession No. Given 
Annotation 
Proposed 
Annotation 
No. Accession No. Given 
Annotation 
Proposed 
Annotation 
5 NP507513 e01b7 usp8 4 XP636128 c19 usp40 
6 NP497006 usp14 usp14 5 XP629788 c19 usp9 
7 NP001254304 f07a11 usp19 6 XP635785 atpase usp12/46 
8 NP504537 c04e6 usp22 7 XP640063 CHO 
binding   
no human 
homologue  
9 NP495932 t24b8 usp24 8 XP643907 usp48 usp48 
10 NP495696 k02c4 usp25/28 9 XP644261 c19 usp16/45 
11 NP495213 h12i13 usp25/28 10 XP628978 c19 usp4/11/15 
12 NP497422 y67d2 usp30 11 XP001733062 c19  usp4/11/15 
13 NP001022992 cyk3 usp32 12 XP645628 c19 usp35/38 
14 NP510570 usp33 usp33 13 XP643807 uhb usp39 
15 NP494298 usp39 usp39 14 XP647829 sap usp10 
16 NP499162 usp46 usp46 15 XP645688 udcp usp14 
17 NP495686 t05h10 usp47 16 XP646784 c19 nh 
18 NP492524 usp48 usp48 Chlamydomonas reinhardtii 
19 NP498519 panl2 usp52 1 XP001697158 ---- usp14 
20 NP001255047 cyld cyld 2 XP001700098 uch usp7 
Hydra magnipapillata 3 XP001689583 ---- usp48 
1 XP004208370 usp2 usp2 4 XP001696423 ---- usp12/46 
2 XP002167244 usp3 usp3 5 XP001692784 ---- usp36/42 
3 XP002168139 usp5 usp5 6 XP001702430 ---- 8/4/11/15 
4 XP002166763 usp7 usp7 7 XP001696552 ---- usp2 
5 XP002164031 ---- usp8 8 XP001700667 ---- usp10 
6 XP004209945 usp9 usp8 9 XP001696671 ---- nh 
7 XP002160338 faf-x usp9 10 XP001701682 ---- usp5/13 
8 XP002158653 usp10 usp10 11 XP001697206 ---- usp39 
9 XP002167422 usp11 usp 12 XP001691395 usp52 usp52 
10 XP002165294 usp12 usp12/46 13 XP001691026 ---- nh 
11 XP002162819 usp14 usp14 
Miscellaneous 
Sequences 
12 XP002169084 usp15 usp15 
13 XP002156339 usp19 usp19 
14 XP004212543 usp20 usp20 
15 XP002159615 --- usp22 
16 XP002156309 usp24 usp24 
17 XP002154564 usp32 usp32 
18 XP004211619 usp32 usp32 
19 XP002169046 usp32 usp32 Bos mutus 
20 XP004206986 usp33 usp33 1 XP00591140 Usp29 9Usp29 
21 XP002159948 usp34 usp34 Gasterosteus aculeatus 
22 XP002169312 usp35 usp35 1 ENSGACG00
000015008 
usp50  usp50 
23 XP002157785 usp36 usp36 2 ENSGACG00
000018996 
usp15  usp15 
24 XP002162018 --- usp37 3 ENSGACG00
000002025 
usp9 usp9 
25 XP002155067 usp39 usp39 4 ENSGACG00
000015728 
usp47 usp47 
26 XP002163722 --- usp45 Latimeria chalumnae 
27 XP004207299 usp64e usp47 1 ENSLACG00
000001725 
usp35  usp35 
28 XP002154983 usp48 usp48 Sarcophilus harissi 
29 XP002160677 usp52 usp52 1 ENSSHAG00
000001467 
Usp33 Usp33 
Disctyostelium discoideum  2 ENSSHAG00
000006863 
Usp10  Usp10 
1 XP643147 --- usp7 3 ENSSHAG00
000006133 
Usp25 Usp25 
2 XP643687 --- usp34 Sus scrofa 
3 XP643982 c19  usp36 1 XP003135158 Usp51 Usp51 
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Appendix V. Molecular partners of USPs 
Symbol Full name 
AKT1  v-akt murine thymoma viral oncogene homolog 1 
ARRB2 arrestin, beta 2 
ATAD5 ATPase family, AAA domain containing 5 
ATG3 autophagy related 3 
ATXN1 ataxin 1 
ATX7NL3 ataxin 7-like 3 
BCL3 B-cell CLL/lymphoma 3 
BMI1 BMI1 polycomb ring finger oncogene 
BIRC2 baculoviral IAP repeat containing 2 
BIRC5 baculoviral IAP repeat containing 5 
BIRC6 baculoviral IAP repeat containing 6 
BRCA1 breast cancer 1, early onset 
BRCA2 breast cancer 2, early onset 
BTBD9 BTB (POZ) domain containing 9 
C10orf2 chromosome 10 open reading frame 2 
C14orf2 chromosome 14 open reading frame 2 
C18orf2 chromosome 18 open reading frame 2 
CASP1 caspase 1 
CBX8 chromobox homolog 8 
CDK4 cyclin-dependent kinase 4 
CDKL2 cyclin-dependent kinase-like 2 
CFTR cystic fibrosis transmembrane conductance regulator 
CHMP1A charged multivesicular body protein 1A 
CHMP2A charged multivesicular body protein 2A 
CHMP4A charged multivesicular body protein 4A 
CHMP4C charged multivesicular body protein 4C 
CHMP6 charged multivesicular body protein 6 
CLSPN claspin 
CTNNB1 catenin (cadherin-associated protein), beta 1 
DAP6 death-domain associated protein 
DAXX death-domain associated protein 
DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 
DIO2 deiodinase, iodothyronine, type II 
DMWD dystrophia myotonica, WD repeat containing 
DNAH5 dynein, axonemal, heavy chain 5 
DNAH12 dynein, axonemal, heavy chain 12 
DNAH14 dynein, axonemal, heavy chain 14 
DNAH19 dynein, axonemal, heavy chain 19 
DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 
DNMT1 DNA (cytosine-5-)-methyltransferase 1 
DVL1 dishevelled, dsh homolog 1 
DYNC1H1 dynein, cytoplasmic 1, heavy chain 1 
EGFR epidermal growth factor receptor 
EIF3CL eukaryotic translation initiation factor 3, subunit C-like 
ENY2 enhancer of yellow 2 homolog 
EPS15 epidermal growth factor receptor pathway substrate 15 
ERG v-ets erythroblastosis virus E26 oncogene homolog 
FANCD2 Fanconi anemia, complementation group D2 
FANCI Fanconi anemia, complementation group I 
FASN fatty acid synthase 
FAM48A suppressor of Ty 20 homolog 
FBXL3 F-box and leucine-rich repeat protein 3 
FBXL7 F-box and leucine-rich repeat protein 7 
FBXL15 F-box and leucine-rich repeat protein 15 
FBXO2 F-box protein 2 
FBXW7 F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase 
FOXO4 forkhead box O4 
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FUCA1 fucosidase, alpha-L- 1, tissue 
G3BP1 GTPase activating protein binding protein 1 
G6PI glucose-6-phosphate isomerase 
G6PD glucose-6-phosphate dehydrogenase 
GMPS guanine monphosphate synthetase 
GRP gastrin-releasing peptide 
GRB2 growth factor receptor-bound protein 2 
H2A Histone 2A 
H2B Histone 2B 
HAT histone acetyltransferase  
HDAC6 histone deacetylase 6 
HUWE1 HECT, UBA and WWE domain containing 1 E3 ubiquitin ligase 
IFNAR2 interferon (alpha, beta and omega) receptor 2 
IKBkE inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon 
IKBkG inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma 
ISG15 ISG15 ubiquitin-like modifier 
ITCH itchy E3 ubiquitin protein ligase 
KAT2A K(lysine) acetyltransferase 2A 
KAT2B K(lysine) acetyltransferase 2B 
KCTD10 potassium channel tetramerisation domain containing 10 
KCTD13 potassium channel tetramerisation domain containing 13 
KIAA1530 UV-stimulated scaffold protein A 
KIF23 kinesin family member 23 
KIR2DL3 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 
KLH13 Kelch-Like Family Member 13 
LCK lymphocyte-specific protein tyrosine kinase 
LSM2 LSM2 homolog, U6 small nuclear RNA associated 
Lys6-D Lymphocyte antigen 6 complex locus protein G6d Precursor 
MARK1 MAP/microtubule affinity-regulating kinase 1 
MARK2 MAP/microtubule affinity-regulating kinase 2 
MARK3 MAP/microtubule affinity-regulating kinase 3 
MARK4 MAP/microtubule affinity-regulating kinase 4 
MCL1 myeloid cell leukemia sequence 1 
MDC1 mediator of DNA-damage checkpoint 1 
MDM2 p53 E3 ubiquitin protein ligase 
MDM4 p53 binding protein 
MLLT4 myeloid/lymphoid or mixed-lineage leukemia translocated to 4 
MTOR mechanistic target of rapamycin 
MYBPC1 myosin binding protein C 
MYC v-myc myelocytomatosis viral oncogene homolog 
NUAK1 NUAK family, SNF1-like kinase, 1 
OPTN optineurin 
OS9 osteosarcoma amplified 9, endoplasmic reticulum lectin 
OTUB1 OTU domain, ubiquitin aldehyde binding 1 
PAN3 PAN3 poly(A) specific ribonuclease subunit homolog 
PHLPP1 PH domain and leucine rich repeat protein phosphatase 1 
PLK1 polo-like kinase 1 
PPMIG protein phosphatase 1G 
PPT1 palmitoyl-protein thioesterase 1 
PRKCI protein kinase C, iota 
PRPF3 PRP3premRNA processing factor3 
PSMA proteasome (prosome, macropain) subunit, alpha  
PSMB proteasome (prosome, macropain) subunit, beta  
PSMD7 proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 
RB1 retinoblastoma 1 
RB2 retinoblastoma-like 2 
RING1 ring finger protein 1 
RIPK receptor (TNFRSF)-interacting serine-threonine kinase 1 
RNF2 ring finger protein 2 
RNF41 ring finger protein 41 
RNF128 ring finger protein 128 
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RNF220 ring finger protein 220 
ROBO1 roundabout, axon guidance receptor, homolog 1 
SAP130 Sin3A-associated protein 
SART3 squamous cell carcinoma antigen recognized by T cells 3 
SARS2 seryl-tRNA synthetase 2 
SCF  Skp, Cullin, F-box containing complex 
SERPINCI serpin peptidase inhibitor 
Sin3A SIN3 transcription regulator homolog A 
SLC25A4 solute carrier family 25 member 4 
SMAD7 SMAD family member 7 
SNX3 sorting nexin 3 
SQSTM1 sequestosome 1 
SRF serum response factor 
SUDS3 suppressor of defective silencing 3 homolog 
SUMO2 SMT3 suppressor of mif two 3 homolog 2 
SUMO3 SMT3 suppressor of mif two 3 homolog 3 
STAGA SPT3-TAF9-GCN5 acetylase complex 
STAMs signal transducing adaptor molecules 
TBK1 TANK-binding kinase 1 
TCEAL1 transcription elongation factor A (SII)-like 1 
TGFβ1 Tumour beta factor beta 1  
TGFβR1 Tumour beta factor beta receptor 1 
TGFβR2 Tumour beta factor beta receptor 2 
TMEM49 vacuole membrane protein 1 
TP53BP1 tumor protein p53 binding protein1 
TRAF2 TNF receptor-associated factor 2 
TRAF6 TNF receptor-associated factor 6 
TRAIP  TRAF interacting protein 
TRRAP transformation/transcription domain-associated protein 
TSPYL4 TSPY-like 4 
UBA52 ubiquitin A-52 residue ribosomal protein fusion product 1 
UBB ubiquitin B 
UBC ubiquitin C 
UCHL5 ubiquitin carboxyl-terminal hydrolase L5 
UFDIL ubiquitin fusion degradation 1 like 
UHRF1 ubiquitin-like with PHD and ring finger domains protein 
VHL von Hippel-Lindau tumor suppressor 
WDR20 WD repeat domain 20 
WDR48 WD repeat domain 48 
WRNIP1 Werner helicase interacting protein 1 
ZBTB32 ubiquitin-like with PHD and ring finger domains 
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Appendix VI. Accession number of Chitinase and 
Chitinase Like Protein 
S.No Species Annotation Nucleotide Protein Rec. 
Annota
tion 
1 
Ailuropoda 
melanoleuca 
Chit1 XM_002925435.1 XP_002925481.1 Chit1 
2 
Ailuropoda 
melanoleuca 
Chia XM_002927484.1 XP_002927530.1 Chia1 
3 
Ailuropoda 
melanoleuca 
Ovgp1 XM_002927484.1 XP_002927530.1 Ovgp1 
4 
Ailuropoda 
melanoleuca 
Chi3l1 XM_002925445 
 
XP_002925491.1 Chil1 
5 
Ailuropoda 
melanoleuca 
Ctbs XP_002930839.1 XM_002930793.1 Ctbs 
6 
Ailuropoda 
melanoleuca 
Chid1 XP_002930842.1 XP_002930842 Chid1 
7 
Anolis 
carolinensis 
Novel gene ENSACAT00000025971 
 
ENSACAP00000020256 chit1 
8 
Anolis 
carolinensis 
chia XM_003220323.1 XP_003220371.1 chia1 
9 
Anolis 
carolinensis 
chia like XM_003220322.1 XP_003220371.1 chia1 
10 
Anolis 
carolinensis 
chi3l1/2 XM_003220374.1 XP_003220422.1 chil2 
11 
Anolis 
carolinensis 
chia like XM_003220321.1 XP_003220369.1 chia3 
12 
Anolis 
carolinensis 
chia like XM_003220376.1 XP_003220424.1 chio 
13 
Anolis 
carolinensis 
chia like XM_003220324.1 XP_003220372.1 chio 
14 
Anolis 
carolinensis 
chia like XM_003220526 XP_003220574.1 chio 
15 
Anolis 
carolinensis 
ctbs XM_003223062.1 XP_003223110.1 ctbs 
16 
Anolis 
carolinensis 
chid1 XM_003214770.1 XP_003214818.1 chid1 
   17 
Bos taurus 
 
Chia NM_174699.2 NP_777124.1 Chia1 
18 
Bos taurus 
 
Ovgp1 NM_001080216.1 NP_001073685.1 Ovgp1a 
19 
Bos taurus 
 
Ovgp1 XM_003585814.1 XP_003585862.1 Ovgp1
b 
20 
Bos taurus 
 
none ENSBTAT00000057237 
 
ENSBTAT00000032129 Chio1 
21 
Bos taurus 
 
Chi3l1 NM_001080219.1 NP_001073688.1 Chil1 
22 
Bos taurus 
 
Chi3l2 XM_003581958.1 XP_003582006.1 Chil2 
23 
Bos taurus 
 
Ctbs NM_001206600.1 NP_001193529.1 Ctbs 
24 
Bos taurus 
 
Chid1 NM_001015515.1 NP_001015515.1 Chid1 
25 
Branchiostoma 
floridae 
Hypothetic
al protein 
XM_002597546.1 XP_002597592.1 cht-a 
26 
Branchiostoma 
floridae 
Hypothetic
al protein 
XM_002597545.1 XP_002597591.1 cht-b 
27 
Bubalus bubalis 
 
Oviductin EU382735.1 ABY84056.1 Ovgp1 
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28 
Bubalus bubalis 
 
Mammary 
gland 
protein 40 
AY295929.2 AAP42568.2 BP40/C
hil1 
28 
Bufo japonicus 
 
Chitinase AJ345054.1 CAC87888.1 chio2 
29 
Caenorabhditis 
elegans 
Chitinase NM_064259.4 NP_496660.2 chit 
30 
Callithrix 
jacchus 
CHIT1 XM_002760664.1 XP_002760710.1 CHIT1 
31 
Callithrix 
jacchus 
CHIA XM_002751246.1 XP_002751292.1 CHIA1 
32 
Callithrix 
jacchus 
OVGP1 XM_002751247.1 XP_002751293.1 OVGP
1 
33 
Callithrix 
jacchus 
CHI3L1 XM_002760663.1 XP_002760709.1 CHIL1 
34 
Callithrix 
jacchus 
CHI3L2 XM_002751215.1 XP_002751261.1 CHIL2 
35 
Callithrix 
jacchus 
CTBS XM_002751015.1 XM_002751015.1 CTBS 
36 
Callithrix 
jacchus 
CHID1 XR_089464.1 In silico translation CHID1 
37 
Callithrix 
jacchus 
Chia like 
(LOC1003
90524) 
XM_002751216.1 XP_002751262.1 CHIA2 
38 
Canis lupus 
familiaris 
Chia XM_537030.3 XP_537030.3 Chia1 
39 
Canis lupus 
familiaris 
Ovgp1 XM_847145.2 XP_852238.2 Ovgp1 
40 
Canis lupus 
familiaris 
Chi3l1 NM_001177807.1 NP_001171278.1 Chil1 
41 
Canis lupus 
familiaris 
Ctbs XM_547309.2 XP_547309.2 Ctbs 
42 
Canis lupus 
familiaris 
Chid1 XM_003432455.1 XP_003432503.1 Chid1 
43 Capra hircus Oviductin DQ482670.1 ABF20534.1 Ovgp1 
44 
Capra hircus BP40 AY081150.1 AAL87007.1 BP40/C
hil1 
45 
Cavia porcellus Chit1 XM_003474681 
 
XP_003474729.1 Chit1 
46 Cavia porcellus Ovgp1 XM_003479002.1 XP_003479050.1 Ovgp1 
47 Cavia porcellus Chi3l1 XM_003474682.1 XP_003474730.1 Chil1 
48 Cavia porcellus Chid1 XM_003461302.1 XP_003461350.1 Chid1 
49 
Choloepus 
hoffmanni 
Chit1 ENSCHOT00000007285 
 
ENSCHOP00000006437 Chit1 
50 
Choloepus 
hoffmanni 
Chia ENSCHOT00000006163 ENSCHOP00000005435 Chia1 
51 
Choloepus 
hoffmanni 
Ovgp1 ENSCHOT00000011219 ENSCHOP00000009901 Ovgp1 
52 
Choloepus 
hoffmanni 
Chi3l1 ENSCHOT00000004023 ENSCHOP00000003546 Chil1 
53 
Choloepus 
hoffmanni 
Chi3l2 ENSCHOT00000005443 ENSCHOP00000004804 Chil2 
54 
Ciona 
intestinalis 
chitinase NM_001114627.1 NP_001108099.1 cht 
55 
Cricetulus 
griseus 
Chit1 XM_003498841.1 XP_003498889.1 Chit1 
56 
Cricetulus 
griseus 
Chia XM_003514388.1 XP_003514436.1 Chia1 
57 
Cricetulus 
griseus 
Ovgp1 XM_003514351.1 XP_003514399.1 Ovgp1 
58 
Cricetulus 
griseus 
Chi3l1 XM_003498875.1 XP_003498923.1 Chil1 
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59 
Cricetulus 
griseus 
Chi3l4 XM_003514389.1 XP_003514437.1 Chil3 
60 
Cricetulus 
griseus 
Chid1 XM_003509772.1 XP_003509820.1 Chid1 
61 Danio rerio chia1 NM_213050.1 NP_998215.1 chit1 
62 Danio rerio chia2 NM_213249.1 NP_998414.1 chioIa 
63 Danio rerio chia3 NM_213213.1 NP_998378.1 chioIb 
64 Danio rerio chia4 NM_200446.1 NP_956740.1 chioIIa 
65 
Danio rerio zgc:17392
7 
NM001110041 NP_001103511.1 chioIIb 
66 
Danio rerio CU571319
.1 
ENSDART00000111829 ENSDARP00000102083 chio/ov
gp 
67 Danio rerio ctbs BC095064.1 AAH95064.1 ctbs 
68 Danio rerio chid1 NM_200057.1 NP_956351.1 chid1 
69 
Dasypus 
novemcinctus 
Chit1 ENSDNOT00000017334 ENSDNOP00000013434 Chit1 
70 
Dasypus 
novemcinctus 
Chia ENSDNOT00000004032 
 
ENSDNOP00000003097 Chia1 
71 
Dasypus 
novemcinctus 
Ovgp1 ENSDNOT00000017564 ENSDNOP0000001362 Ovgp1 
72 
Dasypus 
novemcinctus 
Chi3l1 ENSDNOT00000009515 ENSDNOP00000007379 Chil1 
73 
Dasypus 
novemcinctus 
Chi3l2 ENSDNOT00000016349 ENSDNOP00000012676 Chil2 
74 
Dipodomys 
ordii 
Chit1 ENSDORT00000010763 
 
ENSDORP00000010115 Chit1 
75 
Dipodomys 
ordii 
Novel gene ENSDORT00000003890 ENSDORP00000003632 Chia1 
76 
Dipodomys 
ordii 
Ovgp1 ENSDORT00000013346 ENSDORP00000012547 Ovgp1 
77 
Dipodomys 
ordii 
Chi3l1 ENSDORT00000002126 ENSDORP00000001991 Chil1 
78 
Dipodomys 
ordii 
Novel gene ENSDORT00000003888 
 
ENSDORP00000003630 Chil2 
79 
Dipodomys 
ordii 
Ctbs ENSDORT00000015059 ENSDORP00000014176 Ctbs 
80 
Dipodomys 
ordii 
Chid1 ENSDORT00000015451 ENSDORP00000014543 Chid1 
81 
Drosophila 
melanogaster 
cht2 NM_057950.2 NP_477298.2 cht2 
82 
Drosophila 
melanogaster 
cht3 NM_001042957.1 NP_001036422.1 cht3 
83 
Drosophila 
melanogaster 
cht4 NM_080223.2 NP_524962.2 cht4 
84 
Drosophila 
melanogaster 
cht5 NM_142057.2 NM_142057.2 cht5 
85 
Drosophila 
melanogaster 
cht6 NM_132370.2 NP_572598.2 cht6 
86 
Drosophila 
melanogaster 
cht7 NM_139511.3 NP_647768.3 cht7 
87 
Drosophila 
melanogaster 
cht8 NM_137698.1 NP_611542.2 cht8 
88 
Drosophila 
melanogaster 
cht9 NM_137699.4 NP_611543.3 cht9 
89 
Drosophila 
melanogaster 
cht11 NM_132133.2 NP_572361.1 cht11 
90 
Drosophila 
melanogaster 
cht12 NM_166420.2 NP_726022.1 cht12 
91 
Drosophila 
melanogaster 
IDGF1 AF102236.1 AAC99417.1 IDGF1 
92 
Drosophila 
melanogaster 
IDGF2 AF102237.1 AAC99418.1 IDGF2 
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93 
Drosophila 
melanogaster 
IDGF3 AF102238.1 AAC99419.1 IDGF3 
94 
Drosophila 
melanogaster 
IDGF4 AF102239 
 
AAC99420.1 IDGF4 
95 
Drosophila 
melanogaster 
IDGF5 NM_137477.3 NP_611321.3 IDGF5 
96 
Drosophila 
melanogaster 
GH20192 BT029919.1 ABM92793.1 IDGF6 
97 
Drosophila 
melanogaster 
CG8460 NM_135346.3 NP_609190.2 -- 
98 
Echinops 
telfairi 
Chit1 ENSETET00000001935 ENSETEP00000001566 Chit1 
99 
Echinops 
telfairi 
Chia ENSETET00000011092 ENSETEP00000008995 Chia1 
100 
Echinops 
telfairi 
Ovgp1 ENSETET00000002991 ENSETEP00000002454 Ovgp1 
101 
Echinops 
telfairi 
Chi3l1 ENSETET00000013193 ENSETEP00000010701 Chil1 
102 
Echinops 
telfairi 
Chi3l2 ENSETET00000004415 ENSETEP00000003616 Chil2 
103 
Echinops 
telfairi 
Chid1 ENSETET00000014627 ENSETEP00000011857 Chid1 
104 Equus caballus Chit1 NM_001143797.1 NP_001137269.1 Chit1 
105 
Equus caballus 
 
Ovgp1 ENSECAT00000024758 
 
ENSECAP00000020584 Ovgp1 
106 
Equus caballus 
 
Chi3l1 XM_001496500.2 XP_001496550.2 Chil1 
107 
Equus caballus 
 
None ENSECAT00000025588 ENSECAP00000021290 Chil2 
108 
Equus caballus 
 
Ctbs XM_003365103.1 XP_003365151.1 Ctbs 
109 
Equus caballus 
 
Chid1 XM_003362643.1 XP_003362691.1 Chid1 
110 
Erinaceus 
europaeus 
Chia ENSEEUT00000005347 ENSEEUP00000004866 Chia1 
111 
Erinaceus 
europaeus 
Ovgp1 ENSEEUT00000011672 ENSEEUP00000010650 Ovgp1 
112 
Erinaceus 
europaeus 
Chi3l1 ENSEEUT00000011096 
 
ENSEEUP00000010116 Chil1 
113 Felis catus Chit1 ENSFCAT00000013116 ENSFCAP00000012160 Chit1 
114 Felis catus Chi3l1 ENSFCAT00000013115 ENSFCAP00000012159 Chil1 
115 Felis catus Ctbs ENSFCAT00000008799 ENSFCAP00000008157 Ctbs 
116 Felis catus Chid1 ENSFCAT00000004824 ENSFCAP00000004457 Chid1 
117 
Gadus morhua chia1 ENSGMOT0000001645
7 
ENSGMOP00000016048 PS 
118 
Gadus morhua chia2 ENSGMOT0000001643
5 
ENSGMOP00000016026 “ 
119 
Gadus morhua None ENSGMOT0000002169
9 
ENSGMOP00000021181 “ 
120 
Gadus morhua ovgp1(1) ENSGMOT0000001722
0 
ENSGMOP00000016801 “ 
121 
Gadus morhua ovgp1(2) ENSGMOT0000001135
3 
ENSGMOP00000011053 “ 
122 
Gadus morhua ovgp1(3) ENSGMOT0000001719
0 
ENSGMOP00000016771 “ 
123 
Gadus morhua ovgp1(4) ENSGMOT0000001136
9 
ENSGMOP00000011068 “ 
124 
Gadus morhua ctbs ENSGMOT0000001794
6 
ENSGMOP00000017514 ctbs 
125 
Gadus morhua chid1 ENSGMOT0000001938
4 
ENSGMOP00000018925 chid1 
126 Gallus gallus E1BZP6 ENSGALT00000005566 ENSGALP00000005553 chia1a 
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(chia) 
127 
Gallus gallus E1BZP4 
(chia) 
ENSGALT00000005565 ENSGALP00000005555 chia1b 
128 Gallus gallus F1NMM2 ENSGALT00000005564 ENSGALP00000005554 chia1c 
129 Gallus gallus ctbs XM_422372.3 XP_422372.1 ctbs 
130 Gallus gallus chid1 NM_001199634.1 NP_001186563.1 chid1 
131 
Gasterosteus 
aculeatus 
chia ENSGACT00000000527 ENSGACP00000000527 chia1a 
132 
Gasterosteus 
aculeatus 
chia ENSGACT00000016542 ENSGACP00000016509 chia1b 
133 
Gasterosteus 
aculeatus 
Novel gene ENSGACT00000015229 ENSGACP00000015200 chio/ov
gp 
134 
Gasterosteus 
aculeatus 
Novel gene ENSGACT00000004677 
 
ENSGACP00000004653 chioIa 
135 
Gasterosteus 
aculeatus 
Novel gene ENSGACT00000004692 
 
ENSGACP00000004687 chioIb 
136 
Gasterosteus 
aculeatus 
Novel gene ENSGACT00000015218 
 
ENSGACP00000015189 Chit1 
137 
Gasterosteus 
aculeatus 
Novel gene ENSGACT00000016635 
 
ENSGACP00000016602 chioII/c
hil 
138 
Gasterosteus 
aculeatus 
ctbs ENSGACT00000012822 ENSGACP00000012798 ctbs 
139 
Gasterosteus 
aculeatus 
chid1 ENSGACT00000007086 ENSGACP00000007068 chid1 
140 Gorilla gorilla CHIT ENSGGOT00000011232 ENSGGOP00000010909 CHIT 
141 Gorilla gorilla CHIA ENSGGOT00000008564 ENSGGOP00000008334 CHIA1 
142 
Gorilla gorilla OVGP1 ENSGGOT00000005228 
 
ENSGGOP00000005097 OVGP
1 
143 Gorilla gorilla CHI3L1 ENSGGOT00000009955 ENSGGOP00000009685 CHIL1 
144 Gorilla gorilla CHI3L2 ENSGGOT00000016075 ENSGGOP00000015627 CHIL2 
145 Gorilla gorilla CTBS ENSGGOT00000015792 ENSGGOP00000015353 CTBS 
146 Gorilla gorilla CHID1 ENSGGOT00000010884 ENSGGOP00000010570 CHID1 
147 Homo sapiens CHIT1 BC105680.1 AAI05681.1 Chit1 
148 Homo sapiens CHIA AF290004.1 AAG60019.1 Chia1 
149 Homo sapiens OVGP1 BC126177.1 AAI26178.1 Ovgp1 
150 Homo sapiens CHI3L1 NM_001276.2 NP_001267.2 CHIL1 
151 Homo sapiens CHI3L2 NM_001025197.1 NP_001020368.1 CHIL2 
152 Homo sapiens CTBS BC126333.1 AAI26334.1 CTBS 
153 Homo sapiens CHID1 NM_001142675.1 NP_001136147.1 CHID1 
154 
Homo sapiens CHIA-
pseudo 
RP11-165H20.1 -- CHIA2
-pseudo 
155 
Homo sapiens CHIA-
pseudo 
RP11-165H20.4 -- CHIA3
-pseudo 
156 
Homo sapiens CHIA-
pseudo 
RP11-1125M8.5 -- CHIO-
pseudo 
157 
Lethenteron 
japonicum 
 chit EU741679.1 ACF10400.1 cht 
158 
Loxodonta 
africana 
Chit1 XM_003410110.1 XP_003410158.1 Chit1 
159 
Loxodonta 
africana 
Chia XM_003409404.1 XP_003409452.1 Chia1 
160 
Loxodonta 
africana 
Ovgp1 XM_003409406.1 XP_003409454.1 Ovgp1 
161 
Loxodonta 
africana 
Chi3l1 XM_003410238.1 XP_003410286.1 Chil1 
162 
Loxodonta 
africana 
Chi3l2 XM_003409572.1 XP_003409620.1 Chil2 
163 
Loxodonta 
africana 
Ctbs ENSLAFT00000011740 ENSLAFP00000009812 Ctbs 
164 
Loxodonta 
africana 
Chid1 XM_003423324.1 XP_003423372.1 Chid1 
165 Macaca mulatta CHIT1 XM_001103012.2 XP_001103012.1 CHIT1 
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166 
Macaca mulatta 
 
CHIA ENSMMUT0000001238
9 
 
ENSMMUP00000011619 CHIA1 
167 
Macaca mulatta 
 
OVGP1 NM_001042787.1 NP_001036252.1 OVGP
1 
168 Macaca mulatta CHI3L1 XM_001103739.2 XP_001103739.1 CHIL1 
169 Macaca mulatta CHI3L2 XM_001093397.2 XP_001093397.2 CHIL2 
170 Macaca mulatta CTBS XM_001107057.2 XP_001107057.1 CTBS 
171 Macaca mulatta CHID1 XM_001089724.2 XP_001089724.1 CHID1 
172 
Macaca mulatta pseudo LOC705382 -- CHIA2
-pseudo 
173 
Macaca mulatta pseudo LOC100425748 -- CHIA3
-pseudo 
174 
Macaca mulatta pseudo LOC100425497 -- CHIO-
pseudo 
175 
Macropus 
eugenii 
Chit1 ENSMEUT00000001040 
 
ENSMEUP00000000957 Chit1 
176 
Macropus 
eugenii 
Chia ENSMEUT00000010728 ENSMEUP00000009760 Chia1 
177 
Macropus 
eugenii 
Chi3l1 ENSMEUT00000009207 ENSMEUP00000008387 Chil1 
178 
Macropus 
eugenii 
Chi3l2 ENSMEUT00000011803 ENSMEUP00000010725 Chil2 
179 
Macropus 
eugenii 
Ctbs ENSMEUT00000007763 
 
ENSMEUP00000007067 Ctbs 
180 
Macropus 
eugenii 
Chid1 ENSMEUT00000006175 ENSMEUP00000005628 Chid1 
181 
Meleagris 
gallopavo 
chia XM_003212987.1 XP_003213035.1 chia1a 
182 
Meleagris 
gallopavo 
chia XM_003212986.1 XP_003213034.1 chia1c 
183 
Meleagris 
gallopavo 
chia XM_003212985.1 XP_003213033.1 chia1b 
184 
Meleagris 
gallopavo 
ctbs XM_003208743.1 XP_003208791.1 ctbs 
185 
Meleagris 
gallopavo 
chid1 XM_003206307.1 XP_003206355.1 chid1 
186 
Mesocricetus 
auratus 
Ovgp1 D32218.1 BAA06977.1 Ovgp1 
187 
Microcebus 
murinus 
CHIT1 ENSMICT00000002309 ENSMICP00000002109 CHIT1 
188 
Microcebus 
murinus 
CHIA ENSMICT00000011956 ENSMICP00000010886 CHIA1 
189 
Microcebus 
murinus 
CHI3L1 ENSMICT00000015438 ENSMICP00000014068 CHIL1 
190 
Microcebus 
murinus 
CHI3L2 ENSMICT00000011945 
 
ENSMICP00000010875 CHIL2 
191 
Microcebus 
murinus 
CTBS ENSMICT00000014904 ENSMICP00000013589 CTBS 
192 
Microcebus 
murinus 
CHID1 ENSMICT00000000972 ENSMICP00000000880 CHID1 
193 
Monodelphis 
domestica 
Chit1 XM_001369883.2 XP_001369920.2 Chit1 
194 
Monodelphis 
domestica 
Chia  XM_001372827.1 XP_001372864.1 Chia1a 
195 
Monodelphis 
domestica 
Chia like XM_001372844.1 
 
XP_001372881.1 Chia1b 
196 
Monodelphis 
domestica 
Chia like XM001381953.1 XP_001381990.1 Chia3 
197 
Monodelphis 
domestica 
Chia like XM_001381960.2 XP_001381997.2 Chio1a 
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198 
Monodelphis 
domestica 
Chia like XM_001381962.2 XP_001381999.2 Chio1b 
199 
Monodelphis 
domestica 
Ovgp1 ENSMODT0000000165
0 
 
ENSMODP00000001616 Ovgp1 
200 
Monodelphis 
domestica 
Chi3l1 XM_001364797.2 XP_001364834.2 Chil1 
201 
Monodelphis 
domestica 
Chi3l2  XM_001381951.2 XP_001381988.2 Chil2  
202 
Monodelphis 
domestica 
Ctbs XM_001367032.1 XP_001367069.1 Ctbs 
203 
Monodelphis 
domestica 
Chid1 XM_003342209.1 XP_003342257.1 Chid1 
204 Mus musculus Chit1 BC138765.1 AAI38766.1 Chit1 
205 Mus musculus Chia DQ349202.1 ABC86699.1 Chia 
206 Mus musculus Ovgp1 BC137995 AAI37996.1 Ovgp1 
207 Mus musculus Chi3l1 NM_007695.3 NP_031721.2 Chil1 
208 Mus musculus Chi3l3 NM_009892.2 NP_034022.2 Chil3 
209 Mus musculus Chi3l4 NM_145126.2 NP_660108.2 Chil4 
210 Mus musculus Chi3l7 XM_003086317.1 XP_003086365.1 Chil7 
211 Mus musculus BYm NM_178412.2 NP_848499.1 Chil8 
212 Mus musculus Ctbs NM_028836.3 NP_083112.1 Ctbs 
213 Mus musculus Chid1 BC061063.1 AAH61063.1 Chid1 
214 
Myotis 
lucifugus 
novel gene ENSMLUT00000010603 ENSMLUP00000009664 Chia1a 
215 
Myotis 
lucifugus 
novel gene ENSMLUT00000008998 ENSMLUP00000008199 Chia1b 
216 
Myotis 
lucifugus 
Ovgp1 ENSMLUT00000012410 ENSMLUP00000011299 Ovgp1 
217 
Myotis 
lucifugus 
novel gene ENSMLUT00000023766 ENSMLUP00000017407 Chil1 
218 
Myotis 
lucifugus 
novel gene ENSMLUT00000010322 ENSMLUP00000009406 Chil1 
219 
Myotis 
lucifugus 
Ctbs ENSMLUT00000016040 ENSMLUP00000014612 Ctbs 
220 
Myotis 
lucifugus 
Chid1 ENSMLUT00000016623 ENSMLUP00000015148 Chid1 
221 
Nomascus 
leucogenys 
 
CHIT1 XM_003264580.1 XP_003264628.1 CHIT1 
222 
Nomascus 
leucogenys 
 
CHIA XM_003267959.1 XP_003268007.1 CHIA1 
223 
Nomascus 
leucogenys 
 
OVGP1 XM_003267966.1 XP_003268014.1 OVGP
1 
224 
Nomascus 
leucogenys 
 
CHI3L1 XM_003264578.1 XP_003264626.1 CHIL1 
225 
Nomascus 
leucogenys 
 
CHI3L2 XM_003267958.1 XP_003268006.1 CHIL2 
226 
Nomascus 
leucogenys 
 
CTBS XM_003278435.1 XP_003278483.1 CTBS 
227 
Nomascus 
leucogenys 
 
CHID1 XM_003281317.1 XP_003281365.1 CHID1 
228 
Ochotona 
princeps 
Chit1 ENSOPRT00000014806 
 
ENSOPRP00000013520 Chit1 
229 
Ochotona 
princeps 
Ovgp1 ENSOPRT00000003825 ENSOPRP00000003520 Ovgp1 
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230 
Ochotona 
princeps 
Chi3l1 ENSOPRT00000014785 ENSOPRP00000013500 Chil1 
231 
Ochotona 
princeps 
Chi3l2 ENSOPRT00000009439 ENSOPRP00000008637 Chil2 
232 
Ochotona 
princeps 
Chid1 ENSOPRT00000001568 ENSOPRP00000001445 Chid1 
233 
Oncorhynchus 
mykiss 
Gastric 
chitinase 
EU877960.1 ACG58867.1 Chia1 
234 
Oncorhynchus 
mykiss 
chit AJ535688.1 CAD59687.1 chioII 
235 
Oreochromis 
niloticus 
chialike XM_003459038.1 XP_003438829.1 chit1a 
236 
Oreochromis 
niloticus 
chialike XM_003459039.1 XP_003459087.1 chit1b 
237 
Oreochromis 
niloticus 
chialike XM_003458530.1 XP_003458578.1 chit1c 
238 
Oreochromis 
niloticus 
chialike XM_003438781.1 XP_003438829.1 chioI 
239 
Oreochromis 
niloticus 
 ctbs XM_003452536.1 XP_003452584.1 ctbs 
240 
Oreochromis 
niloticus 
chid1 XM_003440467.1 XP_003440515.1 chid1 
241 
Ornithorhynchu
s anatinus 
Chit1 XM_001518544.2 XP_001518594.2 Chit1 
242 
Ornithorhynchu
s anatinus 
novel ENSOANT00000015751 ENSOANP00000015748 Chit2 
243 
Ornithorhynchu
s anatinus 
novel ENSOANT00000003822 ENSOANP00000003821 Chit3 
244 
Ornithorhynchu
s anatinus 
Ovgp1 XM_001517948.2 XP_001517998.2 Ovgp1 
245 
Ornithorhynchu
s anatinus 
Chi3l1 XM_001518538.2 XP_001518588.2 Chil1 
246 
Ornithorhynchu
s anatinus 
Ctbs XM_001514909.1 XP_001514959.1 Ctbs 
247 
Ornithorhynchu
s anatinus 
Chid1 XM_001515150.2 XP_001515200.2 Chid1 
248 
Oryctolagus 
cuniculus 
Chit1 XM_002717457.1 XP_002717503.1 Chit1 
249 
Oryctolagus 
cuniculus 
Ovgp1 NM_001082105.1 NP_001075574.1 Ovgp1 
250 
Oryctolagus 
cuniculus 
Chi3l1 XM_002717458.1 XP_002717504.1 Chil1 
251 
Oryctolagus 
cuniculus 
Chi3l2 XM_002715779.1 XP_002715825.1 Chil2 
252 
Oryctolagus 
cuniculus 
Ctbs XM_002715538.1 XP_002715584.1 Ctbs 
253 
Oryctolagus 
cuniculus 
Chid1 XM_002724161.1 XP_002724207.1 Chid1 
254 
Oryzias latipes Novel gene ENSORLT00000013331 
 
ENSORLP00000013330 chioI 
255 
Oryzias latipes Novel gene ENSORLT00000017136 
 
ENSORLP00000017135 chioIIa 
256 
Oryzias latipes Novel gene ENSORLT00000017096 
 
ENSORLP00000017095 chioIIb 
257 
Oryzias latipes Novel gene ENSORLT00000013269 
 
ENSORLP00000013268 chit1 
258 
Oryzias latipes Novel gene ENSORLT00000013259 
 
ENSORLP00000013258 chit2 
259 
Oryzias latipes ctbs ENSORLT00000007814 
 
ENSORLP00000007813 ctbs 
260 Oryzias latipes chid1 ENSORLT00000008210 ENSORLP00000008209 chid1 
261 Otolemur CHIT1 ENSOGAT00000000928 ENSOGAP00000000830 CHIT1 
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262 
Otolemur 
garnettii 
CHIA ENSOGAT00000010811 ENSOGAP00000009675 CHIA1 
263 
Otolemur 
garnettii 
novel gene ENSOGAT00000010810 
 
ENSOGAP00000009674 CHIA2 
264 
Otolemur 
garnettii 
novel gene ENSOGAT00000033204 ENSOGAP00000021751 CHIA3 
265 
Otolemur 
garnettii 
CHI3L1 ENSOGAT00000000924 ENSOGAP00000000826 CHIL1 
266 
Otolemur 
garnettii 
CHI3L2 ENSOGAT00000010808 ENSOGAP00000009672 CHIL2 
267 
Otolemur 
garnettii 
CTBS ENSOGAT00000004652 ENSOGAP00000004154 CTBS 
268 
Otolemur 
garnettii 
CHID1 ENSOGAT00000031647 ENSOGAP00000021384 CHID1 
269 Ovis aries Chia EF063144.1 ABP98946 Chia1 
270 Ovis aries Ovgp1 NM_001009779.1 NP_001009779.1 Ovgp1 
271 
Ovis aries BP40 AY392761.1 AAQ94054.1 Chil1/B
P40 
272 Ovis aries Chid1 EF581383.1 ABQ51216.1 Chid1 
273 Pan troglodytes CHIT1 XM_514112.3 XP_514112.3 CHIT1 
274 Pan troglodytes CHIA XR_024811.2 In silico translation CHIA1 
275 
Pan troglodytes OVGP1 XM_003338996.1 XP_003339044.1 OVGP
1 
276 Pan troglodytes CHI3L1 XM_001153636.2 XP_001153636.2 CHIL1 
277 Pan troglodytes CHI3L2 XM_513645.3 XP_513645.3 CHIL2 
278 Pan troglodytes CTBS XM_513520.3 XP_513520.1 CTBS 
279 Pan troglodytes CHID1 XM_001151962.2 XP_001151962.2 CHID1 
280 
Papio anubis OVGP1 NM_001112617.1 NP_001106087.1 OVGP
1 
281 
Pelodiscus 
sinensis 
chia ENSPSIT00000012771 ENSPSIP00000012710 chia 
282 
Pelodiscus 
sinensis 
ovgp1 ENSPSIT00000011841 ENSPSIP00000011784 chio 
 
283 
Pelodiscus 
sinensis 
Novel gene ENSPSIT00000011195 ENSPSIP00000011139 chio 
284 
Pelodiscus 
sinensis 
Novel gene ENSPSIT00000014733 ENSPSIP00000014664 chio 
285 
Pelodiscus 
sinensis 
ctbs ENSPSIT00000019583 ENSPSIP00000019492 ctbs 
286 
Pelodiscus 
sinensis 
chid1 ENSPSIT00000015979 ENSPSIP00000015904 chid1 
287 
Petromyzon 
marinus 
chid1 ENSPMAT00000009060 ENSPMAP00000009021 chid1 
288 
Pongo abelii 
 
CHIT1 XM_002809597.1 XP_002809643.1 CHIT1 
289 Pongo abelii CHIA XM_002810445.1 XP_002810491.1 CHIA1 
290 
Pongo abelii OVGP1 XM_002810442.1 XP_002810488.1 OVGP
1 
291 Pongo abelii CHI3L1 NM_001131991.1 NP_001125463.1 CHIL1 
292 Pongo abelii CHI3L2 ENSPPYT00000001247 ENSPPYP00000001207 CHIL2 
293 Pongo abelii CTBS ENSPPYT00000001438 ENSPPYP00000001393 CTBS 
294 
Pongo abelii 
 
CHID1 NM_001133685.1 NP_001127157.1 CHID1 
295 
Procavia 
capensis 
Chit1 ENSPCAT00000003734 
 
ENSPCAP00000003506 not 
assigne
d 
296 
Procavia 
capensis 
Ovgp1 ENSPCAT00000003785 ENSPCAP00000003553 “ 
297 
Procavia 
capensis 
Chi3l1 ENSPCAT00000010583 ENSPCAP00000009872 “ 
298 Procavia Chi3l2 ENSPCAT00000000396 ENSPCAP00000000369 “ 
Mushtaq Hussain, 2013  294 
capensis  
299 
Procavia 
capensis 
Chid1 ENSPCAT00000010327 ENSPCAP00000009637 “ 
300 
Pteropus 
vampyrus 
Ovgp1 ENSPVAT00000010601 ENSPVAP00000009989 Ovgp1 
301 
Pteropus 
vampyrus 
Ctbs ENSPVAT00000008138 ENSPVAP00000007688 Ctbs 
302 
Pteropus 
vampyrus 
Chid1 ENSPVAT00000001560 ENSPVAP00000001470 Chid1 
303 
Rana 
catesbeiana 
chit AF447579.1 AAL38179.1 chia1 
304 
Rattus 
norvegicus 
Chit1 NM_001079689.1 NP_001073157.1 Chit1 
305 
Rattus 
norvegicus 
Chia NM_207586.1 NP_997469.1 Chia1 
306 
Rattus 
norvegicus 
Chi3l1 NM_053560.1 NP_446012.1 Chil1 
307 
Rattus 
norvegicus 
Chi3l3 NM_001191712.1 NP_001178641.1 Chil3 
308 
Rattus 
norvegicus 
Chi3l4 XM_227566.5 XP_227566.4 Chil7 
309 
Rattus 
norvegicus 
LOC29535
2 
 
NM_001134512.1 NP_001127984.1 Chil8 
310 
Rattus 
norvegicus 
Ctbs NM_031023.1 NP_112285.1 Ctbs 
311 
Rattus 
norvegicus 
Chid1 NM_001047854.2 NP_001041319.2 Chid1 
312 
Sarcophilus 
harrisii 
Chit1 ENSSHAT00000019889 ENSSHAP00000019732 Chit1 
313 
Sarcophilus 
harrisii 
novel ENSSHAT00000014785 ENSSHAP00000014661 Chia1a 
314 
Sarcophilus 
harrisii 
Novel ENSSHAT00000014578 ENSSHAP00000014457 Chia3 
315 
Sarcophilus 
harrisii 
Novel ENSSHAT00000014916 ENSSHAP00000014791 Chia1b 
316 
Sarcophilus 
harrisii 
novel ENSSHAT00000015082 ENSSHAP00000014957 Chio1 
317 
Sarcophilus 
harrisii 
Ovgp1 ENSSHAT00000015439 ENSSHAP00000015312 Ovgp1 
318 
Sarcophilus 
harrisii 
Chi3l1 ENSSHAT00000019702 ENSSHAP00000019545 Chil1 
319 
Sarcophilus 
harrisii 
Chi3l2 ENSSHAT00000014471 ENSSHAP00000014352 Chil2 
320 
Sarcophilus 
harrisii 
Ctbs ENSSHAT00000020721 ENSSHAP00000020557 Ctbs 
321 
Sarcophilus 
harrisii 
Chid1 ENSSHAT00000003724 ENSSHAP00000003687 Chid1 
322 Sorex araneus Chia ENSSART00000005351 ENSSARP00000004846 Chia 
323 Sorex araneus Ovgp1 ENSSART00000002045 ENSSARP00000001859 Ovgp1 
324 Sorex araneus Ctbs ENSSART00000002000 ENSSARP00000001819 Ctbs 
325 Sorex araneus Chid1 ENSSART00000008518 ENSSARP00000007704 Chid1 
326 
Spermophilus 
tridecemlineatus 
Chit1 ENSSTOT00000023652 ENSSTOP00000013500 Chit1 
327 
Spermophilus 
tridecemlineatus 
Chia ENSSTOT00000002559 ENSSTOP00000002289 Chia1a 
328 
Spermophilus 
tridecemlineatus 
Chia ENSSTOT00000005561 ENSSTOP00000004975 Chia1b 
329 
Spermophilus 
tridecemlineatus 
Ovgp1 ENSSTOT00000000474 ENSSTOP00000000426 Ovgp1 
330 
Spermophilus 
tridecemlineatus 
Chi3l1 ENSSTOT00000015439 ENSSTOP00000013826 Chil1 
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331 
Spermophilus 
tridecemlineatus 
Ctbs ENSSTOT00000015317 ENSSTOP00000013724 Ctbs 
332 
Spermophilus 
tridecemlineatus 
Chid1 ENSSTOT00000006593 ENSSTOP00000005894 Chid1 
333 Sus scrofa Chit1 XM_003130296.1 XP_003130344.1 Chit1 
334 Sus scrofa Chia XR_130567.1   translation Chia 
335 Sus scrofa Ovgp1 NM_214070.1 NP_999235.1 Ovgp1 
336 
Sus scrofa Heparin 
binding 
protein 
U19900.1 AAA86482 Chil1 
337 
Sus scrofa BP40 AY762599.1 AAV30548.1 BP40/C
hil1 
338 Sus scrofa Chi3l2 XM_003481491.1 XP_003481539.1 Chil2 
339 Sus scrofa Ctbs XM_003356418.2 XP_003356466.2 Ctbs 
340 Sus scrofa Chid1 NM_001243810.1 NP_001230739.1 Chid1 
341 
Taeniopygia 
guttata 
chia ENSTGUT00000018139 ENSTGUP00000017736 chia1 
342 
Taeniopygia 
guttata 
ctbs ENSTGUT00000006829 ENSTGUP00000006761 ctbs 
343 
Taeniopygia 
guttata 
chid1 ENSTGUT00000010151 
 
ENSTGUP00000010044 chid1 
344 Tarsius syrichta CHIT1 ENSTSYT00000006197 ENSTSYP00000005672 CHIT1 
345 Tarsius syrichta CHIA ENSTSYT00000011237 ENSTSYP00000010306 CHIA1 
346 Tarsius syrichta CHI3L1 ENSTSYT00000005582 ENSTSYP00000005109 CHIL1 
347 Tarsius syrichta CHI3L2 ENSTSYT00000002608 ENSTSYP00000002398 CHIL2 
348 Tarsius syrichta CTBS ENSTSYT00000010032 ENSTSYP00000009202 CTBS 
349 Tarsius syrichta CHID1 ENSTSYT00000009359 ENSTSYP00000008587 CHID1 
350 
Tetraodon 
nigroviridis 
Novel gene ENSTNIT00000002411 ENSTNIP00000000910 chioI 
351 
Tetraodon 
nigroviridis 
Novel gene ENSTNIT00000003839 ENSTNIP00000001773 chioII 
352 
Tetraodon 
nigroviridis 
Novel gene ENSTNIT00000002465 ENSTNIP00000003161 chit1 
353 
Tetraodon 
nigroviridis 
ctbs ENSTNIT00000018854 ENSTNIP00000018627 ctbs 
354 
Tetraodon 
nigroviridis 
chid1 ENSTNIT00000019388 ENSTNIP00000019160 chid1 
355 
Tupaia 
belangeri 
Chia ENSTBET00000006966 ENSTBEP00000006015 Chia1 
356 
Tupaia 
belangeri 
Ovgp1 ENSTBET00000009993 ENSTBEP00000008647 Ovgp1 
357 
Tupaia 
belangeri 
Chi3l1 ENSTBET00000010066 ENSTBEP00000008711 Chil1 
358 
Tupaia 
belangeri 
Chi3l2 ENSTBET00000011188 ENSTBEP00000009665 Chil2 
359 
Tupaia 
belangeri 
Ctbs ENSTBET00000006121 ENSTBEP00000005268 Ctbs 
360 
Tupaia 
belangeri 
Chid1 ENSTBET00000012200 
 
ENSTBEP00000010565 Chid1 
361 
Tursiops 
truncatus 
Chit1 ENSTTRT00000000835 
 
ENSTTRP00000000788 Chit1 
362 
Tursiops 
truncatus 
Chia ENSTTRT00000007832 ENSTTRP00000007407 Chia1 
363 
Tursiops 
truncatus 
Ovgp1 ENSTTRT00000012152 ENSTTRP00000011522 Ovgp1 
364 
Tursiops 
truncatus 
Chi3l1 ENSTTRT00000009513 ENSTTRP00000009014 Chil1 
365 
Tursiops 
truncatus 
Chi3l2 ENSTTRT00000007808 ENSTTRP00000007384 Chil2 
366 
Tursiops 
truncatus 
Ctbs ENSTTRT00000012373 ENSTTRP00000011740 Ctbs 
367 Tursiops Chid1 ENSTTRT00000012505 ENSTTRP00000011864 Chid1 
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368 
Takifugu 
rubripes 
Novel gene ENSTRUT00000001850 ENSTRUP00000001842 chioIa 
369 
Takifugu 
rubripes 
Novel gene ENSTRUT00000022661 ENSTRUP00000022567 chioIb 
370 
Takifugu 
rubripes 
Novel gene ENSTRUT00000033584 ENSTRUP00000033458 chioIIa 
371 
Takifugu 
rubripes 
Novel gene ENSTRUT00000006584 ENSTRUP00000006542 chioIIb 
372 
Takifugu 
rubripes 
Novel gene ENSTRUT00000044944 ENSTRUP00000044793 ctbs 
373 
Takifugu 
rubripes 
chid1 ENSTRUT00000009179 ENSTRUP00000009125 chid1 
374 Vicugna pacos Chit1 ENSVPAT00000008798 ENSVPAP00000008186 Chit1 
375 
Vicugna pacos Chia ENSVPAT00000000342 
 
ENSVPAP00000000318 Chia1 
376 Vicugna pacos Ovgp1 ENSVPAT00000000345 ENSVPAP00000000321 Ovgp1 
378 
Vicugna pacos Chi3l1 ENSVPAT00000003605 
 
ENSVPAP00000003341 Chil1 
379 Vicugna pacos Ctbs ENSVPAT00000000313 ENSVPAP00000000290 Ctbs 
380 
Xenopus laevis 
 
chia AF447580.1 AAL38180.1 chia 
381 
Xenopus laevis 
 
chit BC073276.1 AAH73276.1 chio 
382 Xenopus laevis ctbs NM_001094061.1 NP_001087530.1 ctbs 
383 Xenopus laevis chid1 NM_001086262.1 NP_001079731.1 chid1 
384 
Xenopus 
tropicalis 
chia NM_001199560.1 NP_001186489.1 chia1 
385 
Xenopus 
tropicalis 
XB-
GENE-
5763443 
ENSXETT00000025880 
 
ENSXETP00000025880 chia3 
386 
Xenopus 
tropicalis 
chit1 NM_001005792.1 NP_001005792.1 chio 
387 
Xenopus 
tropicalis 
Ctbs ENSXETT00000066334 ENSXETP00000059660 ctbs 
388 
Xenopus 
tropicalis 
Chid1 ENSXETT00000041328 ENSXETP00000041328 chid1 
 
